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Stroke is a major cause of death and disability worldwide, of which ischemic 
stroke accounts for 87% of all stroke cases. Its impact on society and economy 
is extensive and profound. This drives translational stroke research discoveries 
for new biomarkers and treatments. However, translational stroke research is 
still in its infancy and requires greater understanding of the pathophysiology 
and pathogenesis of ischemic stroke. Circulating miRNAs were used as a 
surrogate marker to study mechanisms in ischemic stroke patients. Changes in 
miRNA expression were studied in rat MCAo model and in ischemic stroke 
patients. miRNA microarray was used as a high-throughput method to screen 
the entire microRNome for dysregulated miRNAs in the shortest possible time.  
miRNA profiles obtained were analysed to identify ischemic stroke specific 
miRNAs as well as miRNAs that were specific for ischemic stroke subtype. 
These clusters contained known associated miRNAs as well as novel miRNAs. 
Furthermore, pathway analysis revealed biological pathways associated with 
inflammation, cell death, vascular maintenance, metabolism and neuronal 
signaling and development were dysregulated during ischemic stroke in 
patients and animal model. These biological pathways included ones 
previously reported, and also new pathways thath were never shown any 
association with ischemic stroke till now. It was inferred from the results that 
neuroinflammation is a critical process in the pathophysiology of ischemic 
stroke and in the pathogenesis of ischemic stroke subtypes. Among the 
biological pathways, complement and coagulation cascades were identified to 
be specific for cardioembolic stroke, a stroke subtype with high mortality rate. 
CD46, an inhibitor of complement activation, was previously reported to be 
ii 
 
able to distinguish cardioembolic stroke from large artery stroke. Using 
bioinformatics and experimental data, miR-19a, -20a, -185 and -374b were 
predicted to target CD46, which were verified using Luciferase assay. These 
miRNAs were shown to have differential expression between cardioembolic 
stroke vs large artery and small vessel stroke. Thus, demonstating the new 
miRNAs interacting with CD46 may act as potential biomarkers for 
cardioembolic stroke. In addition, chemokine signaling pathway, also 
associated with neuroinflammation was found to be highly ranked in all the 
pathway analysis. Chemokine CCL2 previously reported to be dysregulated in 
ischemic stroke was studied. mRNA expression in rat correlated with infarct 
volume, and protein expression in human patients showed positive correlation 
with outcome. Hence, searching for miRNA targeting CCL2 may also be 
useful as biomarkers or therapeutic targets in stroke. 
Hence, this study discovered the crucial mechanisms underlying ischemic 
stroke pathophysiology and highlighted clusters of miRNAs which may act as 
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Stroke is the second leading cause of death and the leading cause of disability 
worldwide [1, 2]. In 2005, it was estimated that 16 million cases of first-time 
stroke and 5.7 million deaths resulting from stroke [3].  In past decade, the 
annual mortality due to stroke has been on the rise. In 2000, stroke accounts 
for 5.6 million deaths worldwide, by 2011, the number had risen to 6.2 million, 
which contributes to 11.4% of deaths worldwide in 2011 [3].  
Stroke has a profound effect on the socioeconomic status of the patients, the 
immediate families and even the world. Stroke patients suffer from disabilities 
and become dependent on their immediate families. In addition, the medical 
cost is an immense burden on the family. In the United States of America, the 
average lifetime cost for stroke is USD$140,048 and in 2010 the total cost of 
stroke was a massive USD$36.5 billion [4].  
Stroke is a disorder resulting from an occlusion or rupture in the cerebral 
artery, that caused a lack of perfusion to affected area of the brain, manifesting 
as deficit in cerebral function [5]. Stroke can be classified into ischemic stroke 
(cerebral ischemia) or hemorrhagic stroke. Ischemic stroke accounts for 87% 
of all stroke cases while hemorrhagic stroke makes up the remaining 13% 
(Figure 1.1) [6, 7]. Ischemic stroke and hemorrhagic stroke can be further sub-
classified into more subtypes based on the location or cause of the stroke. 
Ischemic stroke cases are generally classified according to the Trial of Org 
10172 in Acute Stroke Treatment (TOAST) classification, where ischemic 
stroke cases can be classified as large artery atherosclerosis, cardioembolic, 
small-vessel occlusion or lacunar, other determined etiology and undetermined 
etiology [8]. As for hemorrhagic stroke cases, they are generally classified 
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intracerebral hemorrhage and subarachnoid hemorrhage [9]. Given that 
ischemic stroke contributes the majority of stroke cases, this project focuses 

































1.1.1 Ischemic stroke 
Ischemic stroke is the disruption of blood flow to a part of the brain as a result 
of a blockage in cerebral vasculature [5]. The consequence of this is a 
devastating injury to the affected part of the brain as the blood supplying 
oxygen and glucose is cut off. Hence, the cells (mainly astrocytes and neurons) 
in the affected region die in response to the insult. The effect of this is 
manifested in the clinical presentation of symptoms such as decreasing level 
of consciousness, vomiting, seizures and weakness in limbs, all of which 
signify a decrease in cerebral function [9].  
 
1.1.2 Ischemic stroke subtypes 
The pathophysiology and pathogenesis of ischemic stroke are complex and 
heterogeneous. There can be more than 150 causes for ischemic stroke [10]. In 
general, ischemic stroke cases are classified according to the TOAST 
classification [8]. Some of the common ischemic stroke subtypes observed are 
large artery stroke (accounts for 30% - 50% of ischemic stroke in Asians and 
10% of ischemic stroke in Caucasians), cardioembolic stroke (makes up 20% - 
30% of ischemic stroke cases) and small vessel stroke (attributes to 20% - 
25% of ischemic stroke cases; Figure 1.1). Large artery stroke is clinically 
defined as having major artery or branch cortical artery with >50% stenosis, 
with infarct ≥ 15mm in diameter and no cardioembolic source [8, 10]. 
Cardioembolic stroke can be characterized with patient having a 
cardioembolic source for blood clot with no atherosclerotic thromboembolic 
source [8, 10]. Small vessel stroke is determined as a traditional lacunar 
syndrome with no evidence of cerebral cortical dysfunction and with infarct < 
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15mm [8, 10]. The prevalent underlying pathologies that contribute to 
ischemic stroke onset are atherosclerosis and heart ailments [8, 9].  
 
1.1.2.1 Large artery and small vessel stroke 
In large artery stroke and small vessel stroke, the blood clot typically 
originates from an atherosclerotic plaque present in the major cerebral artery 
or carotid artery [11]. Atherogenesis is the progressive buildup of 
atherosclerotic plaque, which is characterized by lipid accumulation in the 
tunica intima, inflammatory cell recruitment, smooth muscle cell proliferation 
and migration [12-14]. The atherosclerotic plaque develops and overtime 
stenosis of the blood vessel ensues [13, 14]. The atherosclerotic plaque can 
also become unstable and ruptures, which causes blood clotting to take place 
[15]. The blood clot formed can move along the circulation and obstructs any 
part of the cerebral circulation, resulting in cerebral infarction [15].  
 
1.1.2.2 Cardioembolic stroke 
In the case of cardioembolic stroke, blood clot occluding cerebral circulation 
is of cardiac origins. Underlying cardiac ailments can result in the formation 
of blood clot in the heart which can be channeled to the brain, causing a 
blockage in cerebral circulation [16-17].  
The most common cardiac comorbidity that results in ischemic stroke is atrial 
fibrillation, accounting for 50% of all cardioembolic stroke cases [16]. Atrial 
fibrillation is a form of cardiac arrhythmia, where the atria (upper chambers of 
the heart) contract in a rapid and irregular manner [18]. This disrupts the 
proper pumping of blood from the atria to the ventricles (lower chambers of 
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the heart), resulting in pooling of blood in the atria [19]. Blood stasis provides 
the condition for blood clot to form.  
Other heart ailments contributing to cardioembolic stroke includes myocardial 
infarction. dilated cardiomyopathy and mitral valve stenosis [16]. Myocardial 
infarction is commonly known as heart attack that occurs when the coronary 
artery which supplies the heart becomes occluded, leading to cardiac injury 
due to lack of oxygen [20]. Dilated cardiomyopathy is a condition where the 
heart becomes enlarged and unable to pump blood efficiently [21]. This is due 
to previous damage to myocardium resulting in cardiac remodeling and heart 
enlargement [21]. Mitral valve stenosis is the narrowing of the mitral valve 
opening [22]. All these conditions result in areas of the heart having stagnant 
pool of blood which promote blood clotting [16]. Blood clot formed in the 
heart gets pumped into circulation reaching the brain, causing an obstruction 
in cerebral blood flow and ischemic stroke ensues. 
 
1.1.3 Risk factors of ischemic stroke 
Ischemic stroke is usually seen as a severe disease resulting from other pre-
existing disorders. These other disorders are typically: hypertension, 
dyslipidemia and type 2 diabetes, which are considered to be risk factors for 
ischemic stroke, as they predispose an individual to ischemic stroke [23].  
 
1.1.3.1 Hypertension 
Hypertension is defined as diastolic blood pressure >90 mmHg or systolic 
blood pressure >140 mmHg when measured at 2 or more times independently 
[24]. The increased blood pressure acting on the vessel wall triggered 
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hypertrophy in the vessel wall [25]. This leads to the stiffening and thickening 
of vessel wall, resulting the narrowing of the lumen. It has also been reported 
that hypertensive patients have decreased vascular tone due to the deficiency 
in endothelial nitric oxide (NO) production [26]. In addition, endothelial cells 
becomes activated from the increased blood pressure, resulting in the 
increased expression of cell adhesion molecules such as vascular cell adhesion 
molecule 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1), P- and E-
selectins [27]. This can aid in the monocytes and leukocytes to infiltrate the 
intima layer. These conditions pave the way for development of 
atherosclerotic plaque and ultimately ischemic stroke. 
Similarly, hypertension also stresses on the cardiac muscles, this in turn causes 
the development of atrial fibrillation, a major cause of cardioembolic stroke 
[28, 29]. The stress brought about by hypertension causes structural 
remodeling of the heart and affects atrial electrical properties [30-32]. This 
causes the atrium to contract prematurely, resulting in atrial fibrillation. 
 
1.1.3.2 Dyslipidaemia 
Dyslipidaemia is defined as having total cholesterol ≥ 5.2 mmol/L, triglyceride 
level ≥ 1.8 mmol/L, high density lipoprotein (HDL) ≤ 1.0 mmol/L and low 
density lipoprotein (LDL) ≥ 3.4 mmol/L [33]. With excess lipid in circulation, 
there is increase in lipid deposition within the blood vessels [34]. Low density 
lipoprotein (LDL) is a lipoprotein that functions as a transport of cholesterol 
from liver to peripheral tissue and LDL can infiltrate into the intima of blood 
vessels [35]. The infiltrated LDL undergoes oxidation to form oxidized LDL 
(oxLDL) [36]. oxLDL induces endothelial cell activation which brings about 
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infiltration of monocytes [37]. oxLDL also triggers the production of 
chemokines (chemotactic molecules) to aid in the migration of leukocytes pass 
the endothelium and into the tunica intima [38]. The monocytes in the intima 
differentiate into macrophages and these macrophages will uptake the oxLDL 
forming foam cells [39]. This is the initial phase of atherosclerosis where fatty 
streak (accumulation of leukocytes, oxLDL and foam cells) is observed in the 
vascular wall [14]. Dyslipidemia together with other risk factors will enhance 
the progression of atherosclerosis and leads to atherosclerotic plaque 
formation. If the plaque occurs in the coronary artery, myocardial infarction 
will occur and myocardial infarction is a pre-condition for cardioembolic 
stroke. The progression of atherosclerosis will ultimately result in plaque 
rupture and hence large artery or small vessel stroke will ensue. 
 
1.1.3.3 Type 2 diabetes 
Type 2 diabetes is a disease characterized by hyperglycemia and insulin 
resistance. Clinically, it is diagnosed by having fasting glucose > 6.1 mmol/L 
and HbA1c ≥ 7% [40, 41]. During hyperglycemic condition, the proteins and 
lipids present in circulation gets glycosylated forming advanced glycation end-
products (AGEs) [42, 43]. AGE by itself can affect the extracellular matrix by 
forming crosslinks with proteins such as type I collagen and elastin, causing 
stiffness of the vessel [44, 45]. AGEs can also act through binding to receptor 
for AGE (RAGE) and thus mediate multiple processes [46, 47]. Generally, 
RAGE signaling triggers inflammation, coagulation, increase smooth muscle 
cell proliferation and increase vascular permeability [48-50]. RAGE signaling 
in endothelial cells causes the increase expression of cell adhesion molecules 
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such as vascular cell adhesion molecule 1 (VCAM-1), intracellular adhesion 
molecule 1 (ICAM-1), P- and E-selectins [51, 52]. These molecules aid in the 
recruitment and infiltration of leukocytes into the intima layer of the vessels. 
AGEs affects the vascular tone by reducing the bioavailability of nitric oxide 
(NO), an important vasodilator, through inhibiting the activity of NO 
producing enzyme, endothelial nitric oxide synthase (eNOS) [53, 54]. 
Furthermore, RAGE signaling triggers an increase in endothelial permeability 
and induces the expression of cytokines, enhancing immune cell infiltration 
into the vessel [55].  RAGE also induces platelet activation, promoting a pro-
coagulation state [56]. All of which promotes the formation and development 
of atherosclerosis.   
Type 2 diabetes can also induce atrial fibrillation. Type 2 diabetes can affect 
blood flow to the nerves involved in atrium contraction, resulting in cardiac 
autonomic neuropathy [57]. This can further develop into atrial fibrillation 
[58]. Type 2 diabetes also causes electrical and structural remodelling of the 
heart [59-62]. This is usually characterized by hypertrophy, interstitial fibrosis 
and impaired myocardial contractile reserve [63]. Thus, individuals with type 
2 diabetes are more prone to suffer from atrial fibrillation. 
 
1.1.4 Ischemic stroke pathophysiology 
Even though the source of the occlusion may arise from different pathologies 
and comorbidities, the resulting trauma to the brain is similar. The occluded 




The ischemic lesion can be segregated into two distinct regions: ischemic core 
and penumbra [64]. Upon ischemic onset, the tissue proximal to the occlusion 
suffers from oxygen and nutrient deficiency. The extreme condition inflicts 
tremendous stress in the cells of this region [65]. These cells succumb to cell 
death via necrosis. This region is known as the ischemic core [65]. The 
damage on the ischemic core is permanent and the cells are beyond rescue.   
The region distal from the occlusion and adjacent to the ischemic core forms 
the penumbra. This region consists of cells that are dysfunction but viable. In 
1977, Astrup et al [66] first characterized ischemic penumbra as the zone 
surrounding the ischemic core with diminished cerebral blood flow and no 
electrical activity, while exhibiting limited energy and ion pump failure. The 
cells in this region though viable, are still faced with the possibility of cell 
death overtime. Hence, the penumbra is the target of therapy due to the 
undetermined fate of the cells in this region.  
 
1.2 Ischemic cascade 
Having looked at the clinical aspect of ischemic stroke, next is to focus on the 
molecular processes underlying the pathophysiology of ischemic stroke. The 
molecular processes in ischemic stroke can be described as a cascade, aptly 
known as the ischemic cascade (Figure 1.2) [67].  
In brief, the ischemia cascade begins due to occlusion in blood vessel resulting 
in a deficit in glucose and oxygen. This brings about energetic failure leading 
to the depolarization of the membrane, resulting in the release of excitotoxic 
neurotransmitter, glutamate [68]. Glutamate binds to the respective glutamate 
receptors that trigger influx of calcium, inducing excitotoxicity [69].  
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Concurrently, the sudden deprivation of oxygen and glucose results in the 
derangement of the metabolic processes such as oxidative phosphorylation 
[70]. Mitochondria dysfunction ensues, triggering apoptosis by the release of 
cytochrome c from mitochondria [71, 72].  
Also, the onset of hypoxia induces the expression of detrimental genes 
including inflammatory molecules, all of which are mediated primarily by 
transcription factor, hypoxia inducible factor-1 (HIF-1) [73-75]. Cells within 
the infarcted region also responds which include astrocytes and microglia that 
become reactive, and endothelial cells that start to express cell adhesion 
molecule and secrete cytokines and chemokine [76, 77]. These actions bring 
about an uncontrolled inflammatory response that is detrimental to the cells 
and the patient.  
All of these processes though described in a cascade are in fact occurring 
simultaneously which ultimately leads to cells dying in the infarct lesion. 
Within the ischemic cascade, there are 4 key molecular processes occurring, 
cell death, excitotoxicity, inflammation and oxidative damage, which will be 
























Excitotoxicity is characterized by the accumulation of calcium ions in neurons 
due to over-stimulation of excitatory neurotransmitter receptors by an excess 
of excitotoxic neurotransmitter (glutamate) [78]. Glutamate is a major 
excitatory neurotransmitter in the central nervous system [79]. It is involved in 
cell to cell communication between neurons by initiating excitatory post-
synaptic potential (EPSP) at adjacent neuron [80]. Glutamate is stored in 
vesicles at the axon terminal, which are released during membrane 
depolarization [79].  
During ischemia, the decrease of blood flow causes the depletion of the ATP 
store in the neurons due to the absence of oxygen and glucose for generation 
of ATP [70]. The metabolic dysfunction causes failure maintenance of ionic 




ATPase [64]. Subsequently, the 
membrane depolarizes and releases all the glutamate stored in the vesicles. 
The glutamate diffuses across the synaptic cleft and bind to the glutamate 
receptors at the postsynaptic membrane. There are three main types of 
glutamate receptors in the central nervous system, α-Amino-3-hydroxy-5-
methyl-isoxazole-4-propionate (AMPA) receptor, N-methyl-D-aspartate 
(NMDA) receptor and metabotropic glutamate receptor (mGluR) [81-83]. 
When glutamate binds to AMPA receptors and NMDA receptors, the 
receptors form open channels to allow the influx of calcium ions into neuron 
[81, 82]. The interaction between glutamate and mGluR will result in the 
release of internal calcium ion store from the endoplasmic reticulum [84]. The 
net effect of glutamate binding to the glutamate receptor is the influx of 
calcium ion and the accumulation of calcium ion in the soma of the neuron. 
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The accumulation of calcium ion is detrimental to the survival of neurons as 
this activates a number of calcium dependent proteases, lipases and 
endonucleases, which can disrupt cell membrane, digest important protein and 
nucleic acids [85-87].  
It has been reported that NMDA receptor activation leads to the activation of 





 exchanger (NCX3) which is an important ion exchanger for 
maintaining Ca
2+
 homeostasis (Figure 1.3) [90]. This potentiates on calcium 
overload during excitotoxicity.  
Mitochondria play an important role in Ca
2+
 homeostasis [91]. During Ca
2+
 
overload, mitochondria act as a temporary store for excess Ca
2+
 [91]. 
However, during excitotoxicity, the excessive Ca
2+
 in the mitochondria causes 
mitochondrial dysfunction, leading to release of cytochrome c and ultimately 
apoptosis (Figure 1.3) [92]. 
Activation of NMDA receptors also couples to inducible nitric oxide synthase 
(iNOS), producing nitric oxide (NO) which reacts to form reactive oxygen 
species (ROS), and increasing oxidative stress (Figure 1.3) [93]. Thus, 
excitotoxicity decrease the viability of cells in the penumbra by promoting 
oxidative stress, activating endogenous endonucleases and proteases; all of 



























1.2.2 Oxidative damage 
The brain utilizes more than 20% of total oxygen consumption, making it 
susceptible to oxidative damage, especially during ischemic stroke [94]. 
Oxidative damage is the event where the over-production of reactive oxygen 
species (ROS) overwhelms the anti-oxidant defenses in the cell and causes 
damage to biologically important macromolecules such as nucleic acid, 
protein and lipids [95].  
The brain is especially susceptible to oxidative damage due to its high lipid 
content, and so it will have a greater extent of lipid peroxidation under 
oxidative stress [96]. During cerebral ischemia, the activation of glutamate 
receptors can be coupled to molecular processes that increase oxidative stress 
in neurons [93]. iNOS is triggered during glutamate receptor activation to 
produce NO which drives ROS production (Figure 1.4) [93]. NO readily reacts 
with superoxide radical (O2
-
) to produce peroxynitrite radical (ONOO
-
) which 
is a potent radical that results in lipid peroxidation [95]. The product from 
lipid peroxidation, 4-hydroxynonenal (4-HNE) is neurotoxic, which 
aggravates the neuronal damage brought on by ischemia and reperfusion 
(Figure 1.4) [97, 98].  
During ischemia, the deficit in oxygen and glucose causes disruption in the 
electron transport chain (ETC) in the mitochondria. Due to the lack of oxygen, 
there is an accumulation of activated complex along the ETC which results in 
electron leakage [99, 100]. This causes the generation of ROS and leads to 
mitochondrial dysfunction and ultimately cell death. 
Under ischemic condition, xanthine dehydrogenase (enzyme involved in the 
metabolism of hypoxanthine) transmutes to xanthine oxidase (XO) [99]. XO 
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can generate superoxide anions which increases the ROS load (Figure 1.4). 
Similarly, NADPH oxidase (NOX), an enzyme generating ROS in phagocytes 
as a form of defense against pathogens, was found to contribute to 




which reacts with water to form hydroxyl radical (•HO) and forms 
peroxynitrite radical (ONOO
-
) when reacting with NO (Figure 1.4) [101]. 
Activation of phospholipase A2 (PLA2) also contributes to oxidative damage 
in cerebral ischemia. The product, arachedonic acid undergoes further 
oxidation which generates more ROS (Figure 1.4) [102]. ROS generated 
during ischemia results in direct modification of important macromolecules 
such as proteins, lipids and nucleic acids. This triggers apoptosis via p53 




































Apoptosis is synonymous to programmed cell death. The weakened neurons in 
the penumbra undergo apoptosis after the onset of cerebral ischemia. 
Apoptosis is triggered by lack of neurotropic factors, oxidative damage, DNA 
damage and mitochondrial dysfunction [104]. Apoptosis can be induced by 
two pathways: Intrinsic pathway and extrinsic pathway [105].  
Intrinsic pathway is activated by mitochondrial damage during ischemic 
stroke. During cerebral ischemia, there is an increase in oxidative stress and 
the mitochondria are damaged by free radicals [106]. In addition, the 
disruption of blood causes depletion of glucose and oxygen which results in 
energy depletion. All of which leads to mitochondrial dysfunction [71, 72]. 
Mitochondria are a store for multitude of pro-apoptotic proteins such as 
cytochrome c, endonuclease G, caspases, AIF and second mitochondria-
derived activator of caspases/direct IAP-binding protein with low p 
(SMAC/DIABLO) (Figure 1.5A) [107]. When mitochondria are damaged, the 
apoptogenic proteins leak into the cytosol which induces apoptosis. 
In addition, ROS signaling also triggers cell death via p53 signaling pathway 
[103, 108]. p53 can mediate the release of cytochrome c from mitochondria 
and up-regulate the expression of pro-apoptotic protein such as Bcl-2 
associated X protein (Bax), BH3 interacting-domain death agonist (Bid) and 
p53 upregulated modulator of apoptosis (PUMA) to bring about apoptosis 
[109]. Also, the influx of calcium ions also activates calpains which are 
calcium dependent proteases that cleave Bid forming tBid that promotes the 
release of pro-apoptotic proteins from mitochondria [110].  
20 
 
Cytochrome c released from mitochondria, together with apoptotic protease 
activating factor 1 (Apaf-1) and caspase 9, assembles into an apoptosome 
which activates the caspase 3 (Figure 1.5A) [111, 112]. Caspase 3 cleaves 
many important proteins which are crucial for cell survival, including poly 
(ADP-ribose) polymerase (PARP) [113]. PARP inactivation prevents DNA 
repair and leads to cell death (Figure 1.5A) [114]. 
External triggers can also induce apoptosis (extrinsic pathway) through the 
death receptor. Ligands such as TNF-α and Fas ligand (FasL) bind to Fas 
receptor (FasR) and induce formation of death inducing signaling complex 
(DISC) which consists of FasL, FasR, Fas-associated death domain protein 
(FADD) and procaspase 8 (Figure 1.5B) [115]. DISC will activate caspase 8 

















Figure 1.5: Apoptosis during cerebral ischemia. A. Intrinsic pathway. B. 





Inflammation is another important biochemical process that is involved in 
cerebral ischemia. Inflammation occurs a few hours after the onset of stroke. It 
is mediated by cells (immune cells and local cells) and protein molecules 
(cytokine and complement) [116-119].   
Inflammation involves the activation of endothelial cells, astrocytes and 
microglial cells (local immune cell) [120]. Under the ischemic condition, 
astrocytes and microglial cells are activated and start producing cytokines and 
chemokines, which are potent mediators of inflammatory response (Figure 
1.6) [121]. Cytokines are molecular mediators of inflammation; they generally 
induce macrophage activation, B-cell and T-cell maturation [118]. 
Chemokines are chemicals that help in the localization of inflammatory cells 
to the site of injury [119, 122]. In response to injury, the endothelial cells 
lining the blood vessel are also activated and start to express vascular cell 
adhesion molecule 1 (VCAM1), which helps in the adhesion of inflammatory 
cells such as monocytes and neutrophil; to facilitate localization of  
inflammatory cells to site of injury [122]. Chemokines are secreted by 
microglial cells and astrocytes, which form a chemical gradient that attracts 
monocytes to site of injury [119]. Endothelial cells also express intracellular 
adhesion molecular 1 (ICAM1) causes the immune cells to tether along the 
lumen side of the endothelial cells [123]. Among these modulators, chemokine 
C-C motif ligand 2 (CCL2) has been shown to be involved in the 
pathophysiology of ischemic stroke. In animal models, Ccl2 has been 
demonstrated to be involved in blood brain barrier disruption [124]. 
Furthermore, animals with CCL2 or its receptor CCR2 knockout have smaller 
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infarct following middle cerebral artery occlusion (MCAo) as compared with 
wild-type [125, 126]. Monocytes will extravasate from the blood and move 
towards the area of ischemic injury down the chemokine gradient. Therefore, 
the increase in chemokine secretion will result in increasing localization of 
inflammatory cells.  
In order for the monocytes to enter into the brain parenchyma, they have to 
pass through the blood brain barrier (BBB; Figure 1.6). Cytokines secreted by 
microglial cells, astrocytes and neurons, such as interleukin 6 (IL-6), 
interleukin 8 (IL-8) and tumor necrosis factor alpha (TNF-α) [120, 121]. IL 8 
induces neutrophils and monocytes to secrete matrix metalloproteinase 9 
(MMP9) which breaks down the BBB to allow the infiltration of inflammatory 
cells to reach the site of injury [127]. The breakdown of BBB is an undesirable 
event as this will lead to edema and hemorrhage. The secretion of pro-
inflammatory cytokines (IL-6, TNF-α) will induce respiratory burst in the 
macrophages present at the site of infarct (Figure 1.6) [122]. This in turn leads 











Figure 1.6: Inflammation during cerebral ischemia. 
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Complement is a component of innate immunity, which responds to pathogen 
during infection, and in pathological state, complement can cause damage to 
self-tissue [128]. Complement is present as zymogens synthesized in the liver 
and becomes activated via proteolytic cleavage by protein components early in 
the complement cascade [128]. Complement activation occurs via 3 pathways 
namely: classical pathway, alternative pathway and lectin pathway (Figure 1.7) 
[128]. These 3 pathways converge on the formation of C5 convertase [128]. 
C5 convertase cleaves C5 into C5a and C5b. C5b is responsible for the 
formation of membrane-attack complex (MAC) which is the effector for 
clearing infected cells and pathogens [128].  
Components of the complement cascade had been reported to be elevated in 
the serum of ischemic stroke patients. Mannose-binding lectin (MBL; 
component in the lectin pathway of complement activation) was found to be 
elevated in serum of ischemic stroke patients and the level of MBL had been 
shown to be associated with outcome of ischemic stroke [129-131]. The MBL 
level also acted as a possible predictor for the outcome of ischemic stroke 
patients, whereby higher level of MBL correlated with worse outcome [129, 
130]. Complement component 3 and 4 (C3 and C4) were found to be in high 
level in young ischemic stroke patients and also pose as a possible predictor 
for outcome similar to MBL [132]. Another study demonstrated strong 
activation of complement, quantified by high level of C4d and soluble 
terminal complex (SC5b-9), was associated with poor outcome in ischemic 
stroke patients [133]. Current literature also highlights possible effects of 
complement activation that could account for having poor outcome in patients. 
Complement activation during ischemic stroke triggered an inflammatory 
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response which aggravated the pathological condition leading to worse 
outcome. Hypo-perfusion performed in mice showed increase in complement 
component 5 (C5) in the brain resulting in increased inflammation in terms of 
increased numbers of reactive astrocytes and microglia [134]. Furthermore, 
C5a (a cleaved fragment of C5) was found to be increased in neurons 
subjected to ischemia and C5a was shown to be responsible for neuronal 
apoptosis during ischemia [135]. In addition, MBL has been demonstrated to 
induce local microvascular thrombosis after ischemia performed in mice [136]. 
Hence, complement activation during ischemic stroke brings about detrimental 
































1.3 microRNA (miRNA)    
For a long time, RNA was thought to play the role of a passive role in the 
transition from genetic code to protein peptide. It was in 1993 that Victor 
Ambros, Rosalind Lee and Rhonda Feinbaum [137] discovered the first 
miRNA, lin-4, which target lin-14 in the regulation of Caenorhabditis elegans 
(C. elegans) development. The second miRNA was discovered in 2000 where 
let-7 RNA was found to target lin-41 in C. elegans [138]. It was soon found 
that let-7 is conserved in many species. miRNAs are a class of short (18 to 22 
nucleotides), endogenous, non-coding RNAs [137, 139].  
1.3.1 Biogenesis    
miRNAs are found within both intragenic and intergenic regions in the 
genome [140] and they can be transcribed as individual miRNAs or as a 
cluster of miRNAs. miRNAs are usually transcribed by RNA polymerase II to 
produce primary-miRNAs (pri-miRNA; Figure 1.8) [141]. Pri-miRNAs 
usually several thousand bases long forming several hairpin loops and contain 
the 7-methylguanosine cap and a poly(A) tail [141-142]. Pri-miRNAs are 
processed by Drosha and Pasha (RNase III endonuclease) in the nucleus to 
produce ~60 to 70 nucleotides long stem-loop structures known as precursor 
miRNAs (pre-miRNAs; Figure 1.8) [143]. Pre-miRNAs are exported out of 
the nucleus by Exportin 5, a nuclear exporting protein [144]. Pre-miRNAs are 
processed by Dicer (RNase III enzyme) to produce miRNA:miRNA* duplex 
with a 2 nucleotides overhang at the 3‘ end (Figure 1.8) [139, 145]. 
miRNA:miRNA* duplex forms a pre-complex with RNA-induced silencing 
complex (RISC; Figure 1.8). Only one strand of the miRNA, the guide, which 
29 
 
is having the low internal stability at the 5′ end, is incorporated into the 
miRNA-RISC complex. [145-147]. 
 
1.3.2 RNA interference (RNAi) 
miRNA-RISC will recognize the 3‘ un-translated region of messenger RNA 
(mRNA) that is perfectly complementary to miRNA sequence. This will 
trigger mRNA degradation which results in post-transcriptional silencing of 
the target gene (Figure 1.8). In the event of partial complementary base-
pairing, the mRNA will be targeted for storage in P-bodies which represses the 
expression of the mRNA (Figure 1.8).  The mRNA within the P-bodies may 
be sent for degradation. This process is RNA interference (RNAi) [148].  A 
single miRNA can have multiple binding sites on the same target mRNA and 
it can also target multiple mRNAs.  Usually, a single miRNA is estimated to 
target about 200 different transcripts [149]. 
 
1.3.3 RNA activation (RNAa) 
Alternatively, microRNA can also enhance gene expression by RNA 
activation [150]. miRNA can be shuttled back into the nucleus and modulate 
gene expression by binding to promoter regions, which have been shown to 
both activate gene expression (Figure 1.8) [151-152]. Gene activation is 
believed to take place via the interaction of miRNAs and their target genes at 
the 5‟ non-coding regulatory regions. Janowski et al [152] showed that 
transfection of short double stranded RNAs which were complementary to the 
progesterone receptor promoter, increased mRNA and protein expression of 










Figure 1.8: miRNA biosynthesis and function. Adapted from Chandrasekaran 











1.3.4 Bioinformatics prediction 
Since the discovery of RNAi, multiple online platforms have been developed 
to exploit the large computing capacity to make prediction for miRNA-mRNA 
target pairs. Most of the prediction algorithms based the concept of seed-
region, which consists of the first 2 to 8 nucleotides on the 5‘ end of the 
miRNA [154].   If the 5‘ end of the miRNA pairs sufficiently well with the 3‘ 
UTR then the pairing at the 3‘ end of miRNA to the target is not essential 
[155]. Most of the prediction databases use sequence alignment, 
thermodynamic calculations and statistical testing to shortlist the possible 
miRNA-mRNA target pairs. Using multiple databases to obtain consensus can 
ensure a more accurate prediction for miRNA-mRNA target pairs.   
 
1.3.5 miRNA prediction databases 
Currently, there are quite a number of databases present for making 
predictions. Each database will have different criteria for selection. Some of 
the most common miRNA prediction databases are: Targetscan version 6.2 
(www.targetscan.org) [156-159], miRanda August 2010 release 
(www.microRNA.org) [160-163], microcosm version 5 
(www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) [163-165], DIANA 
microT version 3 (http://diana.cslab.ece.ntua.gr/microT/) [166, 167], miRDB 
version 4 (mirdb.org/) [168, 169], miRWalk March 2011 update 
(www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) [170], PITA 2007 release 
(genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html) [171], RepTar 
version 1.2 (reptar.ekmd.huji.ac.il/) [172] and StarBase version 2 
(starbase.sysu.edu.cn/) [173, 174]. 
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Targetscan takes into account various aspects of the seed region when it comes 
to prediction. The length of the seed region is taken into account as it affects 
the binding strength (8 nucleotide site > 7 nucleotide site > 6 nucleotide site) 
[158, 175].  The TargetscanS algorithm picks up targets with 6 nucleotide seed 
region [156]. As for microRNA.org and microcosm, both uses miRanda 
algorithm [162]. It gives an alignment score which is a weighted sum of match 
and mismatch scores for base pairs and gap penalties [162, 163]. An estimate 
of free energy of binding was calculated using Vienna package [176]. 
Similarly, DIANA microT algorithm takes into account 7 to 9 nucleotides of 
5‘ end of miRNA that form Watson–Crick base pairing nucleotides with target 
mRNA [167]. As for miRDB, mRNA sequences were obtained from NCBI 
databases and genome-wide miRNA target prediction was performed using 
MirTarget2 algorithm [177, 178]. miRWalk algorithm ‗walks‘ along complete 
sequence of a gene identifying multiple consecutive Watson–Crick 
complementary subsequences between miRNA and gene sequences [170]. The 
probability distribution of the pairing was calculated using Poisson 
distribution [179]. RepTar database uses RepTar algorithm which search for 
statistically significant repetitive motifs in each 3‘ UTR, represented in the 
form of hidden Markov model [172]. The thermodynamic stability was 
evaluated using Vienna package RNA cofold program [180].  PITA looks for 
perfect miRNA target seeds 6 to 8 bases long, disallowing G:U wobbles, 
mismatches or loops [171]. Similarly, the free energy of miRNA-mRNA 
duplex was also calculated using Vienna RNA package [180]. StarBase uses 
ClipSearch program to search for 6–8-mers in CLIP-Seq sequence data sets 
from 8 studies [173, 174, 181-188]. Using results from all these databases, the 
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consensus miRNA-mRNA target pair will be more accurate as it has taken into 
account multiple variables using different methodologies. 
 
1.3.6 miRNAs and ischemic stroke 
Being important regulators of gene expression, during disease states, miRNAs 
also becomes dysregulated. miRNAs have been reported to be dysregulated in 
diseases. It has been demonstrated that miRNAs are dysregulated during 
cerebral ischemia, shown in animal model [189]. Subsequently, circulating 
miRNAs in ischemic stroke patients were also found to be dysregulated [190]. 
Following which, other groups have reported more on the miRNA 
dysregulation in animal models [191-196] as well as in patients [197-205]. 
Since miRNA dysregulation can be studied in human patients, it is plausible to 
elucidate the mechanisms underlying ischemic stroke pathology and to 
validate experimentally.  
 
1.4 Hypothesis and objectives 
Since miRNA dysregulation have been demonstrated to be involved in 
ischemic stroke clinically and experimentally, it is possible to study the 
dysregulated miRNA both in patients and animal models, as well as to study 
the underlying mechanisms of ischemic stroke pathology. The hypothesis of 
this study is that through miRNA profiling and analysis, it is possible to 
identify miRNAs that are specific for ischemic stroke and various stroke 
subtypes. By studying these miRNAs and the processes that they regulate, 
there can be better understanding of the mechanisms underlying the 
pathogenesis and pathophysiology of ischemic stroke. These miRNAs can also 
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become potential markers and therapeutic targets in cerebral ischemia where 
expression of these miRNAs can be manipulated by using anti-miRNAs or 
miRNA mimics. 
The objectives of this study are as follows: 
1. Identify ischemic stroke specific miRNAs from a comparative analysis 
of miRNA profiles between ischemic stroke patients with and without 
risk factors, and highlight the biological pathways regulated by these 
miRNAs 
2. Identify stroke subtype specific miRNAs by comparing miRNA 
profiles of each stroke subtypes and highlight the biological pathways 
regulated by these miRNAs 
3. Create middle cerebral artery occlusion (MCAo) models in rats at 
various stages or time-points (12, 24, 48, 72, 120 and 168 hours) in 
cerebral ischemia 
4. Identify miRNAs that correlate with infarct volume in miRNA profile 
of rats subjected to MCAo 
5. Identify biological pathways commonly dysregulated among animal 
models and ischemic stroke patients and subsequently study the effects 
of regulating the genes in these biological pathways using anti-miRNA 






























2. Materials and methods 
2.1.1 Reagents animal procedure and anaesthesia  
2.1.1.1 Animal  
Male Wistar (~250 to 300g) rats were obtained from the Laboratory Animal 
Centre (National University of Singapore, Singapore) and maintained on an ad 
libitum intake of standard laboratory chow and drinking water. All animals 
were handled according to the guidelines given by the Council for 
International Organization of Medical Sciences on animal experimentation 
(WHO, Geneva, Switzerland) and the National University of Singapore 
(IACUC/NUS) guidelines for handling laboratory animals.  
 
2.1.1.2 Saline, NaCl 0.9% w/v 
NaCl    9g 
Deionised water  1L 
 
2.1.1.3 Anesthesia  
Ketamine  75mg/kg  
Xylazine  10mg/kg  
Ketamine and xylazine were dissolved in sterile saline (NaCl 0.9%) and used 
to anesthetize the rats.  
 
2.1.1.4 2,3,5-triphenyltetrazolium chloride (TTC) 2% w/v  
2, 3, 5-triphenyltetrazolium chloride   1g  




2.1.2 Reagents for RNA isolation from brain tissues  
2.1.2.1 Ethanol 75% v/v 
Absolute ethanol 37.5ml  
Autoclaved water 12.5ml 
Stored at 4°C.  
 
2.1.3 Reagents for RNA isolation from whole blood  
2.1.3.1 NaCl (5M)  
NaCl    2.922g 
Autoclaved water 10ml  
 
2.1.3.2 Wash 1: Ethanol (70%):Denaturation Solution (30%)  
Absolute ethanol (100%)  24.5ml  
Denaturation solution  10.5ml  
 
2.1.3.3 Wash 2: Ethanol (80%):NaCl (50mM)  
Absolute ethanol (100%)  56ml  
NaCl (5M)    0.7ml  
Autoclaved water  13.3ml 
 
2.1.4 Reagents for RNA agarose gel electrophoresis 
2.1.4.1 10X MOPS running buffer  
Morpholinopropanesulfonic acid (MOPS, pH7.0) 0.4M 
Sodium acetate     0.1M 
EDTA (pH 8.0)      10mM 
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10X MOPS was prepared using autoclaved water and sterile-filtered with a 
0.22μm filter. The solution was diluted with deionised water to 1X MOPS for 
gel running. 
 
2.1.4.2 Deionised formamide 
Formamide (500ml) was stirred with 500mg Dowex XG8 resin for 1 hr and 
filtered through Whatman No.1 paper. Deionised formamide was stored at 
room temperature in the dark. 
 
2.1.4.3 Ethidium bromide (10mg/ml) 
Ethidium bromide 10mg 
Autoclaved water 1ml 
Store at room temperature in dark. 
 
2.1.4.4 RNA loading buffer 
Glycerol   50% (v/v) 
Bromophenol blue  0.4% (w/v) 
EDTA (pH8.0) 1mM 
 
2.1.4.5 RNA sample buffer (per sample) 
Deionised formamide  10μl 
37% formaldehyde  3.5μl 
10X MOPS   2μl 




2.1.4.6 RNA agarose gel (1%) 
Electrophoresis grade agarose  0.5g 
Deionised water    43.5ml 
37% formaldehyde    1.5ml 
10X MOPS     5ml 
Ethidium bromide (10mg/ml)  1ul 
Powdered agarose was mixed with water and heated to 100°C, to dissolve 
completely. It was then cooled to about 60°C before the addition of 37% 
formaldehyde, 10X MOPS and ethidium bromide  
 
2.1.5 Reagents for RNA polyacrylamide gel electrophoresis 
2.1.5.1 Ammonium persulfate (APS) 10% w/v 
Ammonium persulfate 100mg 
Autoclaved water  10ml 
 
2.1.5.2 10X Tris-Borate-EDTA (TBE) buffer 
Tris base   108g 
Boric acid   55g 
0.5M EDTA (pH 8.0) 40ml 
Deionised water 960ml 
Tris base and boric acid was dissolved in 960ml of deionised water before  
addiing of 40ml of EDTA, pH 8.0.  
 
2.1.5.3 Denaturing polyacrylamide gel (15%) 
Urea      7.2g 
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40% Acrylamide    5.63ml 
10X TBE Buffer    1.5ml 
Deionised water    0.95ml 
TEMED     7.5μl 
10% APS     37μl 
Acrylamide, urea and 10X TBE buffer were heated to 60°C. Once urea was 
dissolved, deionised water, TEMED and APS were added to the mixture and 
the gel was cast immediately. 
 
2.1.5.4 RNA sample buffer (per sample) 
10X TBE Buffer    2μl 
Deionised Formamide   10μl 
RNA Loading Buffer    3μl 
Ethidium bromide (10mg/ml)  1ul 
 
2.1.6 Reagents for cell culture 
2.1.6.1 Cell lines 
Human umbilical vein endothelial cells (HUVEC, CRL-1730
™
) and HeLa 
cells (CCL-2™) were obtained from the American Type Cell Culture (ATCC, 
USA). 
 
2.1.6.2 1X Phosphate-buffered saline (PBS)  
NaCl    8g  
KCl    0.2g  
Na2HPO4.2H2O  1.4g  
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KH2PO4   0.24g  
Deionised water 1L 
The solution was adjusted to pH7.4 and autoclaved.  
 
2.1.6.3 Trypsin 
10X trypsin was diluted to 1X with 1X PBS and stored at -20°C 
 
2.1.6.4 Basal Dulbecco’s Modified Eagle Medium (DMEM, 1L) 
DMEM      16.2g 
L-glutamine      0.4g 
Sodium bicarbonate     1.74g 
Penicillin-streptomycin (50U-50mg/ml)  1% 
Deionised water    1L 
The solution was adjusted to pH7.4 and filtered sterilized. Stored at 4°C. 
 
2.1.6.5 Complete DMEM (1L) 
Basal DMEM    900ml 
Fetal bovine serum (FBS)  100ml 
 
2.1.6.6 Freezing medium (100ml) 
Basal DMEM    30ml 
Fetal bovine serum (FBS)  70ml 





2.1.7 Reagents for reverse transcription (RT) 
2.1.7.1 RT mixture for mRNA 
10X Taqman RT buffer     1μl 
25mM MgCl2       2.2μl 
DeoxyNTPs mixture      2μl 
50μM Random hexamers     0.6μl 
20 U/μl RNase inhibitor     0.2μl 
50 U/μl MultiScribe™ Reverse transcriptase  0.25μl 
Autoclaved water      1.75μl 
The individual components were obtained from Taqman RT Reagents kit 
(Applied Biosystems, Carlsbad, CA, USA.). 
 
2.1.7.2 RT mixture for miRNA 
10X RT buffer      1.5μl 
100mM DeoxyNTPs mixture    0.15μl 
20 U/μl RNase inhibitor     0.19μl 
50 U/μl MultiScribe™ Reverse transcriptase  1μl 
Autoclaved water      4.16μl 
The individual components for the miRNA RT mixture were obtained from 
Taqman miRNA RT kit (Applied Biosystems, Carlsbad, CA, USA). 
 
2.1.8 Reagents for quantitative real-time polymerase chain reaction (PCR) 
2.1.8.1 SYBR green assay for mRNA 
2X SYBR Green PCR Master Mixture  10μl 
Forward primer    0.6μl (300nM) 
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Reverse primer    0.6μl (300nM) 
RT product     5 μl 
Autoclaved water     3.8μl 
2.1.8.2 SYBR green assay for mRNA/miRNA 
2X SYBR Green PCR Master Mixture  10μl 
Forward primer    0.6μl (300nM) 
Reverse primer    0.6μl (300nM) 
RT product     1μl 
Autoclaved water     7.8μl 
The real-time PCR master mixture reagents and primer-probes were obtained 
from Applied Biosystems (Carlsbad, CA, USA.). Gene specific forward and 
reverse primers for Sybr Green assays were purchased from 1st Base 
(Singapore) or Integrated DNA Technologies (IDT, Singapore). 
 
2.1.8.3 Taqman assay for miRNA 
2X TaqMan Universal PCR Master Mixture  10μl 
Taqman miRNA probe    1μl 
RT product     1.33μl 
Autoclaved water     7.67μl 
The TaqMan Universal PCR Master Mixture reagent was obtained from the 
Applied Biosystems (Carlsbad, CA, USA.). 
 
2.1.9 Reagents for Cloning 
2.1.9.1 Reverse Transcription (RT) 
Random hexamer     1μl (100pmol) 
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5X Reaction Buffer     4μl 
RiboLock™ RNase Inhibitor    1μl (20U/μl) 
dNTP Mixture, 10 mM each    2μl 
RevertAid™ Reverse Transcriptase   1μl (200U/μl) 
RNase free water     Top up to 20μl 
The individual components for the RT mixture were obtained from the 
RevertAid™ H Minus First Strand cDNA Synthesis Kit (Fermentas, 
Lithuania). 
 
2.1.9.2 Polymerase chain reaction (PCR) 
10X Taq buffer with MgCl2   2.5μl 
dNTP mixture    2.5μl 
Forward Primer (1 OD stock)  2.5μl 
Reverse Primer (1 OD stock)  2.5μl 
Taq DNA Polymerase (2 units/μl)  1μl 
Nuclease free water    Top up to 25μl 
 
2.1.9.3 DNA agarose gel (1%) 
Electrophoresis grade agarose  0.5g 
1X TBE Buffer    50ml 
Ethidium bromide (10mg/ml)  1ul 
Powdered agarose was mixed with 1X TBE buffer and heated to 100°C. It was 





2.1.9.4.1 Ligation of TA cloning vector 
TOPO® vector  1μl 
Salt Solution   1μl 
Autoclaved water  Top up to 6μl 
The individual components for TA ligation were obtained from TOPO® TA 
Cloning Kit for Sequencing (Invitrogen, USA). 
 
2.1.9.4.2 Ligation of luciferase vector 
2X DNA Ligation buffer  5μl 
T4 DNA Ligase (5U/μl)  1μl 
Autoclaved water   Top up to 10μl 
The individual components for ligation were obtained from Rapid DNA 
ligation kit (Roche, Germany). 
 
2.1.9.5 Luciferase vectors 
The various luciferase vectors used in this study are as follows: 
pRL-CMV Vector (Promega, Madison, USA) 
pMIR-REPORT™ Luciferase miRNA Expression Reporter Vector (Ambion, 
USA) 
 
2.1.9.6 Competent cells 
50μl of chemically competent TOP10 E. coli cells were used for each 





Powdered ampicillin (Sigma, USA) was dissolved in autoclaved water to 
make concentrated stocks of 100mg/ml. The stocks were aliquoted into small 
volumes and stored at -20°C. Working concentration for ampicilin was 
100μg/μl. 
 
2.1.9.8 Lysogeny broth (LB) 
Tryptone   1% (w/v) 
NaCl    1% (w/v) 
Yeast Extract   0.5% (w/v) 
The pH of the LB Broth was adjusted to 7.0 prior to autoclaving. The LB 
broth was stored at 4°C. 
 
2.1.9.9 LB agar plates 
Powdered agar (Gibco, Carlsbad, CA, US)  1.3% (w/v)  
Agar was mixed with the LB broth and autoclaved. The mixture was cooled to 
approximately 55°C prior to the addition of the antibiotic ampicillin. 20ml of 
the molten agar was poured into each 90mm sterile petri dish and allowed to 
set at room temperature. The LB agar plates were sealed using parafilm and 
stored at 4°C in an inverted position. All plates were pre-warmed at 37°C for 1 
hour before use. 
 
2.1.10 Reagents for plasmid isolation  
2.1.10.1 Resuspension buffer 
Glucose   50mM 
Tris-HCL (pH 8.0)  25mM 
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EDTA (pH 8.0)  10mM 
The resuspension buffer without glucose was sterilised by autoclaving and 
cooled to room temperature. Filter sterilised glucose was later added to the 
buffer and stored at 4°C. 
 
2.1.10.2 Lysis buffer 
NaOH   0.2M 
SDS   1% (w/v) 
Freshly prepared lysis buffer was used for plasmid extraction. 
 
2.1.10.3 Precipitation buffer 
Potassium acetate  3M 
Glacial acetic acid  1.5% (w/v) 
Precipitation buffer was stored at 4°C. 
 
2.1.10.4 RNase 
Powdered RNase dissolved in sterile nuclease free water at 10mg/ml. The 
solution was heated to 60°C and stored at - 20°C. 
 
2.1.11 Reagents for restriction enzyme digestion 
10X Restriction Enzyme Buffer  2μl 
Autoclaved water   Top up to 20μl 
Restriction Enzyme    1 U 
The restriction enzymes used in this study were purchased from Roche (USA). 
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For each reaction, the respective compatible buffers with 100% activity were 
used. 
2.1.12 Reagents for sequencing 
2.1.12.1 Cycle sequencing reaction 
Terminator Ready Reaction Mixture   4μl 
Sequencing Buffer     4μl 
Primer (5 OD)     1μl 
Autoclaved water     Top up to 20μl 
 
2.1.12.2 Purification of extension products reaction 
3M Sodium acetate (pH 4)   3μl 
95% Ethanol     62.5μl 
Nuclease free water    14.5μl 
 
2.1.13 Reagents for miRNA array 
2.1.13.1 Calf intestinal phosphatase (CIP) master mix (per sample) 
Spike –in miRNA  1μl 
CIP Buffer   0.5μl 
CIP Enzyme   0.5μl 
 
2.1.13.2 miRNA labelling master mix (per sample) 
Labelling buffer   3μl 
Hy3 Fluorescent label   1.5μl 
DMSO    2μl 




2.1.13.3 Wash buffers 
2.1.13.3.1 Wash buffer A 
20X Salt buffer   60ml 
10% Detergent solution  12ml 
Sterile water    528ml 
Wash buffer A together with two containers was pre warmed overnight to 
56°C prior to use. 
2.1.13.3.2 Wash buffer B 
20X Salt buffer   20ml 
Sterile water    380ml 
2.1.13.3.3 Wash buffer C 
20X Salt buffer   2ml 
Sterile water    198ml 
 
2.1.14 Reagents for luciferase assay 
2.1.14.1 Passive lysis buffer 
5X Passive lysis buffer 1ml 
Autoclaved water  4ml 
Freshly prepared lysis buffer was used for luciferase assay 
 
2.1.14.2 Stop and Glo™ reagent 
Stop and Glo™ substrate  18μl  




2.1.15 Reagents for milliplex assay 
2.1.15.1 Antibody-immobilized beads 
Antibody beads  60μl each 
Bead diluent   Top up to 3ml 
 
2.1.15.2 Wash buffer 
10X Wash buffer  30ml 
Autoclaved water  270ml 
 
2.1.15.3 Standard 
Reconstitute lysophilized rat cytokine standard with 250μl of autoclaved water. 
Serial dilution with assay buffer for the following dilution ratio: 1:4, 1:16, 
1:64, 1:256, 1:1,024, and 1:4,096. 
 
2.1.15.4 Serum Matrix 
Reconstitute lysophilized serum matrix with 1ml autoclaved water and 4ml 
assay buffer. 
 
2.1.16 Reagents for CCL2 ELISA 
2.1.16.1 Substrate solution 
Colour reagent A and B mixed together in equal volume within 15 min of use. 
 
2.1.16.2 Wash buffer 
25X Wash buffer  20ml 





Reconstitute the CCL2 Standard with 5.0 mL of Calibrator Diluent RD6Q. 
Serial dilution with Calibrator Diluent RD6Q for the following dilution ratio: 
1:2, 1:4, 1:8, 1:16, 1:32, and 1:64. 
 
2.2 Methods 
2.2.1 Animal models  
2.2.1.1 Transient focal middle cerebral artery occlusion (intraluminal  
filaments or suture method)  
Adult male Wistar rats were anesthetized with 200μl/100g weight of ketamine 
and xylazine (section 2.1.1.3) intraperitoneally. The animal was considered 
sufficiently anesthetized when there was a complete loss of pedal reflex. The 
body temperature of the animal was maintained by placing the animal on the 
Right Temp Homeothermic Warming System set at 37 ± 0.5°C (Kent 
Scientific Corporation, Torrington, CT).  
The left Middle Cerebral Artery (MCA) was temporarily occluded using a 4/0 
silicon rubber-coated monofilament (Doccol Corporation, CA, USA) as 
described by Longa et al. [206] (Figure 2.1). In brief, region around the neck 
of rat was shaved and cleaned with betadine™. A skin incision was made from 
the petrous bone to the scapula and the neck muscles were dissected to gain 
access to the common carotid artery (CCA). The CCA, the origin of internal 
carotid artery (ICA), the external carotid artery (ECA), the occipital artery 
(OA), and the superior thyroid artery (STA) were then exposed. OA and STA 
were cauterized using Aura 20 watt bipolar electrosurgical coagulator (Kirwan 
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Surgical Products, Inc., Marshfield, MA, US). The ICA and its bifurcation 
were dissected carefully as close to its entrance to the skull as possible. The 
pterygopalatine artery (PPA) that is proximal to the skull was ligated using 5/0 
Silk Black, (B.Braun, Melsungen, Germany). The ECA was also ligated as 
proximal as possible. Microvascular clips (World Precision Instruments, Inc. 
Sarasota, FL, US) were applied to the proximal side of CCA and ICA.  
The origin of the ECA was tied loosely with 5/0 Silk Black, and an incision 
was made on the ECA to allow access to the lumen. A 4/0 silicon rubber-
coated monofilament was carefully inserted into the lumen of ECA, the stump 
of ECA was tightened together with the monofilament inside and the clip on 
ICA was removed. The monofilament was further introduced carefully into 
ICA until it reached the origin of middle cerebral artery (MCA), which is 
about 17mm from the bifurcation and the clip on CCA was released. After 
60min, a clip was applied to CCA again and the suture was gently removed (to 
allow reperfusion to take place) and the ligation on ECA stump tightened and 

















Figure 2.1: Diagram of vessels exploited in the middle cerebral artery 
occlusion (MCAo) in rat. Mid cerebral a: middle cerebral artery. Int. carotid a: 
internal carotid artery. Pterygopal. a: pterygopalatine artery. Sup. thyr. a: 
Superior thyroid artery. Occip. a: occipital artery. Ext. carotid a: external 










2.2.1.2 Laser-doppler flowmetry  
To evaluate the cerebral blood flow (CBF) reduction in the MCA during 
occlusion, cerebral cortical perfusion was monitored by laser-doppler 
flowmetry (OxyFlo, Oxford Optronix, UK) during pre-occlusion, immediately 
post occlusion, at the time of reperfusion and before the end point of the 
experiments. CBF was expressed as a percentage relative to pre-occlusion 
baseline levels. CBF reduction of more than 80% was observed upon 
occlusion.  
The area around the frontal bone of the skull was shaved and cleaned with 
betadine™. An incision was made in the midline of the scalp. The temporal 
muscle was dissected from the bone. The skull of the animal was thinned 
(1mm in diameter) at 2mm posterior and 6mm lateral to the bregma using a 
high speed micro-drill (Fine-Science Tool, USA). The tubing of Terumo® 
Surflo® Winged Infusion Set (Terumo Corporation, Tokyo, Japan) was cut 
into 5mm in length, glued on the hole using Krazy Glue All Purpose (Elmer's 
Products, Inc, Columbus, OH, USA) and fixed using ZAP Zip Kicker PT-29 
CA Accelerator (Pacer Technology, CA, USA) to allow placement of a 5mm 
LDF probe (OxyFlo XP Probe, UK) for the measurement of CBF. The signals 
of CBF were digitized using a 4 channel Powerlab 4SP (ML760) and 
recordings were displayed with Chart 5 software (AD Instruments Pty Ltd, 
Australia). 
 
2.2.1.3 Neurological measurement for animal models  
The neurological status of each rat was assessed as described by Bederson et 
al. [207]. The neurological examination was carried out for 5min. In brief, 
each rat was evaluated carefully at the following time-points 24, 72 and 120 
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hours post occlusion and graded according to the Bederson score (Table 2.1) 
[207].  
Firstly, rats were held gently and carefully by the tail, suspended about a meter 
above the floor, and examined for any forelimb flexion. Rats that extended 
both forelimbs toward the floor with no other neurological deficit were graded 
0. Rats that exhibited any extent of consistent forelimb flexion without any 
other abnormal behaviour were assigned grade 1.  
Subsequently, rats were put on to a large sheet of soft, plastic coated paper 
(counter protection paper, Kimberly Clarke). While holding the tail of rats, 
lateral pressure was applied gently at the back of the rat's shoulder until the 
forelimbs slid for several inches and the same way of examination was 
repeated several times at different directions. Rats with severe neurological 
dysfunction exhibited minimal or no resistance consistently to lateral push 
toward the paretic side, and were assigned grade 2.  
This group of rats was then permitted to move without any restriction and 
were examined for any circling behaviour. Grade 3 was given to rats which 
circled toward the paretic side consistently. 
 
Table 2.1: Bederson score. Adapted from Bederson et al [207] 
Severity Grade Observation 
Normal 0 No observable deficit 
Moderate 1 Decrease forelimb flexion 
Severe 2 Decrease forelimb flexion and resistance to lateral 
push 






2.2.1.4 Histological analysis of brain infarct volume  
At the end of different reperfusion time points (12, 24, 48, 72, 120 and 168 
hours), the rats were sacrificed and their whole brains were sectioned 
coronally into 2mm slices using an Alto SA-2160 brain-sectioning matrix 
(Roboz, Gaithersburg, MD, USA). The slices were incubated in 2% TTC 
(section 2.1.1.4) and stained for 30min and photographed. The infarcted region 
was left unstained while the surrounding (surviving) area were stained red. 
The infarct volume was quantified using Image J (http://rsbweb.nih.gov/ij/) 




VI = Σ(CA – IA) x Thickness of slice / (conversion from pixel to mm2)  
where  VI = Infarct Volume  
CA = Contralateral Area  
IA = Ipsilateral Area 
 
2.2.1.5 Collection of brain slices  
Ipsilateral and contralateral brain tissue samples (2nd to 5th slices) were 
immediately snap-frozen and stored at -80°C until use. 
 
2.2.2 Patient recruitment 
This study was approved by the Medical Ethics Committee of the University 
of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia and the 
Institutional Review Board of the National University of Singapore (NUS). 
The patients were recruited from University Malaya Medical Centre (UMMC), 
Kuala Lumpur, Malaysia. The patients were admitted into UMMC via the 
 56 
 
Neurology service and Accident and Emergency (A&E) department. Ischemic 
stroke in patients were diagnosed through either magnetic resonance imaging 
(MRI) or computed tomography (CT) scan. For acute samples, the patients‘ 
blood samples were collected between admission and 24 hours after (Day 1), 
between 24 hours to 48 hours (Day 2) and on seventh day after admission 
(Day 7). For the low or no risk ischemic stroke samples, blood was collected 
after patient discharge during their follow-up at outpatient clinics (3 months 
onwards). For healthy control samples, blood was collected from healthy 
volunteers for this study. The whole blood was stored in RNAlater™ (Ambion, 
Life Technology, Carlsbad, CA, USA) according to manufacturer‘s protocol 
and stored at -80°C until required. 
 
2.2.3 Total RNA (include miRNAs) isolation 
2.2.3.1 Total RNA isolation from brain tissue/cells 
100mg of rat brain was weighed out and placed in 1ml of TRIzol® reagent 
(Invitrogen, USA). The sample was homogenised until a fine consistency with 
no visible pieces were achieved. For cell culture, upon completion of a 
treatment, medium from 24-well plates was removed and washed with 1X 
PBS (section 2.1.6.2) twice. 1ml of TRIzol® reagent was added into three 
wells of a 24-well plate. The reagent was pipetted up and down to mix and 
lyse the cells before they were collected into a 1.5ml eppendorf tube. This was 
then used for RNA extraction according to manufacturer‘s protocol. Briefly, 
add 200μl of saturated chloroform to each sample and mixed vigorously 
before it was centrifuged at 12,000g for 15min at 4°C. The aqueous phase was 
transferred to a new tube. DNase I (3μl) was added to the aqueous phase and it 
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was incubated at 37°C for 20min, followed by the addition of 500μl of 
isopropanol. The mixture was mixed vigorously and left overnight at -80°C. 
Total RNA was pelleted by centrifuging at 12,000g for 10min at 4°C. The 
pellet was washed by centrifuging it with 1ml of ice-cold 75% ethanol (section 
2.1.2.1) at 7,500g for 5min at 4°C. The supernatant was removed and the 
pellet was air dried before it was solubilised in 20μl of autoclaved water at 
50°C for 5min. RNA concentration and integrity were determined by 
Nanodrop™ N2000C spectrophotometer (Thermo Scientific™, Rockford, IL, 
USA) and RNA gel electrophoresis. The presence of small RNA species was 
verified using denaturing gel (15% polyacrylamide) electrophoresis.. 
 
2.2.3.2 Total RNA isolation from blood 
Total RNA (including small RNA) from blood was isolated using Ambion 
Ribopure™ blood extraction kit according to manufacturer‘s protocol 
(Ambion, Texas, USA). Briefly, the sample was centrifuged at 14,500rpm for 
5min. The supernatant was discarded and 1ml of lysis solution was added and 
vortexed vigorously to obtain a clear solution. 
10μl acetic acid was added to each sample and incubated on ice for 5min. 
400μl of Acid-Phenol: Chloroform was added and each sample was vortexed 
vigorously and centrifuged at 14,500rpm for 5min. The aqueous phase 
(~1.2ml) was transferred to fresh 15ml tube. 1ml of denaturation solution was 
added and vortexed thoroughly. 2.7ml of 100% ethanol was added and 
vortexed until the mixture became clear. 700μl of this solution was filtered 
through filter cartridge followed by a short spin (~7sec). This step was 
repeated until all solution went through the filter cartridge. The filter cartridge 
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was washed once with 700μl of Wash 1 (section 2.1.3.2) followed by a short 
spin (~7sec).  Wash 2 (section 2.1.3.3) was used to wash through the filter 
cartridge twice 700μl each and centrifuged at 14,500rpm for 2min. The filter 
cartridge was transferred into a new labelled collection tube. 75μl of preheated 
(75°C) elution solution was added to the filter cartridge and incubated at room 
temperature for 2min and centrifuged at 14,500rpm for 2min. This step was 
repeated again. The concentration and integrity of RNA concentration were 
determined using Nanodrop™ N2000C spectrophotometer (Thermo 
Scientific™, Rockford, IL, USA and RNA gel electrophoresis. The presence 
of small RNA species was verified using denaturing gel (15% polyacrylamide) 
electrophoresis. 
 
2.2.4 RNA gel electrophoresis 
2.2.4.1 Denaturing agarose (1%) gel electrophoresis 
RNA was separated by electrophoresis in denaturing agarose gels containing 
formaldehyde. This is necessary to determine the integrity of the RNA isolated. 
Molten RNA gel (section 2.1.4.6) was poured into a horizontal gel-casting tray 
and an appropriate ―comb‖ was inserted immediately to create wells for 
sample loading. Once the gel solidified, the ―comb‖ was removed and the gel 
was placed into the electrophoresis tank containing 1X MOPS running buffer. 
RNA samples (0.4-1.0μg) were mixed with the sample buffer (section 2.1.4.5) 
and incubated for 10min at 65°C prior to loading into the gel. Electrophoresis 
was carried out at 80V for about 30 min and the migration of the bands was 




2.2.4.2 Denaturing polyacrylamide (15%) gel electrophoresis (PAGE) 
Denaturing polyacrylamide gel electrophoresis was used to analyse the 
presence and integrity of small RNAs. Molten PAGE gel was poured into a 
vertical gel casting tray and an appropriate ―comb‖ was inserted immediately 
to create wells for sample loading. Once the gel solidified, the ―comb‖ was 
removed and the gel was placed into the electrophoresis tank containing 1X 
TBE running buffer. The gel was pre-ran for 30min at 100V. Meanwhile the 
RNA samples (5-10μg) were mixed with the sample buffer (section 2.1.5.2) 
and heated up to 95°C for 5min. Samples were chilled immediately and pulse 
down prior to loading into the gel. Electrophoresis was carried out at 100V for 
about 1.5 hours and the migration of bands was visualized using a UV 
transilluminator (Cell Biosciences, Santa Clara, CA, USA). 
 
2.2.5 LNA-based miRCURY LNA™ arrays  
LNA-modified oligonucleotide (Exiqon, Denmark) probes for human, mouse 
and rat miRNAs annotated in based on miRBase version 11.0 and 12.0 
annotations (http://www.miRBase.org) were used in the microarray [165].  
2.2.5.1 miRCURY LNA™ miRNA power labelling  
All the components were thawed on ice. 500ng of total RNA (included 
miRNA) were used on each array which contains over 1769 capture probes 
that are complementary to human, rat, mouse and related viral sequences from 
miRBase version 11.0 and 12.0. Total RNAs were 3‘-end-labelled with Hy3 




Firstly, the master mix for CIP reaction (section 2.1.13.1) was prepared The 
CIP master mix was pulsed down and 2μl of CIP master mix was aliquoted 
into 0.5ml PCR tubes containing 2μl of total RNA (500ng). The tubes were 
pulsed down briefly and the mixture was incubated at 37°C for 30min and 
then at 95°C for 5min on PCR cycler (GeneAmp®, PCR System 9700, 
Applied Biosystems, CA, USA). The tubes were then snapped cool on ice to 
stop the reaction.  
Secondly, master mix for labelling reaction was prepared (section 2.1.13.2) 
and pulsed down. 8.5μl of labelling master mix was added into each PCR 
tubes containing the 4μl CIP reaction. Following this step, all the samples had 
to be kept in the dark due to the use of fluorophores. The labelling reactions 
were pulsed down and incubated at 16°C for 90min followed by 65°C for 
15min on PCR cycler.  
 
2.2.5.2 Array preparation for hybridization  
Hybridization was performed on the MAUI® Hybridization system according 
to manufacturer‘s protocol (Exiqon, Vedbaek, Denmark). MAUI hybridization 
chamber was switched on and set at 56°C. The arrays were placed on the pre-
heated block for 5min. The SL mixer was aligned and adhered carefully onto 
the array slide in the jig with the tab facing away from the barcode. MAUI® 
Gasket brayer was used to press the mixer-slide with moderate pressure to 
ensure complete adhesion. The mixer-slide assembly was then removed from 
the jig and placed back onto the 56°C heated block with the mixer side up. 




2.2.5.3 Reagents preparation for hybridization  
12.5μl of RNase free water was added into each labelled reaction products to 
bring the sample volume to 25μl. 25μl of 2X Hyb buffer was added into the 
sample, vortexed to mix and followed by pulsing down. Subsequently, the 
samples (labelled sample Hyb buffer, 50μl) were denatured at 95°C for 2min 
using PCR cycler with heated lid and then snapped cool on ice for 2 to 15min. 
The samples were spun briefly and heated to 56°C for 5min. Another 25μl of 
2X Hyb buffer with 25μl of RNase free water was prepared and incubated at 
56°C for wetting the tips prior to loading the samples to the mixer-slide 
assembly.  
 
2.2.5.4 Hybridization of samples 
The pipette tips were pre-wetted with (Hyb + RNase free water) solution. 45μl 
of sample was aspirated (avoid bubbles formation) and loaded carefully. The 
pipette tip was removed from the vent with the plunger depressed and surface 
of SL-mixer + array was wiped for any excess amount of samples. Adhesive 
port seals were placed directly over both the ports with forcep and pressed 
down simultaneously to seal the ports effectively. The loaded slide-mixer was 
then placed back onto the bay of MAUI mixer (pre-heated at 56°C) and loaded 
into the chamber slot. The bay was covered up with pre-wet humidity chamber 
and the lid was closed. The mixing chamber was switched on to mode B and 
the slides were incubated for 16hr at 56°C.  
 
2.2.5.5 Washing of array chips 
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After 16hr of hybridization, the slide-mixer assembly was removed from 
MAUI and the slides were washed gently using 400ml of pre-warmed (56°C) 
buffer A (section 2.1.13.3.1) for 2min. The slides were then transferred to 
200ml of buffer B (section 2.1.13.3.2) at room temperature for about 2min 
twice. Subsequently, they were washed with 200ml of buffer C (section 
2.1.13.3.3) and slides were washed by gentle plunging of the rack for 2min. 
Finally, the slides were dipped in 99% ethanol for about 1min and dried by 
centrifugation (AllegraTM X-12R Centrifuge, eckman Coulter, CA, USA) at 
800rpm, 25 C for 5min. before proceeding with scanning at 532nm (Hy3) in 
an InnoScan 700, microarray scanner (Innopsys, Carbonne, France) and 
analysed on Mapix® Version 4.3 software (Innopsys, France). 
 
2.2.5.6 Scanning of miRNA array chips and data anlaysis 
Scanning of the miRNA array chips was performed using the InnoScan 700 
Microarray scanner (Innopsys, Carbonne, France) and the signal intensity was 
quantified using Mapix® Version 4.3 software (Innopsys, Carbonne, France). 
Background subtraction and normalisation were performed on the raw signal 
intensity data using the internal controls inherent in the chips. Signal values 
lower than 300 were omitted from the analysis. For comparison purposes, the 
data was expressed as relative fold change with respect to controls. Statistical 
comparisons between controls and test samples are performed using Student‘s 
t-test and ANOVA. False discovery rate (FDR) was obtained, where FDR < 
0.05 was considered to be statistically significant. Hierarchical clustering plot 





2.2.6 Reverse Transcription (RT) 
2.2.6.1 RT of mRNA 
200ng of total RNA (100ng/μl) was reverse transcribed using 8μl of RT 
mixture (section 2.1.7.1) to generate 10μl of first strand complementary DNA 
(cDNA). Synthesis of cDNA was carried out in a PCR machine (Perkin-Elmer, 
Germany) at 25°C for 10min; 37°C for 60min followed by 95°C for 5min. 
 
2.2.6.2 RT of miRNA 
10ng of total RNA (2ng/μl) was reverse transcribed using 7μl of miRNA RT 
mixture (section 2.1.7.2) and 3ul of miRNA specific primers to generate 15μl 
of RT product. Synthesis was carried out using a PCR machine (Perkin-Elmer, 
Germany) at 16°C for 30min; 42°C for 30min followed by 85°C for 5min. The 
miRNA specific primers were purchased as MicroRNA Assay kits (Applied 
Biosystems, Carlsbad, CA, USA.). 
 
2.2.7 Quantitative real-time PCR (qRT-PCR) 
2.2.7.1 qPCR (mRNA) 
Gene expression was quantified using real-time PCR technology. SYBR green 
assay uses two (forward and reverse) gene specific primers and a DNA 
intercalating dye (SYBR). Sequences for gene specific primers were designed 
using the PrimerExpress 2.0 software and the respective mRNA strands. The 
primers were designed to yield amplicons of about 200bp. GAPDH was used 
as an internal calibrator. 15μl of the SYBR green assay master mix (section 
2.1.8.1) was mixed with 5μl of RT product (section 2.2.6.1) and loaded into 96 
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well optical plates. The plates were sealed with a clear plastic cover and the 
PCR reaction was carried out on ABI PRISM 7900 cycler with thermal 
cycling conditions of 50°C for 2min, 95°C for 10min followed by 40 cycles at 
94°C for 15sec and 60°C for 1min per cycle. All reagents and consumables 
needed for the PCR reaction were purchased from Applied Biosystems, 
Carlsbad, CA, USA. 
 
2.2.7.2 qPCR (stem-loop) 
18.67μl of the Taqman miRNA mixture (section 2.1.8.2) was mixed with 
1.33μl of miRNA RT product (section 2.2.6.2) and loaded into 96 well optical 
plates. The plates were sealed with a clear plastic cover and the PCR reaction 
was carried out on ABI PRISM 7900 cycler with thermal cycling conditions of  
95°C for 10min followed by 40 cycles at 94°C for 15s and 60°C for 1min per 
cycle. All reagents and consumables needed for the PCR reaction was 
purchased from Applied Biosystems, USA. The miRNA specific primers were 
purchased as MicroRNA Assay kits (Applied Biosystems, Carlsbad, CA, 
USA). 
 
2.2.8 First strand cDNA synthesis for cloning 
Total RNA from rat brain or patient blood sample were used to reverse 
transcribe all expressed mRNAs. Briefly, the individual components of the 
Fermentas RevertAid™ H Minus First Strand cDNA Synthesis Kit (section 
2.1.9.1) were thawed on ice. 1μg of total RNA and 1μl (100 pmol) of random 
hexamers were aliquoted into a sterile PCR tube containing RNase free water. 
The volume was adjusted to 12μl. The contents in the tube were mixed gently, 
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centrifuged briefly and incubated at 65°C for 5min. The tube was then chilled 
on ice. The remaining components of the Fermentas RevertAid™ H Minus 
First Strand cDNA Synthesis Kit were added to the tube. The contents were 
mixed and centrifuged briefly. The PCR tube was incubated at 25°C for 10min 
followed by 60min at 42°C. The reaction was terminated by heating at 70°C 
for 5min.  
 
2.2.9 Polymerase chain reaction (PCR) 
The PCR reaction was prepared in 0.2ml PCR tubes on ice according to 
section 2.1.9.2. 2.5μl of the cDNA (section 2.2.8) was directly used to perform 
PCR in a 25μl volume and the mixture in the PCR tubes were pulsed down. 
The PCR cycling conditions were set depending on the melting temperatures 
(Tm) of the primers used and the size of the product amplified. Typically the 
annealing temperature was set 5°C below the primer Tm for 45s while the 
extension temperature was kept at 72°C. At the end of the run, 10μl of the 
product was analysed on a 1% DNA agarose gel. 
 
2.2.10 DNA agarose (1%) gel electrophoresis 
Nucleic acids were separated by electrophoresis in 1% agarose gels. This is 
necessary to determine the integrity of the DNA isolated as well as to analyse 
PCR products. Molten DNA gel (section 2.1.9.3) was poured into a horizontal 
gel-casting tray and an appropriate ―comb‖ was inserted immediately to create 
wells for sample loading. Once the gel solidified, the ―comb‖ was removed 
and the gel was submerged into the electrophoresis tank containing 1X TBE 
running buffer. DNA samples were mixed with the 6X loading buffer (Thermo 
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Fisher Scientific, Fermentas, Waltham, MA, US) prior to loading into the gel. 
100 basepairs or 1 kilo basepair markers (Thermo Fisher Scientific, Fermentas, 
Waltham, MA, US) were used according to the requirement. Electrophoresis 
was carried out at 90V for about 60min and the migration of the bands was 
viewed using a UV illuminator (Cell Biosciences, Santa Clara, CA, USA). 
Once the desired fragment size was obtained, the fragment was excised out 
with a clean, sharp scalpel for further processing. 
 
2.2.11 DNA gel extraction 
The excised DNA/PCR fragment from the agarose gel was weighed and QG 
buffer, (Qiagen, Hilden, Germany), volume equivalent to 3 times the weight of 
the gel was added. The gel and buffer mixture was incubated at 50°C for 
10min. Once the gel fragment had completely dissolved, 1 gel volume of 
isopropanol was added and mixed. The sample was put through QIAquick spin 
column 700µl each time and centrifuged at 10,000rpm for 1min. The flow-
through was discarded and the column was washed with 700µl of PE buffer 
(Qiagen, Hilden, Germany) twice and centrifuged at 10,000rpm for 1min each 
time. The QIAquick column was transferred into a clean 1.5ml 
microcentrifuge tube and the DNA was eluted with 20μl of autoclaved water 
by centrifuging for 2min at 13,000rpm. 2μl of the DNA was loaded onto a 1% 
agarose gel to check its integrity. The remaining DNA extract was used 
directly for cloning or stored at –20°C. 
 
2.2.12 Ligation and transformation 
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Ligation reactions were carried out with a vector: insert molar ratio of 
approximately 1:3 to increase the ligation efficiency. Generally 50ng of 
plasmid vector was used for each reaction (section 2.1.9.4). The reaction 
mixture was incubated at room temperature for 30min before the addition of 
competent cells. Competent cells (Invitrogen, USA) stored in -80°C were 
thawed on ice. The ligation mixture was added to 50μl of the competent cells 
and mixed gently. The tube was kept in ice for 1 hour. The cells were then 
heat-shocked at 42°C for 90s, transferred to a 15ml falcon tube with 250μl 
SOC medium (Invitrogen, USA). The cells were incubated for 1 hour at 37°C 
before plating them on LB-agar plates (section 2.1.9.9) containing ampicillin 
(section 2.1.9.7). The plates were left at 37°C for about 18 hours to allow for 
the colonies to grow. Single colonies were then picked using sterile toothpicks 
and re-grown for 18 hours in 1.5ml LB broth (section 2.1.9.8) containing 
ampicillin. 
 
2.2.13 Plasmid extraction 
Plasmid extraction was necessary for further analysis of cloned fragments. 
1.5ml of individually grown colonies were transferred into an eppendorf tube 
and centrifuged at maximum speed for 2min to pellet the cells. The 
supernatant was aspirated and the pellet was resuspended in 100μl of cold 
resuspension buffer (section 2.1.10.1). The tube was vortexed vigorously to 
resuspend the cells. 200μl of freshly prepared lysis buffer (section 2.1.10.2) 
was added and the tube was inverted 5-6 times to mix the contents. Following 
which, 150μl of cold precipitation buffer (section 2.1.10.3) was added to the 
tube and also mixed by inversion (5-6 times). The tube was incubated in ice 
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for 10min and centrifuged at maximum speed for 20min. The supernatant was 
transferred to a new tube. 3μl of RNase solution (section 2.1.10.4) was added 
to the supernatant and incubated at 60 °C for 20min. The tube was then cooled 
on ice and the plasmid was precipitated with addition of 450μl isopropanol 
and kept at -80°C for 1 hour. After which, the tube was spun at maximum 
speed for 30min. The supernatant was discarded and 200μl of 70% ethanol 
was added for wash. The sample was centrifuged at maximum speed for 
30min. The supernatant was removed and the pellet was air dried before being 
resuspended in 20μl of autoclaved water. 
 
2.2.14 Restriction enzyme digestion 
To check for the presence of the cloned fragment in the vector, restriction 
enzyme digestion was carried out. About 1μg of the plasmid (section 2.2.13) 
was added to the restriction enzyme mixture (section 2.1.11). The final volume 
was adjusted to 20μl and the tubes were incubated at 37°C overnight. For 
double digests, buffers compatible to both enzymes were used, where the 
buffer and enzyme with low salt content were added first and incubated at 
37°C for 6 hours, followed by addition of buffer and enzyme with high salt 
content and incubation at 37°C overnight. The digested products were 
analyzed on a 1% DNA agarose gel (section 2.2.10). If the digested fragment 
was needed for further sub-cloning, the fragment was excised out with a clean, 






2.2.15.1 Cycle sequencing reaction 
The PCR reaction was prepared in 0.2ml PCR tubes on ice according to 
section 2.1.12.1, with 1μl of plasmid template (section 2.2.13) and primer 
specific for the plasmid. The mixtures in the PCR tubes were pulsed down. 
The thermal cycling conditions were 96°C for 30sec, 50°C for 15sec followed 
by 60°C for 4min for 25 cycles. The product was kept on ice for further 
purification. 
 
2.2.15.2 Purification of extension products and sequencing  
80μl of reaction mix for purification of extension products (section 2.1.12.2) 
was added to each PCR tube and the mixture was transferred to 1.5ml 
eppendoff tube. The mixture was vortexed briefly and incubated on ice for 
15min. After which, samples were centrifuged at maximum speed for 30min. 
The supernatant was aspirated and 500μl of 75% ethanol was added. The 
samples were centrifuged for 20min and the ethanol was removed. The pellet 
was dried by Hetovac (Heto lab equipment, Denmark). The pellet was 
resuspended in 10μl Hi-Di™ formamide and vortexed for 1min followed by a 
short pulse. The resuspended pellet was transferred to 96 well plate. The plate 
was sealed and heated at 95°C for 2min. The plate was loaded into ABI 
PRISM® 3100 genetic analyser (Applied Biosystems, Carlsbad, CA, USA). 
All reagents and consumables were purchased from Applied Biosystems, 
Carlsbad, CA, USA. 
 
2.2.16 Cell culture 
 70 
 
HeLa and HUVEC cell lines were cultured using complete DMEM (section 
2.1.6.6).  All cells were cultured in T-75 flasks and maintained in a 37°C 
incubator with 5% CO2. 
 
2.2.17 Transfection 
2.2.17.1 miRNA transfection 
SiPORT NeoFX transfection reagent (Ambion, Carlsbad, CA, US) and Opti-
MEM (Gibco, Carlsbad, CA, US) was complexed at a ratio of 1:49μl and 
incubated for 10min at room temperature. The miRNA (Ambion, Carlsbad, 
CA, US) was diluted to the appropriate concentration in 50μl Opti-MEM. The 
diluted transfection reagent and the miRNA were then mixed at a ratio of 1:1 
and incubated at room temperature for another 20min. HUVECs were seeded 
at density of 3 x 10
4
per well in 24-well plates. 100μl of miRNA-transfection 
reagent mixture was added dropwise to the wells. After 24 hrs of incubation, 
500μl of complete medium was added to the wells. Transfection was stopped 
at 48 hrs. Wells treated with negative control (Ambion, Carlsbad, CA, US), 
composed of scrambled miRNA fragments, were used to analyse the 
percentage of gene knockdown in the miRNA treated wells. 
 
2.2.17.2 miRNA and reporter plasmid transfection 
For miRNA target interaction studies, anti-miRNA or miRNA mimic was co-
transfected with luciferase reporter plasmids containing the target recognition 
sites. For miRNA transfection, lipofectamine transfection reagent (Invitrogen, 
Carlsbad, CA, US) and Opti-MEM (Gibco, Carlsbad, CA, US) was complexed 
at a ratio of 1.5:150μl and incubated for 10min at room temperature. The anti-
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miRNA or miRNA mimic (Ambion, Carlsbad, CA, US) was diluted to a 
concentration of 50nM in 150μl Opti-MEM. The diluted transfection reagent 
and the miRNA complex were then mixed at a ratio of 1:1 and incubated at 
room temperature for further 20min. Cells were pre-seeded 24 hrs earlier at a 
density of 7 x 10
4
/per well in 24-well plates. The wells were washed with 
300μl of Opti-MEM twice followed by the addition of 300μl of the miRNA-
transfection reagent mixture. The cells were left in the 37°C CO2 incubator for 
3 hours. After which, preparation for plasmid transfection was done. For 
plasmid transfection, lipofectamine transfection reagent and Opti-MEM was 
complexed at a ratio of 3:150μl and incubated for 10min at room temperature. 
The luciferase plasmid (section 2.1.9.5) was diluted to a concentration of 
200nM in 150μl Opti-MEM. 10ng of pRL-CMV (Promega, Madison, WI, 
USA) vector was used to determine transfection efficiency. The diluted 
transfection reagent and the plasmids were then mixed at a ratio of 1:1 and 
incubated at room temperature for further 20min. At the end of the 3 hours 
incubation the cells, the medium was aspirated and the cells were washed 
again with Opti-MEM. 300μl of the plasmid - transfection reagent mixture 
was then added to the cells. The cells were left in the 37°C CO2 incubator for 
another 3 hrs. At the end of the 3 hours, the medium was replaced with 
complete medium (DMEM) and the cells were left to grow for 48 hrs, 
following which luciferase assays were performed. 
 
2.2.18 Luciferase assay 
To study the miRNA and its target gene interaction, the Dual-Luciferase® 
Reporter (DLR) assay system was used (Promega, Madison, WI, USA). This 
 72 
 
assay allows the simultaneous expression and measurement of two individual 
reporter enzymes within a single system. The Firefly luciferase expression is 
used to correlate the effect of miRNA and its target interaction, while the 
activity of the co-transfected Renilla luciferase provides an internal control 
that serves as the baseline response. Firefly and Renilla luciferases, because of 
their distinct evolutionary origins, have dissimilar enzyme structures and 
substrate requirements. These differences make it possible to selectively 
discriminate between their respective bioluminescent reactions. 48 hours after 
transfection, the medium was aspirated and the cells were washed with 1X 
PBS (section 2.1.6.2). 100μl of passive lysis buffer was added to each well 
and the cells were left on IKA MS 3 basic (IKA, Wilmington, NC, US) for 
10min with gentle agitation. The cells were then collected and centrifuged at 
maximum speed for 5min. The cell lysate was transferred into a separate tube. 
25μl of the cell lysate was transferred into a white optical plate in a 
luminometer. Upon addition of 50μl Dual-Glo™ Luciferase substrate, the 
firefly luciferase activity was measured. To quench the firefly luciferase 
activity and read the Renilla luciferase activity, 50μl of Stop & Glo™ reagent 
was added and the luminescence measured. 
 
2.2.19 Milliplex cytokine assay 
Serum samples were obtained from rats subjected MCAo. Whole blood was 
collected and left to clot at 4°C for at least 2 hours and centrifuged at 1000 X g 
for 10 min. Serum was collected and stored in -80°C until required. Serum 
samples were diluted by five folds using serum matrix (section 2.1.15.4). The 
wells were pre-wetted with 200μl of assay buffer and placed on IKA MS 3 
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basic (IKA, Wilmington, NC, US) shaking for 10min at room temperature. 
Assay buffer was removed by vacuum. Add 25μl of standard or samples into 
each well. Add 25μl of serum matrix to standard wells and add 25μl of assay 
buffer to sample wells. Add 25μl of mixed beads (section 2.1.15.1) to each 
wells. The plate was sealed with a plate sealer and placed on IKA MS 3 basic 
(IKA, Wilmington, NC, US) shaking for overnight (18-20 hours) at 4°C. 
Remove fluid by vacuum and wash wells with 200μl of wash buffer (section 
2.1.15.2) per well twice. Following that, add 25μl of detection antibody per 
well and place on IKA MS 3 basic (IKA, Wilmington, NC, US) shaking for 2 
hours at room temperature. After which, add 25μl of Streptavidin-
Phycoerythrin to each well. The plate was sealed and covered with lid, which 
was placed on shaker for another 30min at room temperature. The contents in 
wells were removed by vacuum and washed twice with 200μl of wash buffer 
per well. 150μl of sheath fluid was added to each well and placed on shaker 
for 5min to resuspend beads. The plate was placed in Luminex 100™ system 
(Luminex Corporation, Austin, TX, US) for detection and analysis. All 
reagents and consumables were purchased from Merck Millipore, Billerica, 
MA, US. 
 
2.2.20 CCL2 ELISA 
Serum samples were obtained from ischemic stroke patients. Samples were 
obtained in BD Vacutainer ® (Becton, Dickinson and Company, New Jersey, 
US) at Day 1, 2 and 7 upon admission. They were left for at least 30 minutes 
to allow clotting and subsequently, spun down and aliquot for storage at -80°C 
until required. To each well, add 50μl of Assay Diluent RD1-83 and 200μl of 
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standard (section 2.1.16.3) or sample. After which, covered the plate with 
adhesive strip and incubated at room temperature for 2 hours. Aspire each well 
and wash each well with 400μl of wash buffer (section 2.1.16.2) three times. 
Following that, 250μl of CCL2-conjugate was added to each well, covered 
with new adhesion strip and incubate at room temperature for 2 hours. 
Subsequently, the content of each well was removed and washed with 400μl 
of wash buffer per well thrice. 200μl of substrate solution (section 2.1.16.1) 
was added to each well and incubated for 30min at room temperature. To stop 
the reaction, 50μl of stop solution was added. Optical density at 450nm of 
each well was determined using Spectramax 190 microplate reader (Molecular 
Devices, US). Readings were corrected by subtracting optical density at 
570nm. All reagents and consumables were purchased from R&D systems, 
Minneapolis, MN, US. 
   
2.2.21 Statistical analysis 
Statistical analysis was performed using two-tailed t-test for case-control 
comparison. For multiple comparisons, One-way ANOVA was used. For 
testing dichotomized parameters between stroke subtypes, chi-square test was 
performed on SPSS version 16. The significance level was kept at p value < 
0.05. Pearson correlation was used to test correlation between 2 variables 
where Pearson correlation coefficient (R) > ± 0.9 indicates strong correlation 
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3.1 miRNAs and ischemic stroke 
miRNAs are endogenous, short (18-22 nucleotides), non-coding RNA that act 
as ribo-regulators for gene expression [137]. miRNA expression was first 
demonstrated to be dysregulated in rat animal model for ischemic stroke by 
Jeyaseelan et al [189], where blood and brain miRNA profile between control 
rats and rats subjected to middle cerebral artery occlusion (MCAo) was 
compared and found to be different. This implied that miRNAs had roles to 
play in the pathophysiology of ischemic stroke. 
Subsequently, blood miRNAs were profiled in young ischemic stroke patients 
by Tan et al [190]. Following that, more data were published with regards to 
miRNAs and ischemic stroke. In 2014, Sepramanium et al [197] and Jickling 
et al [198] reported on miRNA profiles in ischemic stroke patients, both 
highlighting groups of miRNAs as potential ischemic stroke specific miRNAs. 
Others published that miRNAs were potential diagnostic markers for ischemic 
stroke. miR-210 was reported to be down-regulated in blood of ischemic 
stroke patients and showed correlation with outcome of patients where good 
outcome correlated with higher miR-210 expression [199, 200]. In addition, 
miR-210 together with miR-21 (up-regulated in ischemic stroke), were shown 
to be potential biomarkers for atherosclerosis and stroke. [201]. miR-145 had 
been reported to have increased expression in ischemic stroke patients [202], 
though it was later shown by Tsai et al [201] that miR-145 expression  
between ischemic stroke patients and healthy controls were not statistically 
different. Other circulating miRNAs such as let-7b, miR-16, -30a, -124-3p, -
126 and -233 have also been reported as potential biomarkers for ischemic 
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stroke [203-205]. miR-30a and miR-126 were shown to be down-regulated in 
ischemic stroke  patients while let-7b showed down-regulation in large artery 
stroke patients and up-regulation in other stroke subtypes [203]. Circulating 
miR-223 level was reported to be increased in ischemic stroke patients by 
Wang et al [204]. As for miR-16 and -124-3p, they were described as markers 
to distinguish between haemorrhagic and ischemic stroke, where miR-16 
concentration was higher and miR-124-3p concentration was lower in 
ischemic stroke patients and vice versa for haemorrhagic stroke patients [205]. 
Interestingly, miR-146aG allele and miR-146aG/-149T/-196a2C/-499G allele 
combination polymorphisms of miRNAs have also been found to predispose 
individual to ischemic stroke, with ischemic stroke occurrence [210].  
Among the recent reports published, only Tan et al [190] and Jickling et al 
[198] highlighted a few biological pathways involved in ischemic stroke. 
More information on the processes taking place during ischemic stroke is still 
unknown. This study seeks to conduct an in-depth analysis of biological 
pathways involved in ischemic stroke and possibly identify the crucial 
processes influencing ischemic stroke pathophysiology and pathogenesis. 
 
3.2 Patient recruitment and sample collection 
The patients for this study were recruited from University Malaya Medical 
Centre (UMMC), Kuala Lumpur, Malaysia. The patients were admitted into 
UMMC via the Neurology service and Accident and Emergency (A&E) 
department. Ischemic stroke patients were diagnosed through either magnetic 
 77 
 
resonance imaging (MRI) or computed tomography (CT) scan. The patients‘ 
peripheral blood samples were collected between admission and 24 hours after 
(Day 1), between 24 hours to 48 hours (Day 2) and on seventh day after 
admission (Day 7). Blood was collected on various timepoints during the acute 
phase of ischemic stroke. The whole blood was stored in RNAlater™ 
(Ambion, Life Technology, Carlsbad, CA, USA) according to manufacturer‘s 
protocol and stored at -80°C until required. The patients were classified into 
the different stroke subtypes according to the Trial of Org 10172 in Acute 
Stroke Treatment (TOAST) classification [8], based on clinical symptoms and 
upon further investigation. Majority of the ischemic stroke cases were 
cardioembolic, large-artery and small vessel occlusion (lacunar). The patients‘ 
clinical data was separated according to the respective ischemic stroke subtype 
(TOAST classification).  
The outcomes of the patients were assessed using the modified Rankin scale 
(mRS) [211]. mRS scores patient outcome on a scale of 0 to 6, where 0 signify 
no symptoms and 6 represents the patient is dead (Table 3.1). The patients‘ 
outcomes were usually assessed a week after admission. For clinical purposes, 
mRS was dichotomized into good and poor outcome. In general, mRS < 2 was 
denoted as good outcome, while mRS ≥ 2 indicated poor outcome. Clinical 
data were collected from the patients and used for further analysis.   
For healthy control samples, healthy volunteers were recruited for this study. 
Exclusion criteria included hypertension, dyslipidaemia, diabetes, cardiac 















0 No symptoms 
1 No significant disability despite some symptoms; able to 
carry out usual activities 
2 Slight disability; unable to carry out all previous 
activities; able to look after own affairs without 
assistance 
3 Moderate disability; require some help; able to walk 
without assistance 
4 Moderately severe disability; unable to attend to bodily 
needs without assistance; unable to walk without 
assistance 
5 Severe disability; bedridden and incontinent; requires 











There were a total of 48 acute ischemic stroke patients recruited for this study. 
They constituted 14 large artery stroke patients, 20 cardioembolic stroke 
patients and 14 small vessel stroke patients (Table 3.2). Various parameters of 
the patients were dichotomized; Chi-square test was used for statistical testing 
performed on SPSS version 16.   
Age (p-value = 0.215) and gender proportion (p-value = 0.708) were found to 
be similar among the stroke subtypes (Table 3.2). As for risk factors, 
incidence of hypertension (p-value = 0.188), dyslipidaemia (p-value = 0.849), 
type 2 diabetes (p-value = 0.285) and alcohol consumption (p-value = 0.289) 
were shown to be similar among the stroke subtypes, while there were more 
smokers (p-value = 0.024; 4 patients; 28.5%) in small vessel stroke patients 
(Table 3.2). As for comorbidities, number of patients with ischemic heart 
disease (p-value = 0.267), aortic stenosis (p-value = 0.489) and previous 
stroke (p-value = 0.074) were similar among the stroke subtypes (Table 3.2). 
There was significantly higher number of cardioembolic stroke patients with 
atrial fibrillation (p-value < 0.001; 16 patients; 80.0%) as compared with large 
artery stroke and small vessel stroke patients (Table 3.2). There were also 
greater numbers of patients with good outcome (p-value = 0.029; 5 patients; 
35.7%) in small vessel stroke as compared with large artery stroke and 






Table 3.2: Patient demographics of acute ischemic stroke patients.  
 
 Large-artery (n=14) Cardioembolic (n=20) Small vessel (n=14) p-value 
Age, mean ± standard deviation 62.3 ± 11.3 66.8 ± 15.2 64.4 ± 11.6 0.215 
Gender, Male, n (%) 8 (57.1%) 10 (50.0%) 9 (64.3%) 
0.708 
Gender, Female, n (%) 6 (42.9%) 10 (50.0%) 5 (35.7%) 
Risk Factors 
Hypertension, n (%) 11 (78.5%) 10 (50.0%) 10 (71.4%) 0.188 
Dyslipidaemia, n (%) 11 (78.5%) 14 (70.0%) 10 (71.4%) 0.849 
Type 2 diabetes, n (%) 6 (42.8%) 6 (30.0%) 8 (57.1%) 0.285 
Smoking, n (%) 1 (7.1%) 0 (0.0%) 4 (28.5%) 0.024 
Alcohol consumption, n (%) 1 (7.1%) 0 (0.0%) 0 (0.0%) 0.289 
Comorbidities 
Ischemic heart disease, n (%) 2 (14.2%) 8 (40.0%) 4 (28.5%) 0.267 
Atrial fibrillation, n (%) 0 (0.0%) 16 (80.0%) 0 (0.0%) <0.001 
Aortic stenosis, n (%) 0 (0.0%) 1 (5.0%) 0 (0.0%) 0.489 
Previous stroke, n (%) 4 (28.5%) 6 (30.0%) 0 (0.0%) 0.074 
Functional outcome (mRS) 
Good outcome, mRS <2, n (%) 1 (7.1%) 1 (5.0%) 5 (35.7%) 
0.029 








3.3 miRNA profiles in ischemic stroke patients 
Total RNA (including small RNAs) was isolated from the peripheral blood 
using Ribopure™ Blood RNA purification kit (Ambion, Life Technology, 
Carlsbad, CA, USA) according to manufacturer‘s protocol. The concentration 
and integrity of the RNA was determined using Nanodrop™ N2000C 
spectrophotometer (Thermo Scientific™, Rockford, IL, USA) and RNA gel 
electrophoresis (1% agarose). The presence and integrity of small RNA 
species (less than 200 nucleotides) were verified using denaturing 
polyacrylamide gel electrophoresis (15% polyacrylamide). 
The isolated RNA was used for miRNA microarray that was performed on 
miRCURY LNA miRNA array (version 11.0) platform, based on miRBase 
version 11.0 and 12.0 annotations [165]. The samples were pooled according 
to stroke subtype and time-point for each array chip. All probes with positive 
raw signal intensities were analysed and statistical testing was performed to 
obtain false discovery rate (FDR), where miRNAs with FDR <0.05 were 
selected. The profiles were visualised using TIGR multiple experiment viewer 
(TMEV) [209].  
In total, 352 miRNAs were detected in this study (Supplementary Table 1). 
Using these 352 miRNAs, hierarchical clustering (HCL) was performed on the 
samples. HCL demonstrated that the control samples segregated away from 
the patients‘ samples, signifying there was a difference in miRNA profile 







Figure 3.1: Hierarchical clustering analysis of 352 miRNAs in ischemic 
stroke patients and healthy controls. The miRNA expression were expressed 
logarithm of raw intensity. Green represents low signal intensity. Red 
represents high signal intensity. Grey represents absence. Patient samples were 
named according to their respective stroke subtype (IS: ischemic stroke; LA: 




Further analysis was performed where HCL of miRNA expression values in 
the patient samples were converted to signal log ratio (SLR; Figure 3.2). SLR 
was obtained by logarithm of fold change with respect to control samples. The 
samples showed the segregation according to stroke subtypes (Large artery: 
LA, cardioembolic: CE and small vessel: SV). This signified that the miRNA 
profiles during acute phase of ischemic stroke could be correlated with 
underlying etiology of the stroke subtypes. Hence this information could be 
used to uncover the mechanism for the pathogenesis of each subtype. 
 
3.4 miRNAs with similar expression in all acute ischemic stroke samples 
From the miRNA profiling, there were 147 miRNAs that showed similar 
expression in all the samples (Table 3.3). Among these 147 miRNAs, 22 
miRNAs were down-regulated in all samples while the remaining 125 
miRNAs were up-regulated in all samples. 
miR-21 and -223 which were previously reported to be increased in ischemic 
stroke patients were also detected in this study as increased in all acute 
ischemic stroke samples [201, 204]. Thus, suggesting that possible biomarkers 









Figure 3.2: Hierarchical clustering analysis of 352 miRNAs in ischemic 
stroke patients. The miRNA expression were expressed as signal log ratio 
(SLR) with respect to control samples. Green represents down-regulation. Red 
represents up-regulation. Grey represents absence. Samples from cohort 1 
were named according to their respective stroke subtype (IS: ischemic stroke; 




Table 3.3: Expression of 147 miRNAs showing similar expression in acute ischemic stroke sample. miRNAs were expressed as fold change 
with respect to healthy controls. LA: large artery stroke. CE: cardioembolic stroke. SV: small vessel stroke.   
 




















Let-7d* -3.70 -4.75 -2.51 -2.20 -2.26 -2.94 -2.35 -2.69 -2.16 -13.00 -3.86 -4.65 
Let-7e 3.19 4.00 5.81 2.72 3.83 4.08 5.41 2.60 3.91 1.99 2.08 1.67 
Let-7f 1.49 1.79 2.57 1.54 1.60 1.77 2.21 1.62 2.01 1.01 1.00 1.31 
miR-15a 1.73 2.08 2.97 1.79 1.85 2.05 2.57 1.88 2.33 2.06 1.16 1.98 
miR-15b* 7.81 6.55 13.07 8.24 7.56 12.53 16.42 6.38 13.15 1.40 3.21 3.22 
miR-17 1.92 2.31 3.31 1.99 2.06 2.28 2.85 2.09 2.59 1.05 1.22 1.07 
miR-19a 1.87 2.25 3.22 1.93 2.00 2.02 2.77 2.03 2.52 1.26 1.25 1.75 
miR-19b 2.63 3.16 4.53 2.72 2.82 3.12 3.91 2.87 3.54 1.57 1.77 2.69 
miR-20b* 2.35 2.50 5.94 2.34 2.08 2.66 2.40 1.99 2.16 1.18 2.68 3.14 
miR-21 9.73 11.03 17.18 10.09 10.67 11.82 14.79 10.70 13.42 4.53 4.76 5.56 
miR-23a 1.19 1.69 2.50 1.17 1.48 1.68 1.67 1.06 1.71 1.16 1.24 1.09 
miR-23b 1.61 2.06 2.85 1.41 2.12 2.39 2.33 1.39 2.07 1.24 1.53 1.23 
miR-25 4.21 4.10 6.48 4.11 4.98 5.71 6.01 3.41 5.39 2.21 3.07 2.81 
miR-25* 2.45 3.33 3.82 2.40 2.53 2.96 2.70 2.50 2.12 2.48 1.93 2.00 
miR-27a 3.57 4.71 6.53 3.34 4.63 6.61 5.13 2.84 5.06 2.69 3.80 3.59 
miR-27a* 5.55 9.92 10.23 6.69 6.86 10.87 6.06 6.03 4.55 5.05 5.34 4.35 
miR-29a 5.14 5.53 10.72 5.14 5.59 8.00 12.14 4.38 9.52 2.16 2.63 2.21 
miR-29b 6.35 6.27 10.99 5.81 6.99 10.71 12.16 5.62 10.81 2.41 3.65 3.82 
miR-29b-2* 3.14 3.24 3.64 2.01 2.67 3.65 4.08 2.35 4.25 1.04 2.34 1.95 
miR-29c 6.39 6.61 13.48 5.94 6.08 8.74 14.80 5.69 12.56 1.35 2.74 2.29 
miR-29c* 2.91 3.21 4.85 3.68 4.43 5.45 5.51 2.60 5.69 2.02 2.54 1.73 
miR-32 8.39 8.49 17.49 9.18 8.92 15.90 20.00 8.16 14.20 3.00 2.82 3.58 



























miR-33a 38.94 37.02 100.04 50.54 44.51 121.51 68.33 43.26 80.84 8.92 23.92 43.69 
miR-34b 2.82 3.46 4.94 2.12 2.34 3.36 2.92 1.89 1.77 3.09 1.93 2.36 
miR-92b 1.85 1.63 2.15 1.52 1.62 1.98 2.01 1.35 1.50 1.01 1.57 1.37 
miR-98 4.24 5.09 8.60 2.57 3.99 5.81 7.10 2.76 6.19 2.44 2.38 2.37 
miR-99b* 1.55 1.59 1.89 1.44 1.58 2.44 1.85 1.15 1.18 1.69 1.87 1.54 
miR-101 3.45 4.15 5.94 3.57 3.54 4.09 5.12 3.75 4.64 1.59 2.32 3.02 
miR-101* 6.52 5.19 10.22 7.76 10.59 11.79 13.72 6.18 11.12 1.52 3.22 2.84 
miR-103 2.83 3.40 4.87 2.92 3.03 3.35 4.19 3.08 3.81 2.13 1.90 2.34 
miR-107 2.34 2.98 4.03 2.44 3.12 3.35 4.40 2.46 3.99 1.48 1.66 1.41 
miR-125b -2.21 -1.34 -1.65 -1.02 -1.25 -1.23 -1.21 -1.34 -1.11 -27.06 -2.51 -6.13 
miR-125b-1* 2.05 2.11 2.44 2.27 2.23 2.84 2.81 2.16 2.10 1.42 2.11 1.44 
miR-125b-2* 4.19 3.06 2.25 6.58 5.48 7.20 5.01 6.17 4.69 2.44 4.62 3.34 
miR-129-5p 2.48 2.09 3.15 3.20 3.29 3.18 2.75 2.90 2.53 2.00 1.76 2.05 
miR-135b 1.90 1.96 3.39 3.87 4.88 7.02 6.78 3.62 4.58 1.58 2.21 2.07 
miR-138-1* 1.74 1.82 1.91 1.35 1.83 2.41 2.50 1.30 1.24 2.18 1.70 1.43 
miR-140-5p 7.27 9.12 17.60 6.50 9.30 14.93 15.41 7.08 13.24 3.44 4.52 4.63 
miR-142-3p 1.73 2.07 2.97 1.78 1.85 2.04 2.56 1.88 2.32 1.80 1.16 1.97 
miR-143 3.08 4.00 8.47 3.75 5.36 8.24 5.52 4.47 6.23 1.15 2.88 4.83 
miR-144* 2.93 3.52 5.05 3.03 3.14 3.47 4.35 3.19 3.95 2.76 1.97 2.59 
miR-146b-3p 1.30 1.38 1.19 1.61 1.45 1.63 1.25 9.76 1.32 1.49 1.72 1.50 
miR-148a 2.82 3.30 5.75 3.61 5.59 7.38 6.90 3.30 5.06 1.42 2.85 2.77 
miR-150 -2.76 -3.97 -5.90 -1.11 -1.18 -1.15 -1.48 -1.47 -1.80 -1.46 -1.15 -1.62 
miR-181a-2* 3.58 2.67 3.60 2.47 1.65 6.07 1.02 1.17 1.29 2.85 3.75 3.02 
miR-183* 1.96 2.46 2.86 1.75 1.77 1.90 2.42 2.19 1.80 1.83 1.59 1.43 
miR-184 2.71 2.86 3.31 2.42 2.50 3.71 2.08 2.20 1.93 2.17 2.56 2.36 



























miR-190 6.71 7.13 15.10 7.27 8.35 12.52 15.48 7.11 13.34 2.06 2.71 2.47 
miR-193b* 1.44 1.47 1.37 2.29 2.54 2.18 2.53 2.40 1.72 2.08 1.71 1.45 
miR-195 7.30 8.76 12.37 7.26 7.71 8.64 10.62 6.25 9.82 4.59 4.90 7.18 
miR-196a* 2.34 2.09 2.50 1.67 1.70 2.20 1.85 1.65 1.62 1.84 2.51 2.17 
miR-197 2.00 1.45 1.76 1.67 1.64 2.08 1.80 1.42 1.65 1.49 1.86 1.94 
miR-198 19.03 3.93 1.75 4.79 5.72 3.01 1.87 1.75 1.38 2.60 2.49 3.03 
miR-199a-3p 5.15 5.18 11.12 8.32 9.04 12.31 6.43 5.05 11.54 2.13 3.94 3.56 
miR-200b* 2.99 3.44 2.97 4.99 4.92 5.23 4.88 5.16 3.74 3.89 3.54 3.70 
miR-206 3.87 2.88 2.59 3.51 3.33 5.77 3.83 2.74 3.09 2.60 4.33 3.27 
miR-208a -1.73 -1.67 -2.89 -2.47 -2.72 -1.52 -2.82 -2.79 -4.08 -2.14 -1.44 -2.23 
miR-210 4.26 4.16 5.48 2.69 3.33 7.09 4.50 2.44 3.76 1.21 3.56 2.91 
miR-221 4.30 6.46 9.19 3.95 6.20 6.28 6.77 3.62 5.51 1.99 3.24 3.14 
miR-223 3.19 4.17 6.18 2.86 3.84 4.21 5.16 3.24 4.76 2.77 2.41 3.89 
miR-300 1.85 1.93 3.10 2.06 2.23 2.51 2.17 1.83 1.62 1.95 1.44 1.42 
miR-302c* 1.31 1.68 1.01 2.98 2.77 4.08 2.63 3.08 1.45 3.28 3.17 2.44 
miR-320b -1.68 -1.36 -1.18 -2.05 -1.82 -1.89 -1.00 -1.74 -1.81 -2.71 -2.19 -3.08 
miR-320c -1.81 -1.57 -1.32 -2.12 -1.86 -2.03 -1.08 -1.82 -1.91 -1.94 -2.44 -3.78 
miR-326 1.71 1.26 1.87 1.89 2.05 2.02 1.79 2.00 1.57 2.57 1.63 1.77 
miR-331-5p -3.24 -4.12 -4.88 -1.53 -1.42 -1.35 -1.00 -1.65 -1.63 -2.54 -1.82 -2.88 
miR-338-3p 29.70 25.30 51.57 18.54 28.16 44.69 23.43 19.01 27.81 1.40 16.28 27.43 
miR-339-5p -1.86 -1.43 -1.05 -1.50 -1.32 -1.40 -1.49 -2.01 -1.33 -3.39 -2.28 -3.20 
miR-340* 2.64 2.87 3.44 2.21 2.47 3.78 2.20 2.05 1.83 2.08 2.39 2.33 
miR-342-3p -2.23 -1.59 -1.40 -2.46 -1.73 -1.86 -1.35 -1.99 -1.63 -3.27 -1.93 -2.92 
miR-342-5p -1.43 -1.14 -1.33 -1.41 -1.28 -1.17 -1.15 -1.61 -1.36 -2.15 -1.35 -2.00 
miR-374b 3.86 4.47 7.53 3.93 5.08 6.87 7.94 3.25 6.87 1.27 2.39 2.13 



























miR-422a 3.74 4.82 6.30 2.65 3.86 5.90 4.56 2.32 3.11 2.28 3.05 2.66 
miR-423-3p -1.53 -1.35 -1.02 -1.23 -1.25 -1.28 -1.01 -1.63 -1.25 -2.00 -1.78 -2.37 
miR-423-5p -2.68 -2.31 -1.84 -3.05 -2.96 -2.72 -2.18 -2.98 -3.16 -9.16 -3.24 -4.24 
miR-424 7.62 7.99 15.14 8.46 9.98 13.43 17.95 6.57 13.59 3.59 3.66 3.83 
miR-425 2.30 2.58 3.21 1.94 2.54 2.56 3.44 1.92 2.71 1.38 1.72 1.32 
miR-454 11.57 8.54 14.74 8.77 10.33 16.37 20.18 8.58 17.87 4.63 5.88 4.80 
miR-483-5p 6.28 4.93 3.69 5.65 5.48 4.90 4.23 3.65 3.10 5.04 3.77 3.57 
miR-487b 5.03 5.30 5.00 3.41 3.51 6.35 4.73 2.41 3.03 3.81 6.50 4.89 
miR-488 3.30 2.34 2.19 5.81 3.88 6.71 3.72 5.18 3.14 1.47 4.71 3.65 
miR-491-3p 2.35 1.75 2.25 1.45 1.39 2.19 1.90 1.12 1.15 1.79 2.24 2.02 
miR-494 4.69 4.92 5.60 5.61 5.31 9.56 5.73 3.39 3.19 7.13 7.05 7.61 
miR-498 4.89 4.00 4.62 4.45 5.05 5.42 4.90 4.16 3.72 6.50 4.04 3.98 
miR-508-5p 5.39 5.79 4.54 2.80 2.71 5.57 3.68 1.67 2.30 5.72 5.02 3.26 
miR-513a-5p -1.74 -1.58 -1.33 -1.39 -1.24 -1.33 -1.74 -1.26 -1.70 -1.27 -1.84 -2.16 
miR-519d -3.40 -3.27 -3.28 -3.18 -2.62 -2.25 -2.89 -3.96 -4.33 -2.58 -2.63 -2.98 
miR-519e 1.31 1.16 1.87 1.65 1.87 1.84 1.34 1.84 1.56 1.72 1.00 1.23 
miR-519e* 2.51 2.90 2.86 2.11 2.41 2.67 2.59 1.83 1.54 2.95 2.54 2.09 
miR-525-5p 1.92 1.63 1.18 2.17 1.71 2.87 1.53 1.67 1.30 2.98 2.43 2.00 
miR-548e 9.89 11.85 11.59 6.09 6.40 10.86 9.10 7.02 7.51 10.74 11.50 11.05 
miR-548n 2.39 1.34 2.97 2.63 3.57 6.37 4.82 3.12 3.99 1.62 3.75 3.04 
miR-549 4.61 5.16 5.61 3.90 3.53 5.08 4.38 3.11 3.27 5.75 4.77 4.11 
miR-551b -1.36 -1.53 -1.14 -1.14 -1.15 -1.29 -1.38 -1.23 -1.42 -1.42 -1.63 -1.62 
miR-552 8.49 2.55 3.28 2.46 2.40 3.90 3.09 2.09 2.06 2.70 2.94 2.53 
miR-557 7.70 9.44 9.67 6.61 7.83 9.85 8.89 6.43 6.49 7.42 5.11 4.93 
miR-576-3p 1.46 1.61 2.17 1.29 1.42 1.64 1.51 1.54 1.29 2.06 1.46 1.42 



























miR-584 6.31 6.02 6.70 4.79 4.56 7.33 6.67 4.75 4.20 6.33 6.66 6.85 
miR-585 7.40 7.55 10.33 7.70 8.16 10.01 7.48 6.67 5.91 6.77 5.40 6.37 
miR-589 4.32 5.46 4.30 2.46 2.75 4.51 4.02 1.95 2.96 3.22 4.64 3.33 
miR-590-5p 10.78 12.65 25.93 10.18 14.47 21.69 25.69 11.58 19.80 1.65 5.47 4.88 
miR-597 5.01 5.61 4.02 3.86 3.78 7.85 4.98 2.23 3.36 3.21 7.45 5.18 
miR-600 4.58 3.13 2.85 3.44 2.59 4.66 2.29 2.63 2.65 4.48 5.12 4.31 
miR-602 2.04 2.33 2.75 2.83 2.84 3.90 2.75 2.34 2.16 1.84 2.11 2.21 
miR-611 3.20 4.84 6.23 2.87 3.28 3.04 3.95 3.18 3.09 2.51 1.77 1.32 
miR-617 3.01 2.43 3.19 1.89 1.97 3.10 1.42 1.74 1.09 2.27 2.69 2.13 
miR-623 2.79 2.53 2.37 4.56 2.88 6.76 2.39 2.98 2.81 3.37 3.12 2.19 
miR-629* 2.94 3.78 3.97 2.93 3.25 6.77 2.96 1.86 1.58 2.77 4.91 4.82 
miR-634 -4.54 -9.26 -37.22 -2.34 -3.30 -2.55 -2.98 -2.70 -3.99 -3.20 -2.50 -2.92 
miR-637 3.03 3.37 4.44 3.59 3.59 3.98 2.97 3.22 2.64 2.37 2.05 1.85 
miR-638 5.28 3.59 4.41 4.59 5.17 5.90 5.07 4.12 3.33 4.40 3.83 4.88 
miR-652 1.78 1.83 2.30 2.00 1.89 1.85 2.47 1.87 2.15 1.38 1.45 1.23 
miR-659 2.95 3.42 2.31 4.45 5.82 3.56 2.77 2.42 2.23 2.56 3.25 3.00 
miR-665 -1.87 -1.44 -1.47 -1.29 -1.03 -1.29 -1.22 -1.23 -1.74 -1.70 -1.71 -2.24 
miR-668 2.64 1.54 2.43 3.28 3.62 5.94 1.86 2.72 2.27 3.69 3.01 3.89 
miR-671-5p 3.87 3.16 2.14 5.00 5.08 6.24 6.33 3.72 3.55 6.18 5.53 6.36 
miR-675 5.48 4.98 3.06 7.15 9.13 8.10 5.94 3.91 3.49 5.47 6.34 7.67 
miR-765 1.26 1.46 1.53 1.51 1.79 1.51 1.27 1.23 1.08 1.66 1.26 1.31 
miR-874 1.64 1.08 1.55 2.69 2.62 3.86 2.41 2.36 1.90 1.78 2.83 2.65 
miR-887 4.99 4.21 4.01 3.37 3.71 5.57 4.51 2.62 2.32 4.48 4.69 4.63 
miR-888* 1.41 1.68 1.87 1.23 1.34 1.72 1.55 1.13 1.17 1.53 1.47 1.32 
miR-890 2.81 2.42 1.57 1.90 1.47 1.96 2.87 1.41 2.12 1.75 2.91 1.10 



























miR-923 -5.93 -4.23 -2.95 -4.49 -3.73 -4.63 -4.03 -3.96 -5.27 -4.86 -7.63 -8.18 
miR-933 3.04 3.22 4.30 2.22 2.32 3.15 2.45 1.73 1.56 3.22 2.64 2.72 
miR-934 2.95 1.64 1.62 2.01 2.08 3.04 1.63 2.54 1.73 2.74 3.12 2.34 
miR-937 2.19 2.09 1.41 1.75 1.48 3.26 2.41 1.14 2.08 3.49 3.47 2.13 
miR-943 2.13 1.10 1.28 3.90 3.76 3.37 3.16 2.91 2.14 3.62 2.29 2.93 
miR-1201 2.13 1.93 1.83 2.40 2.13 2.36 2.05 2.35 2.38 1.11 2.48 2.11 
miR-1255a 1.24 1.33 1.58 1.41 1.48 1.55 1.40 1.50 1.26 1.37 1.25 1.29 
miR-1259 2.64 2.09 3.22 1.95 1.93 2.40 1.89 1.85 2.02 3.14 2.82 2.81 
miR-1260 1.71 1.37 1.17 1.73 1.17 2.73 1.39 1.16 1.09 1.17 2.40 1.79 
miR-1261 7.05 9.21 9.86 8.52 7.87 11.12 7.68 7.42 5.66 4.67 6.32 4.12 
miR-1264 1.79 2.01 3.31 1.50 1.71 2.26 1.68 1.74 1.55 2.09 1.91 2.10 
miR-1265 -1.95 -1.86 -1.57 -2.41 -2.59 -1.97 -2.58 -2.79 -3.20 -2.30 -1.92 -2.79 
miR-1274a 4.32 4.30 4.97 5.34 5.17 12.29 5.11 2.90 2.99 4.18 7.63 7.84 
miR-1274b 8.45 8.75 10.06 4.81 4.82 10.06 5.76 3.15 3.81 6.06 8.68 8.06 
miR-1280 -1.93 -1.89 -1.51 -1.51 -1.96 -1.01 -1.78 -2.54 -2.54 -2.58 -1.25 -1.52 
miR-1297 5.80 5.29 9.35 5.57 9.96 13.77 14.31 4.91 9.92 2.39 3.67 3.43 
miR-1299 -1.70 -1.64 -1.23 -1.49 -1.32 -1.18 -1.59 -1.17 -1.62 -2.02 -1.42 -1.77 
miR-1301 1.38 1.31 1.20 1.30 1.16 1.66 1.98 1.05 1.38 1.16 1.57 1.31 
miR-1307 2.53 2.30 3.30 2.40 2.48 3.67 3.48 1.60 2.75 1.12 2.13 1.62 








3.5 miRNAs specific for various stroke subtypes 
From the previous results, the miRNA profiles demonstrated segregation of 
samples according to stroke subtypes. Hence, an in-depth analysis was 
performed to identify miRNAs specific for each of the stroke subtype. The 
results from the analysis yielded lists of miRNAs specific for each stroke 
subtype. 
For large artery (LA) stroke, there were 10 miRNAs (miR-27a*, -129-5p, -382, 
-585, -602, -637, -659, -744, -1184 and -1261) showing unique expression 
pattern for large artery stroke and were able to distinguish large artery stroke 
samples from the other samples (demonstrated by hierarchical clustering of 
samples; Figure 3.3A; Table 3.4). All of these 10 miRNAs were found to have 
higher expression in large artery stroke samples as compared to other stroke 
subtypes (CE and SV; Figure 3.3A; Table 3.4). 
As for cardioembolic stroke specific miRNAs, there were 14 miRNAs (miR-
19a, -130b*, -181a-2*, -198, -200b, -208a, -412, -525-5p, -550, -617, -618, -
630, -668 and -1321) detected (Figure 3.3B; Table 3.4). Among these 14 
miRNAs, 2 miRNAs (hsa-miR-19a and -550) had higher expression in 
cardioembolic stroke samples as compared with large artery stroke and small 
vessel stroke samples, while the remaining 12 miRNAs (miR-130b*, -181a-2*, 
-198, -200b, -208a, -412, -525-5p, -617, -618, -630, -668 and -1321) showed 
lower expression in cardioembolic stroke samples in contrast with large artery 
stroke and small vessel stroke samples (Figure 3.3; Table 3.4).  
In the case of small vessel stroke specific miRNAs, 141 miRNAs were 
detected as capable of distinguishing small vessel stroke samples from 
cardioembolic stroke samples and large artery stroke samples (Figure 3.3C; 
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Table 3.4). The expression of these 141 miRNAs was shown to be lower in 
small vessel stroke samples when compared against other stroke subtypes (CE 
and LA; Figure 3.3C; Table 3.4).  
Among these stroke subtype specific miRNAs, there were 8 miRNAs (miR-
19a, -129-5p, -198, -320b, -320d, -331-3p, -637 and -744) that were able to 
segregate the samples according to stroke subtype, shown in the hierarchical 
clustering of the samples (Figure 3.3D; Table 3.4). These 8 miRNAs (miR-19a, 
-129-5p, -198, -320b, -320d, -331-3p, -637 and -744)  may serve as potential 
diagnostic markers for stroke subtype and further investigation, especially 
pathway analysis could yield more information on the pathogenesis for 




















Figure 3.3: Hierarchical clustering of stroke subtype specific miRNAs. A. 
Large artery stroke specific miRNAs. B. Cardioembolic stroke subtype 
specific miRNAs. C. Small vessel stroke subtype specific miRNAs. D. 
MiRNAs that can segregate samples according to stroke subtype. The miRNA 
expression were expressed as signal log ratio (SLR) with respect to control 
samples Green represents down-regulation. Red represents up-regulation. 
Grey represents absence. LA: large artery stroke. CE: cardioembolic stroke. 
SV: small vessel stroke.   
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Table 3.4: List of stroke subtype specific miRNAs. miRNAs were expressed as fold change compared with healthy controls. ND represents not 
detected. LA: large artery stroke. CE: cardioembolic stroke. SV: small vessel stroke.  miRNAs highlighted in bold are able to segregate samples 
according to stroke subtypes.  
 
Hsa-miRNA LA 24hr LA 48hr LA 168hr CE 24hr CE 48hr CE 168hr SV 24hr SV 48hr SV 168hr 
LA specific miRNAs 
miR-27a* 6.69 6.86 10.87 6.06 6.03 4.55 5.05 5.34 4.35 
miR-129-5p 3.20 3.29 3.18 2.75 2.90 2.53 2.00 1.76 2.05 
miR-382 1.47 1.70 1.88 -1.06 1.36 1.03 1.38 1.43 1.07 
miR-585 7.70 8.16 10.01 7.48 6.67 5.91 6.77 5.40 6.37 
miR-602 2.83 2.84 3.90 2.75 2.34 2.16 1.84 2.11 2.21 
miR-637 3.59 3.59 3.98 2.97 3.22 2.64 2.37 2.05 1.85 
miR-659 4.45 5.82 3.56 2.77 2.42 2.23 2.56 3.25 3.00 
miR-744 1.52 1.48 1.72 1.36 1.25 1.35 -1.27 -1.08 -1.11 
miR-1184 1.25 1.29 2.05 1.05 -1.13 -1.13 -1.59 -1.04 -1.35 
miR-1261 8.52 7.87 11.12 7.68 7.42 5.66 4.67 6.32 4.12 
CE specific miRNAs 
miR-19a 1.93 2.00 2.02 2.77 2.03 2.52 1.26 1.25 1.75 
miR-130b* 1.89 1.96 3.25 -1.81 1.25 1.15 2.63 2.57 1.57 
miR-181a-2* 2.47 1.65 6.07 1.02 1.17 1.29 2.85 3.75 3.02 
miR-198 4.79 5.72 3.01 1.87 1.75 1.38 2.60 2.49 3.03 
miR-200b 1.37 1.68 2.20 1.28 1.16 -1.40 1.82 2.99 1.98 
miR-208a -2.47 -2.72 -1.52 -2.82 -2.79 -4.08 -2.14 -1.44 -2.23 
miR-412 -1.11 -1.57 -1.23 -4.66 -5.19 ND -4.16 -1.12 -3.01 
miR-525-5p 2.17 1.71 2.87 1.53 1.67 1.30 2.98 2.43 2.00 
miR-550 -1.00 1.03 -1.23 1.05 1.16 1.16 -1.18 -1.10 -1.25 
miR-617 1.89 1.97 3.10 1.42 1.74 1.09 2.27 2.69 2.13 
miR-618 3.52 2.62 3.37 ND 1.58 1.55 3.36 3.11 4.36 
miR-630 2.17 2.65 1.79 -1.38 1.67 -1.49 2.11 2.37 1.70 







Hsa-miRNA LA 24hr LA 48hr LA 168hr CE 24hr CE 48hr CE 168hr SV 24hr SV 48hr SV 168hr 
miR-1321 4.09 4.19 5.49 3.92 4.03 3.02 4.60 4.57 5.48 
SV specific miRNAs 
Let-7a 1.70 1.86 1.99 2.58 1.80 2.34 1.05 1.08 -1.09 
Let-7a* 4.13 4.22 6.89 4.84 3.51 4.26 -1.27 2.22 2.49 
Let-7b 1.00 1.25 1.03 1.87 -1.05 1.28 -1.45 -1.38 -1.90 
Hsa-miRNA LA 24hr LA 48hr LA 168hr CE 24hr CE 48hr CE 168hr SV 24hr SV 48hr SV 168hr 
Let-7b* 1.40 1.48 1.57 2.45 1.22 1.79 -3.08 -1.13 -1.42 
Let-7c 1.22 1.84 1.62 2.69 1.29 1.85 -1.10 -1.08 -1.44 
Let-7d 2.18 2.97 3.04 4.72 2.25 3.99 1.30 1.49 1.28 
Let-7d* -2.20 -2.26 -2.94 -2.35 -2.69 -2.16 -13.00 -3.86 -4.65 
Let-7e 2.72 3.83 4.08 5.41 2.60 3.91 1.99 2.08 1.67 
Let-7f 1.54 1.60 1.77 2.21 1.62 2.01 1.01 1.00 1.31 
Let-7g 1.52 2.30 2.08 3.38 1.72 3.22 -1.89 -1.55 -1.63 
Let-7i 1.16 1.98 1.60 3.11 1.28 2.69 -2.09 -1.84 -1.96 
miR-7 1.08 1.42 1.70 2.83 1.14 2.55 -1.75 -1.57 -1.68 
miR-15b* 8.24 7.56 12.53 16.42 6.38 13.15 1.40 3.21 3.22 
miR-16-2* 3.27 3.40 3.91 5.23 2.16 4.26 -2.45 -1.08 -1.68 
miR-17 1.99 2.06 2.28 2.85 2.09 2.59 1.05 1.22 1.07 
miR-17* 3.43 3.90 6.57 6.43 3.12 6.02 -1.03 2.22 2.01 
miR-18a 2.57 3.13 3.76 5.86 2.73 4.98 -1.59 1.44 1.08 
miR-18a* -1.03 1.15 1.14 1.35 -1.10 -1.14 -2.13 -1.21 -1.61 
miR-18b 2.15 2.72 3.45 5.01 2.25 4.02 -1.61 1.19 1.00 
miR-19b 2.72 2.82 3.12 3.91 2.87 3.54 1.57 1.77 2.69 
miR-20a 1.29 1.89 1.70 2.66 1.36 2.31 -2.43 -1.59 -1.83 
miR-20a* 4.15 4.56 6.03 7.45 3.54 7.89 -12.06 1.93 1.49 
miR-20b 2.43 3.82 4.47 5.12 2.15 3.69 -1.26 1.58 1.40 
miR-21 10.09 10.67 11.82 14.79 10.70 13.42 4.53 4.76 5.56 
miR-22* 1.03 1.20 1.47 1.75 -1.14 1.76 -3.04 -1.20 -1.51 
miR-24 1.16 1.42 1.67 2.01 1.17 2.14 -1.46 -1.10 -1.14 







Hsa-miRNA LA 24hr LA 48hr LA 168hr CE 24hr CE 48hr CE 168hr SV 24hr SV 48hr SV 168hr 
miR-26a 2.02 2.75 3.01 3.80 1.85 3.04 -1.27 1.06 -1.03 
miR-26b 1.84 1.90 2.11 2.64 1.94 2.39 -1.27 1.19 1.38 
miR-28-5p 2.23 3.35 3.16 5.81 2.64 4.69 -1.03 1.46 1.57 
miR-29a 5.14 5.59 8.00 12.14 4.38 9.52 2.16 2.63 2.21 
miR-29b 5.81 6.99 10.71 12.16 5.62 10.81 2.41 3.65 3.82 
miR-29c 5.94 6.08 8.74 14.80 5.69 12.56 1.35 2.74 2.29 
miR-29c* 3.68 4.43 5.45 5.51 2.60 5.69 2.02 2.54 1.73 
miR-30a 1.59 1.60 1.82 2.21 1.67 2.07 -1.29 1.03 1.29 
miR-30b 1.53 2.11 2.41 3.64 1.52 3.01 -1.48 -1.24 -1.51 
miR-30c 1.14 1.71 1.90 2.81 1.18 2.51 -2.84 -1.47 -1.70 
miR-30d 1.25 1.58 1.59 1.86 1.20 1.37 -1.73 -1.01 -1.28 
miR-30e 1.51 2.21 2.65 3.44 1.49 2.53 -2.14 -1.25 -1.47 
miR-30e* 1.47 2.20 2.63 3.43 1.57 2.74 -1.75 -1.10 -1.27 
miR-32 9.18 8.92 15.90 20.00 8.16 14.20 3.00 2.82 3.58 
miR-32* -1.99 -1.91 -2.27 -1.62 -1.72 -1.95 -2.43 -2.59 -3.01 
miR-96 2.26 3.46 3.71 4.93 2.47 4.09 -1.37 1.24 1.28 
miR-98 2.57 3.99 5.81 7.10 2.76 6.19 2.44 2.38 2.37 
miR-99a 1.12 2.10 1.32 2.33 2.34 1.36 -1.88 -1.49 -2.93 
miR-101 3.57 3.54 4.09 5.12 3.75 4.64 1.59 2.32 3.02 
miR-101* 7.76 10.59 11.79 13.72 6.18 11.12 1.52 3.22 2.84 
miR-103 2.92 3.03 3.35 4.19 3.08 3.81 2.13 1.90 2.34 
miR-106a 2.34 2.42 2.68 3.36 2.46 3.05 -1.41 1.50 1.34 
miR-106a* 3.82 3.76 5.18 4.53 2.07 3.04 ND 1.62 -5.12 
miR-106b 1.49 1.54 1.71 2.11 1.57 1.94 1.18 -1.03 1.17 
miR-106b* 1.52 1.67 1.92 2.44 1.20 2.05 -1.21 1.10 -1.16 
miR-107 2.44 3.12 3.35 4.40 2.46 3.99 1.48 1.66 1.41 
miR-125b -1.02 -1.25 -1.23 -1.21 -1.34 -1.11 -27.06 -2.51 -6.13 
miR-125b-2* 6.58 5.48 7.20 5.01 6.17 4.69 2.44 4.62 3.34 
miR-126 1.42 1.78 1.96 2.27 1.18 2.29 -1.86 -1.58 -1.89 







Hsa-miRNA LA 24hr LA 48hr LA 168hr CE 24hr CE 48hr CE 168hr SV 24hr SV 48hr SV 168hr 
miR-128 1.80 2.12 2.58 3.30 1.77 3.15 ND 1.26 -1.14 
miR-130a 1.31 1.65 1.63 1.67 1.16 1.48 -3.35 -1.30 -1.77 
miR-130b 1.13 1.44 1.47 2.00 1.08 1.59 -1.11 1.00 -1.38 
miR-135b 3.87 4.88 7.02 6.78 3.62 4.58 1.58 2.21 2.07 
miR-140-3p -1.01 1.39 1.31 2.10 1.13 1.74 -2.31 -1.24 -1.52 
miR-140-5p 6.50 9.30 14.93 15.41 7.08 13.24 3.44 4.52 4.63 
miR-142-5p 1.98 2.06 2.29 2.86 1.74 2.60 -1.54 1.05 -1.18 
miR-144* 3.03 3.14 3.47 4.35 3.19 3.95 2.76 1.97 2.59 
miR-146a 2.19 2.94 2.97 3.04 2.23 3.39 -2.24 1.23 -1.42 
miR-146b-5p 1.27 1.76 1.86 2.39 1.34 2.43 -1.53 -1.37 -1.96 
miR-148a 3.61 5.59 7.38 6.90 3.30 5.06 1.42 2.85 2.77 
miR-148b -1.10 1.28 1.26 1.79 -1.11 1.60 -4.93 -1.92 -2.25 
miR-149* 1.34 1.67 1.10 1.68 1.49 1.15 1.07 -1.34 -1.41 
miR-151-3p 1.20 1.32 1.55 2.62 1.21 2.44 -4.90 -1.56 -1.41 
miR-151-5p 1.22 1.80 1.60 2.93 1.48 2.65 -2.67 -1.40 -1.35 
miR-155 1.01 1.12 1.39 1.49 -1.06 1.48 -4.03 -1.43 -1.89 
miR-181a 1.73 1.97 2.09 2.78 1.52 2.37 -1.19 1.12 -1.02 
miR-181b 3.09 2.77 4.03 3.59 2.38 3.61 -1.21 2.10 1.71 
miR-182 1.08 1.50 1.44 2.59 1.13 2.27 -5.10 -1.61 -1.92 
miR-185 -1.52 -1.19 1.01 1.83 -1.58 1.58 -3.07 -2.36 -3.25 
miR-185* 1.07 1.20 1.10 1.14 1.07 -1.04 -1.39 -1.82 -2.02 
miR-186 1.42 1.75 1.61 2.68 1.28 2.35 -1.42 -1.31 -1.28 
miR-188-5p 6.85 5.34 11.73 7.91 5.69 9.66 ND 3.69 3.82 
miR-190 7.27 8.35 12.52 15.48 7.11 13.34 2.06 2.71 2.47 
miR-191 -1.07 1.18 -1.00 1.90 1.08 1.82 -2.60 -1.57 -1.83 
miR-192 1.81 2.30 2.83 3.88 1.69 3.11 -1.48 -1.09 -1.39 
miR-193a-3p 1.29 1.70 2.47 1.68 -1.02 1.38 ND -1.14 -1.54 
miR-194 2.11 2.25 2.98 4.04 1.60 3.88 -1.34 -1.04 -1.15 
miR-196b 4.86 4.70 6.70 5.31 3.52 6.00 -14.05 2.34 1.94 







Hsa-miRNA LA 24hr LA 48hr LA 168hr CE 24hr CE 48hr CE 168hr SV 24hr SV 48hr SV 168hr 
miR-215 1.86 2.46 3.07 4.01 1.82 3.15 -1.71 1.00 -1.12 
miR-221 3.95 6.20 6.28 6.77 3.62 5.51 1.99 3.24 3.14 
miR-222 1.30 1.68 1.84 2.01 1.03 1.90 -2.58 -1.03 -1.20 
miR-301a 2.05 2.64 3.42 6.03 2.46 5.40 -2.15 -1.12 -1.07 
miR-301b 3.16 2.93 5.32 8.13 3.10 8.75 ND 1.42 -1.60 
miR-320b -2.05 -1.82 -1.89 -1.00 -1.74 -1.81 -2.71 -2.19 -3.08 
miR-320d -1.48 -1.36 -1.49 1.23 -1.28 -1.30 -2.31 -1.75 -2.52 
miR-324-5p -1.45 -1.51 -1.83 1.05 -1.54 1.01 -2.72 -2.67 -2.99 
miR-331-3p 1.06 1.04 1.03 1.59 1.08 1.36 -2.50 -1.14 -1.70 
miR-331-5p -1.53 -1.42 -1.35 -1.00 -1.65 -1.63 -2.54 -1.82 -2.88 
miR-335 1.00 1.12 1.49 1.66 -1.13 1.57 -3.61 -2.26 -2.76 
miR-339-3p 1.35 1.62 1.41 1.50 -1.05 1.46 -1.74 -1.09 -1.46 
miR-339-5p -1.50 -1.32 -1.40 -1.49 -2.01 -1.33 -3.39 -2.28 -3.20 
miR-340 1.24 1.23 1.71 1.61 1.12 1.47 -1.70 1.01 -1.28 
miR-361-3p 1.59 1.96 1.62 2.95 1.93 2.06 1.14 1.03 -1.00 
miR-361-5p -1.07 1.00 1.01 1.42 -1.17 1.21 -1.56 -1.25 -1.38 
miR-362-3p 2.46 2.56 4.13 3.90 1.78 3.09 ND 1.00 -3.88 
miR-362-5p 1.01 1.40 1.37 2.35 1.10 1.83 -1.96 -1.55 -1.76 
miR-363 2.11 2.30 2.26 2.76 1.57 3.02 -1.99 -1.37 -1.56 
miR-374a 2.21 2.76 3.43 4.25 2.04 3.71 -2.52 -1.07 -1.22 
miR-374b 3.93 5.08 6.87 7.94 3.25 6.87 1.27 2.39 2.13 
miR-378 -1.24 1.08 1.01 1.66 -1.18 1.30 -3.62 -2.20 -2.52 
miR-381 2.47 1.91 2.86 1.98 2.62 1.86 -1.10 1.84 1.13 
miR-421 2.25 2.50 2.81 4.15 2.13 3.35 -1.29 1.52 1.50 
miR-423-3p -1.23 -1.25 -1.28 -1.01 -1.63 -1.25 -2.00 -1.78 -2.37 
miR-423-5p -3.05 -2.96 -2.72 -2.18 -2.98 -3.16 -9.16 -3.24 -4.24 
miR-424 8.46 9.98 13.43 17.95 6.57 13.59 3.59 3.66 3.83 
miR-425 1.94 2.54 2.56 3.44 1.92 2.71 1.38 1.72 1.32 
miR-425* 1.10 1.32 1.47 1.71 1.04 1.64 -2.07 -1.18 -1.29 







Hsa-miRNA LA 24hr LA 48hr LA 168hr CE 24hr CE 48hr CE 168hr SV 24hr SV 48hr SV 168hr 
miR-484 1.17 1.40 1.29 1.40 1.12 1.17 -1.39 1.00 -1.30 
miR-500 1.18 1.48 1.47 2.14 1.10 1.88 -1.36 -1.10 -1.51 
miR-500* -1.16 1.03 1.04 1.46 -1.27 1.05 -2.16 -1.42 -2.06 
miR-501-5p -1.53 -1.44 -1.68 1.02 -1.79 -1.11 -3.01 -2.64 -3.91 
miR-502-3p -1.31 -1.10 -1.16 1.35 -1.35 -1.11 -2.21 -1.68 -2.55 
miR-505 1.88 3.02 3.22 3.91 2.10 3.54 ND 1.21 -1.02 
miR-532-5p 1.29 1.50 1.61 2.06 1.11 1.90 -5.23 -1.37 -1.44 
miR-550* 1.46 1.67 1.61 2.24 1.27 1.96 -1.23 1.04 -1.29 
miR-551b -1.14 -1.15 -1.29 -1.38 -1.23 -1.42 -1.42 -1.63 -1.62 
miR-574-5p -1.07 -1.01 -1.26 1.17 -1.02 -1.02 -1.96 -1.40 -1.67 
miR-576-5p 1.12 1.07 1.27 1.72 -1.11 1.38 -1.14 -1.27 -1.41 
miR-590-5p 10.18 14.47 21.69 25.69 11.58 19.80 1.65 5.47 4.88 
miR-611 2.87 3.28 3.04 3.95 3.18 3.09 2.51 1.77 1.32 
miR-620 -1.32 -1.19 -1.06 -1.61 -1.09 -1.34 1.04 1.13 1.02 
miR-625 1.10 1.35 1.17 1.15 -1.11 1.02 -3.05 -1.37 -1.55 
miR-627 4.52 5.34 6.48 6.35 4.02 6.77 -2.33 3.72 1.80 
miR-628-3p 1.56 1.52 1.34 1.48 1.67 1.30 -1.50 -1.10 -1.27 
miR-629 -1.13 1.17 1.35 1.61 -1.03 1.12 -2.29 -1.42 -1.82 
miR-652 2.00 1.89 1.85 2.47 1.87 2.15 1.38 1.45 1.23 
miR-660 2.51 3.12 3.73 5.02 2.32 4.61 -1.21 1.04 -1.04 
miR-665 -1.29 -1.03 -1.29 -1.22 -1.23 -1.74 -1.70 -1.71 -2.24 
miR-1259 1.95 1.93 2.40 1.89 1.85 2.02 3.14 2.82 2.81 
miR-1284 2.95 3.18 1.74 2.76 3.77 2.54 2.10 1.64 2.18 







3.6 Pathway analysis of miRNAs with similar expression in acute ischemic 
stroke 
Previously, there were 147 miRNAs highlighted to show similar expression in 
all the ischemic stroke samples (Table 3.3). These miRNAs were used for 
pathway analysis to identify the dysregulated pathways in ischemic stroke 
patients. 
Pathway analysis was conducted in the following manner: The list of 147 
miRNAs was used to predict for their gene targets through miRWalk database 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html) [170]. The 
list of target gene was used for further analysis in an online gene annotation 
software, GENECODIS (http://genecodis.cnb.csic.es/) [212-214]. The result 
of the analysis produced a number of pathways found to be significantly (p-
value < 0.05) targeted by the 147 miRNAs. The pathways were annotated 
according to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
database [215-217]. The p-value of each pathway was converted to enrichment 










Figure 3.4: Top 100 biological pathways according to enrichment score, 
regulated by 147 miRNAs that showed similar expression in all the ischemic 
stroke samples.  
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From the pathway analysis, biological pathways associated with inflammation 
(Adipocytokine signaling pathway, B cell receptor signaling pathway, 
Chemokine signaling pathway, Complement and coagulation cascade, 
Cytokine-cytokine receptor interaction, Leukocyte transendothelial migration, 
T cell receptor signaling pathway and Toll-like receptor signaling pathway), 
cell death (Apoptosis, Natural killer cell mediated cytotoxicity and p53 
signaling pathway), neurons (Axon guidance, Glutamatergic synapse, Long-
term depression, Long-term potentiation, Neuroactive ligand-receptor 
interaction, Neurotrophin signaling pathway, Notch signaling pathway and 
Wnt signaling pathway), metabolic dysregulation (Glycerolipid metabolism, 
Glycerophospholipid metabolism, Glycine, serine and threonine metabolism, 
Glycolysis / Gluconeogenesis, Oxidative phosphorylation, Pyrimidine 
metabolism, Purine metabolism, Pyruvate metabolism and Valine, leucine and 
isoleucine degradation) and vascular permeability (Cell adhesion molecules 
(CAMs), ECM-receptor interaction,  Focal adhesion, Tight junction and 
VEGF signaling pathway) were detected  (Figure 3.4).  
Within the top 10 pathways, inflammation related biological pathways, 





, while other processes such as neuron related 
biological pathway (Neuroactive ligand-receptor interaction: ranked 4
th
) and 
metabolic dysregulation related biological pathway (Purine metabolism: 
ranked 7
th
) only had 1 biological pathway in the top 10 (Figure 3.4). This 





3.7 Pathway analysis of stroke subtype specific miRNAs  
In previous section (section 3.5), stroke subtype specific miRNAs were 
highlighted for each stroke subtype (large artery stroke, cardioembolic stroke 
and small vessel stroke). The list of miRNAs specific for each stroke subtype 
was used for pathway analysis to identify the pathways dysregulated in each 
stroke subtype and compared among the stroke subtypes. 
From previous results in section 3.5, 10 large artery specific miRNAs (miR-
27a*, -129-5p, -382, -585, -602, -637, -659, -744, -1184 and -1261), 14 
cardioembolic stroke specific miRNAs (miR-19a, -130b*, -181a-2*, -198, -
200b, -208a, -412, -525-5p, -550, -617, -618, -630, -668 and -1321) and  141 
small vessel stroke specific miRNAs were described (Figure 3.3A-C; Table 
3.4). These lists of miRNAs were therefore used for pathway analysis that was 














Figure 3.5: Top 100 biological pathways according to enrichment score, 
regulated by the 10 large artery stroke specific miRNAs (miR-27a*, -129-5p, -







Figure 3.6: Top 100 biological pathways according to enrichment score, 
regulated by the 14 cardioembolic stroke specific miRNAs (miR-19a, -130b*, 








Figure 3.7: Top 100 biological pathways according to enrichment score, 




The results of the pathway analysis showed that the biological pathways 
previously detected in 147 miRNAs showing similar expression in all 
ischemic stroke samples, were also detected, such as biological pathways 
associated with inflammation (Adipocytokine signaling pathway, B cell 
receptor signaling pathway, Chemokine signaling pathway, Complement and 
coagulation cascade, Cytokine-cytokine receptor interaction, Leukocyte 
transendothelial migration, T cell receptor signaling pathway and Toll-like 
receptor signaling pathway), cell death (Apoptosis, Natural killer cell 
mediated cytotoxicity and p53 signaling pathway), neurons (Axon guidance, 
Glutamatergic synapse, Long-term depression, Long-term potentiation, 
Neuroactive ligand-receptor interaction, Neurotrophin signaling pathway, 
Notch signaling pathway and Wnt signaling pathway), metabolism 
dysregulation (Glycerolipid metabolism, Glycerophospholipid metabolism, 
Glycine, serine and threonine metabolism, Glycolysis / Gluconeogenesis, 
Oxidative phosphorylation, Pyrimidine metabolism, Purine metabolism, 
Pyruvate metabolism and Valine, leucine and isoleucine degradation) and 
vascular permeability (Cell adhesion molecules (CAMs), ECM-receptor 
interaction,  Focal adhesion, Tight junction and VEGF signaling pathway) 
(Figure 3.5, 3.6 and 3.7)  
While comparing the biological pathways detected in each stroke subtype, 
there were biological pathways which were distinctly detected for a particular 
stroke subtype. The biological pathways, Arginine and proline metabolism and 
Glycosphingolipid biosynthesis - ganglio series, were only found among the 
biological pathways regulated by large artery stroke specific miRNAs (Figure 
3.5). Also, biological pathways, ABC transporters, Glycosphingolipid 
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biosynthesis - lacto and neolacto series, Inositol phosphate metabolism and 
Pyruvate metabolism, were specifically found in the pathway analysis of 
miRNAs specific for cardioembolic stroke (Figure 3.6). As for small vessel 
stroke, there were 2 biological pathways (Glycerolipid metabolism and PPAR 
signaling pathway) that were exclusively present (Figure 3.7). Furthermore, 
there were biological pathways commonly detected in all stroke subtypes but 
showed major difference in the ranks between respective groups. B cell 
receptor signaling pathway and Cell adhesion molecules (CAMs) were highly 
ranked in large artery stroke as compared with cardioembolic stroke and small 
vessel stroke, while Tight junction was having lower rank in large artery 
stroke compared with other stroke subtype (Table 3.5). The biological 
pathways, Dilated cardiomyopathy, Gap junction and Glycerophospholipid 
metabolism, were having higher ranks in cardioembolic stroke, whilst 
Adherens junction and Complement and coagulation cascades were very lowly 
ranked in cardioembolic stroke (Table 3.5). As for small vessel stroke, 
Chemokine signaling pathway and TGF-beta signaling pathway were scored 
higher compared with other stroke subtypes (Table 3.5). On the other hand, 
the biological pathways, Amino sugar and nucleotide sugar metabolism and 












Table 3.5: List of biological pathways with distinct ranks for respective stroke 




LA CE SV 
Adherens junction 52 98 57 
Amino sugar and nucleotide sugar metabolism 67 66 98 
B cell receptor signaling pathway 9 36 46 
Cell adhesion molecules (CAMs) 6 19 20 
Chemokine signaling pathway 28 22 5 
Complement and coagulation cascades 51 99 51 
Dilated cardiomyopathy 62 47 62 
Gap junction 88 10 78 
Glycerophospholipid metabolism 85 44 88 
TGF-beta signaling pathway 76 77 40 
Tight junction 54 29 26 









The 8 miRNAs (miR-19a, -129-5p, -198, -320b, -320d, -331-3p, -637 and -
744) that have been selected, which segregated the samples according to 
stroke subtypes, were also subjected to pathway analysis (Figure 3.3D; Table 
3.4). The results of the analysis highlighted biological pathways such as ABC 
transporters, Amino sugar and nucleotide sugar metabolism, B cell receptor 
signaling pathway, Cell adhesion molecules (CAMs), Chemokine signaling 
pathway, Complement and coagulation cascades, Dilated cardiomyopathy, 
Gap junction, Glycerophospholipid metabolism, Glycosphingolipid 
biosynthesis - lacto and neolacto series, TGF-beta signaling pathway, Tight 
junction and VEGF signaling pathway (Figure 3.8). Among these biological 
pathways, the inflammation related pathways, B cell receptor signaling 





respectively. This signified that the dysregulation of inflammatory processes 
may differ between different stroke subtypes which may be potential markers 














Figure 3.8: Top 100 biological pathways according to enrichment score, 
regulated by the 8 miRNAs (miR-19a, -129-5p, -198, -320b, -320d, -331-3p, -














Minimal or no risk ischemic stroke 
patients - implication of 












4.1 Risk factors of ischemic stroke 
Ischemic stroke can be viewed as a possible end point for patients afflicted by 
metabolic syndrome. The pathogenesis of ischemic stroke in an individual is a 
process which intertwines with multiple pre-existing risk factors such as 
hypertension, dyslipidaemia and type 2 diabetes, to bring about a possible 
final disorder, cerebral ischemia. However, there are reports in current 
literature discussing the implication of miRNAs in the pathogenesis and 
pathophysiology of these risk factors. 
Hypertension is the chronic increase of blood pressure above that of the 
normal blood pressure (Diastolic blood pressure: < 90 mmHg; Systolic blood 
pressure: < 140 mmHg; Table 4.1) [24]. Hypertension results in an increased 
sheer stress on the endothelial cells, leading to endothelial dysfunction and 
atherogenesis [26]. miRNA profiling had been performed in essential 
hypertension (most common form of hypertension) patients, demonstrating 
miRNA involvement in pathogenesis of essential hypertension [218]. 
Furthermore, miR-9 and -126 were reported to show lower level in blood of 
essential hypertension patients [219].  In addition, miR-21 and -26b were 
demonstrated to be involved in hypertension induced arterial remodelling 
[220]. Karolina et al [221] had also highlighted exosomal miR-130a and -195 
as contributors to hypertension. 
Dyslipidaemia is characterized by abnormal amount of lipids present in 
circulation. Clinically, it is defined as the following: having total cholesterol ≥ 
5.2 mmol/L, triglyceride level ≥ 1.8 mmol/L, high density lipoprotein (HDL) 
≤ 1.0 mmol/L and low density lipoprotein (LDL) ≥ 3.4 mmol/L (Table 4.1) 
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[33]. Dyslipidaemia often results in the deposition of excess lipid within the 
endothelium, leading to plaque formation. Similarly, miRNA profiling had 
been performed in humans as well as in animal models [221-224]. miRNA 
profile was obtained from baboon animal model for dyslipidaemia where the 
animals were fed high-cholestrol and high fat diet [222].  This study 
demonstrated miRNA dysregulation during dyslipidaemia. In addition, 
miRNA profile performed in human highlighted miRNAs associated with 
dylipidaemia. Circulating miR-21 was observed to be decreased in South 
Asian male with atherogenic dyslipidaemia and exosomal miR-23a, -197 and -
509-5p were associated with dyslipidaemia [221, 223]. Liu et al [224] also 
reported miR-17-92 cluster was associated with dyslipidaemia in patients with 
coronary artery disease. 
Type 2 diabetes is a disorder characterized by hyperglycemia due to insulin 
resistance or lack of insulin. This is diagnosed by measuring fasting glucose (> 
6.1 mmol/L) and HbA1c (≥ 7%; Table 4.1) [40, 41]. The excessive glucose 
present in circulation can lead to endothelial dysfunction and promote 
formation of atherosclerotic plaque. miRNAs had also been shown to be 
involved in its pathophysiology and pathogenesis. miRNA profile of type 2 
diabetes patients had been reported to demonstrate dysregulation of miRNA 
during onset of type 2 diabetes [225-227]. Moreover, miRNA expression in 
tissues affected by type 2 diabetes were also determined and showed miRNA 
dysregulation in these tissues as well [228, 229].   
Given that risk factors of ischemic stroke also alters miRNA expression, it is 
imperative to look into the dysregulation of miRNA in no risk ischemic stroke 
patients so as to determine which miRNAs‘ expression become altered solely 
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due to ischemic stroke. Not to mention, the condition of no risk ischemic 
stroke patient is related most closely to the experimental setting for cellular 
and animal models of ischemic stroke, which could be compared with. Hence, 
this study was dedicated to identify miRNAs and the biological pathways that 
they regulate as a way of bridging clinical data with experimental data. 
 
Table 4.1: Clinical measurements for risk factors of ischemic stroke [23]. 
Risk factor Clinical parameters 
Hypertension Blood pressure > 140/90 mmHg 
Dyslipidaemia Total cholesterol level ≥ 5.2 mmol/L, triglyceride 
level ≥ 1.8 mmol/L, high density lipoprotein (HDL) ≤ 
1.0 mmol/L and low density lipoprotein (LDL) ≥ 3.4 
mmol/L. 
Type 2 diabetes Fasting blood glucose > 6.1 mmol/L or HbA1c ≥ 7% 
Smoking Smoked > 10 cigarettes per day for more than one 
year 
Alcohol consumption Intake ≥ 30g of ethanol per day 











4.2 Patient recruitment and sample collection 
Similar to chapter 3, patients were recruited from University Malaya Medical 
Centre (UMMC), Kuala Lumpur, Malaysia via the Neurology service and 
Accident and Emergency (A&E). Ischemic stroke was confirmed by magnetic 
resonance imaging (MRI) or computed tomography (CT) scan. Blood samples 
were collected after patient discharge during their follow-up at outpatient 
clinics (3 months onwards). The whole blood was stored in RNAlater™ 
(Ambion, Life Technology, Carlsbad, CA, USA) according to manufacturer‘s 
protocol and stored at -80°C until required. 
For low or no risk ischemic stroke patients, stringent exclusion criteria were 
implemented. Exclusion criteria included hypertension, dyslipidaemia, 
diabetes, cardiac ailments, previous stroke, transient ischemic attack (TIA) 
cancer and other inflammatory diseases. Similar to acute ischemic stroke 
patients (Chapter 3), the patients classified into the different stroke subtypes 
according to TOAST classification and outcomes of patients represented by 
modified Rankin scale (mRS) [8, 211]. For research purposes, mRS was 
dichotomized into good and poor outcome. In general, mRS < 2 were denoted 
as good outcome, while mRS ≥ 2 indicated poor outcome. 
There were a total of 8 low or no risk ischemic stroke patients, of which, 
majority of the patients were large artery stroke (n=6), while there were only 1 
cardioembolic stroke and 1 small vessel stroke (Table 4.2). As low or no risk 
patients are rather limited and difficult to recruit, further studies were carried 
out with these available patients.  
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For healthy control samples, healthy volunteers were recruited for this study. 
Exclusion criteria included hypertension, dyslipidaemia, diabetes, cardiac 
ailments, previous stroke, cancer and other inflammatory diseases. 
 
Table 4.2: Patient demographics of ischemic stroke patients with low or no 
risk factors. 
 
 Low or no risk ischemic stroke 
(n=8) 
Male, n (%) 6 (75.0%) 
Female, n (%) 2 (25.0%) 
Age, mean ± standard deviation 36.7 ± 8.48 
Stroke Subtype 
Large-artery atherosclerosis, n (%) 6 (75.0%) 
Cardioembolic, n (%) 1 (12.5%) 
Small vessel occlusion, n (%) 1 (12.5%) 
Functional outcome (mRS) 
mRS <2, n (%) 7 (87.5%) 
mRS ≥2, n (%) 1 (12.5%) 
Blood test results for risk factors 
Cholesterol, mmol/L, mean 5.20 
Triglyceride, mmol/L, mean 1.57 
HDL, mmol/L, mean 1.10 
LDL, mmol/L, mean 3.51 
Fasting glucose, mmol/L, mean 5.81 










4.3 miRNA profiles of low or no risk ischemic stroke patients 
Ribopure™ Blood RNA purification kit (Ambion, Life Technology, Carlsbad, 
CA, USA) was used to isolate total RNA (including small RNAs). Similar to 
acute ischemic stroke samples, Nanodrop™ N2000C spectrophotometer 
(Thermo Scientific™, Rockford, IL, USA) and RNA gel electrophoresis (1% 
agarose) was used to measure RNA concentration and determine integrity. 
Small RNAs species (less than 200 nucleotides) was visualised using 
denaturing polyacrylamide gel electrophoresis (15% polyacrylamide). 
RNA samples were used on the same miRNA microarray platform, 
miRCURY LNA™ miRNA array. Same selection criteria (raw signal 
intensities > 0 and FDR < 0.05) were also applied for this cohort of patient 
samples. The results were also visualized on TMEV [209]. 
Three hundred and fifty two (352) miRNAs were detected in this cohort of 
patients (Figure 4.1, 4.2; Supplementary table 2). The hierarchical clustering 
showed that the control samples segregated away from the ischemic stroke 








Figure 4.1: Hierarchical clustering analysis of 352 miRNAs in low or no risk 
ischemic stroke patients and healthy controls. The miRNA expression were 
expressed logarithm of raw intensity. Green represents low signal intensity. 
Red represents high signal intensity. Grey represents absence. LA: large artery; 





Figure 4.2: Heatmap of 352 miRNAs in low or no risk ischemic stroke 
patients. The miRNA expression were expressed as signal log ratio (SLR) with 
respect to control samples. Green represents down-regulation. Red represents 
up-regulation. Grey represents absence. LA: large artery; CE: cardioembolic; 
SV: small vessel 
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4.4 miRNAs with similar expression in all ischemic stroke samples 
Among the 352 miRNAs, there were 111 miRNAs that showed similar 
expression in all the low or no risk ischemic stroke patients (Table 4.3).  54 
miRNAs were down-regulated in all the low or no risk samples while 57 
miRNAs were up-regulated in all the low or no risk samples (Table 4.3).  
In comparison with the 147 miRNAs that showed similar expression in all the 
acute ischemic stroke samples, there were 38 miRNAs (let-7d*, -7f, miR-15a, 
-29b-2*, -32*, -92b, -103, -125b-2*, -138-1*, -142-3p, -146b-3p, -196a*, -
200b*,  -302c*, -320b, -320c, -331-5p, -374b*, -423-3p, -423-5p, -487b, -488, 
-494, -498, -508-5p, -576-3p, -585, -617, -659, -668, -887, -923, -934, -943, -
1255a, -1299, -1301 and -1321) that were common between the 2 cohorts 
(Figure 4.3). Among these 38 miRNAs, 27 miRNAs (let-7d*, miR-29b-2*, -
32*, -125b-2*, -146b-3p, -196a*, -200b*,  -302c*, -320b, -320c, -331-5p, -
374b*, -423-3p, -423-5p, -488, -494, -498, -576-3p, -585, -659, -668, -923, -
934, -943, -1255a, -1299 and -1321) showed similar expression in both 
cohorts (Figure 4.3). These 27 miRNAs were considered to provide clues to 








Table 4.3: Expression of 111 miRNAs showing similar expression in low or no risk ischemic stroke sample. miRNAs were expressed as fold 























Let-7a -1.75 -1.01 -1.78 -2.55 -2.06 -3.09 -2.04 -5.00 
Let-7b -1.81 -1.23 -2.43 -3.72 -2.17 -3.31 -3.30 -3.11 
Let-7c -1.36 -1.02 -2.39 -3.34 -1.91 -3.22 -2.88 -3.22 
Let-7d* -1.43 -1.48 -2.44 -5.39 -1.82 -2.80 -3.77 -1.53 
Let-7f -2.03 -1.18 -1.84 -1.94 -2.40 -1.29 -1.35 -2.35 
miR-7 1.88 1.39 -2.20 -1.33 -2.01 -1.67 -1.92 -4.82 
miR-15a -1.76 -1.02 -1.59 -1.67 -2.07 -1.29 -1.77 -4.39 
miR-15b -2.63 -1.53 -2.38 -2.51 -3.11 -1.54 -1.75 -2.87 
miR-16 -2.64 -1.53 -2.38 -2.51 -3.11 -1.54 -1.76 -2.87 
miR-18a* -1.04 -1.13 -1.64 -2.32 -1.21 -1.39 -2.60 -1.78 
miR-22 -2.60 -1.51 -2.35 -2.48 -3.07 -1.52 -1.73 -2.83 
miR-26b* 2.14 1.66 1.43 1.40 1.64 1.50 1.06 1.51 
miR-29a* 4.12 3.88 3.09 3.39 2.52 4.22 1.98 2.04 
miR-29b-2* 2.13 1.47 1.51 1.33 1.73 1.30 1.01 1.02 
miR-30a -1.98 -1.15 -1.79 -1.89 -2.33 -1.29 -1.87 -2.16 
miR-32* -1.44 -1.31 -1.18 -2.16 -1.20 -1.80 -2.05 -1.26 
miR-92b -1.19 -1.16 -1.42 -2.20 -1.24 -1.45 -1.68 -1.34 
miR-93 -2.05 -1.19 -1.86 -2.16 -2.42 -2.06 -2.78 -2.74 
miR-103 -1.07 -1.21 -1.90 -3.41 -1.33 -2.97 -3.72 -6.31 
miR-122 -2.20 -2.07 -1.97 -2.15 -3.32 -1.86 -1.70 -2.79 





























miR-125b-2* 1.72 1.41 1.99 1.05 1.09 -1.23 2.04 1.20 
miR-130b* 1.96 2.00 2.40 1.67 2.01 1.63 1.93 2.24 
miR-138-1* -1.16 -1.03 -1.10 -1.33 -1.37 -1.14 -1.65 -1.50 
miR-138-2* 2.75 2.85 1.90 1.34 1.27 -1.02 -1.85 -5.57 
miR-142-3p -1.76 -1.02 -2.05 -1.68 -2.07 -1.19 -1.79 -6.45 
miR-144 -2.56 -1.49 -2.31 -2.44 -3.02 -1.49 -1.70 -2.79 
miR-145 2.70 2.19 1.80 2.52 2.77 5.20 3.17 2.58 
miR-145* 1.12 1.18 1.67 1.19 1.33 1.53 1.07 1.12 
miR-146b-3p 1.29 1.57 1.86 1.35 1.74 1.27 1.16 1.57 
miR-186 -1.15 -2.02 -3.77 -5.11 -2.43 -2.92 -7.72 -5.19 
miR-191 -2.09 -1.22 -1.89 -2.02 -2.47 -1.73 -1.83 -2.28 
miR-196a* 1.48 1.13 1.39 1.90 1.50 1.45 1.94 1.29 
miR-199b-5p 3.70 2.31 1.50 2.02 1.72 1.74 2.11 1.26 
miR-200b* 1.40 1.52 1.51 1.05 1.12 -1.36 2.00 1.52 
miR-299-3p 1.14 1.28 1.59 1.28 1.54 2.20 1.58 1.37 
miR-302c* 1.84 1.77 1.86 1.54 1.20 1.78 1.21 1.26 
miR-302e 2.09 2.24 1.71 1.36 1.42 1.41 1.70 1.03 
miR-320a -1.75 -2.06 -1.76 -4.26 -2.06 -2.90 -4.80 -2.22 
miR-320b -1.64 -2.16 -1.92 -4.07 -1.88 -3.03 -5.01 -2.27 
miR-320c -1.76 -1.15 -1.60 -2.37 -2.08 -1.68 -2.35 -1.92 
miR-320d -1.11 -1.44 -1.42 -2.89 -1.32 -2.06 -3.24 -1.66 
miR-328 1.71 1.47 1.61 1.46 2.02 2.14 1.11 1.50 
miR-331-5p -1.55 -2.90 -2.96 -4.27 -1.93 -4.85 -9.51 -4.45 
miR-345 2.72 2.96 1.47 1.51 2.50 2.12 1.40 1.27 





























miR-363* 1.37 1.23 2.24 2.74 1.64 2.03 1.91 1.52 
miR-365 2.10 2.54 1.31 1.46 2.51 1.90 1.21 1.03 
miR-374b* 1.74 1.43 1.79 1.60 1.69 1.39 1.40 1.73 
miR-382 1.41 1.66 1.51 1.19 1.18 1.29 1.88 1.65 
miR-412 -1.26 -1.48 -1.23 -1.81 -1.34 -1.94 -1.85 -1.38 
miR-421 -1.33 -2.60 -1.92 -2.15 -1.72 -2.73 -2.60 -3.42 
miR-423-3p -1.35 -1.30 -1.76 -2.78 -1.31 -1.25 -3.27 -1.22 
miR-423-5p -2.05 -1.87 -1.99 -4.06 -2.41 -2.24 -3.88 -2.23 
miR-450a 1.57 1.50 1.88 2.63 1.69 2.59 2.19 1.28 
miR-451 -2.63 -1.53 -2.38 -2.51 -3.11 -1.54 -1.75 -2.87 
miR-486-5p -2.64 -1.53 -2.38 -2.51 -3.11 -1.54 -1.75 -2.87 
miR-487b -1.10 -1.56 -1.26 -1.65 -1.31 -1.14 -2.12 -2.83 
miR-488 2.75 2.82 2.30 1.23 1.21 1.30 2.15 1.02 
miR-490-3p 2.20 1.34 3.01 1.77 3.15 1.71 1.09 3.03 
miR-494 1.76 1.69 1.61 1.64 1.39 2.16 1.47 1.35 
miR-498 1.30 1.62 1.64 1.37 1.25 1.66 1.77 1.50 
miR-501-5p -1.19 -1.79 -1.80 -3.54 -1.59 -2.84 -5.25 -2.89 
miR-502-5p -1.26 -1.10 -1.66 -2.82 -2.17 -2.35 -1.81 -3.77 
miR-504 -7.13 -8.12 -4.50 -4.06 -4.40 -4.53 -5.74 -4.43 
miR-505* -1.22 -1.30 -1.42 -2.12 -1.34 -1.96 -2.07 -1.72 
miR-508-5p -1.09 -1.49 -1.08 -1.53 -1.70 -2.38 -1.26 -2.40 
miR-513a-3p 2.19 2.71 1.39 1.13 1.17 1.34 1.51 1.18 
miR-516a-5p -2.17 -2.73 -2.00 -3.10 -2.35 -3.38 -3.71 -2.07 
miR-516b 1.61 1.60 1.98 2.01 1.70 1.79 1.81 1.77 





























miR-550* -1.03 -1.45 -1.54 -3.39 -1.10 -2.20 -3.20 -1.77 
miR-551a 1.58 2.02 1.52 1.48 1.57 2.05 1.57 1.24 
miR-553 2.56 3.11 3.09 1.42 1.45 1.39 2.42 1.39 
miR-576-3p 1.21 1.32 1.59 1.43 1.77 1.55 1.50 1.89 
miR-578 1.34 1.94 1.86 2.34 1.33 3.57 2.81 1.60 
miR-581 1.07 1.08 1.55 1.84 1.20 2.72 1.92 1.35 
miR-585 1.76 3.34 2.19 2.85 1.26 3.23 3.88 1.35 
miR-601 2.26 1.97 2.46 2.70 2.21 3.48 2.10 2.26 
miR-615-3p 2.14 2.04 2.36 2.01 1.78 2.38 1.90 1.66 
miR-617 -1.56 -1.24 -1.12 -1.57 -1.46 -1.89 -1.21 -1.53 
miR-618 1.78 1.84 1.92 1.99 1.77 2.68 2.63 1.95 
miR-620 1.42 1.38 1.93 1.46 1.91 1.51 1.57 2.42 
miR-625* -1.29 -1.48 -1.30 -1.38 -1.50 -1.10 -1.51 -1.52 
miR-629 -1.02 -1.46 -2.57 -2.36 -1.02 -2.05 -2.84 -2.15 
miR-630 1.11 1.31 1.88 1.15 1.62 1.24 1.29 1.69 
miR-642 -1.41 -1.08 -1.15 -1.56 -1.33 -1.23 -1.46 -1.23 
miR-659 1.46 1.41 1.70 1.38 1.55 1.55 1.53 1.55 
miR-664 1.73 2.28 1.90 1.64 1.69 2.08 1.71 1.44 
miR-668 1.19 2.77 2.38 2.55 1.51 2.77 2.76 1.68 
miR-720 -2.26 -1.31 -2.04 -2.15 -2.66 -1.32 -1.52 -2.46 
miR-769-5p -1.13 -4.27 -1.69 -2.19 -1.05 -1.81 -16.31 -2.36 
miR-877 -2.27 -2.79 -2.11 -2.43 -1.93 -1.69 -2.77 -1.85 
miR-877* 2.40 2.77 2.41 2.56 1.59 3.79 2.62 2.03 
miR-887 -1.72 -3.23 -1.61 -2.49 -2.20 -2.25 -4.29 -2.57 





























miR-923 -1.81 -2.22 -1.64 -4.71 -2.14 -3.84 -3.36 -1.98 
miR-934 1.35 1.21 1.98 1.39 1.70 1.17 1.32 1.60 
miR-941 -1.81 -2.47 -5.79 -2.20 -4.17 -3.87 -2.95 -2.60 
miR-942 3.02 1.45 3.37 4.37 2.71 4.45 2.93 2.64 
miR-943 2.30 3.89 2.27 1.84 1.34 2.66 3.34 1.22 
miR-1227 1.98 2.41 2.57 2.37 1.78 3.12 2.53 1.59 
miR-1249 2.00 2.43 1.56 1.66 1.23 2.50 2.07 1.22 
miR-1255a 1.03 1.43 1.52 1.38 1.50 1.37 1.16 1.50 
miR-1275 -1.67 -1.44 -2.07 -2.29 -2.37 -2.64 -1.90 -2.21 
miR-1285 1.44 2.44 1.61 1.34 1.23 1.84 1.72 1.34 
miR-1299 -1.41 -1.33 -1.02 -2.10 -1.08 -1.61 -2.05 -1.24 
miR-1301 -1.07 -1.21 -1.56 -1.97 -1.40 -1.94 -1.86 -1.82 
miR-1304 2.07 1.22 2.28 1.65 3.48 -1.08 1.22 2.01 
miR-1321 1.18 1.29 1.51 1.32 1.42 1.24 1.28 1.48 













Figure 4.3: Hierarchical clustering (HCL) of 38 miRNAs commonly detected 
as ischemic stroke specific miRNAs. The miRNA expression were expressed 
as signal log ratio (SLR) with respect to control samples. Green represents 





4.5 miRNA profile in low or no risk large artery stroke patients 
In this cohort, the samples were derived from low or no risk ischemic stroke 
patients. Due to the exclusive nature of the samples, there were only 8 samples 
in this cohort. 6 of the 8 samples were classified as large artery (LA) stroke 
samples (according to TOAST classification; Table 4.2). In-depth analysis was 
carried out on these 6 samples to identify the underlying relationship between 
the miRNA expression and large artery stroke pathophysiology. Principal 
component analysis (PCA) was used for analysis. In brief, PCA transforms the 
miRNA expression profile of each sample into 3 principal components and 
these components form coordinates in a 3-dimensional plot (PCA plot). The 
spatial location of the sample represents the underlying relationship between 
the samples. PCA was performed and visualized on the TMEV [209].  
In the PCA plot, the samples appeared to be distributed in a radial fashion 
according to the functional outcome of the patients (Figure 4.4). The patients 
with good functional outcome (LB, LX and BB; mRS=1) were clustered 
together in the center of the PCA plot, while patients with mRS=2 (LC and E) 
segregated along the periphery of the cluster of patients with mRS=1 (Figure 
4.4). Sample DB with mRS=4 was located at the extreme periphery of the plot 
(Figure 4.4). Hence, the miRNA profiles of low or no risk large artery stroke 
patients were associated with the functional outcome of patients. 
Upon closer inspection, there was group of 24 miRNAs (let-7e, miR-125b, -
125b-2*, -138-2*, -150, -181a-2*,  -195, -200b*, -206, -208a, -214, -221, -
221*, -361-5p, -509-5p, -519e*, -574-3p, -635, -636, -874, -937, -1275, -1304 
and -1827) which showed a differential expression between patients with mRS 
≤ 2 (BB, E, LB, LC and LX) and patient with mRS > 2 (DB; Table 4.4). 
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Amongst these 24 miRNAs, 2 miRNAs (miR-208 and -636) were found to be 
up-regulated only in DB (mRS > 2) and down-regulated in other samples with 
mRS ≤ 2 (BB, E, LB, LC and LX; Table 4.4). Whilst the other 22 miRNAs 
(let-7e, miR-125b, -125b-2*, -138-2*, -150, -181a-2*,  -195, -200b*, -206, -
214, -221, -221*, -361-5p, -509-5p, -519e*, -574-3p, -635, -874, -937, -1275, -
1304 and -1827) were up-regulated in large artery samples with mRS ≤ 2 and 
showing opposite expression in DB (mRS > 2; Table 4.4). However, due to 
the small sample size, further investigation in a larger cohort will be required 





















Table 4.4: 24 miRNAs that showed differential expression between patients with mRS ≤ 2 and patient with mRS > 2. Expression of miRNAs 
were presented as fold change with respect to healthy controls. 
 













Let-7e 1.83 1.57 1.71 2.04 1.00 -1.12 
miR-125b 2.03 1.43 2.35 1.10 1.82 -1.39 
miR-125b-2* 1.41 1.99 1.09 1.72 1.05 -1.23 
miR-138-2* 2.85 1.90 1.27 2.75 1.34 -1.02 
miR-150 1.54 1.48 2.14 2.39 1.32 -1.74 
miR-181a-2* 1.86 1.50 1.42 2.94 1.10 -1.75 
miR-195 1.84 1.04 2.04 3.44 1.13 -2.02 
miR-200b* 1.52 1.51 1.12 1.40 1.05 -1.36 
miR-206 3.46 1.43 1.19 1.49 1.07 -1.48 
miR-208a -1.11 -1.36 -1.58 -1.15 -1.41 1.10 
miR-214 1.58 1.77 1.86 1.84 1.04 -1.49 
miR-221 1.39 1.30 1.66 3.28 1.07 -1.26 
miR-221* 1.61 1.82 1.59 2.07 1.19 -1.45 
miR-361-5p 1.14 1.29 1.73 2.03 1.26 -1.19 
miR-509-5p 1.86 2.22 2.03 2.07 1.21 -1.30 
miR-519e* 1.15 2.27 1.91 1.89 1.11 -1.09 
miR-574-3p 1.20 1.62 1.73 1.68 1.01 -1.06 
miR-635 2.75 2.06 1.05 2.02 1.09 -3.06 








Hsa-miRNA mRS=1 mRS=2 mRS=4 












miR-874 1.40 1.75 1.93 1.94 1.11 -1.32 
miR-937 1.65 1.14 1.44 1.90 1.13 -1.19 
miR-1275 1.25 1.19 1.10 1.24 1.04 -1.55 
miR-1304 1.22 2.28 3.48 2.07 1.65 -1.08 












4.6 Pathway analysis of miRNAs with similar expression in all ischemic 
stroke samples 
In section 4.4, 27 miRNAs (let-7d*, miR-29b-2*, -32*, -125b-2*, -146b-3p, -
196a*, -200b*,  -302c*, -320b, -320c, -331-5p, -374b*, -423-3p, -423-5p, -488, 
-494, -498, -576-3p, -585, -659, -668, -923, -934, -943, -1255a, -1299 and -
1321) were identified as ischemic stroke specific miRNAs. These 27 miRNAs 
were used for pathway analysis. Pathway analysis was performed in the same 
manner as described in section 3.6 
Similar to results from section 3.6, biological pathways associated with 
inflammation (B cell receptor signaling pathway, Chemokine signaling 
pathway, Complement and coagulation cascade, Cytokine-cytokine receptor 
interaction, Leukocyte transendothelial migration and T cell receptor signaling 
pathway), cell death (Apoptosis, Natural killer cell mediated cytotoxicity and 
p53 signaling pathway), neurons (Axon guidance, Glutamatergic synapse, 
Hedgehog signaling pathway, Long-term depression, Long-term potentiation, 
Neuroactive ligand-receptor interaction, Neurotrophin signaling pathway and 
Wnt signaling pathway), metabolism dysregulation (Amino acid and 
nucleotide sugar metabolism, Fructose and mannose metabolism, Galactose 
metabolism, Glycosaminoglycan degradation, Glycerophospholipid 
metabolism, Glycolysis / Gluconeogenesis, Inositol phosphate metabolism, 
Lysine degradation, Pyrimidine metabolism, Purine metabolism and Valine, 
leucine and isoleucine degradation) and vascular permeability (Adherens 
junction, Cell adhesion molecules (CAMs), Focal adhesion, Gap junction, 
Tight junction and VEGF signaling pathway) were also detected (Figure 4.5).  
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Looking at the top 10 biological pathways, they mainly consisted of neuron-
related biological pathways (Neuroactive ligand-receptor interaction: ranked 
4
th
, Neurotrophin signaling pathway: ranked 5
th
 and Wnt signaling pathway: 
ranked 7
th
), inflammation-related pathway (Chemokine signaling pathway: 
ranked 6
th
) and pathways associated with vascular permeability (Focal 
adhesion: ranked 9
th
; Figure 4.5). The results suggest that neuro-inflammation 

















Figure 4.5: Top 100 biological pathways according to enrichment score, 
regulated by 27 miRNAs (let-7d*, miR-29b-2*, -32*, -125b-2*, -146b-3p, -
196a*, -200b*,  -302c*, -320b, -320c, -331-5p, -374b*, -423-3p, -423-5p, -488, 
-494, -498, -576-3p, -585, -659, -668, -923, -934, -943, -1255a, -1299 and -













miRNA profiles in rat middle 
cerebral artery occlusion (MCAo) 















5.1 miRNAs in animal models of ischemic stroke 
Dysregulation of miRNAs was first discovered in rat animal model, 
demonstrated in brain and blood [189]. Subsequently, other groups performed 
miRNA profiles on animal models for ischemic stroke and other forms of 
stroke. Dharp et al [191] profiled miRNA in ipsilateral cortex of rats subjected 
to MCAo while Liu et al [192] compared blood and brain profiles of rat 
animal models for ischemic stroke, haemorrhagic stroke and kainate-induced 
seizure. Lim et al [193] reported on the temporal miRNA profile in brains of 
rats subjected to MCAo and correlated with the corresponding protein 
expression as well as compared with profile of NMDA antagonist (MK801) 
treated animal. On the other hand, other groups looked at miRNA in different 
aspect ischemic stroke. Ziu et al [194] looked at the specific miRNA 
expression in astrocytes and neurons after ischemic injury, while Lee et al 
[195] looked into miRNA expression during ischemic preconditioning. More 
recently, Liu et al [196] profiled temporal miRNA changes in an embolic 
stroke model and demonstrated a spontaneous recovery in the animal up to 7 
days with the corresponding changes in miRNA expression. 
Translation between clinical data from ischemic stroke patients and 
experimental data had little success, probably due to factors not taken into 
account. One of which is the presence of risk factors present in human patients 
while these were not taken into account for experimental setup.   
In the previous chapter 4, miRNA profiles from low or no risk ischemic stroke 
patients were obtained and the clinical setting was closest to that of 
experimental setup. In this chapter, miRNA profile in animal model of 
ischemic stroke obtained and biological pathways affected were highlighted. 
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These biological pathways were compared with those biological pathways 
from human ischemic stroke patients.  In addition, to have a parallel for stroke 
subtype comparison in animal model, miRNA profiles for suture model was 
compared with the miRNA profiles of embolic model, where suture model 
resembles large artery and small vessel stroke while the embolic model 
resembles cardioembolic stroke.  
Suture model involved the occlusion of the middle cerebral artery (MCA) by 
introducing a silicone-coated suture at the origin of MCA, while embolic 
model was achieved by using a blood clot instead of a suture. The models also 
differ in the nature of the occlusion, where embolic model results in 
permanent occlusion until the autolysis of blood clot while suture model 
results in a transient occlusion such that reperfusion is achieved upon 
removing suture.  
5.2 Laser-doppler flowmetry 
For this study, the well-established suture model was used to mimic ischemic 
stroke in rat animal model. In order to assess the successful occlusion of 
middle cerebral artery, laser-doppler flowmetry was utilised to measure the 
blood flow in the left middle cerebral artery. The laser-doppler probe was 
fixed on the temporal surface of the cranium, adjacent to the middle cerebral 
artery. The probe detected the blood flow in terms of blood perfusion units. 
The basal level of blood flow was measured and expressed as 100%. Upon 
occluding the left middle cerebral artery using the silicon coated suture, the 
blood perfusion in the vessel decreased to a level of 20% of the basal level or 
less, to signify a successful occlusion of the left middle cerebral artery (Figure 
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5.1). The blood flow in the vessel was monitored throughout the period of 
occlusion (1 hour). After an hour of occlusion, the suture was removed to 
allow for reperfusion which is denoted by the increase in blood perfusion in 

























Figure 5.1: Laser-doppler flowmetery. Blood flow in the left middle cerebral 
artery was measured and expressed as a percentage to basal blood flow. 








5.3 Neurological outcome 
The neurological deficit of the operated animal is accessed at 24 hours after 
surgery followed by every other day. The animals were observed and scored 
according to the Bederson score (range from 0 to 3; Table 5.1) [207]. Operated 
animals that were scored as normal (grade 0) or moderate (grade 1) at 24 hours 
after surgery were excluded from the study. The rat subjected to MCAo 
developed decreased right forelimb flexion and decreased resistance to lateral 
push towards the right. Rats having very severe neurological deficit exhibited 
the above mentioned physical presentations together with the manifestation of 
circling movement in a clockwise direction. The neurological scoring of the 
animals showed improvement as time progressed (Table 5.2).  
Subsequently, the animals were sacrificed at various time points after 
reperfusion (12hr, 24hr, 48hr, 72hr, 120hr and 168hr) and the brains were 
harvested for further study. Three animals were sacrificed for each time point 
for this study (12hr, 24hr, 48hr, 72hr, 120hr and 168hr) and 6 control animals 
were used.  
 
Table 5.1: Bederson score. Adapted from Bederson et al [207] 
 
Severity Grade Observation 
Normal 0 No observable deficit 
Moderate 1 Decrease forelimb flexion 
Severe 2 Decrease forelimb flexion and resistance to lateral 
push 





5.4 Infarct volume 
The brains harvested were sectioned into 2mm slices and stained with 2,3,5-
triphenyltetrazolium chloride (TTC) for an hour. The viable cells in the tissue 
were stained red as the TTC become oxidized to red 1,3,5-triphenylformazan 
(TPF), while the dead cell remained unstained. The left hemisphere is denoted 
as the ipsilateral half where infarction had occurred, while the right 
hemisphere is designated as the contralateral half. The infarct volume was 
calculated using ImageJ software and plotted in the graph shown (Figure 5.2). 
The infarct volume was expressed as percentage based on the total infarct 
volume that was observed at 24 hours. The infarct volume was shown to 
increase from 12 hours to 24 hours and thereafter gradually decreased from 24 
hours to 168 hours (Figure 5.2). The rats were also imaged at 24, 48, 72 and 
168 hours using magnetic resonance imaging (MRI). The brain was visualized 
using T2 imaging which demonstrated decrease of the infarct lesion with time, 
similar to the results of TTC staining (Figure 5.3). The infarct lesion is 













Figure 5.2: Infarct volume of rats subjected to MCAo. A. Brain slices of rats 
subjected MCAo and subsequently sacrificed at various time points after 
reperfusion (12, 24, 48, 72, 120 and 168 hours). Brain slices were stained with 
TTC, where red stain denotes viable cells and unstained region consists of 
dead cells. B. Graph showing infarct volume of rats sacrificed at various time 
points after reperfusion (12, 24, 48, 72, 120 and 168 hours). Infarct volume 
was expressed as mean percentage ± standard deviation, 12hr: 47.71% ± 
3.00%; 24hr: 100% ± 3.30%; 48hr: 68.55% ± 8.92%; 72hr: 55.58% ± 7.64%; 
120hr: 40.69% ± 4.15% and 168hr: 29.74% ± 5.23%. There were n=3 animals 
for each time-point. * denoted tested significantly different (p value < 0.05) as 
compared to control. The neurological score is the average score of n=3 based 














Figure 5.3: T2 images of rat brain. A. Control. B. 24 hours after reperfusion. 
C. 48 hours after reperfusion. D. 72 hours after reperfusion. E. 168 hours after 










5.5 miRNA profiles of rats MCAo suture model 
Total RNA was isolated from the brain slices using TRIzol (Invitrogen, Life 
Technology, Carlsbad, CA, USA) method. The concentration and integrity of 
the RNA was determined using Nanodrop™ N2000C spectrophotometer 
(Thermo Scientific™, Rockford, IL, USA) and RNA gel electrophoresis (1% 
agarose). The presence and integrity of small RNAs species (less than 200 
nucleotides) was verified using denaturing polyacrylamide gel electrophoresis 
(15% polyacrylamide). 
 Total RNA from the brain was used to perform miRNA microarray on 
miRCURY LNA miRNA array (version 11.0) platform, based on miRBase 
version 12.0 annotations [165]. The data obtained were analysed using TIGR 
multiple experiment viewer (TMEV) [209]. All positive raw intensities were 
taken into account and statistical testing was performed at 5% significance 
level comparing control rats and rats subjected to MCAo. False discovery rate 
(FDR) was also calculated (at 5% significance level) to identify miRNAs that 
are significantly different across the time-points. 250 miRNAs were observed 
to be significantly different, of which 242 miRNAs were detectable at all 6 
time points (Figure 5.4; Supplementary Table 3). There were 13 miRNAs that 
were up-regulated at all 6 time points while there were 195 miRNAs that were 
down-regulated at all 6 time points (Supplementary Table 3). 
According to the miRNA profile, majority of the miRNAs were down-
regulated in all the time points (12hr: 218 miRNAs; 24hr: 220 miRNAs; 48hr: 
220 miRNAs; 72hr: 226 miRNAs; 120hr: 218 miRNAs; 168hr: 220 miRNAs; 
Table 5.3). Among all the time points, there were higher numbers of up-
 150 
 
regulated miRNAs within 24 hours of reperfusion (12hr: 31 miRNAs; 24hr: 29 
miRNAs; Table 5.3) and at the time points after 72 hours (120hr: 31 miRNAs; 
168hr: 27 miRNAs; Table 5.3).  
Table 5.3: Number of miRNAs up-regulated and down-regulated at various 
time points. 
 
 Number of miRNAs 
12hr 24hr 48hr 72hr 120hr 168hr 
Down-regulated 218 220 220 226 218 220 
Up-regulated 31 29 24 23 31 27 
 
 
Hiearchical clustering (HCL) was performed using TMEV software based on 
the raw signal intensity of the 250 miRNAs detected.  In Figure 5.4, HCL 
showed segregation of control samples from MCAo sample, demonstrating 
that there was differential miRNA expression between rats subjected to MCAo 
and normal control rats. Subsequently, HCL was performed using expression 
value of the 250 miRNAs. HCL demonstrated the clustering of samples 
according to early time-points (12hr, 24hr and 48hr) and late time-points (72hr, 









Figure 5.4: Hierarchical clustering analysis of 250 miRNAs in samples across 
6 time-points (12hr, 24hr, 48hr, 72hr, 120hr and 168hr) and normal control 
samples. The miRNA expression were expressed logarithm of raw intensity 
Green represents low signal intensity. Red represents high signal intensity. 






Figure 5.5: Heatmap of 250 miRNAs across the 6 time-points (12hr, 24hr, 
48hr, 72hr, 120hr and 168hr). The miRNA expression were expressed as 
signal log ratio (SLR) with respect to control samples. Green represents down-





5.6 miRNAs correlating with infarct volume 
Within the miRNA profiles, 28 miRNAs (let-7b, -7c, miR-9, -21*, -24-2*, -
27a, -29a, -30a, -30b-5p, -30c, -125b*, -129, -135b, -181a, -186, -195, -204*, -
206, -212, -218, -291a-5p, 300-5p, -322, -340-3p, -376c, -383, -409-3p and -
674-5p) were found to positively correlate with infarct volume, where 
expression of these miRNAs increased and decreased with corresponding 
increase and decrease of infarct volume respectively (Figure 5.6).  It is 
noteworthy to mention that amongst these 28 miRNAs, miR-206 has been 
determined to show the strongest correlation (Pearson‘s R for miR-206: 0.963) 
with infarct volume.  
5.7 Temporal miRNA profile in rat MCAo suture model 
Within the miRNA profiles, there were miRNAs that showed a progressive 
expression pattern across time. There were 35 miRNAs (let-7e, miR-7b, -26a, 
-29c, -32, -92b, -103, -107, -130a, -136, -136*, -137, -140*, -148b-3p, -298, -
300-3p, -300-5p, -320, -323, -329, -330*, -337, -351, -361, -365, -376a, -376b-
5p, -379, -381, -409-5p, -410, -433, -495, -539 and -541) that showed 
decreasing expression as time progresses (Figure 5.7A).  
In addition, there were 26 miRNAs (let-7e*, miR-10b, -16, -25, -27a*, -29c*, -
128, -139-5p, -144, -146b, -147, -151, -192, -199a-5p, -204, -217, -221, -222, -
326, -328, -375, -382*, -540, -542-3p, 542-5p and -881) demonstrated to have 
biphasic expression across time (Figure 5.7B). Among these 26 miRNAs, 
miR-29c* and -542-3p were found to have a lower expression at 24 and 120 






Figure 5.6: Expression of 28 miRNAs that positively correlate with infarct volume in suture model. The expression of the miRNAs were 










Figure 5.7: Expression of A. 35 miRNAs that showed decreasing expression 
across time. B. 26 miRNAs that showed biphasic expression. The expression 




5.8 Comparison of miRNA expression between suture model and embolic 
model 
Comparison of miRNA profiles between embolic model and suture model was 
conducted. Embolic model miRNA profile was obtained from Liu et al [196] 
which deposited in NCBI‘s gene expression omnibus (GEO) with accession 
number GSE46269. The infarct volume of embolic model was similar to that 
of suture model where it increased and reacted maximal infarction at 24 hours 
and decrease after that [196]. The miRNA profiles of suture model and 
embolic model were visualized on TMEV. HCL was performed on the 
miRNA profiles (Figure 5.8). The samples clustered according to the 
respective models which demonstrated difference in miRNA expression 
between the 2 animal models.  
There were 28 miRNAs (let-7e, miR-10b, -21*, -24-2*, -136, -142-3p, -181c, -
183, -200a, -208, -290, -300-3p, -300-5p, -326, -345-5p, -351, -376b-5p, -382, 
-382*, -409-5p, -423, -425, -466b, -494, -503, -542-3p, -872* and -877) that 
showed differential expression patterns between the 2 animal models (Figure 
5.9). 2 of these miRNAs (miR-10b and -200a) were up-regulated in suture 
model and down-regulated in embolic model while the remaining 26 miRNAs 
(let-7e, miR-21*, -24-2*, -136, -142-3p, -181c, -183, -208, -290, -300-3p, -
300-5p, -326, -345-5p, -351, -376b-5p, -382, -382*, -409-5p, -423, -425, -
466b, -494, -503, -542-3p, -872* and -877) were down-regulated in suture 
model and up-regulated in embolic model(Figure 5.9). 
Liu et al [196] previously identified 10 miRNAs (miR-21*,-30c-1*, -206, -290, 
-291a-5p, -300-5p, -503, -542-5p, -874 and -877) in embolic model that 
correlated well with infarct volume. Together with the suture model which 
 157 
 
identified 28 miRNAs (let-7b, -7c, miR-9, -21*, -24-2*, -27a, -29a, -30a, -
30b-5p, -30c, -125b*, -129, -135b, -181a, -186, -195, -204*, -206, -212, -218, 
-291a-5p, -300-5p, -322, -340-3p, -376c, -383, -409-3p and -674-5p) that 
positively correlated with infarct volume, there 4 miRNAs (miR-21*, -206, -
291a-5p and -300-5p) that showed strong correlation with infarct volume 
(Figure 5.10). Among which, miR-206 had been determined to show the 
strongest correlation (Pearson‘s R for rno-miR-206: 0.963) with infarct 
volume.  
Similarly, there were 26 miRNAs (let-7e*, miR-10b, -16, -25, -27a*, -29c*, -
128, -139-5p, -144, -146b, -147, -151, -192, -199a-5p, -204, -217, -221, -222, -
326, -328, -375, -382*, -540, -542-3p, 542-5p and -881) that showed biphasic 
expression. When compared with embolic model, 4 miRNAs (miR-10b, -217, 
-326 and -881) showed biphasic expression in both animal model (Figure 

















Figure 5.8: Hierarchical clustering (HCL) analysis of 250 miRNAs between 
suture model and embolic stroke. The miRNA expression were expressed as 
signal log ratio (SLR) with respect to control samples. Green represents down-
regulation. Red represents up-regulation. Grey represents absence. Suture 
model samples were denoted with (S) and embolic model samples were 







Figure 5.9: Heatmap of 28 miRNAs with differential expression patterns 
between embolic model and suture model.   The miRNA expression was 
expressed as fold change with respect to control samples. Green represents 
down-regulation. Red represents up-regulation. Suture model samples were 









Figure 5.10: Expression of 4 miRNAs (miR-21*, -206, -291a-5p and -300-5p) 
that were positively correlate with infarct volume in A. suture model and B. 
embolic model. The miRNA expression were expressed as fold change with 








Figure 5.11: Expression of 4 miRNAs (miR-10b, -217, -326 and -881) that 
showed biphasic expression in A. suture model and B. embolic model. The 




5.9 Pathway analysis of miRNAs with differential expression pattern 
between embolic and suture model 
The 28 miRNAs (let-7e, miR-10b, -21*, -24-2*, -136, -142-3p, -181c, -183, -
200a, -208, -290, -300-3p, -300-5p, -326, -345-5p, -351, -376b-5p, -382, -382*, 
-409-5p, -423, -425, -466b, -494, -503, -542-3p, -872* and -877) with 
differential expression pattern between embolic and suture model were used 
for pathway analysis. Pathway analysis was performed in the same manner as 
described in section 3.6.  
The pathway analysis of the 28 miRNAs detected cardioembolic associated 
biological pathways from human patient analysis such as Complement and 
coagulation cascades, Dilated cardiomyopathy, Gap junction, 
Glycerophospholipid metabolism and Pyruvate metabolism. This signified that 
these biological pathways were significant in the pathogenesis of 
cardioembolic stroke in both human patients as well as in animal model. Thus, 
investigation into genes and miRNAs in these pathways may yield potential 
















Figure 5.12: Top 100 biological pathways according to enrichment score, 
regulated by 28 miRNAs that showed differential expression patterns between 
embolic and suture model. 
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5.10 Pathway analysis of miRNAs that positively correlate with infarct 
volume 
Similarly, the 5 miRNAs (miR-21*, -206, -291a-5p and -300-5p) that 
correlated well with infarct volume were used for pathway analysis. The result 
showed similar biological pathways detected in human patients. Same 
biological pathways associated with inflammation (B cell receptor signaling 
pathway, Chemokine signaling pathway, Complement and coagulation 
cascade, Cytokine-cytokine receptor interaction, Leukocyte transendothelial 
migration and T cell receptor signaling pathway), cell death (Natural killer cell 
mediated cytotoxicity and p53 signaling pathway), neurons (Glutamatergic 
synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-
receptor interaction, Neurotrophin signaling pathway and Wnt signaling 
pathway), metabolism dysregulation (Amino acid and nucleotide sugar 
metabolism, Glycerophospholipid metabolism, Glycolysis / Gluconeogenesis, 
Purine metabolism and Valine, leucine and isoleucine degradation) and 
vascular permeability (Adherens junction, Cell adhesion molecules (CAMs), 
Focal adhesion, Gap junction, Tight junction and VEGF signaling pathway). 
Similarly, in the top 10 biological pathways, neuron-related biological 
pathways (Neuroactive ligand-receptor interaction: ranked 2
nd
) and 
inflammation-related pathway (Chemokine signaling pathway: ranked 4
th
) 
were highly ranked. This suggested that neuroinflammation played a critical 
role in ischemic stroke pathophysiology in both clinical and experimental 
setting. Thus, further investigation into neuroinflammation during ischemic 
stroke was required for further understanding of the miRNA-regulated 
















Figure 5.13: Top 100 biological pathways according to enrichment score, 
regulated by 4 miRNAs (miR-21*, -206, -291a-5p and -300-5p) that correlated 












miRNAs in neuroinflammation – potential 













6.1 Neuroinflammation and ischemic stroke 
The results from the previous chapters suggested that neuroinflammation is a 
critical process in the pathophysiology of ischemic stroke [230]. Inflammation 
in the central nervous system is a complex process involving leukocytes and 
other blood-derived protein components or modulators [231].  
Complement and coagulation cascade (biological pathway associated with 
inflammation) was found to be differentially regulated stroke subtypes: large 
artery and small vessel stroke versus cardioembolic stroke. Complement is a 
component of innate immunity, which responds to pathogen during infection, 
and in pathological state, complement can cause inflammation in self-tissue 
[128]. Among the components of complement, Cluster of differentiation 46 
(CD46) was previously reported by Jickling et al [232] to be among a list of 
40 genes that can distinguish between cardioembolic stroke and large artery 
stroke. CD46 functions as a negative regulator of complement activation such 
that it binds to C3b and C4b complement protein fragments, and recruits 
serum factor I to degrade the protein fragments [233]. CD46 exists as 4 protein 
isoforms (BC1, BC2, C1 and C2) and has 8 transcript varients (a, b, c, d, e, f, l 
and n) of which transcript a is most abundant [234, 235].  Being an important 
regulator of complement activation, CD46 may be used as potential diagnostic 
marker for cardioembolic stroke and hence the study of miRNAs regulating 
CD46 is also beneficial. 
Pathway analysis described in chapters 3 to 5, highlighted Chemokine 
signaling pathway as a crucial pathway as it was consistently found to be in 
the top 10 biological pathways. Chemokines are protein molecules involved in 
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recruitment of leukocytes to site of injury [236]. There had been many reports 
about the involvement of chemokines in ischemic stroke [237]. Among which, 
monocyte chemoattractant protein-1(MCP-1) or chemokine C-C motif ligand 
2 (CCL2) demonstrated to be involved in the pathophysiology of ischemic 
stroke. In animal models, Ccl2 has been demonstrated to be involved in blood 
brain barrier disruption [124]. Furthermore, animals with CCL2 or its receptor 
CCR2 knockout have smaller infarct following middle cerebral artery 
occlusion (MCAo) as compared with wild-type [125, 126]. In addition, CCL2 
in serum of patients had been demonstrated to correlate with outcome of 
patients [238]. However, there were also other reports stating the possible 
beneficial effect of CCL2 during ischemic stroke [239, 240]. Ccl2 had been 
demonstrated to be involved in ischemic preconditioning [239] and Ccl2 was 
reported to mediate neuroblast migration after cerebral ischemia [240]. In 
addition, CCL2 was reported to promote angiogenesis in ischemia affected 
brain tissue [241]. Thus, the role of CCL2/Ccl2 in ischemic stroke is worth 
investigating as well as the miRNAs targeting CCL2/Ccl2, as CCL2 may 
prove to be a useful therapeutic target in ischemic stroke. 
 
6.2 CD46 mRNA level in different ischemic stroke subtype 
CD46 mRNA level was quantified using real-time qPCR. The measurements 
showed that CD46 mRNA level was significantly higher (p-value=0.002) in 
large artery stroke and small vessel stroke (median relative expression=2.00) 
as compared with cardioembolic stroke (median relative expression=1.32; 
Figure 6.1). Hence, the identification of miRNAs targeting CD46 was 
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considered a useful line of investigation in understanding the regulation of 
expression of CD46 as it may become a possible marker in diagnosis of stroke 

























Figure 6.1: CD46 mRNA relative expression in individual ischemic stroke 
patients according to various ischemic stroke subtypes. The relative expression 
of CD46 mRNA was expressed as relative expression as compared with 
healthy controls (n=8). CE: cardioembolic stroke (n=13); LA: large artery 
stroke (n=13); SV: small vessel stroke (n=13). The box represents the 
interquartile range. The line denotes the range of readings. ♦ represents the 








6.3 miRNAs predicted to target CD46 
Bioinformatics prediction was carried out to select miRNAs that could target 
CD46. The search was conducted on 9 databases: Targetscan version 6.2 
(www.targetscan.org) [156-159], miRanda August 2010 release 
(www.microRNA.org) [160-163], microcosm version 5 
(www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) [163-165], DIANA 
microT version 3 (http://diana.cslab.ece.ntua.gr/microT/) [166, 167], miRDB 
version 4 (mirdb.org/) [29, 30], miRWalk March 2011 update (www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/) [170], PITA 2007 release 
(genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html) [171], RepTar 
version 1.2 (reptar.ekmd.huji.ac.il/) [172] and StarBase version 2 
(starbase.sysu.edu.cn/) [173, 174].  
A total of 857 miRNAs (at least in one of the database) found to target CD46 
3‘UTR (Supplementary Table 4). Of which, 157 miRNAs (at least in one of 
the database) were detected in the microarray. Among these 157 miRNAs, 12 
miRNAs (miR-17, -18a, -19a, -19b, -20a, -20b, -106a, -181a, -181b, -185, -
374b and -421) were selected for further screening as these 12 miRNAs (miR-
17, -18a, -19a, -19b, -20a, -20b, -106a, -181a, -181b, -185, -374b and -421) 
had been predicted by a large number of databases (more than 5). Interestingly, 
these miRNAs have also been found to belong to miRNA clusters [miR-17-
92a cluster (miR-17, -18a, -19a, -19b and -20a), miR-106a-363 cluster (miR-
19b, -20b and -106a), miR-181a cluster (miR-181a and -181b) and miR-374b-




6.4 miRNA expression in ischemic stroke subtype 
The expression of the 12 miRNAs (miR-17, -18a, -19a, -19b, -20a, -20b, -106a, 
-181a, -181b, -185, -374b and -421) were measured in the pooled samples for 
each stroke subtype (cardioembolic, large artery and small vessel), using 
stemloop PCR (Figure 6.2). The results showed that 4 miRNAs (miR-19a, -
20a, -185 and -374b) demonstrated corresponding inverse expression as 
compared with CD46 mRNA expression, where the expression of the miRNAs 
were higher in cardioembolic stroke samples as compared to large artery 
stroke and small vessel stroke samples (Figure 6.2).  
The expression pattern of 4 miRNAs (miR-19a, -20a, -185 and -374b) were 
further measured in individual stroke samples. It was found that the expression 
of miR-19a, miR-185 and miR-374b were significantly different (miR-19a: p-
value=0.009, miR-185: p-value=0.024 and miR-374b: p-value=0.027) 
between cardioembolic stroke (miR-19a: median=0.90, miR-20a: 
median=0.69, miR-185: median=0.55 and miR-374b: median=0.59) and large 
artery and small vessel stroke (miR-19a: median=0.32, miR-20a: median=0.33, 
miR-185: median=0.23 and miR-374b: median=0.22; Figure 6.3). In order to 
validate the interaction between the miRNAs and CD46 mRNA, the 
3‘untranslated region (3‘UTR) of CD46 was cloned into luciferase reporter 






Figure 6.2: Relative expression of 12 miRNAs predicted to target 3‘UTR of CD46 in pooled samples. The expression of the 12 miRNAs were 













Figure 6.3: Relative expression of 4 miRNAs (miR-19a, -20a, -185 and -374b) 
in individual ischemic stroke patients according to their various stroke subtype. 
The expression of the 4 miRNAs were expressed relative to healthy control 
samples. CE: cardioembolic stroke (n=13); LA: large artery stroke (n=13); SV: 
small vessel stroke (n=13). The box represents the interquartile range. The line 
denotes the range of readings. ♦ represents the median reading. Levels of miR-
19a, -185 and -374b were found to be significantly different (miR-19a: p-
value=0.009, miR-185: p-value=0.024 and miR-374b: p-value=0.027) 







6.5 Cloning of CD46 3’UTR 
For validation of microRNA-mRNA interaction, the 3‘UTR of CD46 mRNA 
was cloned for downstream luciferase reporter assay. Since there were 8 
mRNA transcripts, a mRNA sequence alignment was performed and found 
that the 3‘UTR region of all the transcripts were mostly conserved including 
the region containing the seed regions for miR-19a, -20a, -185 and -374b 
(Supplementary Figure 1; Table 6.1). The following primer pairs were used 
cloning the selected region of CD46 3‘UTR (Table 6.2). The selected region 
of CD46 3‘UTR was cloned as a single fragment of size 1028 base pair. The 
fragment was amplified using polymerase chain reaction (PCR) and visualized 
using DNA gel electrophoresis (Figure 6.4). The fragment was sub-cloned into 
pCR
®
4-TOPO vector and subsequently sequenced using pCR
®
4-TOPO vector 
specific primers (M13F and M13R) to verify the correct sequence for the 
cloned fragment (Figure 6.5A). 
The verified fragment was later sub-cloned the pMIR-REPORT™ Luciferase 
vector (Figure 6.5B). Restriction sites (SpeI and HindIII) were introduced into 
the fragment using the following primer pair (Table 5.1). The fragment in 
pCR
®
4-TOPO vector was amplified using the primer set with RE sites and 
sub-cloned into pCR
®
4-TOPO vector. The clones were sequenced to verify for 
correct sequence of fragment and presence of RE sites.  
The correct fragment and pMIR-REPORT™ luciferase vector were excised 
using the appropriate restriction enzymes (SpeI and HindIII) via sequential 
digestion. The resultant fragments were ligated together using T4 DNA ligase. 
The ligated vector containing CD46 3‘UTR was sequenced using primers 
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specific for pMIR-REPORT™ luciferase vector to verify the presence of 


























Table 6.1: Seed regions of miR-19a, -20a, -185 and -374b on CD46 mRNA 
transcript variant a (NM_002389.4) 
 
Nucleotide number on CD46 
mRNA transcript variant a 
(NM_002389.4) 
Respective miRNA and miRNA seed region 
2311 – 2332 miR-185 AGUCCUUGACGGAAAGAGAGGU      
        gttacatgtgtttttctctccc 
 
2584 – 2606 miR-20a GAUGGACGUGAUAUUCGUGAAAU 
        aatatagctcaggtagcacttta 
 
2731 – 2753 miR-19a AGUCAAAACGUAUCUAAACGUGU 
        gaaattttatgtttagttgcaca 
 
3063 – 3084 miR-374b GUGAAUCGUCCAACAUAAUAUA 
         atgtataaaataaatattatac 
 
 
Table 6.2: Primers used in cloning of CD46 3‘UTR. The table above shows 
the sequences of primers using in cloning of CD46 3‘UTR. Sub-cloning of 
fragment into pMIR report vector was performed with primers containing 
specific restriction sites at the 5‘ ends of the primers. 
 
Primer Primer Sequence (5‘ to 3‘) 
CD46 Forward GACAGCCATAACAGGAGTGC 
CD46 Reverse ACTTCCAGAGAAAACTGGTC 
CD46 Forward with Spe I site GACACTAGTAACAGGAGTGC 















Figure 6.4: Amplification of selected region of CD46 3‘UTR. The region of 
CD46 3‘UTR containing the seed regions of the selected miRNAs (miR-19a, -
20a, -185 and -374b) was amplified using sequence specific primers. The size 












Figure 6.5: Vector maps of pCR
®
4-TOPO vector and pMIR-REPORT™ 
Luciferase vector. A. pCR
®
4-TOPO vector was used in the TA-cloning of 
amplified PCR product. B. The fragment of interest was ligated into pMIR-
REPORT™ Luciferase vector using restriction enzymes (Spe I and Hind III).   
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 6.6 Luciferase reporter assays for CD46 3’UTR 
In order to show the interaction between the miRNA and CD46 3‘UTR, 
luciferase assay was performed. The assay was typically performed in HELA 
cells as the cell line can be easily transfected. The cells were first transfected 
with the respective anti-miRNAs or miRNA mimics (miR-19a, -20a, -185 and 
-374b) along with their corresponding negative controls. Subsequently, the 
cells were transfected with the pMIR-Report™ Luciferase vector containing 
CD46 3‘UTR construct. Luciferase activity was measured 48 hours after 
transfection. 
In order to validate that the transfection of anti-miRNA and miRNA mimic 
had repressed or elevated the miRNA levels in the cells, total RNA isolated 
from the cells were used to measure miRNA level using stem-loop qPCR. The 
measurement showed a significant change (p-value < 0.05) in miRNA level 
after transfection (Table 6.3).  
It was observed that cells transfected with anti-miRNAs demonstrated an 
increase in luciferase activity (anti-miR-19a: 140.63%; anti-miR-20a: 
124.08%; anti-miR-185: 141.47% and anti-miR-374b: 141.52%), while cells 
transfected with miRNA mimics showed lower luciferase activity (miR-19a 
mimic: 78.17%; miR-20a mimic: 82.86%; miR-185 mimic: 62.51% and miR-
374b mimic: 64.02%; Figure 6.6), when compared to control. The differences 
in luminescence between respective anti-miRNA/miRNA mimic and control 
were tested and found to be statistically significant (p-value < 0.05; Figure 
6.6). Among the 4 miRNAs (miR-19a, -20a, -185 and -374b), miR-19a, -185 
and -374b showed stronger interaction with CD46 3‘UTR as demonstrated by 
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greater increase luciferase activity when transfected with anti-miRNAs and 
more reduction in luciferase activity when transfected with miRNA mimics 
(Figure 6.6).  
In order to investigate the differentiate expression of CD46 and the 4 miRNAs 
(miR-19a, -20a, -185 and 374b) targeting CD46 in cardioembolic stroke 
patients, transfection study was performed on human umbilical vein 




), as the endothelial cells are 
in constant contact with circulation and there is a possible difference in the 
endothelial cell gene expression in cardioembolic stroke patients as compared 



















Table 6.3: Relative expression of respective miRNAs (miR-19a, -20a, -185 
and -374b) in anti-miRNA and miRNA mimic transfected HELA cells. The 
levels of miRNAs were expressed relative to controls. The expression of 
miRNAs were found to be statistically significant (p-value < 0.05) as 
compared with control. 
 
Anti-miRNA/miRNA mimic transfected  Relative expression ± SEM 
 miR-19a 
Anti-miR-19a 0.30 ± 0.13 
miR-19a mimic 277.33 ± 33.07 
 miR-20a 
Anti-miR-20a 0.54 ± 0.04 
miR-20a mimic 189.93 ± 38.07 
 miR-185 
Anti-miR-185 0.07 ± 0.00 
miR-185 mimic 3280.01 ± 868.17 
 miR-374 
Anti-miR-374b 0.07 ± 0.01 
















Figure 6.6: Dual Luciferase assay for miRNAs (miR-19a, -20a, -185 and -
374b) predicted to target CD46. The plasmid construct was co-transfected 
with either anti-miRNA or miRNA mimic. Relative luminescence was 
obtained by normalizing the values against control plasmids, pMIR-
REPORT™ Luciferase vector without any 3‘UTR insert. * denoted tested 
significantly different (p value < 0.05) as compared to control. Data were 








6.7 Anti-miRNA and miRNA mimic transfection in HUVEC 
To investigate the possible regulation of CD46 by miRNAs in the endothelium, 
anti-miRNA and miRNA mimic were transfected into HUVECs which is an in 
vitro mimic for endothelial cells. HUVECs were seed at density of 3 X 10
4
 
cells per well in 24 well plate. The cells were transfected with anti-miRNA 
and miRNA mimic for 48 hours after which the cells were collected in 
TRIzol™ reagent (Invitrogen, Life Technology, Carlsbad, CA, USA). Total 
RNA (including miRNAs) were isolated from the cells according to 
manufacturer‘s protocol. The concentration and integrity was determined 
using Nanodrop™ N2000C spectrophotometer (Thermo Scientific™, 
Rockford, IL, USA) and RNA gel electrophoresis (1% agarose). Presence of 
small RNAs was verified using denaturing polyacrylamide gel electrophoresis 
(15% polyacrylamide). RNA samples were used for qPCR and stem-loop 
qPCR to quantitate level of mRNA and miRNAs respectively. 
The results of stem-loop qPCR demonstrated successful transfection of anti-
miRNA and miRNA mimics. Upon transfection of respective anti-miRNAs 
(miR-19a, -20a, -185 and -374b), the level of respective miRNAs decreased 
significantly (p value < 0.05), while transfection of respective miRNA mimics 
resulted in increase of the respective miRNAs level (Table 6.4).  
Following which, the CD46 mRNA level was quantified and the results 
showed that these 4 miRNAs (miR-19a, -20a, -185 and -374b) target CD46. 
HUVECs transfected with respective anti-miRNAs showed increased level of 




The results suggested that miR-19a, -20a, -185 and 374b can regulate CD46 
expression in endothelial cells which may be a possible source of differential 
expression of CD46 and miRNAs targeting CD46, in cardioembolic stroke as 
compared with large artery and small vessel stroke. This put forth a possible 
cause for the observation seen in the clinical samples and also a possible 
mechanism. Hence, miR-19a, -185 and 374b could possibly act as a marker 





















Table 6.4: Relative expression of respective miRNAs (miR-19a, -20a, -185 
and -374b) in anti-miRNA and miRNA mimic transfected HUVECs. The 
levels of miRNAs were expressed relative to control. The expression of 
miRNAs were found to be statistically significant (p-value < 0.05) as 
compared with control. 
 
Anti-miRNA/miRNA mimic transfected  Relative expression ± SEM 
 miR-19a 
Anti-miR-19a 0.55 ± 0.14 
miR-19a mimic 23.09 ± 4.17 
 miR-20a 
Anti-miR-20a 0.54 ± 0.07 
miR-20a mimic 24.52 ± 11.03 
 miR-185 
Anti-miR-185 0.13 ± 0.06 
miR-185 mimic 180.77 ± 52.08 
 miR-374 
Anti-miR-374b 0.33 ± 0.15 

















Figure 6.7: CD46 mRNA expression in anti-miRNA and miRNA mimic 
transfected HUVECs. All values were expressed relative to control. * denoted 
tested significantly different (p value < 0.05) as compared to control. Data 







6.8 Screening for chemokines in rat MCAo model 
Results from previous chapters demonstrated that biological pathway, 
Chemokine signaling pathway, was critical to pathophysiology of ischemic 
stroke. Thus, chemokine screening was performed on serum collected from rat 
animal models using MILLIPLEX
®
 MAP rat cytokine/chemokine kit assay 
(Millipore Corporation, Billerica, MA, US). For screening, the following time 
points, 12, 24 and 48 hours were used, as 24 hours was when the maximum 
infarct volume occurred while 12 and 48 hours were time-points before and 
after that.  
In brief, whole blood samples collected from rats subjected to middle cerebral 
artery occlusion (MCAo) were left to clot at 4°C for at least 2 hours and 
centrifuged at 1000 X g for 10 minutes. Serum was collected and stored in -
80°C until required. Serum samples were diluted five folds using sample 
diluent provided. Assay was performed based on manufacturer‘s protocol. 
Detection and analysis was conducted on Luminex 100™ system (Luminex 
Corporation, Austin, TX, US). 
The assay detected 3 chemokines, chemokine CXC motif ligand 1 (CXCL1), 
chemokine CC motif ligand 2 (CCL2) and chemokine CC motif ligand 5 
(CCL5; Figure 6.8). CCL2 and CCL5 showed similar expression in suture and 
embolic model while CXCL1 did not (Figure 6.8A, B and C). CCL2 showed 
upregulation from 12 hours, reached maximum expression at 24 hours and 
decreased after 24 hours (Figure 6.8B). CCL5 expression was maximal at 12 






Figure 6.8: Chemokine levels in suture and embolic models at 12, 24 and 48 
hours. A. CXCL1. B. CCL2. C. CCL5. Levels of chemokine were expressed 
as fold change with respect to control. For each time-point, there were n=3 for 
rats used in stroke models and there were n=6 for control rats. * denoted tested 
significantly different (p value < 0.05) as compared to control. Data were 
shown as mean ± SD. 
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6.9 Ccl2 and Ccl5 mRNA level in embolic and suture model 
After screening chemokine level in serum of embolic and suture model, CCL2 
and CCL5 were found to have similar expression in embolic and suture 
models. Hence, Ccl2 and Ccl5 mRNA level was measured in embolic and 
suture model by qRT PCR.   
The results showed that the Ccl2 and Ccl5 mRNA expression pattern were 
similar between suture and embolic model. Ccl2 mRNA was upregulated at 12 
hours, reached maximum level at 24 hours and decreased progressively after 
24 hours (Figure 6.9A). While Ccl5 mRNA level reached maximal expression 
at 12 hours, followed by a decrease from 12 hours to 72 hours, then the 
expression increased again at 120 hours and decreased after 120 hours (Figure 
6.9B). Between Ccl2 and Ccl5, Ccl2 mRNA and protein level correlated better 
compared with Ccl5. In addition, Ccl2 mRNA expression pattern correlated 
with infarct volume (Figure 6.10). Thus, it would be useful to identify 















Figure 6.9: Expression of A. Ccl2 and B. Ccl5 in suture and embolic model. 
All values were expressed relative to control. * denoted tested significantly 











   
Figure 6.10: Expression of Ccl2 and infarct volume in A. suture model and B. 
embolic model. All values were expressed relative to control. For each time-
point, there were n=3 animals and there were n=6 for controls. Data were 






6.10 CCL2 level in serum of ischemic stroke patients 
Ccl2 was shown to be associated with infarct volume in animal models of 
ischemic stroke, it was necessary to determine the similar role in human 
ischemic stroke patients. Hence, measurement of CCL2 levels in patient serum 
samples were performed using CCL2 ELISA kit (R&D systems, MN, US) 
according to manufacturer‘s protocol. Samples were obtained in BD 
Vacutainer ® (Becton, Dickinson and Company, New Jersey, US) at Day 1, 2 
and 7 upon admission. They were left for at least 30 minutes to allow clotting 
and subsequently, spun down and aliquot for storage at -80°C until required. 
The results showed that CCL2 levels in patient serum were higher than that of 
healthy control at all time-points (Day 1, 2 and 7; Figure 6.11A). When 
compared with between samples with good outcome (mRS < 2) and samples 
with poor outcome (mRS ≥ 2), CCL2 levels were higher in samples with good 
outcome across all the time-points (Figure 6.11B). This unexpected finding 
suggested that CCL2 up-regulation in ischemic stroke patients may be 
beneficial. In order to further investigate, identification of miRNAs targeting 
CCL2 is necessary as these miRNAs can be used to regulate CCL2 in in vitro 
experiment mimicking ischemic stroke, to elucidate possible function of CCL2 









   
 
Figure 6.11: Level of CCL2 in serum of ischemic stroke patients. A. Level of 
CCL2 in ischemic stroke patients at Day 1, 2 and 7. B. Level of CCL2 in 
patients with good outcome (mRS < 2) and patients with poor outcome (mRS 
≥ 2) at Day 1, 2 and 7. The box represents the interquartile range. The line 
denotes the range of readings. ♦ represents the median reading. All values 
were expressed relative to control. * denoted tested significantly different (p 
value < 0.05) as compared to control. Data obtained from 39 ischemic stroke 
patients and 8 healthy controls. Day 1, 2 and 7 mRS < 2: n = 9. Day 1, 2 and 7 





6.11 miRNAs predicted to target Ccl2 and CCL2 
In the search for miRNAs targeting Ccl2 and CCL2, miRNA prediction 
databases were used for the shortlisting of miRNAs. The bioinformatics 
prediction utilized 5 databases for predicting miRNAs targeting Ccl2: 
Targetscan version 6.2 (www.targetscan.org) [156-159], miRanda August 
2010 release (www.microRNA.org) [160-163], microcosm version 5 
(www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) [163-165], miRDB 
version 4 (mirdb.org/) [168, 169] and miRWalk March 2011 update 
(www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) [170]. While for prediction 
of miRNAs targeting CCL2, 8 databases were used:  Targetscan version 6.2 
(www.targetscan.org) [156-159], miRanda August 2010 release 
(www.microRNA.org) [160-163], microcosm version 5 
(www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) [163-165], DIANA 
microT version 3 (http://diana.cslab.ece.ntua.gr/microT/) [166, 167], miRDB 
version 4 (mirdb.org/) [168, 169], miRWalk March 2011 update 
(www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) [170], PITA 2007 release 
(genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html) [171] and StarBase 
version 2 (starbase.sysu.edu.cn/) [173, 174].  
The results from the prediction showed 66 miRNAs predicted to target Ccl2 
3‘UTR (Supplementary Table 5). Among these 66 miRNAs, there were 47 
miRNAs that were detected in the microarray. Of these 47 miRNAs, 12 
miRNAs (miR-23a, -23b, -27a, -27b, -33, -124, -137, -290, -323, -369-3p, -
434 and -664) were selected for screening as these miRNAs were predicted by 
more than 1 database. As for CCL2, there were 419 miRNAs predicted to 
target it (Supplementary Table 6). There were 134 miRNAs detectable from 
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the microarray analysis. Amongst the 134 miRNAs, 10 miRNAs (miR-23a, -
23b, -33a, -122, -206, -374a, -374b, -421, -518a-5p and -664) were selected 
for screening as these miRNAs were predicted by more than 4 databases.  
By comparing the Ccl2 mRNA measurements and the expression of 12 
miRNAs (miR-23a, -23b, -27a, -27b, -33, -124, -137, -290, -323, -369-3p, -
434 and -664) predicted to target Ccl2 mRNA from miRNA profiles, miRNA-
27b seems to show inverse correlation with the expression of Ccl2 mRNA 
(Figure 6.12). The expression of these miRNAs still need to be quantified 
using stem-loop qPCR. The expression of CCL2 mRNA and the 10 miRNAs 
(miR-23a, -23b, -33a, -122, -206, -374a, -374b, -421, -518a-5p and -664) 
predicted to target CCL2 in ischemic stroke patients also need to be 




















Figure 6.12: Expression of Ccl2 and 12 miRNAs predicted to target Ccl2 in A. 
suture model and B. embolic model. All values were expressed relative to 
control. Green represents down-regulation. Red represents up-regulation. Grey 
represents absence. For each time-point, there were n=3 animals and there 


























7.1 Circulating miRNAs detected during systemic response to ischemic 
stroke 
In this study, blood miRNAs were profiled in ischemic stroke patients. 
Though it was observed that blood miRNAs were dysregulated in patients as 
compared to healthy controls, the question remained to be answered that is: 
what does the dysregulated miRNAs reflect?  
From the miRNA profile of the human ischemic stroke patients, there is a 
general correlation between miRNA expression with time, where the 
expression of miRNAs tend to increase with time. This observation seems to 
suggest that the up-regulation of miRNA can be part of the mechanism 
involving in progression of ischemic stroke towards either recovery or 
worsening. There is a need to profile patients according to their functional 
outcome as to identify the specific biological pathway involved in recovery so 
that this can form the basis for therapeutic intervention to promote recovery. 
Jickling et al [198] recently published miRNA expression in ischemic stroke 
patients indicating that miRNAs detected were predominantly from circulating 
leukocytes. They identified 8 miRNAs (let-7i, miR-19a, -122, -148a, -320d, -
363, -487b and -4429) as ischemic stroke specific miRNAs. Of these 8 
miRNAs, 7 miRNAs (let-7i, miR-19a, -122, -148a, -320d, -363, -487b and -
4429) were detectable in the array results from this study. From this 
observation, it could suggest that circulating miRNA profile could be 
reflective of the leukocyte response to stroke onset.   
miRNAs can also be compartmentalized into secretory vesicles such as 
exosomes and apoptotic bodies [242, 243]. In addition, miRNAs can also be 
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found to complex with proteins such as Argonaute2 (Ago2) and high density 
lipoprotein (HDL) [244, 245]. These miRNA complexes and vesicles could be 
reflective of the condition of the source tissue. Apoptotic bodies are small 
membrane vesicles (0.5 µm – 200 µm) released from cells undergoing 
apoptosis [246]. Exosomes are small (diameter < 100nm) microvesicles 
secreted by various cells for cell to cell communication [247, 248].  Exosomal 
miRNAs had been shown to be stable and protected from RNaseA treatment 
[249]. Furthermore, some miRNAs enriched in exosomes (miR-26, -126 and -
191) have been associated with neuronal function [249]. Interestingly, these 
miRNAs were also detected as dysregulated miRNAs in this study, suggesting 
that the miRNA profile was also reflective of conditions in the brain after 
stroke onset.  
Therefore, blood miRNA profiling provides information about the local 
response in the brain and also a systemic response of the leukocytes, a possible 
inflammatory related response. Hence, blood miRNA profiling can provide 
much insight into the mechanisms underlying ischemic stroke 
pathophysiology. 
 
7.2 Patient cohorts used for this study 
The patient number recruited for this study was small in comparison with the 
numbers in published work [190, 197-205], which ranged from 24 to about 
100 patient samples. There was a higher proportion of patients suffering for 
cardioembolic stroke. This was in agreement with literature as it was 
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previously reported that Asians have a higher incidence of cardioembolic 
stroke as compared with Caucasians [250]. 
From the statistical testing of the variables between the stroke subtypes (large 
artery, cardioembolic and small vessel stroke), there were no significant 
differences between age and gender. This ensures that the patient cohorts used 
for this study were not confounded by these 2 important variables.  
There were slight differences in the comorbidities and outcome between stroke 
subtypes, where there were greater portion of cardioembolic stroke patients 
with atrial fibrillation as compared with large artery and small vessel stroke 
patients, and there were more small vessel stroke patients having good 
outcome as compared with cardioembolic and large artery stroke patients. 
These differences were well within expectations. Atrial fibrillation is a major 
cause of cardioembolic stroke and higher number of cardioembolic stroke 
patients with atrial fibrillation as compared with other stroke subtype was to 
be expected [16]. The demographics of the patients used were in agreement 
with the literature. Small vessel stroke was shown to have better outcome as 
compared with large artery stroke and cardioembolic stroke, similar with 
previous reports [251, 252]. Thus, these observations demonstrated that the 
patient cohorts used for this study are somewhat representative of the patient 
population needed for this study.  
Despite the small sample size of the low or no risk ischemic stroke patients 
cohort, the findings were comparable with the findings in the animal model 
which is a close parallel in experimental setting. This evidence suggested that 
low or no risk ischemic stroke patients may be the bridge between 
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experimental and clinical setting. It will be beneficial to validate the findings 
observed in a larger cohort of low or no risk ischemic stroke patients. 
 
7.3 Stroke subtype specific miRNAs 
Among the 10 large artery specific miRNAs (miR-27a*, -129-5p, -382, -585, -
602, -637, -659, -744, -1184 and -1261; Table 7.1), 4 miRNAs (miR-382, -637, 
-659 and -744) have been found to have validated targets specific to the 
etiology of large artery stroke [253-259]. These 4 miRNAs had higher 
expression in large artery stroke as compared with other stroke subtypes 
(cardioembolic and small vessel stroke). Large artery stroke is usually caused 
by the rupture of atherosclerotic plaque [258]. These 4 miRNAs were 
associated with atherosclerosis. miR-382-5p targets nuclear factor IA (NFIA) 
which inhibits atherogenesis by increasing high density lipoprotein and 
decreasing low density lipoprotein [253]. The up-regulated miR-382-5p in 
large artery stroke enhanced atherogenesis in the patients. V-akt murine 
thymoma viral oncogene homolog 1 (AKT1) is a gene protecting endothelial 
cells through the AKT1/eNOS pathway and is targeted by miR-637 [254]. The 
higher expression of miR-637 in large artery stroke patients contributes to the 
progression of atherosclerosis. While the up-regulated miR-659 targets the 
anti-inflammatory progranulin, resulting in atherosclerosis-promoting 
inflammation, enhancing atherosclerosis in large artery stroke [255, 256]. 
miR-744 had been shown to target Transforming Growth Factor Beta-1 
(TGFβ-1) which inhibits atherogenesis [257, 259]. In large artery stroke 
patients, the up-regulated miR-744 exacerbated the progression of 
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atherosclerosis. Hence, these observations showed that the 10 large artery 
specific miRNAs are relevant to the pathogenesis of large artery stroke and 
hence are worthy of further investigation. 
Similarly, 14 cardioembolic stroke specific miRNAs (miR-19a, -130b*, -181a-
2*, -198, -200b, -208a, -412, -525-5p, -550, -617, -618, -630, -668 and -1321; 
Table 7.1) has validated targets specific to the etiology. miR-19a has been 
known to target atrogin-1 and MuRF-1 (muscle RING-finger protein-1) which 
are anti-hypertrophy genes [260]. Cardiac hypertrophy can be seen as a pre-
existing condition leading to atrial fibrillation which is the underlying cause of 
most cardioembolic stroke [261]. Hence, the up-regulated miR-19a promotes a 
hypertrophic condition. Similarly, miR-200b which was found to have lower 
expression in cardioembolic stroke patients, targets GATA-4 that is pro-
hypertrophy [262, 263]. This signified that lower expression of miR-200b in 
cardioembolic stroke patients could possibly correlate to cardiac hypertrophy. 
From the above-mentioned evidence, the miRNAs in this cluster could 
possibly be specific for cardioembolic stroke and account for the underlying 
etiology. Thus, these miRNAs should be considered for further study on their 
possible mechanism of actions.  
Interestingly, among the 8 miRNAs (miR-19a, -129-5p, -198, -320b, -320d, -
331-3p, -637 and -744; Table 7.1) that could segregate samples into various 
stroke subtypes (large artery, cardioembolic and small vessel stroke), 3 of 
them (miR-320b, -320d and -331-5p) have been reported by  Sepramaniam et 
al [197] as miRNAs that could distinguish samples according to various stroke 
subtypes. Literature search was performed to identify reported biological 
pathways regulated by these 8 miRNAs. Among the 8 miRNAs, miR-19a had 
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been reported to be associated with inflammation [198], miR-129-5p regulates 
hippo signalling pathway and Wnt signalling pathway [264, 265], miR-198 
was reported to regulate immune response, cell proliferation, apoptosis, cell 
metabolism and cell migration [266], miR-320 was found to be involved in 
angiogenesis, metabolic process regulation and hypoxia regulation [190], miR-
331-3p was reported to regulate androgen receptor signalling [267] and miR-
744 was found to regulate MAPK/ERK pathway [268]. Hence, these 3 
miRNAs are most likely to be miRNAs that regulate processes that are 
explicitly different between individual stroke subtypes and should be 





















Table 7.1: List of stroke subtype specific miRNAs. 
 
Groups of miRNAs miRNAs 
Large artery stroke specific miRNAs miR-27a*, -129-5p, -382, -585, -
602, -637, -659, -744, -1184 and -
1261 
Cardioembolic stroke specific miRNAs miR-19a, -130b*, -181a-2*, -198, -
200b, -208a, -412, -525-5p, -550, -
617, -618, -630, -668 and -1321 
miRNAs that could segregate samples 
into various stroke subtypes  
miR-19a, -129-5p, -198, -320b, -










7.4 Biological pathways specific for stroke subtype 
The biological pathways were ranked from 1 to 100 in this study. The 
difference in ranking the biological pathways signified the difference in the 
degree of dysregulation among the ischemic stroke subtypes. Those biological 
pathways ranked higher implied that more components in the pathway are 
modulated by the dysregulated miRNAs. For complement and coagulation 
cascades, it was ranked 51st for LA and SV, while it was ranked 99th for CE. 
This suggests that complement and coagulation cascade could be more 
dysregulated in LA and SV as compared with CE. 
In the pathway analysis for large artery stroke, the following biological 
pathways have been associated with large artery stroke: Arginine and proline 
metabolism, B-cell receptor signaling pathway, Cell adhesion molecules 
(CAM), Glycosphingolipid biosynthesis-ganglio series and Tight junction. 
Some of these pathways are associated with the etiology of large artery stroke. 
The cause of large artery stroke is often due to the formation and rupture of 
atherosclerotic plaque. Hypertension, hyperglycemia and dyslipidaemia are 
the pre-conditions to trigger atherogenesis which often involve endothelial 
dysfunction. One of the hallmarks of endothelial dysfunction is the loss of 
vascular tone due to decrease in nitric oxide (NO) production by the 
endothelium [269]. This usually implicates the de-regulation of arginine 
metabolism as arginine is a pre-cursor for NO production [269]. Furthermore, 
atherosclerosis progression is driven by inflammation, involving leukocytes 
and lymphocytes to infiltrate the endothelium, which include B-cells [270]. 
The infiltration of these immune cells involved the disruption of tight junction. 
Thus explaining the dysregulation of Cell adhesion molecules and Tight 
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junction [271].  It is known that gangliosides, the products of 
glycosphingolipid biosynthesis accumulate within atherosclerotic vessels 
[272]. Hence, the 10 miRNAs (miR-27a*, -129-5p, -382, -585, -602, -637, -
659, -744, -1184 and -1261; Table 7.1) specific for large artery stroke are 
likely to be involved in these etiological processes, demonstrating the potential 
of these miRNAs for diagnosis of large artery stroke. 
As for cardioembolic stroke, there were 9 biological pathways (ABC 
transporters, adherens junction, complement and coagulation cascades, dilated 
cardiomyopathy, gap junction, glycerophospholipid metabolism, 
glycosphingolipid biosynthesis – lacto and neolacto series, inositol phosphate 
metabolism and pyruvate metabolism) associated with it. Some of these 
pathways are also intricately related with the underlying pathogenesis of 
cardioembolic stroke. The generation of blood clot in cardioembolic stroke is 
generally by coagulation of stagnant pool of blood which is often due to 
cardiac ailment, explaining the dysregulation in complement and coagulation 
cascades and dilated cardiomyopathy [16, 273]. Atrial fibrillation is one of the 
important cause of cardioembolic stroke [16]. The structure of the heart 
undergoes remodelling during atrial fibrillation and these involve changes 
adherens junction and gap junction [274]. Thus, these 14 cardioembolic 
specific miRNAs (miR-19a, -130b*, -181a-2*, -198, -200b, -208a, -412, -525-
5p, -550, -617, -618, -630, -668 and -1321; Table 7.1) could possibly reflect 
the underlying mechanism for cardioembolic stroke pathogenesis. 
As for small vessel stroke, the pathogenesis is similar to that of large artery 
stroke. However, the small vessel stroke associated biological pathways 
(amino sugar and nucleotide sugar metabolism, chemokine signaling pathway, 
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glycerolipid metabolism, PPAR signaling pathway, TGF-beta signaling 
pathway and VEGF signaling pathway) showed novel dysregulated processes 
in small vessel stroke pathogenesis. The implications of these novel processes 
need to be elucidated to further the understanding in small vessel stroke 
pathogenesis. 
 
7.5 Ischemic stroke specific miRNAs 
In this study, the miRNA profiles of ischemic stroke patients with and without 
risk factors and 27 miRNAs (let-7d*, miR-29b-2*, -32*, -125b-2*, -146b-3p, -
196a*, -200b*,  -302c*, -320b, -320c, -331-5p, -374b*, -423-3p, -423-5p, -488, 
-494, -498, -576-3p, -585, -659, -668, -923, -934, -943, -1255a, -1299 and -
1321) were identified as ischemic stroke specific miRNAs that showed similar 
expression pattern in ischemic stroke patients with and without risk factors. 
Among these 27 miRNAs, miR-494 has validated targets which are relevant to 
the pathology of ischemic stroke. miR-494 targets anti-apoptosis genes 
leukemia inhibitory factor (LIF) and fibroblast growth factor receptor 2 
(FGFR2) [275]. miR-494 was detected to be up-regulated in all ischemic 
stroke samples, which signifies increased apoptosis in the patients due to the 
down-regulation of LIF and FGFR2. In addition, 7 of the 27 miRNAs (let-7d*, 
miR-125b-2*, -320b, -423-3p, -488, -1299 and -1321) were previously 
reported by Sepramaniam et al [197] as ischemic stroke specific miRNAs. 




From previous reports, only Tan et al [190] and Jickling et al [198] have 
reported on pathways associated with ischemic stroke. Comparing the 27 
ischemic stroke specific miRNAs with data from Tan et al [190] and Jickling 
et al [198], miR-320 was found to be involved in angiogenesis, metabolic 
process regulation and hypoxia regulation [190]. While searching through 
literature, the following miRNAs were found to be associated with known 
pathways: miR-488 was found to be associated with Corticotropin Releasing 
Hormone (CRH) Signaling [276], miR-494 is associated with PI3K/Akt 
pathway [277]; miR-659 is associated with focal adhesion pathway [278]; miR 
-1255a is associated with aging [279]. These pathways are related with 
ischemic stroke pathophysiology, demonstrating the relevance of these 27 
ischemic stroke specific miRNAs. 
 
7.6  miRNA profiles of rats subjected to MCAo by suture method 
The miRNAs reported in several of the previously published reports were 
found to have similar expression patterns to those identified in this study.  
In the rat MCAo model, miR-320 has been found to be up-regulated in early 
time-points (12, 24 and 48 hours) which coincided with high infarct volume. 
This is consistent with report that treatment with anti-miR-320 can reduce 
infarct volume [280]. miR-223 has been shown to target glutamate receptor 
subunits GluR2 and NR2B and proven to be neuroprotective [281]. In line 
with this report, miR-223 has been found to be down-regulated at 12 and 24 
hours with a corresponding increase in infarct volume. Another miRNA, miR-
181c which was down-regulated in all time-points, has been demonstrated to 
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target tumor necrosis factor α (TNF-α) that regulates microglial-mediated cell 
death [282]. This is in agreement with previous reported findings that TNF-α 
is increased upon ischemia. Furthermore, the down-regulated miR-21 seen in 
our miRNA profile also suggested an increased in microglial-mediated cell 
death, as miR-21 targets Fas ligand (FasL) which is part of death receptor 
induced cell death [283]. Interestingly, neuroprotective miR-124 was found to 
be down-regulated throughout our miRNA profile, as reported by several 
workers [284-287]. The miR-29 isoforms (miR-29a, -29b and 29c) that were 
previously reported [288-290] to be down-regulated during cerebral ischemia, 
were also found to be down-regulated in this study. In the case of miR-139-5p 
that was found to be down-regulated in this study, it was reported that miR-
139-5p down-regulation during hypoxia-ischemia up-regulates human growth 
transformation dependent protein (HGTD-P), promoting neuronal apoptosis 
[291]. miR-376b-5p was demonstrated to be down-regulated after ischemia 
and is also in line with current literature [292]. Similarly for miR-375 which 
was down-regulated in the miRNA profile, had also been reported to be down-
regulated during ischemia/reperfusion [293].  
From the above data, it is evident that the miRNA profile in this study is 
consistent with the previously reported findings from various laboratories. 
Furthermore, this study also identified other miRNAs that were not reported in 
literature which may be of use in advancing the knowledge about ischemic 
stroke.  
 
7.7 miRNAs correlating with infarct volume 
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Four miRNAs (miR-21*, -206, -291a-5p and -300-5p) were demonstrated to 
positively correlate with infarct volume. Among which, miR-206 showed the 
strongest correlation. However, miR-206 expression was found to be down-
regulated during 12 hours time-point in suture model while it was up-regulated 
in the embolic model. This could be due to the difference in the extent of 
ischemia, where suture model is a transient ischemic model with reperfusion 
after 1 hour of occlusion while embolic is a permanent ischemic model 
without reperfusion. The time of ischemic insult differed between the models. 
Hence, the initial down-regulation of miR-206 at 12 hours in suture model 
could be due to a potential rescue mechanism which was more evident in the 
transient ischemic stroke model.  
Some of the known targets of miR-206 may explain the possible mechanism 
of miR-206 correlating with infarct volume. miR-206 had been proven to 
target anti-apoptotic gene, Notch3 and insulin-like growth factor 2 (Igf1) [294, 
295]. Thus, the up-regulation of miR-206 corresponded with a decrease in 
Notch3 and Igf1 which resulted in increased cell death corresponding to infarct 
volume. In addition, miR-206 also targets brain-derived neurotrophic factor 
(Bdnf) which had been proven to reduce infarct volume [296-298]. Therefore, 
up-regulation of miR-206 repressed the neuroprotective Bdnf which led to 
increase cell death and greater infarct volume. These evidence showed that 
miR-206 could potentially be a predictor for severity of ischemic stroke while 
the other 3 miRNAs (miR-21*, -291a-5p and -300-5p) may be useful as 




7.8 miRNAs with biphasic expression pattern 
Four miRNAs (miR-10b, -217, -326 and -881) were highlighted to have 
biphasic expression during cerebral ischemia, where their expression peaked at 
24 hours and decreased till 72 hours and then increased at 120 hours followed 
by decreased expression. It was reported that inflammation played a biphasic 
role during ischemic stroke [299]. It was without surprise that 2 miRNAs 
(miR-10b and -326) have known targets associated with inflammation. 
Transfection of anti-miR-10b has been reported to reduction in matrix 
metalloproteinase 2 and 9 (MMP2 and MMP9) expression [300]. miR-326 had 
been reported to promote differentiation of interleukin 17 producing T helper 
cells (TH-17 cells), hence it was found to be increased during ischemic stroke 
[301, 302]. Thus, miR-10b and -326 up-regulation corresponded to an increase 
in MMP2, MMP9 and TH-17 cells at 24 and 120 hours, denoting a biphasic 
inflammatory response, agreeing with current reports.  
This biphasic inflammation has been speculated to play dual role in the 
pathophysiology of ischemic stroke, where the initial inflammatory response 
could be viewed as detrimental, while inflammation in the late phase was seen 
as beneficial for recovery [299]. In this case, anti-miRNAs can be 
administered during the acute phase of ischemic stroke to ameliorate the 
detrimental effects of inflammation while miRNA mimics can be applied 
during the late recovery phase to enhance inflammation to promote recovery. 
 
7.9 Biological pathways in ischemic stroke 
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Five key processes namely: inflammation, cell death, neuron signaling and 
development, metabolism and vascular maintenance, have been previously 
described in ischemic stroke pathophysiology [303-307]. Biological pathways 
related to these processes were identified in the pathway analysis in patients 
and animal model. Among these processes, inflammation, cell death and 
vascular maintenance were the only processes that were detected in ischemic 
stroke patients as well as animal models (Table 7.2). To a certain extent, 
majority of the biological pathways associated with neuron signaling and 
development were also common between patients and animal models. It can 
be inferred from this observation that these 4 processes (inflammation, cell 
death, vascular maintenance and neuron signaling and development) are likely 
to respond to ischemic stroke in a similar manner in both patients and animal 
model. While in the case of metabolism, there were only three biological 
pathways (Amino sugar and nucleotide sugar metabolism, 
glycerophospholipid metabolism and Purine metabolism) associated with 
metabolism that were commonly detected in patients and animal model. 
Among all the biological pathways, Chemokine signaling pathway was highly 
ranked in both patients (ranked 6
th
) and animal model (ranked 4
th
). This was 
within expectation as chemokines are crucial modulators of inflammation. 
Some of the chemokines hav been reported to be potential markers for 
ischemic stroke [233, 234]. Therefore, by studying the mechanism of actions 
of chemokines in ischemic stroke, there can be better understanding of the 







Table 7.2: Biological pathways associated with known processes 
(inflammation, cell death, neuron signaling and development, metabolism and 
vascular maintenance) involved in ischemic stroke 
 
Biological Pathway Human  Rat 
Inflammation 
B cell receptor signaling pathway   
Chemokine signaling pathway   
Complement and coagulation cascades   
Cytokine-cytokine receptor interaction   
Leukocyte transendothelial migration   
T cell receptor signaling pathway   
Cell Death 
Natural killer cell mediated cytotoxicity   
p53 signaling pathway   
Neuron signaling and development 
Axon guidance   
Glutamatergic synapse   
Long-term depression   
Long-term potentiation   
Neuroactive ligand-receptor interaction   
Neurotrophin signaling pathway   
Vascular maintenance 
Adherens junction   
Cell adhesion molecules (CAMs)   
Focal adhesion   
Gap junction   
Tight junction   
VEGF signaling pathway   
Metabolism 
Alanine, aspartate and glutamate metabolism   
Amino sugar and nucleotide sugar metabolism   
D-Glutamine and D-glutamate metabolism   
Ether lipid metabolism   
Fructose and mannose metabolism   
Galactose metabolism   
Glycerophospholipid metabolism   
Glycine, serine and threonine metabolism   
Glycolysis / Gluconeogenesis   
Inositol phosphate metabolism   
Nicotinate and nicotinamide metabolism   
Phenylalanine metabolism   
Purine metabolism   
Pyrimidine metabolism   
Sphingolipid metabolism   
Tryptophan metabolism   




Knowing the pathways involved in ischemic stroke, it would be useful to 
compare the difference between ischemic stroke and haemorrhagic stroke. In 
order to compare the mechanism is ischemic stroke with haemorrhagic stroke, 
data-mining was performed for the haemorrhagic stroke specific miRNAs in 
rat models reported by Liu et al [192]. 25 miRNAs were identified specific for 
haemorrhagic stroke and used for pathway analysis. The biological pathways 
in ischemic stroke rat animal models were compared with haemorrhagic stroke 
rat animal models. There were 9 biological pathways (Alanine, aspartate and 
glutamate metabolism, Arachidonic acid metabolism, Arginine and proline 
metabolism, beta-Alanine metabolism, D-Glutamine and D-glutamate 
metabolism, Glycolysis / Gluconeogenesis, Nicotinate and nicotinamide 
metabolism, Phenylalanine metabolism and Tryptophan metabolism) detected 
only in ischemic rat and 13 biological pathways (Adipocytokine signaling 
pathway, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Axon 
guidance, Dilated cardiomyopathy, ECM-receptor interaction, Hedgehog 
signaling pathway, Hypertrophic cardiomyopathy (HCM), Inositol phosphate 
metabolism, Notch signaling pathway, Pyrimidine metabolism, Toll-like 
receptor signaling pathway, Ubiquitin mediated proteolysis and Vasopressin-
regulated water reabsorption) detected in haemorrhagic rat (Table 7.3). There 
were 7 biological pathways (B cell receptor signaling pathway, Cell adhesion 
molecules (CAMs), Complement and coagulation cascades, ErbB signaling 
pathway, Ether lipid metabolism, Purine metabolism and T cell receptor 
signaling pathway) that showed different ranking between ischemic and 
haemorrhagic stroke models (Table 7.3). Among these, 3 biological pathways 
(B cell receptor signaling pathway, Purine metabolism and T cell receptor 
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signaling pathway) showed higher ranking in haemorrhagic stroke model 
while the remaining 4 (Cell adhesion molecules (CAMs), Complement and 
coagulation cascades, ErbB signaling pathway and Ether lipid metabolism) 
showed higher ranking in ischemic stroke model (Table 7.3). These 
dysregulated molecular pathways are currently uncharacterized in ischemic 
and haemorrhagic strokes. They are crucial for understanding the molecular 




























Table 7.3: Biological pathways distinct for ischemic stroke and hemorrhagic 
stroke. 





Adipocytokine signaling pathway - 65 
Alanine, aspartate and glutamate metabolism 24 - 
Arachidonic acid metabolism 75 - 
Arginine and proline metabolism 22 - 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 
- 31 
Axon guidance - 5 
B cell receptor signaling pathway 92 43 
beta-Alanine metabolism 43 - 
Cell adhesion molecules (CAMs) 12 87 
Complement and coagulation cascades 56 96 
D-Glutamine and D-glutamate metabolism 46 - 
Dilated cardiomyopathy - 27 
ECM-receptor interaction - 72 
ErbB signaling pathway 26 99 
Ether lipid metabolism 50 98 
Glycolysis / Gluconeogenesis 95 - 
Hedgehog signaling pathway - 76 
Hypertrophic cardiomyopathy (HCM) - 37 
Inositol phosphate metabolism - 74 
Nicotinate and nicotinamide metabolism 85 - 
Notch signaling pathway - 47 
Phenylalanine metabolism 67 - 
Purine metabolism 91 38 
Pyrimidine metabolism - 64 
T cell receptor signaling pathway 68 19 
Toll-like receptor signaling pathway - 48 
Tryptophan metabolism 47 - 
Ubiquitin mediated proteolysis - 6 








7.10 Implication of CD46 in stroke subtype 
CD46 mRNA expression was found to be higher expression in large artery and 
small vessel stroke as compared with cardioembolic stroke. This observation 
was due to difference in the etiology between the stroke subtypes as large 
artery and small vessel strokes are caused by the rupture of atherosclerotic 
plaque while cardioembolic stroke is caused by the formation of blood clot in 
the ailing heart. Complement has been known to participate in atherogenesis. 
Furthermore, complement inhibitors have been reported to be present in 
atherosclerotic lesions and CD46 protein was shown to be increased in in vitro 
model of endothelial cells undergoing atherogenesis [308, 309]. Thus, it was 
observed that CD46 mRNA level was higher in large artery and small vessel 
stroke.  
In this study, 4 miRNAs (miR-19a, -20a, -185 and -374b) were demonstrated 
to target CD46. miR-19a was also among the cluster of 14 miRNAs that were 
specific for cardioembolic stroke and able to distinguish between individual 
stroke subtypes. These 4 miRNAs could potentially be diagnostic markers for 
cardioembolic stroke. To further investigate how these 4 miRNAs relate with 
the underlying pathogenesis of cardioembolic stroke, in silico prediction was 
performed to identify other gene targets (Table 7.4) in the biological pathway, 
Complement and coagulation cascades. The prediction was performed in a 
similar manner as described in previous chapters. The prediction showed 
interesting results. These 4 miRNAs targeted multiple regulators within the 
biological pathway, complement and coagulation cascades. This signifies that 
these 4 miRNAs could potentially act on the pathway to bring about a net 









Table 7.4: Predicted targets of miR-19a, -20a, -185 and -374b in biological 
pathway, Complement and coagulation cascades. AT3: Anti-thrombin III. 
CD46: Cluster of differentiation 46. CD55: Cluster of differentiation 55. F5: 
Factor V. F7: Factor VII. F8: Factor VIII. F11: Factor XI. F13: Factor XIII. 
PAI-1: Plasminogen activator inhibitor-1. PAI-2: Plasminogen activator 
inhibitor-2. PLAT: tissue plasminogen activator. PLAU: urokinase-type 
plasminogen activator. TF: Tissue factor. TFPI: Tissue factor pathway 
inhibitor.  
 
Hsa-miRNA Predicted targets 
miR-19a AT3, CD46, CD55, F5, F13, PAI-1, 
TF, TFPI and PLAU   
miR-20a CD46 and PAI-1 
miR-185 CD46, F7, F8, F11, F13 and PLAT  










7.11 Role of CCL2 in ischemic stroke 
In this study, CCL2 protein level in serum was examined in human ischemic 
stroke patients as well as in rats subjected to MCAo. The results showed that 
in rats CCL2 protein level as well as Ccl2 mRNA level was highest at 24 
hours corresponding to maximum infarct volume, while in ischemic stroke 
patients, CCL2 protein level was found to be at higher level in patients with 
good outcome (mRS < 2) as compared with patients with poor outcome (mRS 
≥ 2). This could possibly suggest that Ccl2 level was high at infarct volume in 
response to ischemic injury and to rescue the cells in the infarct region. This in 
turn was able to correlate with the observation that CCL2 level being higher in 
patients with good outcome.  
Furthermore, some had reported CCL2 to be beneficial during ischemic stroke 
[235-237], Stowe et al [235] demonstrated that hypoxic pre-conditioning only 
protected wildtype mice while CCL2-null mice were not conferred the same 
protection, which suggests that CCL2 expression during ischemic stroke could 
be beneficial. In addition, Yan et al [236] showed that CCL2 was crucial in 
neuroblast migration from the subventricular zone to the penumbra after 
cerebral ischemia and CCL2 was also found to be on blood vessels undergoing 
angiogenesis after cerebral ischemia, suggesting CCL2 to have pro-angiogenic 
properties [237]. Thus, CCL2 could possibly be beneficial during ischemic 
stroke and anti-miRNAs can be used to up-regulate CCL2 in patients in order 
to bring about a good outcome. 
 
7.12 Limitation of study 
 221 
 
This study is limited by the number of ischemic stroke samples obtained. The 
findings from this study needs to be validated in a larger cohort of patients. 
Furthermore, there was limited study into the selected pathways. There is a 
need for an in-depth study on how the dysregulated miRNAs affect the 
biological pathways, including its inner workings in an in vivo model. There 
was also a lack of a functional study to determine how regulating deregulating 
miRNAs using miRNA inhibitors and mimics has any therapeutic effect.  
In addition, there was a lack of investigation into the relation between miRNA 
and outcome of patients. This is aspect of study can provide information about 
the mechanism of ischemic stroke progression and identify potential marker to 
prognosticating outcome of patients 
 
7.13 Potential application of miRNAs in clinical setting 
The results from this study demonstrated 4 miRNAs (miR-19a, -20a, -185 and 
-374b) were differentially expressed in cardioembolic stroke as compared with 
other stroke subtypes. These 4 miRNAs could be potential diagnostic 
biomarkers for cardioembolic stroke. It would be beneficial to have a 
diagnostic biomarker for cardioembolic stroke as it is the stroke subtype which 
has the highest portion of mortality and morbidity, and the early treatment of 
these patients can promote good outcome [16, 17]. 
Blood miRNAs are stable markers in circulation and can be assayed readily. 
These biomarkers could be used in diagnosing cardioembolic stroke patients 
by measuring the levels of these miRNAs using point of care or bedside 
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testing PCR which are mainly based on fluidic chip platforms. These miRNAs 
can be used in combination with various other potential markers of 
cardioembolic stroke such as brain natriuretic peptide (BNP) or CD46 mRNA 
to enhance the accuracy of diagnosis, which needs further fine-tuning. 
Furthermore, the time taken to assay for miRNA expression is merely a few 
hours as compared with traditional blood biochemical test which takes a day to 
perform. There has been some success in a point of care PCR being used for 
influenza A diagnosis, which is a microfluidic chip-based real-time PCR [310]. 
A similar fluidic chip may be developed with a specific panel of miRNAs for 
cardioembolic stroke diagnosis.  
In addition to being markers for disease, miRNAs can also be potential 
therapeutic targets. Anti-miRNAs or miRNA mimics may be delivered to the 
patients to regulate the expression of the miRNA to bring about good outcome 
in the patients. Chemical modifications have been made to increase stability of 
the oligonucleotides, among which locked nucleic acid (LNA™) has been 
widely cited [311]. The delivery system for miRNA therapy has been 
thoroughly investigated. There have been many different types of delivery 
systems of which liposomes have been used widely in pre-clinical and clinical 
trials [312]. Currently, there are 2 clinical trials involving miRNAs that are 
ongoing. Miravirsen developed by Santaris Pharma to treat Hepatitis C by 
inhibiting miR-122, and mRX34 developed miRNA Therapeutics as a miRNA 
replacement therapy for liver cancer [313-316].  Hence, in the case of CCL2, 
anti-miRNAs could be utilized to target miRNAs targeting CCL2 to increase 
CCL2 expression to bring about good outcome in patients. 
7.14 Future work 
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In this study, the crucial molecular processes in ischemic stroke that are 
common between experimental and clinical samples were identified. 
Neuroinflammation was the process selected for further study. Complement 
cascade and chemokine signaling were studied in detail as they were shown to 
be the most relevant in cardioembolic stroke pathogenesis and ischemic stroke 
pathophysiology. Other inflammatory processes highlighted such as cell-
mediated inflammation mediated by B-cells and T-cells, and also cytokine 
signaling, should also be investigated. Inflammation also has a much greater 
impact on ischemic stroke as it is also involved in the pathogenesis of various 
stroke subtypes. This is worth researching on as it may identify potential 
diagnostic biomarkers for stroke subtypes. 
This study also highlighted clusters of miRNAs which were associated with 
the respective stroke subtypes. These clusters of miRNAs should be validated 
on another cohort of ischemic stroke patients to verify the validity. These 
miRNAs have been shown through pathway analysis to be involved in 
processes critical to the etiology of each subtype. The mechanisms of these 
miRNA should be researched upon as this could add new knowledge onto the 
current understanding of the etiology of stroke subtype.  
Coagulation and complement cascade was identified as a biological pathway 
associated with cardioembolic stroke etiology and 4 miRNAs (miR-19a, -20a, 
-185 and -374b) have been demonstrated to target CD46, a regulator of 
complement activation. Further in silico prediction showed that these 4 
miRNAs could potentially target other genes within this biological pathway. 
The regulation of these other genes (AT3, CD46, CD55, F5, F7, F8, F11, F13, 
PAI-1, PAI-2, TF, TFPI, PLAT and PLAU; Table 7.3) by these 4 miRNAs 
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should be inquired upon, to better understand how the regulation of 
coagulation and complement cascade differ between cardioembolic stroke and 
non cardioembolic stroke. 
In this study, chemokine signaling pathway was determined to be a crucial 
biological pathway in ischemic stroke pathophysiology by pathway analysis 
and literature search. CCL2 was selected as an important gene in ischemic 
stroke which was determined by measuring its protein and mRNA level in 
animal model and ischemic stroke patients. Though CCL2 seems to have a 
contradictory role in ischemic stroke, which was also shown in the results, 
there is still a need to be resolved the possible detrimental or beneficial role 
that CCL2 is playing. With the 3‘UTR of CCL2 and Ccl2 subcloned in pMIR-
REPORT™ luciferase vector, all that is needed is to identify miRNAs that 
target CCL2 and Ccl2 and demonstrate the targeting using luciferase assay. 
These miRNAs can be used to regulate CCL2 and Ccl2 by anti-miRNA and 
miRNA mimic transfection in experiments such as oxygen-glucose 
deprivation in SY5Y cells for human in vitro study and rat subjected to MCAo 
for animal in vivo study. By experimentally testing the function of CCL2, the 
therapeutic use of CCL2 and miRNAs targeting CCL2 can be determined.  
There have been miRNAs associated with infarct volumes. The next step will 
be to conduct an in-depth analysis into the expression of miRNAs with can 
correlate with infarct volume at different time-points. However, this will 
require generation of more animal models at different time-points. This can 
provide more clarity on the processes critical for determining infarct volume. 
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There is a need to identify miRNAs correlating with outcome. Profiling of 
miRNAs according to functional outcome is needed. Once these miRNAs are 
identified, they can be compared with the stroke subtype specific miRNAs to 
investigate any miRNAs are specific for small vessel stroke and associated with 
good outcome as these miRNAs can possibly explain the higher proportion of 
good outcome in small vessel stroke. 
7.15 Conclusion 
In this study, miRNA profiles from ischemic stroke patients with and without 
risk factors were compared. 27 miRNAs (let-7d*, miR-29b-2*, -32*, -125b-2*, 
-146b-3p, -196a*, -200b*,  -302c*, -320b, -320c, -331-5p, -374b*, -423-3p, -
423-5p, -488, -494, -498, -576-3p, -585, -659, -668, -923, -934, -943, -1255a, -
1299 and -1321) have been found to be specific for ischemic stroke. Among 
these miRNAs, there are 7 miRNAs (let-7d*, miR-125b-2*, -320b, -423-3p, -
488, -1299 and -1321) that have been previously reported as ischemic stroke 
specific miRNAs [197]. This denotes that this cluster of miRNAs could 
potentially be markers for ischemic stroke and are worth further investigation. 
In addition, stroke subtype specific miRNAs were also highlighted where 
there were 10 large artery stroke specific miRNAs (miR-27a*, -129-5p, -382, -
585, -602, -637, -659, -744, -1184 and -1261), 14 cardioembolic stroke 
specific miRNAs (miR-19a, -130b*, -181a-2*, -198, -200b, -208a, -412, -525-
5p, -550, -617, -618, -630, -668 and -1321) and 141 small vessel stroke 
specific miRNAs. Pathway analysis of these miRNAs revealed that the 
biological pathways regulated by each group of miRNAs were relevant to the 
etiology of the stroke subtype. Furthermore, some of the miRNAs have 
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validated targets associated with the pathogenesis of the stroke subtype as well, 
suggesting that these 3 groups of miRNAs were specific for each stroke 
subtype and could be utilized for further studies to better understand the 
mechanism for the pathogenesis of each stroke subtype. Furthermore, among 
these miRNAs, there were 8 miRNAs (miR-19a, -129-5p, -198, -320b, -320d, 
-331-3p, -637 and -744) that could segregate samples into various stroke 
subtypes, and 3 of them (miR-320b, -320d and -331-5p) had been reported 
previously [197]. This panel of 8 miRNAs could be exploited for the diagnosis 
of stroke subtypes in patients. 
In comparison with the animal study, common biological pathways between 
patients and animal models were identified. Based on the pathway analysis, 
neuroinflammation was determined to be a critical process in the 
pathophysiology of ischemic stroke and it was also differentially regulated in 
different stroke subtype. 4 miRNAs (miR-19a, -20a, -185 and -374b) were 
demonstrated to target CD46, a potential biomarker for cardioembolic stroke. 
Thus, these 4 miRNAs can potentially form a panel of diagnostic biomarker 
for diagnosis of cardioembolic stroke. This requires further evaluations before 
being recommended as a panel to be used in differentiating clinical samples.  
Ccl2 was shown to be correlated with infarct volume in animal experiments 
while in human patients, serum CCL2 level seems to correlate positively with 
outcome of patients. The ambiguous role of CCL2 in ischemic stroke needs to 
be clarified and possibly through the use of miRNAs. Regardless of the role 
CCL2 being detrimental or beneficial, CCL2 and miRNAs targeting CCL2 still 
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Supplementary Table 1: Expression of 352 miRNAs detected in acute ischemic stroke patients. MiRNAs were expressed as fold change 
compared with normal control. All miRNAs selected have positive raw intensity values and FDR < 0.05. ND represents not detected. LA: large 
artery stroke. CE: cardioembolic stroke. SV: small vessel stroke.   
 
Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
Let-7a 1.64 2.09 3.00 1.70 1.86 1.99 2.58 1.80 2.34 1.05 1.08 -1.09 
Let-7a* 3.54 2.83 5.69 4.13 4.22 6.89 4.84 3.51 4.26 -1.27 2.22 2.49 
Let-7b 1.00 1.56 1.97 1.00 1.25 1.03 1.87 -1.05 1.28 -1.45 -1.38 -1.90 
Let-7b* 1.26 1.29 1.61 1.40 1.48 1.57 2.45 1.22 1.79 -3.08 -1.13 -1.42 
Let-7c 1.25 1.85 2.23 1.22 1.84 1.62 2.69 1.29 1.85 -1.10 -1.08 -1.44 
Let-7d 2.43 3.21 4.66 2.18 2.97 3.04 4.72 2.25 3.99 1.30 1.49 1.28 
Let-7d* -3.70 -4.75 -2.51 -2.20 -2.26 -2.94 -2.35 -2.69 -2.16 -13.00 -3.86 -4.65 
Let-7e 3.19 4.00 5.81 2.72 3.83 4.08 5.41 2.60 3.91 1.99 2.08 1.67 
Let-7f 1.49 1.79 2.57 1.54 1.60 1.77 2.21 1.62 2.01 1.01 1.00 1.31 
Let-7g 1.50 2.32 3.62 1.52 2.30 2.08 3.38 1.72 3.22 -1.89 -1.55 -1.63 
Let-7i 1.30 2.00 3.13 1.16 1.98 1.60 3.11 1.28 2.69 -2.09 -1.84 -1.96 
miR-7 1.35 1.64 2.80 1.08 1.42 1.70 2.83 1.14 2.55 -1.75 -1.57 -1.68 
miR-15a 1.73 2.08 2.97 1.79 1.85 2.05 2.57 1.88 2.33 2.06 1.16 1.98 
miR-15b 1.15 1.38 1.98 1.19 1.23 1.37 1.71 1.25 1.55 1.21 -1.28 1.32 
miR-15b* 7.81 6.55 13.07 8.24 7.56 12.53 16.42 6.38 13.15 1.40 3.21 3.22 
miR-16 1.15 1.38 1.99 1.19 1.23 1.36 1.71 1.25 1.55 1.56 -1.28 1.32 
miR-16-2* 2.60 2.80 5.03 3.27 3.40 3.91 5.23 2.16 4.26 -2.45 -1.08 -1.68 
miR-17 1.92 2.31 3.31 1.99 2.06 2.28 2.85 2.09 2.59 1.05 1.22 1.07 
miR-17* 3.67 3.58 7.12 3.43 3.90 6.57 6.43 3.12 6.02 -1.03 2.22 2.01 
miR-18a 2.67 2.91 5.06 2.57 3.13 3.76 5.86 2.73 4.98 -1.59 1.44 1.08 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-18b 2.11 2.41 4.15 2.15 2.72 3.45 5.01 2.25 4.02 -1.61 1.19 1.00 
miR-19a 1.87 2.25 3.22 1.93 2.00 2.02 2.77 2.03 2.52 1.26 1.25 1.75 
miR-19b 2.63 3.16 4.53 2.72 2.82 3.12 3.91 2.87 3.54 1.57 1.77 2.69 
miR-20a 1.02 1.43 2.42 1.29 1.89 1.70 2.66 1.36 2.31 -2.43 -1.59 -1.83 
miR-20a* 3.63 4.02 7.49 4.15 4.56 6.03 7.45 3.54 7.89 -12.06 1.93 1.49 
miR-20b 2.70 2.71 3.85 2.43 3.82 4.47 5.12 2.15 3.69 -1.26 1.58 1.40 
miR-20b* 2.35 2.50 5.94 2.34 2.08 2.66 2.40 1.99 2.16 1.18 2.68 3.14 
miR-21 9.73 11.03 17.18 10.09 10.67 11.82 14.79 10.70 13.42 4.53 4.76 5.56 
miR-22 1.17 1.40 2.01 1.21 1.25 1.38 1.73 1.27 1.57 1.08 -1.27 1.21 
miR-22* -1.07 1.05 1.36 1.03 1.20 1.47 1.75 -1.14 1.76 -3.04 -1.20 -1.51 
miR-23a 1.19 1.69 2.50 1.17 1.48 1.68 1.67 1.06 1.71 1.16 1.24 1.09 
miR-23b 1.61 2.06 2.85 1.41 2.12 2.39 2.33 1.39 2.07 1.24 1.53 1.23 
miR-24 1.31 1.75 2.83 1.16 1.42 1.67 2.01 1.17 2.14 -1.46 -1.10 -1.14 
miR-24-1* 1.88 1.64 1.73 1.32 1.45 1.84 2.10 1.14 1.45 2.09 1.55 -1.02 
miR-25 4.21 4.10 6.48 4.11 4.98 5.71 6.01 3.41 5.39 2.21 3.07 2.81 
miR-25* 2.45 3.33 3.82 2.40 2.53 2.96 2.70 2.50 2.12 2.48 1.93 2.00 
miR-26a 2.00 2.84 4.29 2.02 2.75 3.01 3.80 1.85 3.04 -1.27 1.06 -1.03 
miR-26a-2* -3.15 -1.79 1.74 1.34 -1.12 2.03 -1.06 -1.19 1.29 ND 1.26 -1.34 
miR-26b 1.78 2.14 3.06 1.84 1.90 2.11 2.64 1.94 2.39 -1.27 1.19 1.38 
miR-26b* 1.28 1.04 2.42 2.39 2.29 3.59 2.18 2.11 1.83 -1.40 2.85 1.85 
miR-27a 3.57 4.71 6.53 3.34 4.63 6.61 5.13 2.84 5.06 2.69 3.80 3.59 
miR-27a* 5.55 9.92 10.23 6.69 6.86 10.87 6.06 6.03 4.55 5.05 5.34 4.35 
miR-28-5p 2.81 2.92 4.64 2.23 3.35 3.16 5.81 2.64 4.69 -1.03 1.46 1.57 
miR-29a 5.14 5.53 10.72 5.14 5.59 8.00 12.14 4.38 9.52 2.16 2.63 2.21 
miR-29a* 2.12 ND ND 5.45 6.47 7.23 6.66 4.71 3.32 1.61 5.41 4.25 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-29b-2* 3.14 3.24 3.64 2.01 2.67 3.65 4.08 2.35 4.25 1.04 2.34 1.95 
miR-29c 6.39 6.61 13.48 5.94 6.08 8.74 14.80 5.69 12.56 1.35 2.74 2.29 
miR-29c* 2.91 3.21 4.85 3.68 4.43 5.45 5.51 2.60 5.69 2.02 2.54 1.73 
miR-30a 1.53 1.84 2.64 1.59 1.60 1.82 2.21 1.67 2.07 -1.29 1.03 1.29 
miR-30b 1.64 2.13 3.29 1.53 2.11 2.41 3.64 1.52 3.01 -1.48 -1.24 -1.51 
miR-30c 1.21 1.52 2.62 1.14 1.71 1.90 2.81 1.18 2.51 -2.84 -1.47 -1.70 
miR-30d 1.22 1.30 1.62 1.25 1.58 1.59 1.86 1.20 1.37 -1.73 -1.01 -1.28 
miR-30e 1.48 2.08 3.67 1.51 2.21 2.65 3.44 1.49 2.53 -2.14 -1.25 -1.47 
miR-30e* 1.61 1.97 3.24 1.47 2.20 2.63 3.43 1.57 2.74 -1.75 -1.10 -1.27 
miR-32 8.39 8.49 17.49 9.18 8.92 15.90 20.00 8.16 14.20 3.00 2.82 3.58 
miR-32* -2.64 -1.98 -1.63 -1.99 -1.92 -2.27 -1.62 -1.72 -1.95 -2.43 -2.59 -3.01 
miR-33a 38.94 37.02 100.04 50.54 44.51 121.51 68.33 43.26 80.84 8.92 23.92 43.69 
miR-34b 2.82 3.46 4.94 2.12 2.34 3.36 2.92 1.89 1.77 3.09 1.93 2.36 
miR-92a 1.18 1.06 1.53 1.01 -1.03 1.50 1.33 -1.12 1.02 -1.36 1.01 -1.08 
miR-92b 1.85 1.63 2.15 1.52 1.62 1.98 2.01 1.35 1.50 1.01 1.57 1.37 
miR-93 1.48 1.78 2.55 1.37 1.58 1.75 2.20 1.61 1.99 1.40 -1.00 1.42 
miR-93* -1.89 -2.26 -1.82 -1.10 -1.10 1.27 1.36 -1.38 1.03 -3.18 -1.24 -1.89 
miR-96 2.18 2.87 4.75 2.26 3.46 3.71 4.93 2.47 4.09 -1.37 1.24 1.28 
miR-98 4.24 5.09 8.60 2.57 3.99 5.81 7.10 2.76 6.19 2.44 2.38 2.37 
miR-99a 1.28 2.20 3.85 1.12 2.10 1.32 2.33 2.34 1.36 -1.88 -1.49 -2.93 
miR-99b* 1.55 1.59 1.89 1.44 1.58 2.44 1.85 1.15 1.18 1.69 1.87 1.54 
miR-101 3.45 4.15 5.94 3.57 3.54 4.09 5.12 3.75 4.64 1.59 2.32 3.02 
miR-101* 6.52 5.19 10.22 7.76 10.59 11.79 13.72 6.18 11.12 1.52 3.22 2.84 
miR-103 2.83 3.40 4.87 2.92 3.03 3.35 4.19 3.08 3.81 2.13 1.90 2.34 
miR-106a 2.26 2.72 3.90 2.34 2.42 2.68 3.36 2.46 3.05 -1.41 1.50 1.34 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-106b 1.44 1.73 2.48 1.49 1.54 1.71 2.11 1.57 1.94 1.18 -1.03 1.17 
miR-106b* 1.58 1.86 2.66 1.52 1.67 1.92 2.44 1.20 2.05 -1.21 1.10 -1.16 
miR-107 2.34 2.98 4.03 2.44 3.12 3.35 4.40 2.46 3.99 1.48 1.66 1.41 
miR-122 -38.66 ND -2.02 -2.36 -3.21 -1.37 -2.20 -2.86 -3.39 -2.80 -1.98 1.12 
miR-122* -1.48 ND ND -1.35 -1.11 1.24 ND -1.18 ND 1.00 1.71 1.27 
miR-124* 2.47 ND ND 5.21 1.19 6.93 -1.46 3.19 -1.33 ND 4.56 4.31 
miR-125a-5p 1.02 -1.12 -1.33 1.00 -1.30 1.18 -1.42 -1.40 -1.41 -1.76 1.02 -1.41 
miR-125b -2.21 -1.34 -1.65 -1.02 -1.25 -1.23 -1.21 -1.34 -1.11 -27.06 -2.51 -6.13 
miR-125b-1* 2.05 2.11 2.44 2.27 2.23 2.84 2.81 2.16 2.10 1.42 2.11 1.44 
miR-125b-2* 4.19 3.06 2.25 6.58 5.48 7.20 5.01 6.17 4.69 2.44 4.62 3.34 
miR-126 1.23 1.48 2.36 1.42 1.78 1.96 2.27 1.18 2.29 -1.86 -1.58 -1.89 
miR-126* 4.04 4.99 9.20 5.29 6.27 7.27 8.10 4.38 7.61 -1.19 1.57 1.93 
miR-128 -1.12 -1.36 1.93 1.80 2.12 2.58 3.30 1.77 3.15 ND 1.26 -1.14 
miR-129* 3.49 -1.00 -2.58 2.30 1.88 3.17 -1.13 1.90 1.58 2.26 3.84 3.31 
miR-129-5p 2.48 2.09 3.15 3.20 3.29 3.18 2.75 2.90 2.53 2.00 1.76 2.05 
miR-130a 1.19 1.65 2.17 1.31 1.65 1.63 1.67 1.16 1.48 -3.35 -1.30 -1.77 
miR-130b 1.23 1.45 1.92 1.13 1.44 1.47 2.00 1.08 1.59 -1.11 1.00 -1.38 
miR-130b* 1.57 -1.47 -1.09 1.89 1.96 3.25 -1.81 1.25 1.15 2.63 2.57 1.57 
miR-132* -1.71 ND ND 1.62 1.38 1.94 1.67 1.82 1.44 -1.25 1.82 2.29 
miR-135b 1.90 1.96 3.39 3.87 4.88 7.02 6.78 3.62 4.58 1.58 2.21 2.07 
miR-138-1* 1.74 1.82 1.91 1.35 1.83 2.41 2.50 1.30 1.24 2.18 1.70 1.43 
miR-138-2* 2.01 1.87 1.42 1.52 1.55 3.19 2.42 -1.18 1.11 1.69 2.53 1.43 
miR-140-3p 1.11 1.53 2.12 -1.01 1.39 1.31 2.10 1.13 1.74 -2.31 -1.24 -1.52 
miR-140-5p 7.27 9.12 17.60 6.50 9.30 14.93 15.41 7.08 13.24 3.44 4.52 4.63 
miR-142-3p 1.73 2.07 2.97 1.78 1.85 2.04 2.56 1.88 2.32 1.80 1.16 1.97 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-143 3.08 4.00 8.47 3.75 5.36 8.24 5.52 4.47 6.23 1.15 2.88 4.83 
miR-144 1.19 1.43 2.04 1.23 1.27 1.41 1.76 1.29 1.60 1.61 -1.25 1.36 
miR-144* 2.93 3.52 5.05 3.03 3.14 3.47 4.35 3.19 3.95 2.76 1.97 2.59 
miR-145 2.58 2.08 2.79 2.54 3.34 6.70 2.25 2.17 1.58 -1.01 3.55 4.88 
miR-145* 1.54 -1.99 ND 2.03 2.48 2.22 2.23 1.53 1.00 2.39 2.17 1.78 
miR-146a 1.60 2.17 3.29 2.19 2.94 2.97 3.04 2.23 3.39 -2.24 1.23 -1.42 
miR-146b-3p 1.30 1.38 1.19 1.61 1.45 1.63 1.25 9.76 1.32 1.49 1.72 1.50 
miR-146b-5p 1.18 5.61 2.23 1.27 1.76 1.86 2.39 1.34 2.43 -1.53 -1.37 -1.96 
miR-148a 2.82 3.30 5.75 3.61 5.59 7.38 6.90 3.30 5.06 1.42 2.85 2.77 
miR-148b -1.35 -1.13 1.52 -1.10 1.28 1.26 1.79 -1.11 1.60 -4.93 -1.92 -2.25 
miR-149* -1.09 1.04 1.24 1.34 1.67 1.10 1.68 1.49 1.15 1.07 -1.34 -1.41 
miR-150 -2.76 -3.97 -5.90 -1.11 -1.18 -1.15 -1.48 -1.47 -1.80 -1.46 -1.15 -1.62 
miR-151-3p 1.37 1.67 2.91 1.20 1.32 1.55 2.62 1.21 2.44 -4.90 -1.56 -1.41 
miR-151-5p 1.42 1.68 2.69 1.22 1.80 1.60 2.93 1.48 2.65 -2.67 -1.40 -1.35 
miR-155 -1.54 -1.25 -1.01 1.01 1.12 1.39 1.49 -1.06 1.48 -4.03 -1.43 -1.89 
miR-181a 1.61 2.15 2.95 1.73 1.97 2.09 2.78 1.52 2.37 -1.19 1.12 -1.02 
miR-181a-2* 3.58 2.67 3.60 2.47 1.65 6.07 1.02 1.17 1.29 2.85 3.75 3.02 
miR-181b 1.62 1.43 3.52 3.09 2.77 4.03 3.59 2.38 3.61 -1.21 2.10 1.71 
miR-182 1.10 1.42 2.37 1.08 1.50 1.44 2.59 1.13 2.27 -5.10 -1.61 -1.92 
miR-183 -1.05 1.13 1.69 -1.17 1.09 1.14 1.60 -1.33 1.49 -1.72 -1.38 -2.08 
miR-183* 1.96 2.46 2.86 1.75 1.77 1.90 2.42 2.19 1.80 1.83 1.59 1.43 
miR-184 2.71 2.86 3.31 2.42 2.50 3.71 2.08 2.20 1.93 2.17 2.56 2.36 
miR-185 -1.07 -1.18 1.58 -1.52 -1.19 1.01 1.83 -1.58 1.58 -3.07 -2.36 -3.25 
miR-185* -1.27 1.12 1.43 1.07 1.20 1.10 1.14 1.07 -1.04 -1.39 -1.82 -2.02 
miR-186 1.46 1.69 2.72 1.42 1.75 1.61 2.68 1.28 2.35 -1.42 -1.31 -1.28 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-188-5p 4.24 ND 6.03 6.85 5.34 11.73 7.91 5.69 9.66 ND 3.69 3.82 
miR-190 6.71 7.13 15.10 7.27 8.35 12.52 15.48 7.11 13.34 2.06 2.71 2.47 
miR-191 -1.01 1.36 1.93 -1.07 1.18 -1.00 1.90 1.08 1.82 -2.60 -1.57 -1.83 
miR-192 1.81 2.21 3.92 1.81 2.30 2.83 3.88 1.69 3.11 -1.48 -1.09 -1.39 
miR-193a-3p -1.10 -1.03 1.71 1.29 1.70 2.47 1.68 -1.02 1.38 ND -1.14 -1.54 
miR-193b* 1.44 1.47 1.37 2.29 2.54 2.18 2.53 2.40 1.72 2.08 1.71 1.45 
miR-194 2.12 2.28 4.28 2.11 2.25 2.98 4.04 1.60 3.88 -1.34 -1.04 -1.15 
miR-194* 2.69 -1.13 -3.53 3.75 3.04 6.32 1.47 2.57 1.25 2.03 3.53 2.97 
miR-195 7.30 8.76 12.37 7.26 7.71 8.64 10.62 6.25 9.82 4.59 4.90 7.18 
miR-196a* 2.34 2.09 2.50 1.67 1.70 2.20 1.85 1.65 1.62 1.84 2.51 2.17 
miR-196b 3.20 3.56 6.66 4.86 4.70 6.70 5.31 3.53 6.00 -14.05 2.34 1.94 
miR-197 2.00 1.45 1.76 1.67 1.64 2.08 1.80 1.42 1.65 1.49 1.86 1.94 
miR-198 19.03 3.93 1.75 4.79 5.72 3.01 1.87 1.75 1.38 2.60 2.49 3.03 
miR-199a-3p 5.15 5.18 11.12 8.32 9.04 12.31 6.43 5.05 11.54 2.13 3.94 3.56 
miR-199a-5p -5.63 -10.61 -2.45 1.08 1.43 1.63 -7.33 -1.11 1.71 ND -1.55 -8.46 
miR-199b-5p 1.01 3.32 5.41 3.08 3.75 5.58 4.58 2.70 3.87 -2.26 3.03 3.79 
miR-200b 2.00 ND ND 1.37 1.68 2.20 1.28 1.16 -1.40 1.82 2.99 1.98 
miR-200b* 2.99 3.44 2.97 4.99 4.92 5.23 4.88 5.16 3.74 3.89 3.54 3.70 
miR-203 1.07 1.16 -2.93 -1.66 -3.91 1.57 -3.49 -4.59 -2.77 ND 1.74 -2.36 
miR-206 3.87 2.88 2.59 3.51 3.33 5.77 3.83 2.74 3.09 2.60 4.33 3.27 
miR-208a -1.73 -1.67 -2.89 -2.47 -2.72 -1.52 -2.82 -2.79 -4.08 -2.14 -1.44 -2.23 
miR-208b 3.86 -7.39 ND 1.72 1.16 4.31 ND 3.13 -1.10 ND 5.66 1.09 
miR-210 4.26 4.16 5.48 2.69 3.33 7.09 4.50 2.44 3.76 1.21 3.56 2.91 
miR-214 2.23 1.24 -1.14 3.42 4.38 4.73 4.52 5.60 2.80 2.31 3.23 2.98 
miR-215 1.79 2.29 3.77 1.86 2.46 3.07 4.01 1.82 3.15 -1.71 1.00 -1.12 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-221* -1.32 ND ND 2.17 -1.42 2.82 -3.28 1.82 1.80 ND 2.71 1.26 
miR-222 1.49 2.00 3.03 1.30 1.68 1.84 2.01 1.03 1.90 -2.58 -1.03 -1.20 
miR-223 3.19 4.17 6.18 2.86 3.84 4.21 5.16 3.24 4.76 2.77 2.41 3.89 
miR-299-3p 1.31 1.11 1.20 -1.11 -1.34 1.25 -1.16 -1.49 -1.43 -1.21 1.26 1.03 
miR-300 1.85 1.93 3.10 2.06 2.23 2.51 2.17 1.83 1.62 1.95 1.44 1.42 
miR-301a 2.47 2.68 5.26 2.05 2.64 3.47 6.03 2.46 5.40 -2.15 -1.12 -1.07 
miR-301b -4.39 -17.04 1.85 3.16 2.93 5.32 8.13 3.10 8.75 ND 1.42 -1.60 
miR-302c* 1.31 1.68 1.01 2.98 2.77 4.08 2.63 3.08 1.45 3.28 3.17 2.44 
miR-302e 1.41 1.46 ND -1.15 1.37 1.82 -1.09 -1.17 -1.16 2.14 2.17 1.44 
miR-320a -1.34 -1.24 1.03 -1.69 -1.60 -1.60 1.11 -1.54 -1.51 -3.88 -1.78 -2.82 
miR-320b -1.68 -1.36 -1.18 -2.05 -1.82 -1.89 -1.00 -1.74 -1.81 -2.71 -2.19 -3.08 
miR-320c -1.81 -1.57 -1.32 -2.12 -1.86 -2.03 -1.08 -1.82 -1.91 -1.94 -2.44 -3.78 
miR-320d -1.38 -1.11 1.06 -1.48 -1.36 -1.49 1.23 -1.28 -1.30 -2.31 -1.75 -2.52 
miR-324-3p -1.21 -1.57 1.04 1.13 -1.06 2.23 1.05 -1.29 1.09 1.22 1.52 1.05 
miR-324-5p -2.42 -2.47 -1.84 -1.45 -1.51 -1.83 1.05 -1.54 1.01 -2.72 -2.67 -2.99 
miR-326 1.71 1.26 1.87 1.89 2.05 2.02 1.79 2.00 1.57 2.57 1.63 1.77 
miR-328 -12.55 ND 1.41 1.41 -1.37 1.81 ND -1.53 -1.35 -3.88 1.25 -1.08 
miR-331-3p 1.05 1.27 1.66 1.06 1.04 1.03 1.59 1.08 1.36 -2.50 -1.14 -1.70 
miR-331-5p -3.24 -4.12 -4.88 -1.53 -1.42 -1.35 -1.00 -1.65 -1.63 -2.54 -1.82 -2.88 
miR-335 -1.38 1.03 2.12 1.00 1.12 1.49 1.66 -1.13 1.57 -3.61 -2.26 -2.76 
miR-335* -3.18 ND ND -2.48 -5.89 1.22 -5.50 -6.00 ND ND -1.33 -2.79 
miR-338-3p 29.70 25.30 51.57 18.54 28.16 44.69 23.43 19.01 27.81 1.40 16.28 27.43 
miR-339-3p -1.18 -1.03 1.23 1.35 1.62 1.41 1.50 -1.05 1.46 -1.74 -1.09 -1.46 
miR-339-5p -1.86 -1.43 -1.05 -1.50 -1.32 -1.40 -1.49 -2.01 -1.33 -3.39 -2.28 -3.20 
miR-340 1.03 -1.00 1.57 1.24 1.23 1.71 1.61 1.12 1.47 -1.70 1.01 -1.28 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-342-3p -2.23 -1.59 -1.40 -2.46 -1.73 -1.86 -1.35 -1.99 -1.63 -3.27 -1.93 -2.92 
miR-342-5p -1.43 -1.14 -1.33 -1.41 -1.28 -1.17 -1.15 -1.61 -1.36 -2.15 -1.35 -2.00 
miR-345 1.01 -2.77 -8.30 -1.10 1.18 1.07 1.08 -1.52 -1.07 -2.90 -1.26 -2.51 
miR-361-3p 1.63 1.69 2.16 1.59 1.96 1.62 2.95 1.93 2.06 1.14 1.03 -1.00 
miR-361-5p -1.11 1.14 1.47 -1.07 1.00 1.01 1.42 -1.17 1.21 -1.56 -1.25 -1.38 
miR-362-3p 1.59 1.67 3.67 2.46 2.56 4.13 3.90 1.78 3.09 ND 1.00 -3.88 
miR-362-5p 1.02 1.31 1.83 1.01 1.40 1.37 2.35 1.10 1.83 -1.96 -1.55 -1.76 
miR-363 1.63 2.16 3.33 2.11 2.30 2.26 2.76 1.57 3.02 -1.99 -1.37 -1.56 
miR-363* -2.07 ND 1.34 1.95 -1.67 4.10 ND 1.52 ND -2.48 2.56 2.29 
miR-365 -1.97 -3.63 ND 1.45 1.71 2.42 1.46 1.28 -1.23 -2.57 1.70 1.38 
miR-370 1.40 1.74 2.59 1.21 1.37 1.71 1.83 1.33 1.39 1.80 -1.02 1.42 
miR-374a 1.88 2.51 4.77 2.21 2.76 3.43 4.25 2.04 3.71 -2.52 -1.07 -1.22 
miR-374b 3.86 4.47 7.53 3.93 5.08 6.87 7.94 3.25 6.87 1.27 2.39 2.13 
miR-374b* 3.07 1.69 2.52 2.48 2.75 3.93 1.77 2.77 1.88 3.18 3.67 2.63 
miR-375 -2.68 ND ND -1.59 -2.04 1.11 -2.64 -2.40 ND -4.00 1.02 -1.53 
miR-378 -1.33 1.01 1.59 -1.24 1.08 1.01 1.66 -1.18 1.30 -3.62 -2.20 -2.52 
miR-381 1.99 2.10 2.27 2.47 1.91 2.86 1.98 2.62 1.86 -1.10 1.84 1.13 
miR-382 -1.06 -1.94 -2.53 1.47 1.70 1.88 -1.06 1.36 1.03 1.38 1.43 1.07 
miR-412 -11.46 -18.44 -35.56 -1.11 -1.57 -1.23 -4.66 -5.19 ND -4.16 -1.12 -3.01 
miR-421 1.37 1.92 2.07 2.25 2.50 2.81 4.15 2.13 3.35 -1.29 1.52 1.50 
miR-422a 3.74 4.82 6.30 2.65 3.86 5.90 4.56 2.32 3.11 2.28 3.05 2.66 
miR-423-3p -1.53 -1.35 -1.02 -1.23 -1.25 -1.28 -1.01 -1.63 -1.25 -2.00 -1.78 -2.37 
miR-423-5p -2.68 -2.31 -1.84 -3.05 -2.96 -2.72 -2.18 -2.98 -3.16 -9.16 -3.24 -4.24 
miR-424 7.62 7.99 15.14 8.46 9.98 13.43 17.95 6.57 13.59 3.59 3.66 3.83 
miR-425 2.30 2.58 3.21 1.94 2.54 2.56 3.44 1.92 2.71 1.38 1.72 1.32 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-450a ND ND ND 3.16 3.13 5.43 4.58 3.47 4.27 ND 2.99 3.14 
miR-451 1.15 1.38 1.98 1.19 1.23 1.36 1.71 1.25 1.55 1.56 -1.28 1.32 
miR-454 11.57 8.54 14.74 8.77 10.33 16.37 20.18 8.58 17.87 4.63 5.88 4.80 
miR-483-5p 6.28 4.93 3.69 5.65 5.48 4.90 4.23 3.65 3.10 5.04 3.77 3.57 
miR-484 1.14 1.19 1.42 1.17 1.40 1.29 1.40 1.12 1.17 -1.39 1.00 -1.30 
miR-485-3p 1.39 1.04 1.26 1.13 1.67 1.52 1.31 1.13 -1.19 2.06 1.10 1.14 
miR-486-3p ND ND ND 1.02 1.64 1.71 1.06 -1.28 1.09 -9.67 -1.31 1.10 
miR-486-5p 1.15 1.38 1.99 1.19 1.23 1.36 1.71 1.25 1.55 1.56 -1.28 1.32 
miR-487b 5.03 5.30 5.00 3.41 3.51 6.35 4.73 2.41 3.03 3.81 6.50 4.89 
miR-488 3.30 2.34 2.19 5.81 3.88 6.71 3.72 5.18 3.14 1.47 4.71 3.65 
miR-489 1.63 1.32 -3.09 2.42 2.25 3.46 2.94 2.26 1.15 1.45 2.73 2.48 
miR-490-3p 5.14 2.51 -1.12 3.11 3.34 4.88 3.53 3.92 2.70 2.96 5.93 3.61 
miR-491-3p 2.35 1.75 2.25 1.45 1.39 2.19 1.90 1.12 1.15 1.79 2.24 2.02 
miR-492 2.66 2.18 ND 5.64 4.39 16.83 6.53 4.26 2.10 2.69 8.94 4.97 
miR-493* 2.09 1.86 1.51 1.34 1.10 2.04 1.91 -1.43 1.59 -1.43 1.95 -1.64 
miR-494 4.69 4.92 5.60 5.61 5.31 9.56 5.73 3.39 3.19 7.13 7.05 7.61 
miR-498 4.89 4.00 4.62 4.45 5.05 5.42 4.90 4.16 3.72 6.50 4.04 3.98 
miR-500 1.22 1.50 1.92 1.18 1.48 1.47 2.14 1.10 1.88 -1.36 -1.10 -1.51 
miR-500* -1.40 -1.61 -1.09 -1.16 1.03 1.04 1.46 -1.27 1.05 -2.16 -1.42 -2.06 
miR-501-5p -2.13 -1.86 -1.73 -1.53 -1.44 -1.68 1.02 -1.79 -1.11 -3.01 -2.64 -3.91 
miR-502-3p -2.05 -1.65 -1.96 -1.31 -1.10 -1.16 1.35 -1.35 -1.11 -2.21 -1.68 -2.55 
miR-502-5p -1.61 1.58 -1.19 -1.54 -1.35 1.02 1.15 -1.91 -1.05 -3.03 -1.46 -3.09 
miR-504 -8.68 -4.39 -1.70 -8.85 -182.46 ND ND -6.38 -8.36 ND -5.40 -9.86 
miR-505 -1.14 1.27 2.69 1.88 3.02 3.22 3.91 2.10 3.54 ND 1.21 -1.02 
miR-505* -1.82 -1.78 -1.94 -1.72 -1.61 -1.56 -1.26 -1.80 -2.27 -1.88 1.06 -1.86 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-509-5p -2.62 -1.92 ND 1.10 1.17 -1.24 -1.08 3.02 -1.32 -1.84 -1.21 -1.75 
miR-510 -1.66 ND ND 2.56 3.06 1.80 2.47 2.53 1.33 1.50 1.83 1.59 
miR-513a-3p 2.09 1.81 1.24 1.79 1.96 3.99 2.51 1.13 -1.06 2.16 2.49 2.29 
miR-513a-5p -1.74 -1.58 -1.33 -1.39 -1.24 -1.33 -1.74 -1.26 -1.70 -1.27 -1.84 -2.16 
miR-516a-5p -8.69 -4.10 ND -2.52 -1.53 -3.96 -4.34 1.68 -5.40 -4.66 -2.79 -4.67 
miR-516b 1.82 1.50 -2.60 2.37 2.04 3.63 -1.13 2.07 1.35 1.94 3.39 2.67 
miR-518a-5p -1.01 1.34 1.16 1.22 1.49 1.69 1.28 1.19 -1.33 1.22 1.10 -1.07 
miR-519c-5p ND -4.29 ND 2.13 2.43 2.19 -2.77 6.14 ND 1.23 2.31 1.19 
miR-519d -3.40 -3.27 -3.28 -3.18 -2.62 -2.25 -2.89 -3.96 -4.33 -2.58 -2.63 -2.98 
miR-519e 1.31 1.16 1.87 1.65 1.87 1.84 1.34 1.84 1.56 1.72 1.00 1.23 
miR-519e* 2.51 2.90 2.86 2.11 2.41 2.67 2.59 1.83 1.54 2.95 2.54 2.09 
miR-520d-5p 1.02 1.04 -1.85 1.50 1.55 2.44 1.41 1.23 -1.47 1.41 1.66 1.28 
miR-525-5p 1.92 1.63 1.18 2.17 1.71 2.87 1.53 1.67 1.30 2.98 2.43 2.00 
miR-532-3p -1.11 -4.57 -12.74 -1.15 -1.09 1.43 -1.00 -1.14 -1.15 -1.68 1.08 -1.16 
miR-532-5p 1.06 1.31 2.21 1.29 1.50 1.61 2.06 1.11 1.90 -5.23 -1.37 -1.44 
miR-542-3p 2.17 1.61 1.83 1.90 1.63 3.66 2.08 1.25 1.65 -1.31 2.73 2.26 
miR-548e 9.89 11.85 11.59 6.09 6.40 10.86 9.10 7.02 7.51 10.74 11.50 11.05 
miR-548n 2.39 1.34 2.97 2.63 3.57 6.37 4.82 3.12 3.99 1.62 3.75 3.04 
miR-549 4.61 5.16 5.61 3.90 3.53 5.08 4.38 3.11 3.27 5.75 4.77 4.11 
miR-550 -1.20 -1.03 1.26 -1.00 1.03 -1.23 1.05 1.16 1.16 -1.18 -1.10 -1.25 
miR-550* 1.30 1.49 1.90 1.46 1.67 1.61 2.24 1.27 1.96 -1.23 1.04 -1.29 
miR-551a 1.86 -1.12 -1.80 2.60 2.06 3.93 1.45 1.68 1.50 1.51 3.27 2.98 
miR-551b -1.36 -1.53 -1.14 -1.14 -1.15 -1.29 -1.38 -1.23 -1.42 -1.42 -1.63 -1.62 
miR-552 8.49 2.55 3.28 2.46 2.40 3.90 3.09 2.09 2.06 2.70 2.94 2.53 
miR-553 1.23 1.32 -1.27 3.94 4.45 3.25 3.03 4.24 2.48 2.92 2.55 1.80 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-574-3p -1.87 -2.92 -1.56 1.19 1.19 1.13 1.08 1.08 -1.09 -1.05 1.48 1.36 
miR-574-5p -1.45 -1.22 1.26 -1.07 -1.01 -1.26 1.17 -1.02 -1.02 -1.96 -1.40 -1.67 
miR-576-3p 1.46 1.61 2.17 1.29 1.42 1.64 1.51 1.54 1.29 2.06 1.46 1.42 
miR-576-5p 1.09 1.11 1.52 1.12 1.07 1.27 1.72 -1.11 1.38 -1.14 -1.27 -1.41 
miR-578 ND ND ND 2.35 1.18 2.11 1.78 1.92 1.96 1.24 1.73 2.04 
miR-581 ND ND -1.72 2.32 1.03 2.46 -2.12 1.89 1.95 1.29 1.36 1.88 
miR-583 1.41 1.89 1.58 1.55 2.02 1.57 1.57 1.43 1.07 1.34 1.15 1.10 
miR-584 6.31 6.02 6.70 4.79 4.56 7.33 6.67 4.75 4.20 6.33 6.66 6.85 
miR-585 7.40 7.55 10.33 7.70 8.16 10.01 7.48 6.67 5.91 6.77 5.40 6.37 
miR-589 4.32 5.46 4.30 2.46 2.75 4.51 4.02 1.95 2.96 3.22 4.64 3.33 
miR-590-5p 10.78 12.65 25.93 10.18 14.47 21.69 25.69 11.58 19.80 1.65 5.47 4.88 
miR-597 5.01 5.61 4.02 3.86 3.78 7.85 4.98 2.23 3.36 3.21 7.45 5.18 
miR-600 4.58 3.13 2.85 3.44 2.59 4.66 2.29 2.63 2.65 4.48 5.12 4.31 
miR-601 1.19 ND -2.57 3.44 2.45 3.62 1.94 3.00 1.78 1.43 3.18 3.02 
miR-602 2.04 2.33 2.75 2.83 2.84 3.90 2.75 2.34 2.16 1.84 2.11 2.21 
miR-605 -1.43 -1.61 -5.94 -1.45 1.21 1.53 -1.17 -1.76 -17.03 1.14 1.61 1.10 
miR-611 3.20 4.84 6.23 2.87 3.28 3.04 3.95 3.18 3.09 2.51 1.77 1.32 
miR-615-3p -1.00 -1.80 -3.47 1.61 -1.44 2.44 -36.74 -1.12 -1.21 1.91 1.73 -1.03 
miR-617 3.01 2.43 3.19 1.89 1.97 3.10 1.42 1.74 1.09 2.27 2.69 2.13 
miR-618 ND ND -1.83 3.52 2.62 3.37 ND 1.58 1.55 3.36 3.11 4.36 
miR-620 -1.00 -1.21 -1.20 -1.32 -1.19 -1.06 -1.61 -1.09 -1.34 1.04 1.13 1.02 
miR-622 -3.24 -1.74 ND -1.33 -1.48 1.49 -1.46 -1.10 -4.80 -1.05 1.09 -1.41 
miR-623 2.79 2.53 2.37 4.56 2.88 6.76 2.39 2.98 2.81 3.37 3.12 2.19 
miR-625 -1.20 1.15 1.38 1.10 1.35 1.17 1.15 -1.11 1.02 -3.05 -1.37 -1.55 
miR-625* -10.85 -5.26 ND -1.38 -1.76 -1.15 -2.66 -1.76 -2.48 -1.26 -1.32 -1.44 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-628-3p 1.22 1.51 2.04 1.56 1.52 1.34 1.48 1.67 1.30 -1.50 -1.10 -1.27 
miR-629 1.01 1.27 1.73 -1.13 1.17 1.35 1.61 -1.03 1.12 -2.29 -1.42 -1.82 
miR-629* 2.94 3.78 3.97 2.93 3.25 6.77 2.96 1.86 1.58 2.77 4.91 4.82 
miR-630 1.22 -7.02 ND 2.17 2.65 1.79 -1.38 1.67 -1.49 2.11 2.37 1.70 
miR-634 -4.54 -9.26 -37.22 -2.34 -3.30 -2.55 -2.98 -2.70 -3.99 -3.20 -2.50 -2.92 
miR-635 1.26 1.94 ND 1.93 -1.15 3.69 -2.87 1.12 -4.67 -2.09 2.26 -2.52 
miR-636 1.07 -1.10 -1.20 -1.11 -1.20 1.30 -1.25 -1.35 -1.04 1.11 1.16 1.04 
miR-637 3.03 3.37 4.44 3.59 3.59 3.98 2.97 3.22 2.64 2.37 2.05 1.85 
miR-638 5.28 3.59 4.41 4.59 5.17 5.90 5.07 4.12 3.33 4.40 3.83 4.88 
miR-642 1.24 -1.34 1.19 1.47 1.40 1.38 1.71 1.35 1.24 1.53 1.08 1.21 
miR-647 1.87 1.33 -1.37 1.89 2.02 2.29 4.17 1.64 2.90 2.14 2.37 1.44 
miR-652 1.78 1.83 2.30 2.00 1.89 1.85 2.47 1.87 2.15 1.38 1.45 1.23 
miR-659 2.95 3.42 2.31 4.45 5.82 3.56 2.77 2.42 2.23 2.56 3.25 3.00 
miR-660 2.29 2.58 4.62 2.51 3.12 3.73 5.02 2.32 4.61 -1.21 1.04 -1.04 
miR-664 -5.12 -68.14 ND 1.98 2.12 2.54 2.59 1.96 1.33 1.91 2.05 2.10 
miR-665 -1.87 -1.44 -1.47 -1.29 -1.03 -1.29 -1.22 -1.23 -1.74 -1.70 -1.71 -2.24 
miR-668 2.64 1.54 2.43 3.28 3.62 5.94 1.86 2.72 2.27 3.69 3.01 3.89 
miR-671-5p 3.87 3.16 2.14 5.00 5.08 6.24 6.33 3.72 3.55 6.18 5.53 6.36 
miR-675 5.48 4.98 3.06 7.15 9.13 8.10 5.94 3.91 3.49 5.47 6.34 7.67 
miR-720 -1.35 -1.20 1.14 -1.05 1.01 -1.08 1.10 -1.27 -1.33 -1.33 -1.29 -1.21 
miR-744 1.21 1.28 1.59 1.52 1.48 1.72 1.36 1.25 1.35 -1.27 -1.08 -1.11 
miR-765 1.26 1.46 1.53 1.51 1.79 1.51 1.27 1.23 1.08 1.66 1.26 1.31 
miR-766 -1.07 -1.23 -3.29 1.57 1.45 1.55 1.59 1.26 -1.15 1.18 1.40 1.16 
miR-769-5p -32.58 ND ND 1.11 1.35 1.00 -2.27 -1.27 -1.01 ND 1.25 -1.86 
miR-874 1.64 1.08 1.55 2.69 2.62 3.86 2.41 2.36 1.90 1.78 2.83 2.65 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-877 -1.27 -1.37 -1.45 -1.06 -1.21 1.29 1.00 -1.13 -1.23 -1.54 1.02 -1.07 
miR-877* ND ND ND 2.60 2.48 3.91 2.28 1.75 ND 5.28 2.45 1.91 
miR-887 4.99 4.21 4.01 3.37 3.71 5.57 4.51 2.62 2.32 4.48 4.69 4.63 
miR-888* 1.41 1.68 1.87 1.23 1.34 1.72 1.55 1.13 1.17 1.53 1.47 1.32 
miR-890 2.81 2.42 1.57 1.90 1.47 1.96 2.87 1.41 2.12 1.75 2.91 1.10 
miR-891a 2.38 2.21 2.67 2.21 2.30 3.20 2.45 2.19 1.94 2.72 2.84 3.16 
miR-920 1.99 -1.60 ND 2.91 2.54 3.34 2.54 3.16 1.74 3.07 3.78 3.45 
miR-923 -5.93 -4.23 -2.95 -4.49 -3.73 -4.63 -4.03 -3.96 -5.27 -4.86 -7.63 -8.18 
miR-933 3.04 3.22 4.30 2.22 2.32 3.15 2.45 1.73 1.56 3.22 2.64 2.72 
miR-934 2.95 1.64 1.62 2.01 2.08 3.04 1.63 2.54 1.73 2.74 3.12 2.34 
miR-937 2.19 2.09 1.41 1.75 1.48 3.26 2.41 1.14 2.08 3.49 3.47 2.13 
miR-939 1.07 1.26 1.46 1.42 1.95 1.28 1.65 1.61 1.29 1.45 -1.04 -1.31 
miR-941 -2.70 1.73 1.73 -4.10 -1.76 -1.63 -1.36 -2.25 -5.10 -1.62 -3.19 -13.67 
miR-942 -14.09 ND 5.46 7.80 2.34 14.58 5.69 4.69 ND 4.40 6.04 8.88 
miR-943 2.13 1.10 1.28 3.90 3.76 3.37 3.16 2.91 2.14 3.62 2.29 2.93 
miR-944 2.87 -6.62 ND 2.42 -1.31 3.74 3.02 1.90 2.05 1.20 5.16 2.25 
miR-1184 1.12 1.99 2.69 1.25 1.29 2.05 1.05 -1.13 -1.13 -1.59 -1.04 -1.35 
miR-1201 2.13 1.93 1.83 2.40 2.13 2.36 2.05 2.35 2.38 1.11 2.48 2.11 
miR-1224-3p 2.79 4.39 4.17 1.12 2.11 2.14 2.32 1.70 1.47 1.43 -1.08 -1.21 
miR-1227 ND ND ND 3.99 3.76 4.49 4.19 2.06 1.35 3.29 3.24 2.45 
miR-1236 -3.48 -1.58 1.27 1.95 1.68 2.71 -1.07 1.24 1.01 1.92 1.36 1.04 
miR-1246 -1.03 1.23 1.76 1.08 1.76 -1.03 -1.04 -1.24 -1.20 1.18 -1.56 1.08 
miR-1249 -3.60 -1.16 -17.51 2.68 1.61 3.31 -1.00 1.39 1.38 3.82 1.31 1.73 
miR-1255a 1.24 1.33 1.58 1.41 1.48 1.55 1.40 1.50 1.26 1.37 1.25 1.29 
miR-1259 2.64 2.09 3.22 1.95 1.93 2.40 1.89 1.85 2.02 3.14 2.82 2.81 








Hsa-miRNA IS 24hr IS 48hr IS 168hr LA 24hr LA 48hr LA 
168hr 
CE 24hr CE 48hr CE 
168hr 
SV 24hr SV 48hr SV 
168hr 
miR-1261 7.05 9.21 9.86 8.52 7.87 11.12 7.68 7.42 5.66 4.67 6.32 4.12 
miR-1264 1.79 2.01 3.31 1.50 1.71 2.26 1.68 1.74 1.55 2.09 1.91 2.10 
miR-1265 -1.95 -1.86 -1.57 -2.41 -2.59 -1.97 -2.58 -2.79 -3.20 -2.30 -1.92 -2.79 
miR-1274a 4.32 4.30 4.97 5.34 5.17 12.29 5.11 2.90 2.99 4.18 7.63 7.84 
miR-1274b 8.45 8.75 10.06 4.81 4.82 10.06 5.76 3.15 3.81 6.06 8.68 8.06 
miR-1275 1.10 1.17 1.06 1.36 1.29 1.50 -1.03 -1.34 -1.43 -1.09 -1.05 1.29 
miR-1280 -1.93 -1.89 -1.51 -1.51 -1.96 -1.01 -1.78 -2.54 -2.54 -2.58 -1.25 -1.52 
miR-1284 1.62 -1.61 -1.15 2.95 3.18 1.74 2.76 3.77 2.54 2.10 1.64 2.18 
miR-1285 -1.10 -1.04 1.31 -1.11 -1.13 1.08 -1.09 -1.19 -1.36 -1.24 -1.18 -1.29 
miR-1290 1.30 1.89 1.93 1.43 3.48 1.03 -1.01 -1.57 -1.49 1.61 -1.35 2.09 
miR-1297 5.80 5.29 9.35 5.57 9.96 13.77 14.31 4.91 9.92 2.39 3.67 3.43 
miR-1299 -1.70 -1.64 -1.23 -1.49 -1.32 -1.18 -1.59 -1.17 -1.62 -2.02 -1.42 -1.77 
miR-1301 1.38 1.31 1.20 1.30 1.16 1.66 1.98 1.05 1.38 1.16 1.57 1.31 
miR-1304 1.29 1.20 -1.30 2.25 2.45 2.28 1.91 1.99 1.50 1.58 2.60 1.92 
miR-1307 2.53 2.30 3.30 2.40 2.48 3.67 3.48 1.60 2.75 1.12 2.13 1.62 
miR-1308 -1.00 -1.13 1.31 -1.00 1.26 1.17 1.03 -1.03 -1.18 1.85 -1.28 -1.03 
miR-1321 4.78 3.18 3.71 4.09 4.19 5.49 3.92 4.03 3.02 4.60 4.57 5.48 
miR-1826 1.15 1.38 1.98 1.19 1.23 1.36 1.71 1.25 1.55 1.56 -1.28 1.32 












Supplementary Table 2: Expression of 352 miRNAs detected in low or no risk patients. MiRNAs were expressed as fold change compared 
with healthy controls. All miRNAs selected have positive raw intensity values and FDR < 0.05. ND represents not detected. LA: large artery 
stroke. CE: cardioembolic stroke. SV: small vessel stroke.   
 
















Let-7a -1.75 -1.01 -1.78 -2.55 -2.06 -3.09 -2.04 -5.00 
Let-7a* 4.09 2.14 1.11 1.25 1.23 1.37 1.08 -1.43 
Let-7b -1.81 -1.23 -2.43 -3.72 -2.17 -3.31 -3.30 -3.11 
Let-7b* 2.68 1.96 -1.33 -1.75 -1.17 -1.57 -1.35 -2.02 
Let-7c -1.36 -1.02 -2.39 -3.34 -1.91 -3.22 -2.88 -3.22 
Let-7d 1.49 2.52 -1.11 -1.46 1.23 -1.59 -1.24 -2.69 
Let-7d* -1.43 -1.48 -2.44 -5.39 -1.82 -2.80 -3.77 -1.53 
Let-7e 2.04 1.83 1.57 1.00 1.71 -1.12 -1.23 2.03 
Let-7f -2.03 -1.18 -1.84 -1.94 -2.40 -1.29 -1.35 -2.35 
Let-7g -1.23 1.39 -1.89 -1.70 -1.45 -1.87 -1.66 -4.59 
Let-7i 1.52 2.16 -2.48 -1.94 -1.37 -2.15 -1.83 -5.48 
miR-7 1.88 1.39 -2.20 -1.33 -2.01 -1.67 -1.92 -4.82 
miR-15a -1.76 -1.02 -1.59 -1.67 -2.07 -1.29 -1.77 -4.39 
miR-15b -2.63 -1.53 -2.38 -2.51 -3.11 -1.54 -1.75 -2.87 
miR-15b* 4.33 1.88 -1.65 -1.27 1.15 -1.31 -3.09 -8.28 
miR-16 -2.64 -1.53 -2.38 -2.51 -3.11 -1.54 -1.76 -2.87 
miR-16-2* 3.96 4.34 -1.74 -2.86 1.20 -2.07 -3.06 -3.38 
miR-17 -1.58 1.08 -2.03 -2.82 -1.86 -2.52 -2.98 -5.23 
miR-17* 3.02 2.07 -1.34 -1.88 1.36 -1.12 -2.29 -1.59 
miR-18a 1.49 1.22 -2.20 -2.65 -1.53 -1.72 -3.86 -4.90 
miR-18a* -1.04 -1.13 -1.64 -2.32 -1.21 -1.39 -2.60 -1.78 
























miR-19a -1.62 1.05 -1.47 -1.55 -1.91 1.05 -1.08 -1.77 
miR-19b -1.15 1.48 -1.04 -1.10 -1.36 1.48 1.29 -1.26 
miR-20a -1.53 1.11 -1.39 -1.46 -1.81 1.11 -1.02 -1.67 
miR-20a* 6.48 3.55 -1.12 -1.40 2.01 -1.67 -1.84 -3.34 
miR-20b 2.27 2.52 -1.06 -1.37 1.21 -1.13 -1.23 -2.25 
miR-20b* 1.19 -1.17 1.05 1.03 1.10 1.07 1.03 1.18 
miR-21 1.21 -3.32 -5.15 -3.66 -4.19 -4.44 -5.59 -27.05 
miR-22 -2.60 -1.51 -2.35 -2.48 -3.07 -1.52 -1.73 -2.83 
miR-22* 3.11 1.82 -1.10 -1.28 1.25 1.07 -1.62 -1.52 
miR-23a 1.64 -1.09 -2.38 -3.27 -1.53 -2.86 -2.41 -5.81 
miR-23b 2.30 1.66 -1.51 -2.20 1.05 -1.47 -1.75 -2.84 
miR-24 1.65 1.98 -1.41 -1.43 1.40 -1.28 -1.29 -2.02 
miR-24-1* 1.46 1.59 1.16 -1.10 1.41 1.04 1.05 1.08 
miR-25 1.58 2.42 -1.34 -1.37 1.16 -1.54 -1.54 -2.69 
miR-25* -1.01 1.58 1.18 1.29 -1.15 1.53 1.64 1.16 
miR-26a -1.18 1.11 -2.25 -3.22 -1.40 -3.60 -3.69 -7.01 
miR-26a-2* 2.40 1.16 -1.50 -1.55 1.09 -1.78 -3.12 -3.99 
miR-26b -1.71 1.00 -1.60 -1.80 -2.01 -2.11 -2.00 -4.84 
miR-26b* 2.14 1.66 1.43 1.40 1.64 1.50 1.06 1.51 
miR-27a 4.08 2.14 -1.56 -1.06 1.59 -1.19 -1.28 -2.08 
miR-27a* 2.82 2.89 1.86 1.17 -1.69 1.00 1.93 -1.41 
miR-28-5p 4.05 2.01 -1.18 -1.13 1.59 -1.20 -1.18 -1.97 
miR-29a 2.47 -1.05 -2.55 -2.12 -1.20 -2.57 -2.50 -3.65 
miR-29a* 4.12 3.88 3.09 3.39 2.52 4.22 1.98 2.04 
miR-29b 4.09 2.50 -1.02 1.38 1.48 1.20 1.09 2.41 
























miR-29c 3.47 1.10 -2.06 -1.86 -1.04 -1.74 -2.37 -3.28 
miR-29c* 1.97 -1.43 -1.35 -1.48 1.06 -1.20 -2.02 -2.40 
miR-30a -1.98 -1.15 -1.79 -1.89 -2.33 -1.29 -1.87 -2.16 
miR-30b -1.16 1.47 -1.24 -1.95 -1.37 -1.53 -1.52 -2.61 
miR-30c -1.10 1.55 -1.57 -2.42 -1.30 -1.82 -2.05 -3.08 
miR-30d 1.23 1.07 -1.21 -2.75 1.02 -2.40 -3.10 -2.02 
miR-30e 1.40 2.41 -1.12 -1.18 1.18 1.07 -1.16 -2.30 
miR-30e* 2.42 1.30 -2.98 -3.52 -1.13 -4.04 -4.58 -6.04 
miR-32 3.99 1.96 -1.91 -2.36 -2.16 -1.85 -2.63 -5.21 
miR-32* -1.44 -1.31 -1.18 -2.16 -1.20 -1.80 -2.05 -1.26 
miR-33a 11.98 1.53 1.76 4.78 1.08 2.81 -1.74 -1.65 
miR-34b -1.06 1.32 -1.49 -1.04 -1.24 1.10 -1.28 -1.15 
miR-92a 1.09 1.08 -1.19 -1.44 -1.07 -1.21 -1.40 -1.09 
miR-92b -1.19 -1.16 -1.42 -2.20 -1.24 -1.45 -1.68 -1.34 
miR-93 -2.05 -1.19 -1.86 -2.16 -2.42 -2.06 -2.78 -2.74 
miR-93* 1.68 1.68 -1.08 -1.67 1.19 -1.25 -2.94 -1.82 
miR-96 -1.26 1.82 -3.52 -1.78 -2.26 -3.94 -3.10 -4.72 
miR-98 2.78 1.59 -2.14 -1.75 -1.50 -1.94 -1.48 -5.48 
miR-99a 2.16 2.40 -1.01 1.10 -1.15 -1.01 1.20 1.35 
miR-99b* -1.06 1.04 -1.17 -1.12 -1.28 1.09 -1.17 -1.54 
miR-101 1.13 1.94 -1.42 -1.54 -1.04 -1.37 -1.83 -3.30 
miR-101* 6.36 1.76 -1.66 -1.53 1.59 -1.40 -2.24 -3.10 
miR-103 -1.07 -1.21 -1.90 -3.41 -1.33 -2.97 -3.72 -6.31 
miR-106a -1.34 1.27 -1.65 -2.51 -1.58 -2.29 -2.57 -4.43 
miR-106a* 8.66 2.91 1.18 -1.21 1.61 -12.29 ND -2.46 
























miR-106b* 1.74 1.07 -1.81 -2.43 -1.20 -2.34 -3.49 -2.80 
miR-107 -1.02 1.24 -1.68 -2.87 -1.21 -2.71 -3.27 -4.40 
miR-122 -2.20 -2.07 -1.97 -2.15 -3.32 -1.86 -1.70 -2.79 
miR-122* -1.14 -1.19 1.58 2.00 1.14 1.79 2.45 -1.02 
miR-124* 2.79 1.97 2.20 2.02 1.75 2.25 2.90 1.84 
miR-125a-5p 1.41 1.27 1.43 -1.02 -1.06 -1.04 1.25 -1.16 
miR-125b 1.10 2.03 1.43 1.82 2.35 -1.39 -2.38 1.48 
miR-125b-1* -1.19 1.46 -1.06 -2.37 -2.10 -2.08 1.16 -2.66 
miR-125b-2* 1.72 1.41 1.99 1.05 1.09 -1.23 2.04 1.20 
miR-126 -1.32 1.29 -1.46 -1.72 -1.55 -2.40 -1.64 -5.43 
miR-126* 3.26 -1.26 -3.15 -2.45 -1.58 -4.06 -3.25 -15.58 
miR-128 2.11 1.02 -1.45 -1.76 -1.10 -1.80 -6.01 -3.02 
miR-129* 1.28 -1.18 1.71 1.35 1.46 1.33 1.48 1.43 
miR-129-5p 1.05 2.42 1.31 1.01 -1.64 1.28 1.88 -1.56 
miR-130a 1.34 2.29 -1.61 -2.67 1.13 -1.46 -1.70 -2.13 
miR-130b 1.31 -1.08 -1.70 -3.63 -1.66 -3.94 -2.97 -3.49 
miR-130b* 1.96 2.00 2.40 1.67 2.01 1.63 1.93 2.24 
miR-132* 7.17 1.95 1.40 1.42 -1.12 1.62 1.66 1.03 
miR-135b 2.90 1.82 1.31 1.30 1.30 2.14 1.03 -1.25 
miR-138-1* -1.16 -1.03 -1.10 -1.33 -1.37 -1.14 -1.65 -1.50 
miR-138-2* 2.75 2.85 1.90 1.34 1.27 -1.02 -1.85 -5.57 
miR-140-3p -1.46 1.13 -1.60 -2.30 -1.72 -1.75 -2.67 -1.88 
miR-140-5p 1.79 -1.16 -2.71 -2.38 -1.91 -2.32 -4.25 -7.40 
miR-142-3p -1.76 -1.02 -2.05 -1.68 -2.07 -1.19 -1.79 -6.45 
miR-142-5p -1.57 1.08 -1.42 -1.50 -1.86 -1.22 -1.27 -2.26 
























miR-144 -2.56 -1.49 -2.31 -2.44 -3.02 -1.49 -1.70 -2.79 
miR-144* -1.04 1.64 -1.42 -1.34 -1.22 -1.85 -1.29 -6.55 
miR-145 2.70 2.19 1.80 2.52 2.77 5.20 3.17 2.58 
miR-145* 1.12 1.18 1.67 1.19 1.33 1.53 1.07 1.12 
miR-146a 2.51 1.48 -1.95 -1.75 -1.27 -1.66 -1.45 -4.97 
miR-146b-3p 1.29 1.57 1.86 1.35 1.74 1.27 1.16 1.57 
miR-146b-5p 2.97 1.73 -1.80 -1.54 -1.19 -1.83 -1.47 -4.25 
miR-148a 5.65 2.92 -1.41 -1.11 1.43 -1.20 1.01 -2.64 
miR-148b 4.48 3.02 -1.32 -1.57 1.88 -1.09 -1.32 -1.50 
miR-149* -1.09 1.53 1.14 -2.42 -1.71 -2.12 -1.23 -1.27 
miR-150 2.39 1.54 1.48 1.32 2.14 -1.74 -1.20 -1.91 
miR-151-3p 1.43 -1.88 -3.28 -3.68 -1.61 -3.03 -4.41 -4.27 
miR-151-5p 2.73 1.39 -1.74 -2.60 1.06 -1.98 -1.97 -2.39 
miR-155 1.06 -1.36 -1.54 -1.49 -1.56 -1.53 -1.69 -1.44 
miR-181a 1.37 -1.88 -2.73 -3.39 -1.37 -7.63 -6.27 -2.26 
miR-181a-2* 2.48 2.63 1.47 1.10 1.11 -1.37 2.69 -1.12 
miR-181b 1.52 2.26 -1.13 1.04 -1.08 -1.08 -1.38 -1.53 
miR-182 1.25 2.76 -2.33 -1.82 -1.35 -4.01 -3.28 -4.46 
miR-183 -1.41 1.96 -1.94 -1.95 -1.16 -3.35 -3.75 -2.15 
miR-183* -1.13 1.23 1.10 -1.55 -1.43 -1.57 -1.18 -1.19 
miR-184 -1.05 1.43 -1.01 1.12 -1.35 1.12 1.42 -1.04 
miR-185 -1.53 1.07 -2.16 -2.70 -1.80 -1.18 -2.90 -3.03 
miR-185* 1.04 2.06 -1.03 -1.84 -2.34 -1.28 1.44 -2.36 
miR-186 -1.15 -2.02 -3.77 -5.11 -2.43 -2.92 -7.72 -5.19 
miR-187* 1.40 1.86 1.32 -1.13 -1.02 1.07 1.44 -1.05 
























miR-190 1.04 -2.33 -5.35 -3.09 -5.34 -3.86 -5.55 -26.35 
miR-191 -2.09 -1.22 -1.89 -2.02 -2.47 -1.73 -1.83 -2.28 
miR-192 1.76 -1.02 -3.23 -4.40 -2.16 -4.23 -8.17 -10.90 
miR-193a-3p 2.09 1.45 -1.16 -1.57 1.18 -1.19 -1.64 -2.09 
miR-193b* -1.17 1.27 1.13 -1.28 -1.07 -1.15 -1.12 -1.06 
miR-194 3.34 1.48 -1.86 -1.58 1.39 -1.00 -2.24 -2.38 
miR-194* 1.58 1.79 1.46 1.34 -1.41 1.50 1.84 1.16 
miR-195 3.44 1.84 1.04 1.13 2.04 -2.02 -1.93 -9.85 
miR-196a* 1.48 1.13 1.39 1.90 1.50 1.45 1.94 1.29 
miR-196b 2.82 -1.00 -1.26 -1.23 -1.72 1.47 -1.42 -2.30 
miR-197 1.03 1.05 1.05 -1.51 1.06 1.05 -1.11 1.18 
miR-198 1.02 -1.04 1.18 1.06 1.02 1.26 1.18 1.06 
miR-199a-3p 7.12 1.91 1.20 -1.04 1.34 1.16 1.09 -39.42 
miR-199a-5p 4.30 2.65 1.14 -1.19 1.20 1.44 -1.00 -1.39 
miR-199b-5p 3.70 2.31 1.50 2.02 1.72 1.74 2.11 1.26 
miR-200b 1.28 -1.21 1.63 1.35 1.46 1.48 1.08 1.00 
miR-200b* 1.40 1.52 1.51 1.05 1.12 -1.36 2.00 1.52 
miR-203 -3.58 ND -2.76 -3.79 -3.78 -11.80 ND -10.10 
miR-206 1.49 3.46 1.43 1.07 1.19 -1.48 2.55 -2.18 
miR-208a -1.15 -1.11 -1.36 -1.41 -1.58 1.10 -1.65 -2.01 
miR-208b 1.87 1.54 1.60 1.08 -1.00 ND 2.29 1.35 
miR-210 3.16 1.49 -1.28 1.11 1.99 3.00 -1.22 1.09 
miR-214 1.84 1.58 1.77 1.04 1.86 -1.49 -1.10 1.24 
miR-215 2.85 2.01 -1.62 -1.46 -1.17 -1.36 -1.92 -3.26 
miR-221 3.28 1.39 1.30 1.07 1.66 -1.26 -1.18 -3.73 
























miR-222 1.06 -1.49 -1.77 -3.52 -1.53 -2.96 -2.38 -4.65 
miR-223 1.17 2.01 -1.13 -1.13 -1.00 1.46 1.24 -1.97 
miR-299-3p 1.14 1.28 1.59 1.28 1.54 2.20 1.58 1.37 
miR-300 -1.22 1.30 -1.46 -2.62 -1.60 -2.09 -2.00 -1.32 
miR-301a 2.89 1.54 -1.94 -3.34 -1.60 -2.22 -2.80 -9.31 
miR-301b 5.82 1.42 -1.00 -1.08 -1.25 -4.60 ND ND 
miR-302c* 1.84 1.77 1.86 1.54 1.20 1.78 1.21 1.26 
miR-302e 2.09 2.24 1.71 1.36 1.42 1.41 1.70 1.03 
miR-320a -1.75 -2.06 -1.76 -4.26 -2.06 -2.90 -4.80 -2.22 
miR-320b -1.64 -2.16 -1.92 -4.07 -1.88 -3.03 -5.01 -2.27 
miR-320c -1.76 -1.15 -1.60 -2.37 -2.08 -1.68 -2.35 -1.92 
miR-320d -1.11 -1.44 -1.42 -2.89 -1.32 -2.06 -3.24 -1.66 
miR-324-3p 1.62 1.40 1.13 1.14 1.60 1.34 -1.07 1.06 
miR-324-5p 1.11 -1.01 -1.36 -2.66 1.20 -2.30 -2.87 -1.72 
miR-326 -2.23 1.04 -1.12 -1.13 -1.53 -1.33 -2.07 -3.33 
miR-328 1.71 1.47 1.61 1.46 2.02 2.14 1.11 1.50 
miR-331-3p 1.01 -1.09 -1.41 -2.42 1.00 -1.40 -2.35 -1.22 
miR-331-5p -1.55 -2.90 -2.96 -4.27 -1.93 -4.85 -9.51 -4.45 
miR-335 5.06 3.81 -1.29 -1.88 1.45 -1.51 -1.51 -2.89 
miR-335* -1.04 1.41 -1.18 -1.35 -2.53 -1.04 1.08 -2.86 
miR-338-3p 2.37 1.29 1.19 1.90 1.34 2.87 1.51 -1.44 
miR-339-3p 1.75 -1.08 -2.05 -2.10 1.65 -2.14 -2.44 -1.05 
miR-339-5p 1.60 1.22 -1.75 -2.72 1.69 -1.53 -2.05 1.60 
miR-340 3.27 1.69 -1.09 -1.37 1.05 -1.12 -1.71 -1.97 
miR-340* 1.76 2.37 1.54 1.31 1.07 1.58 2.09 -1.18 
























miR-342-5p 1.17 -1.95 -1.53 -1.39 1.02 -2.46 -2.28 -2.38 
miR-345 2.72 2.96 1.47 1.51 2.50 2.12 1.40 1.27 
miR-361-3p 1.08 1.22 -1.37 -1.39 -1.49 -1.50 -1.56 -1.47 
miR-361-5p 2.03 1.14 1.29 1.26 1.73 -1.19 -2.89 -3.60 
miR-362-3p 5.99 2.04 -1.23 -2.29 -1.00 -3.04 -4.63 -5.20 
miR-362-5p 1.32 -1.23 -2.46 -3.92 -1.84 -3.99 -5.69 -5.50 
miR-363 1.16 -1.00 -1.57 -3.02 -1.13 -2.93 -3.59 -2.90 
miR-363* 1.37 1.23 2.24 2.74 1.64 2.03 1.91 1.52 
miR-365 2.10 2.54 1.31 1.46 2.51 1.90 1.21 1.03 
miR-370 -1.08 1.40 -1.08 -1.01 -1.31 1.59 1.35 -1.15 
miR-374a 1.09 1.81 -1.56 -1.98 -1.11 -2.02 -2.34 -8.06 
miR-374b 3.46 1.57 -1.64 -1.99 1.07 -2.26 -2.38 -6.46 
miR-374b* 1.74 1.43 1.79 1.60 1.69 1.39 1.40 1.73 
miR-375 1.00 -1.00 1.15 1.03 -1.28 1.02 -1.35 -1.40 
miR-378 2.11 1.34 -1.16 -1.86 1.19 -1.45 -1.75 -1.02 
miR-381 -1.14 1.36 -1.01 -2.30 -1.72 -1.76 1.01 -1.35 
miR-382 1.41 1.66 1.51 1.19 1.18 1.29 1.88 1.65 
miR-412 -1.26 -1.48 -1.23 -1.81 -1.34 -1.94 -1.85 -1.38 
miR-421 -1.33 -2.60 -1.92 -2.15 -1.72 -2.73 -2.60 -3.42 
miR-422a 1.15 -1.66 -1.26 -1.41 -1.22 -1.45 -1.71 -1.84 
miR-423-3p -1.35 -1.30 -1.76 -2.78 -1.31 -1.25 -3.27 -1.22 
miR-423-5p -2.05 -1.87 -1.99 -4.06 -2.41 -2.24 -3.88 -2.23 
miR-424 3.07 -1.41 -1.74 -1.29 -2.01 -4.71 -2.30 -3.53 
miR-425 1.35 1.02 -1.27 -2.38 1.03 -2.42 -2.35 -3.30 
miR-425* 1.48 1.16 -1.22 -1.79 1.06 -1.57 -1.70 -1.44 
























miR-451 -2.63 -1.53 -2.38 -2.51 -3.11 -1.54 -1.75 -2.87 
miR-454 3.51 1.45 -1.13 1.17 1.20 -1.19 -1.36 ND 
miR-483-5p -1.26 3.90 1.15 1.01 1.04 1.24 1.19 1.18 
miR-484 1.47 1.45 -1.03 -1.91 1.31 1.22 -1.21 1.05 
miR-485-3p -1.28 1.43 1.22 1.22 -1.07 1.10 -1.21 -1.42 
miR-486-3p 3.52 4.67 -1.17 1.31 1.00 2.90 2.29 -3.04 
miR-486-5p -2.64 -1.53 -2.38 -2.51 -3.11 -1.54 -1.75 -2.87 
miR-487b -1.10 -1.56 -1.26 -1.65 -1.31 -1.14 -2.12 -2.83 
miR-488 2.75 2.82 2.30 1.23 1.21 1.30 2.15 1.02 
miR-489 2.10 2.92 1.59 1.13 -1.01 1.31 2.32 1.17 
miR-490-3p 2.20 1.34 3.01 1.77 3.15 1.71 1.09 3.03 
miR-491-3p -1.04 -1.94 -1.08 1.46 1.27 1.99 -1.84 1.56 
miR-492 1.15 ND 2.36 1.20 -1.48 ND -1.23 -1.86 
miR-493* -1.47 1.49 -1.89 -3.03 -2.94 -3.29 -1.14 -5.52 
miR-494 1.76 1.69 1.61 1.64 1.39 2.16 1.47 1.35 
miR-498 1.30 1.62 1.64 1.37 1.25 1.66 1.77 1.50 
miR-500 1.00 -1.98 -2.29 -4.55 -1.45 -3.55 -6.09 -4.29 
miR-500* 1.01 -1.35 -1.85 -2.81 -1.49 -3.49 -3.97 -3.38 
miR-501-5p -1.19 -1.79 -1.80 -3.54 -1.59 -2.84 -5.25 -2.89 
miR-502-3p 1.20 -1.14 -1.61 -2.48 -1.22 -3.02 -4.13 -2.60 
miR-502-5p -1.26 -1.10 -1.66 -2.82 -2.17 -2.35 -1.81 -3.77 
miR-504 -7.13 -8.12 -4.50 -4.06 -4.40 -4.53 -5.74 -4.43 
miR-505 1.43 -1.60 -2.14 -2.86 -1.45 -3.86 ND -3.57 
miR-505* -1.22 -1.30 -1.42 -2.12 -1.34 -1.96 -2.07 -1.72 
miR-508-5p -1.09 -1.49 -1.08 -1.53 -1.70 -2.38 -1.26 -2.40 
























miR-510 1.61 2.15 2.14 -1.10 1.38 -1.28 1.42 1.57 
miR-513a-3p 2.19 2.71 1.39 1.13 1.17 1.34 1.51 1.18 
miR-513a-5p -1.21 1.70 1.24 1.19 -1.13 1.59 1.92 1.75 
miR-516a-5p -2.17 -2.73 -2.00 -3.10 -2.35 -3.38 -3.71 -2.07 
miR-516b 1.61 1.60 1.98 2.01 1.70 1.79 1.81 1.77 
miR-518a-5p 1.09 1.04 -1.02 -1.84 -1.15 -1.46 -1.87 -1.56 
miR-519c-5p 1.77 -1.16 1.97 1.50 1.54 1.09 -1.22 1.49 
miR-519d 1.10 -1.00 1.08 -1.37 -1.15 1.18 -2.07 -1.70 
miR-519e -1.01 1.68 1.08 1.03 -1.19 1.68 1.47 -1.10 
miR-519e* 1.89 1.15 2.27 1.11 1.91 -1.09 -2.21 -1.59 
miR-520d-5p 2.02 1.50 1.86 1.13 1.59 1.44 -1.11 1.19 
miR-525-5p 1.30 -1.07 1.54 1.14 1.33 1.28 1.13 1.51 
miR-532-3p 1.78 1.28 1.42 -1.28 1.92 1.19 -1.28 1.68 
miR-532-5p 2.33 1.55 -1.47 -2.53 -1.02 -2.15 -3.12 -2.61 
miR-542-3p -1.35 -1.48 -1.55 -1.46 -2.01 -1.72 -1.33 -1.82 
miR-548e 1.73 -1.03 1.49 2.17 1.44 1.31 1.35 -1.06 
miR-548n -1.05 1.02 1.33 1.65 1.24 1.65 1.19 -1.04 
miR-549 1.13 1.02 1.29 -1.09 1.29 -1.13 -1.15 1.11 
miR-550 1.00 -1.16 1.03 -1.59 1.15 -1.64 -1.99 -1.00 
miR-550* -1.03 -1.45 -1.54 -3.39 -1.10 -2.20 -3.20 -1.77 
miR-551a 1.58 2.02 1.52 1.48 1.57 2.05 1.57 1.24 
miR-551b 1.13 2.04 1.41 1.03 -1.01 1.84 1.16 1.11 
miR-552 1.05 1.06 -1.06 -1.14 -1.41 1.16 1.26 1.81 
miR-553 2.56 3.11 3.09 1.42 1.45 1.39 2.42 1.39 
miR-557 1.33 1.30 1.02 -1.51 -1.45 -1.55 -1.02 -1.27 
























miR-574-5p -1.02 1.02 -1.03 -1.80 -1.05 -1.36 -1.80 -1.35 
miR-576-3p 1.21 1.32 1.59 1.43 1.77 1.55 1.50 1.89 
miR-576-5p 1.09 1.03 -2.45 -2.52 -1.93 -1.36 -2.28 -2.72 
miR-578 1.34 1.94 1.86 2.34 1.33 3.57 2.81 1.60 
miR-581 1.07 1.08 1.55 1.84 1.20 2.72 1.92 1.35 
miR-583 1.00 1.02 1.11 -1.39 -1.02 -1.28 -1.23 1.03 
miR-584 -1.27 -2.27 -1.64 -2.27 -1.21 -1.70 -2.97 -1.95 
miR-585 1.76 3.34 2.19 2.85 1.26 3.23 3.88 1.35 
miR-589 1.10 -1.11 -1.07 -1.17 -1.03 -1.13 -1.16 -1.19 
miR-590-5p 2.61 -1.26 -2.03 -1.98 -2.07 -2.59 -19.55 ND 
miR-597 1.03 -1.91 -1.23 -1.47 -1.42 -2.61 -2.08 -5.38 
miR-600 1.57 1.34 2.20 2.23 1.77 2.81 2.51 -2.97 
miR-601 2.26 1.97 2.46 2.70 2.21 3.48 2.10 2.26 
miR-602 1.55 2.61 1.39 1.25 -1.09 1.71 2.05 1.46 
miR-605 1.01 -1.24 1.30 -1.20 -1.02 1.04 -1.85 -1.72 
miR-611 1.53 2.25 1.32 1.12 -1.24 1.46 1.32 1.18 
miR-615-3p 2.14 2.04 2.36 2.01 1.78 2.38 1.90 1.66 
miR-617 -1.56 -1.24 -1.12 -1.57 -1.46 -1.89 -1.21 -1.53 
miR-618 1.78 1.84 1.92 1.99 1.77 2.68 2.63 1.95 
miR-620 1.42 1.38 1.93 1.46 1.91 1.51 1.57 2.42 
miR-622 1.70 -1.24 1.00 -1.27 -1.19 1.06 -3.31 1.18 
miR-623 1.62 1.61 1.35 -1.17 -1.15 -1.00 1.36 1.28 
miR-625 1.09 1.00 -1.58 -2.11 -1.30 1.17 -2.81 -1.35 
miR-625* -1.29 -1.48 -1.30 -1.38 -1.50 -1.10 -1.51 -1.52 
miR-627 2.61 1.04 -1.60 1.30 2.58 -1.73 -2.19 -2.27 
























miR-629 -1.02 -1.46 -2.57 -2.36 -1.02 -2.05 -2.84 -2.15 
miR-629* -1.19 -1.33 1.04 -1.12 -1.30 1.01 -1.78 -1.70 
miR-630 1.11 1.31 1.88 1.15 1.62 1.24 1.29 1.69 
miR-634 -1.17 1.02 -1.09 -1.44 -1.38 -1.18 -1.73 -1.88 
miR-635 2.02 2.75 2.06 1.09 1.05 -3.06 1.95 -1.23 
miR-636 -1.02 -1.37 -1.16 -1.15 -1.01 1.27 -1.04 -1.44 
miR-637 1.73 2.75 1.71 -1.17 -1.96 -1.01 2.27 -1.93 
miR-638 1.39 1.81 2.00 1.38 -1.04 1.68 2.08 1.22 
miR-642 -1.41 -1.08 -1.15 -1.56 -1.33 -1.23 -1.46 -1.23 
miR-647 1.19 1.55 -1.19 -1.29 1.07 -1.10 1.15 -1.08 
miR-652 1.07 -1.36 -1.33 -2.66 -1.21 -2.98 -3.91 -2.18 
miR-659 1.46 1.41 1.70 1.38 1.55 1.55 1.53 1.55 
miR-660 5.06 2.71 -1.32 -1.66 1.00 -1.61 -1.67 -3.16 
miR-664 1.73 2.28 1.90 1.64 1.69 2.08 1.71 1.44 
miR-665 1.61 1.62 1.93 -1.01 1.85 1.23 -1.80 2.80 
miR-668 1.19 2.77 2.38 2.55 1.51 2.77 2.76 1.68 
miR-671-5p -1.02 -1.36 1.03 1.25 1.32 -1.27 -4.22 1.71 
miR-675 1.40 1.26 1.21 -1.20 -1.14 -1.19 -1.30 1.05 
miR-720 -2.26 -1.31 -2.04 -2.15 -2.66 -1.32 -1.52 -2.46 
miR-744 -1.02 1.47 -1.07 -2.07 -1.55 -1.15 -1.09 -1.56 
miR-765 -1.34 -1.09 1.00 -1.29 1.00 -1.12 -1.38 1.24 
miR-766 1.09 -1.01 1.05 -1.44 1.08 -1.11 -1.60 1.16 
miR-769-5p -1.13 -4.27 -1.69 -2.19 -1.05 -1.81 -16.31 -2.36 
miR-874 1.94 1.40 1.75 1.11 1.93 -1.32 -1.41 1.06 
miR-876-3p 1.59 -1.83 1.19 1.14 1.09 1.30 -1.25 -1.63 
























miR-877* 2.40 2.77 2.41 2.56 1.59 3.79 2.62 2.03 
miR-887 -1.72 -3.23 -1.61 -2.49 -2.20 -2.25 -4.29 -2.57 
miR-888* 1.13 1.24 1.10 -1.30 -1.23 1.37 -1.34 -1.15 
miR-890 -1.25 -1.27 1.00 -1.67 -1.13 -1.53 -1.20 -1.57 
miR-891a -1.28 1.26 1.16 1.35 1.06 1.22 -1.20 -1.20 
miR-920 1.77 1.58 2.15 1.94 2.29 1.68 1.75 2.34 
miR-923 -1.81 -2.22 -1.64 -4.71 -2.14 -3.84 -3.36 -1.98 
miR-933 1.08 1.11 1.46 1.16 1.22 1.40 -1.04 -1.03 
miR-934 1.35 1.21 1.98 1.39 1.70 1.17 1.32 1.60 
miR-937 1.90 1.65 1.14 1.13 1.44 -1.19 1.92 -1.03 
miR-939 -1.07 1.26 1.04 -2.52 -1.42 -2.17 -1.62 -1.00 
miR-941 -1.81 -2.47 -5.79 -2.20 -4.17 -3.87 -2.95 -2.60 
miR-942 3.02 1.45 3.37 4.37 2.71 4.45 2.93 2.64 
miR-943 2.30 3.89 2.27 1.84 1.34 2.66 3.34 1.22 
miR-944 6.78 -1.13 1.40 1.19 1.26 -2.37 -1.46 -1.54 
miR-1184 -1.13 2.07 -1.12 -1.96 -2.41 -1.52 -1.31 -2.78 
miR-1201 1.44 -1.03 1.22 1.09 1.38 -1.54 1.05 1.11 
miR-1224-3p 2.11 3.50 1.26 1.95 -1.27 1.94 2.48 1.40 
miR-1227 1.98 2.41 2.57 2.37 1.78 3.12 2.53 1.59 
miR-1236 1.08 1.58 1.13 -1.32 -1.41 1.09 -1.00 -1.34 
miR-1246 -1.09 1.45 -1.04 -1.01 1.02 1.26 1.24 1.11 
miR-1249 2.00 2.43 1.56 1.66 1.23 2.50 2.07 1.22 
miR-1255a 1.03 1.43 1.52 1.38 1.50 1.37 1.16 1.50 
miR-1259 1.05 -1.01 1.17 1.60 1.08 1.26 1.52 -1.00 
miR-1260 1.18 1.02 1.09 -1.50 -1.22 -1.04 -1.48 -1.46 
























miR-1264 -1.32 1.32 1.21 1.32 -1.02 1.52 -1.25 -1.59 
miR-1265 -1.21 -1.01 1.14 -1.03 1.01 1.31 -1.29 -1.18 
miR-1274a 1.84 1.31 1.31 1.14 1.01 1.61 -1.21 -1.08 
miR-1274b -1.08 -1.59 -1.14 -1.32 -1.51 1.01 -1.58 -2.00 
miR-1275 -1.67 -1.44 -2.07 -2.29 -2.37 -2.64 -1.90 -2.21 
miR-1280 1.47 1.28 1.39 -1.12 1.15 1.36 -1.39 -1.03 
miR-1284 -2.52 1.15 1.04 -1.31 -1.07 -1.14 -1.64 -1.50 
miR-1285 1.44 2.44 1.61 1.34 1.23 1.84 1.72 1.34 
miR-1290 -1.55 -1.62 -1.96 -1.92 1.01 -1.76 -2.16 1.90 
miR-1297 7.57 8.35 1.32 2.43 2.63 2.26 2.98 -2.25 
miR-1299 -1.41 -1.33 -1.02 -2.10 -1.08 -1.61 -2.05 -1.24 
miR-1301 -1.07 -1.21 -1.56 -1.97 -1.40 -1.94 -1.86 -1.82 
miR-1304 2.07 1.22 2.28 1.65 3.48 -1.08 1.22 2.01 
miR-1307 1.43 -1.69 -1.80 -1.55 1.11 1.05 -3.74 -1.03 
miR-1308 -1.34 1.47 -1.04 -1.10 -1.36 1.48 1.29 -1.25 
miR-1321 1.18 1.29 1.51 1.32 1.42 1.24 1.28 1.48 
miR-1826 -2.64 -1.53 -2.39 -2.51 -3.11 -1.54 -1.75 -2.87 













Supplementary Table 3: Expression of 250 miRNAs detected at various time-points (12hr, 24hr, 48hr, 72hr, 120hr and 168hr). MiRNAs were 
expressed as fold change compared with normal control. All miRNAs selected have positive raw intensity values and FDR < 0.05. ND 
represents not detected. 
 
Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr 
let-7a -1.46 -1.39 -1.46 -2.14 -2.08 -2.81 miR-22* -3.87 -3.10 -2.67 -4.94 -4.26 -5.20 
let-7b -1.34 -1.23 -1.42 -1.87 -2.12 -2.44 miR-23a -2.55 -1.64 -1.59 -2.42 -1.70 -2.30 
let-7b* -1.47 -1.47 -1.33 -1.81 -1.71 -2.66 miR-23b -2.96 -2.50 -2.53 -3.35 -2.92 -4.00 
let-7c -1.07 -1.03 -1.14 -1.62 -1.87 -2.15 miR-24 -5.62 -3.42 -3.15 -4.98 -3.80 -5.85 
let-7d -2.26 -2.18 -2.16 -2.98 -2.79 -3.40 miR-24-1* -2.92 -2.27 -2.20 -3.57 -3.29 -3.61 
let-7d* -1.80 -1.47 -1.45 -2.18 -1.65 -2.02 miR-24-2* -1.68 -1.21 -1.38 -2.24 -2.27 -2.29 
let-7e -2.24 -2.28 -2.75 -4.29 -4.42 -6.19 miR-25 -3.01 -2.65 -3.48 -3.07 -1.64 -1.82 
let-7e* -1.66 -1.33 -1.54 -1.90 -1.22 -1.41 miR-26a -1.52 -1.52 -1.57 -2.23 -2.49 -3.18 
let-7f -1.31 -1.51 ND -2.27 -2.65 ND miR-26b -1.96 -1.95 -2.08 -3.05 -3.13 -3.86 
let-7i -2.33 -2.36 -2.11 -3.46 -3.28 -4.07 miR-27a -3.48 -2.56 -2.67 -3.08 -3.25 -4.34 
let-7i* 3.07 2.13 -2.10 1.59 4.73 -2.82 miR-27a* 3.87 5.30 5.18 7.39 21.97 7.03 
miR-7a 1.61 -1.77 -2.00 -2.78 -7.87 -6.84 miR-27b -2.12 -2.31 -2.08 -2.93 -1.85 -3.38 
miR-7b -1.66 -1.94 -2.24 -2.72 -2.75 -2.89 miR-28 -2.75 -2.46 -2.55 -3.51 -3.36 -3.95 
miR-9 -4.57 -3.64 -4.18 -6.01 -6.43 -9.35 miR-29a -2.82 -2.35 -2.76 -3.26 -3.38 -4.70 
miR-9* -3.63 -5.24 -3.65 -7.00 -8.83 -14.97 miR-29a* -2.97 -2.42 -2.37 -2.93 -2.68 -3.04 
miR-10b 1.30 1.85 1.31 1.44 2.64 1.44 miR-29b -8.11 -9.82 -7.48 -14.78 -17.73 -26.20 
miR-15b -2.54 -2.58 -1.88 -1.94 -1.01 -1.12 miR-29c -4.12 -4.32 -5.29 -7.45 -12.44 -13.83 
miR-16 -2.99 -2.35 -2.54 -4.51 -3.50 -3.60 miR-29c* -2.68 -3.73 -3.09 -3.43 -4.21 -3.04 
miR-19a -3.80 -4.97 -2.56 -3.00 -5.13 -5.62 miR-30a -3.01 -2.65 -3.17 -4.36 -5.41 -6.41 
miR-19b -7.39 -7.06 -5.94 -8.39 -8.96 -13.68 miR-30b-3p -2.43 -2.79 ND -3.04 -4.32 -4.67 
miR-21 -1.76 -1.80 -1.11 -1.71 -1.36 -1.92 miR-30b-5p -1.62 -1.29 -1.97 -2.51 -2.70 -3.21 
miR-21* -1.10 -1.06 -1.83 -3.85 -4.45 -7.98 miR-30c -1.83 -1.51 -1.76 -2.22 -2.44 -3.07 








Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr 
miR-30e -5.60 -5.65 -4.21 -7.77 -8.96 -13.45 miR-125b-5p -3.75 -3.30 -2.90 -3.94 -3.23 -4.42 
miR-30e* -3.58 -3.41 -3.18 -4.22 -4.15 -5.43 miR-126 -1.63 -1.64 -1.64 -2.60 -2.28 -3.32 
miR-31 -2.22 -4.20 -2.70 -4.36 -3.81 -4.51 miR-126* -3.68 -3.78 -3.55 -5.49 -6.34 -7.88 
miR-32 -2.36 -3.00 -3.69 -4.74 -5.29 -9.53 miR-127 -2.93 -3.24 -3.45 -4.74 -4.56 -5.37 
miR-33 -3.94 -6.02 -4.69 -6.53 -9.07 -4.61 miR-128 -4.80 -2.82 -3.04 -4.27 -3.83 -5.98 
miR-34a -3.52 -3.23 -2.38 -4.20 -3.95 -5.12 miR-129 -1.47 -1.19 -1.45 -1.93 -2.01 -2.48 
miR-34b -2.77 -6.44 -6.52 -7.87 -18.97 -15.29 miR-129* -2.83 -2.80 -2.61 -2.81 -3.13 -4.37 
miR-34c -2.97 -4.17 -5.67 -5.86 -5.41 -8.16 miR-130a -1.07 -1.27 -1.92 -2.65 -3.31 -3.93 
miR-34c* -4.60 -5.16 -4.11 -5.06 -7.60 -7.97 miR-132 -5.16 -2.22 -3.30 -3.60 -3.94 -3.76 
miR-92b -1.58 -1.73 -1.83 -2.42 -2.76 -3.42 miR-135a -2.60 -5.07 -4.27 -5.44 -9.26 -13.13 
miR-93 -2.30 -2.24 -2.35 -2.31 -1.84 -2.26 miR-135b -2.75 -2.60 -2.94 -3.82 -3.83 -4.06 
miR-98 -1.72 -1.94 -1.94 -3.09 -4.24 -5.10 miR-136 -2.78 -4.11 -4.65 -7.43 -9.61 -12.87 
miR-99a -2.39 -3.04 -2.79 -4.30 -3.25 -5.02 miR-136* -1.33 -1.63 -2.09 -2.79 -5.45 -7.26 
miR-99b -1.14 -1.19 -1.15 -1.51 -1.44 -2.07 miR-137 -2.62 -4.19 -7.58 -8.22 -18.23 -20.12 
miR-99b* -3.72 -2.89 -2.52 -2.86 -2.86 -3.39 miR-138 -7.92 -7.83 -5.30 -8.46 -7.06 -10.13 
miR-100 -2.58 -2.72 -2.43 -3.64 -3.20 -4.60 miR-138* -3.08 -2.59 -2.27 -3.94 -4.27 -5.17 
miR-101a -3.19 -3.71 -3.07 -5.69 -9.45 -12.08 miR-139-3p 3.45 3.16 1.56 1.73 2.81 -1.02 
miR-101a* 9.45 12.82 9.90 7.07 11.98 16.60 miR-139-5p -2.31 -1.66 -2.17 -2.42 -1.78 -2.34 
miR-101b -2.91 -3.80 -3.38 -5.34 -7.93 -9.36 miR-140 -2.40 -2.85 -3.39 -4.27 -4.76 -4.66 
miR-103 -2.54 -2.66 -3.26 -3.89 -3.89 -4.47 miR-140* -1.13 -1.26 -1.44 -1.76 -1.94 -2.16 
miR-106b -1.21 -1.45 -1.33 -1.83 -1.81 -2.19 miR-142-3p -2.40 -2.34 -1.38 -2.01 -1.47 -1.21 
miR-107 -3.66 -4.76 -5.53 -7.11 -7.12 -8.13 miR-142-5p -1.35 -1.39 1.30 -1.20 1.17 1.26 
miR-124 -2.69 -2.25 -2.02 -2.74 -2.20 -3.58 miR-143 -1.27 -1.89 -1.46 -2.36 -2.18 -2.75 
miR-124* -2.67 -2.57 -2.08 -3.54 -2.58 -4.07 miR-144 -2.27 -1.37 -4.33 -9.06 -5.14 -9.14 
miR-125a-5p -1.67 -1.82 -2.05 -2.23 -2.21 -3.06 miR-145 -3.04 -4.46 -3.99 -4.46 -4.62 -5.21 
miR-125b* -2.00 -1.91 -2.58 -4.02 -5.58 -6.24 miR-146a 1.02 -1.07 -1.09 -1.24 1.20 2.60 








Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr 
miR-147 3.00 4.53 3.54 2.83 4.71 3.88 miR-204 -5.26 -5.17 -6.68 -5.29 -4.31 -5.16 
miR-148b-3p -1.74 -1.77 -1.84 -2.48 -2.58 -3.33 miR-204* -3.44 -3.05 -3.35 -5.40 -5.71 -6.79 
miR-148b-5p 5.39 2.40 -2.10 3.69 6.54 3.36 miR-206 -1.39 1.79 1.09 -2.27 -2.08 -2.99 
miR-150 -4.89 -5.11 -1.31 -3.97 -7.41 -8.65 miR-207 -6.21 -7.45 -4.34 -11.95 -13.50 -18.53 
miR-151 -2.25 -2.06 -2.23 -3.16 -3.01 -3.56 miR-208 -2.97 -1.83 -1.17 -4.60 -3.53 -3.50 
miR-181a -5.54 -4.57 -5.07 -5.56 -6.90 -8.42 miR-212 -2.87 -1.73 -2.34 -3.58 -4.22 -5.82 
miR-181a* -3.71 -3.23 -3.04 -3.65 -4.04 -6.74 miR-214 -1.67 -1.77 -2.10 -3.01 -1.28 -1.46 
miR-181b -2.96 -2.77 ND -4.39 -5.22 -6.07 miR-217 4.59 8.06 3.55 -1.56 2.92 1.94 
miR-181c -7.88 -5.42 -7.99 -10.57 -8.01 -9.67 miR-218 -5.14 -3.94 -5.40 -7.52 -11.06 -14.12 
miR-181d ND -1.87 -2.25 ND -1.97 -2.03 miR-219-2-3p -4.73 -4.93 -4.44 -7.01 -8.14 -10.04 
miR-183 -8.45 -4.40 -2.72 -7.08 -9.54 -5.25 miR-219-5p -5.57 -12.61 -6.33 -12.65 -21.97 -34.81 
miR-184 -1.91 -2.61 -2.59 -1.70 -3.95 -4.42 miR-221 -6.73 -4.86 -5.57 -6.85 -5.45 -6.99 
miR-185 1.08 -1.21 -1.17 -1.75 -2.04 -2.73 miR-222 -2.20 -1.85 -2.17 -3.05 -2.91 -3.96 
miR-186 -3.00 -2.64 -3.29 -3.89 -4.79 -4.87 miR-223 -1.35 -1.12 1.52 1.12 1.61 1.01 
miR-190 -2.68 -4.02 -2.57 -5.13 -6.92 -8.60 miR-290 -1.04 -1.45 -1.28 -3.24 -3.81 -4.82 
miR-191 -1.20 -1.31 -1.27 -1.67 -1.68 -1.86 miR-291a-3p -2.70 -3.05 -2.40 -3.71 -3.52 -2.36 
miR-192 -1.19 -1.17 -1.68 -2.01 -1.04 -12.88 miR-291a-5p 2.59 3.01 1.05 -1.46 -1.76 -2.08 
miR-193 -1.13 -1.28 -1.04 -1.68 -1.68 -2.58 miR-292-3p 5.29 4.43 12.75 5.26 4.59 3.50 
miR-194 -3.66 -3.55 -4.51 -3.80 -4.37 -9.73 miR-298 2.38 1.03 -1.07 -1.22 -1.79 -2.28 
miR-195 -1.82 -1.30 -1.62 -2.31 -2.88 -3.46 miR-300-3p -1.01 -1.39 -1.89 -2.32 -4.05 -4.18 
miR-196a* -4.96 -4.41 -4.20 -4.86 -6.67 -7.87 miR-300-5p -1.24 -1.26 -2.06 -3.26 -4.26 -5.73 
miR-199a-3p -1.10 -1.21 -1.84 -1.36 1.53 2.25 miR-320 1.67 1.29 1.18 1.00 -1.10 -1.26 
miR-199a-5p -1.05 1.09 -2.38 -1.29 1.73 1.53 miR-322 -1.95 -1.93 -2.62 -3.17 -3.46 -3.57 
miR-200a 4.55 16.03 1.12 3.10 7.77 8.23 miR-322* 8.29 3.68 -2.10 -1.56 5.20 -2.25 
miR-200b -1.27 1.44 -1.05 -1.22 -1.46 1.03 miR-323 -3.45 -3.75 -3.80 -5.36 -6.37 -8.05 
miR-200c 1.59 2.42 2.62 1.38 1.49 1.56 miR-324-5p -2.39 -3.49 -4.78 -5.04 -3.85 -4.77 








Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr 
miR-325-5p -1.44 -1.67 -1.52 -2.25 -2.82 -3.44 miR-365 -1.95 -2.11 -2.24 -2.33 -2.62 -3.68 
miR-326 -1.50 -1.33 -1.99 -3.48 -3.32 -3.98 miR-369-3p -1.95 -2.99 -2.84 -4.43 -8.80 -9.42 
miR-328 -3.02 -2.29 -2.38 -2.88 -2.36 -2.64 miR-369-5p -2.09 -2.57 -3.81 -3.26 -4.60 -4.69 
miR-329 -1.53 -1.78 -1.81 -2.32 -2.74 -3.23 miR-370 -2.49 -2.03 -1.67 -2.30 -1.70 -2.26 
miR-330 -2.54 -2.89 -2.43 -2.94 -2.95 -3.48 miR-374 -6.95 -7.25 -8.48 -8.10 -3.92 -4.72 
miR-330* -1.81 -2.33 -2.44 -2.82 -4.09 -5.31 miR-375 -2.84 -1.83 -2.68 -2.31 -1.82 -1.87 
miR-331 -3.61 -3.70 -3.59 -5.18 -6.48 -7.13 miR-376a -1.53 -2.57 -2.74 -4.08 -6.36 -10.50 
miR-335 -1.18 -1.74 -1.48 -2.74 -4.42 -6.22 miR-376a* -1.40 -1.55 -2.41 -2.84 -2.30 -2.49 
miR-336 -4.77 -2.85 -2.42 -3.50 -3.57 -3.35 miR-376b-3p -2.00 -2.74 -2.63 -3.77 -6.35 -7.85 
miR-337 1.14 -1.18 -1.40 -1.82 -2.01 -2.04 miR-376b-5p -2.25 -2.27 -2.53 -3.13 -3.16 -3.26 
miR-338* -2.11 -2.27 -2.28 -3.19 -3.83 ND miR-376c -2.12 -2.07 -2.29 -2.71 -4.31 -4.85 
miR-339-5p -2.21 -2.22 -1.62 -1.76 1.12 1.38 miR-377 -4.28 -3.38 -2.78 -3.88 -4.56 -4.70 
miR-340-3p -4.37 -3.92 -3.98 -5.06 -5.07 -5.45 miR-378 -2.06 -1.89 -2.05 -2.19 -1.42 -1.67 
miR-340-5p -4.76 -8.33 -5.37 -10.12 -17.39 -24.20 miR-378* 22.21 40.77 36.12 14.66 30.69 19.92 
miR-341 1.11 -1.46 -2.22 -2.63 -6.17 -5.36 miR-379 -1.24 -1.55 -1.72 -2.53 -3.66 -5.58 
miR-342-3p -2.20 -2.09 -2.39 -2.86 -2.60 -2.61 miR-381 -1.19 -1.58 -1.94 -2.54 -3.66 -3.98 
miR-342-5p -1.11 -1.39 -2.13 -1.38 -1.59 -1.43 miR-382 -2.32 -2.33 -2.33 -3.37 -3.36 -4.13 
miR-344-3p -1.26 -1.96 -3.24 -1.94 -1.38 -4.51 miR-382* -3.41 -1.57 -1.99 -4.09 -2.67 -4.21 
miR-345-5p -1.30 -1.59 -1.55 -1.91 -1.62 -3.20 miR-383 -1.13 -1.11 -1.47 -1.75 -1.77 -1.81 
miR-346 -1.48 -1.64 -1.58 -1.47 -1.04 1.23 miR-384-3p -2.97 -3.30 -3.00 -5.53 -9.88 -17.06 
miR-347 -4.09 -3.78 -2.55 -4.51 1.28 -1.34 miR-384-5p -2.22 ND ND -4.63 -7.78 -13.52 
miR-350 -1.70 -1.90 -1.51 -2.13 -2.31 -3.50 miR-409-3p -1.97 -1.77 -2.53 -2.69 -3.15 -4.03 
miR-351 -1.10 -1.43 -1.50 -3.06 -4.19 -5.07 miR-409-5p -1.78 -2.01 -2.09 -2.83 -3.22 -3.47 
miR-352 -4.11 -4.31 -5.09 -4.97 -5.02 -9.11 miR-410 -1.40 -2.09 -3.74 -3.80 -5.75 -8.48 
miR-361 -1.05 -1.17 -1.22 -1.59 -2.14 -2.20 miR-411 -2.73 -3.04 2.13 -3.96 -4.70 -6.83 
miR-363 8.78 12.82 10.44 8.86 10.87 21.38 miR-412 -1.67 -1.69 -1.53 -2.18 -2.01 -2.41 








Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr Rno-miRNA 12hr 24hr 48hr 72hr 120hr 168hr 
miR-425 -2.69 -5.95 -2.96 -1.06 -2.06 -3.40 miR-540 17.08 19.37 7.36 9.99 10.22 8.48 
miR-429 5.30 -2.33 -2.10 4.47 6.19 4.25 miR-541 1.17 -1.03 -1.58 -1.84 -1.98 -2.58 
miR-431 -1.27 -1.84 1.07 -1.36 1.11 1.44 miR-542-3p -2.34 -2.56 -2.27 -3.42 -4.95 -3.52 
miR-433 -1.71 -2.55 -3.07 -3.73 -4.66 -5.10 miR-542-5p 1.82 2.89 1.38 -1.16 1.23 -1.00 
miR-434 -1.18 -1.23 -1.25 -1.70 -1.72 -2.36 miR-551b -4.58 -4.07 -3.93 -5.87 -5.68 -7.22 
miR-448 -1.44 -1.46 -2.35 -1.48 1.34 -1.13 miR-598-3p -2.61 -2.58 -3.26 -3.50 -3.11 -2.91 
miR-451 -5.41 -2.49 -4.83 -19.32 -16.53 -6.85 miR-598-5p 8.74 16.56 6.16 7.49 14.61 26.61 
miR-466b -1.01 -1.15 -1.56 -2.12 -2.65 -2.29 miR-652 -2.67 -3.82 -3.34 -4.84 -5.53 -3.98 
miR-466c -1.41 -1.82 ND -2.26 ND ND miR-664 -1.69 -1.71 ND -2.79 -2.97 -3.84 
miR-471 -2.62 -3.31 -1.69 -3.81 -3.38 -5.44 miR-673 2.40 3.63 -2.10 7.17 5.49 18.15 
miR-485 -1.88 -2.43 -2.51 -2.48 -2.76 -2.37 miR-674-3p -1.46 1.08 1.21 -1.05 -1.09 -1.18 
miR-487b -3.65 -4.30 -3.33 -7.28 -7.79 -8.49 miR-674-5p -1.46 -1.08 -1.13 -1.46 -1.54 -1.89 
miR-488 -1.84 -1.91 -2.26 -3.27 -2.10 -2.07 miR-708 -1.56 -1.56 -2.29 -3.10 -4.68 -5.68 
miR-489 13.16 1.28 -2.10 5.07 -2.13 -2.82 miR-742 -1.84 -2.56 -1.68 -3.32 -3.75 -5.02 
miR-493 9.76 8.87 10.38 14.52 27.01 14.83 miR-743b -2.95 -4.43 -2.53 -4.39 -6.52 -6.51 
miR-494 -4.89 -4.83 -4.65 -11.34 -12.01 -19.76 miR-872 -2.15 -1.71 -2.48 -2.81 -3.11 -2.47 
miR-495 -2.14 -2.81 -3.33 -4.42 -7.23 -8.38 miR-872* -1.95 -2.35 -1.85 -3.97 -4.87 -6.29 
miR-497 -4.23 -4.36 -3.83 -4.97 -5.03 -10.45 miR-873 -1.61 -1.36 -2.99 -3.12 -3.47 -2.88 
miR-503 -1.38 -1.67 -1.63 -3.31 -3.90 -4.23 miR-877 -1.29 -1.51 -1.60 -2.40 -2.85 -2.69 
miR-505 -1.83 -1.45 -1.66 -1.98 -2.30 -1.88 miR-879 -3.58 -3.53 -6.29 -3.98 -4.90 -5.42 





















let-7a 3 miR-1231 1 miR-1279 2 
let-7a* 2 miR-1233 1 miR-128 1 
let-7b 3 miR-1234 1 miR-1281 1 
let-7b* 3 miR-1236 1 miR-1283 4 
let-7c 3 miR-1237 1 miR-1284 3 
let-7d 3 miR-1238 1 miR-1285 1 
let-7e 3 miR-124 1 miR-1286 1 
let-7f 3 miR-124* 3 miR-1288 1 
let-7f-1* 2 miR-1243 1 miR-1289 1 
let-7f-2* 2 miR-1244 1 miR-1290 1 
let-7g 3 miR-1245 1 miR-1292 1 
let-7i 3 miR-1246 1 miR-1293 1 
miR-1 1 miR-1247 1 miR-1294 1 
miR-101 1 miR-1248 2 miR-129-5p 4 
miR-103 1 miR-1250 1 miR-1297 1 
miR-103-2* 3 miR-1251 1 miR-1298 1 
miR-105 4 miR-1252 1 miR-1299 1 
miR-106a 6 miR-1253 1 miR-1300 1 
miR-106b 6 miR-1255a 1 miR-1301 6 
miR-107 1 miR-1255b 1 miR-1302 1 
miR-10a 1 miR-1256 3 miR-1303 6 
miR-10b 1 miR-1257 1 miR-1304 1 
miR-1178 1 miR-1258 1 miR-1305 2 
miR-1179 2 miR-1259 1 miR-1306 2 
miR-1180 1 miR-125a-3p 1 miR-1308 1 
miR-1182 1 miR-125a-5p 1 miR-130a 1 
miR-1184 2 miR-125b 1 miR-130b 1 
miR-1185 1 miR-1261 1 miR-132 2 
miR-1185-1* 1 miR-1262 1 miR-1321 1 
miR-1185-2* 1 miR-1263 2 miR-1322 1 
miR-1197 1 miR-1264 1 miR-1323 2 
miR-1200 3 miR-1265 1 miR-1324 1 
miR-1201 1 miR-1266 1 miR-133a 1 
miR-1202 2 miR-1267 1 miR-133b 1 
miR-1203 1 miR-1268 1 miR-134 2 
miR-1204 1 miR-1269 1 miR-135a 7 
miR-1205 1 miR-1270 1 miR-135b 7 
miR-1206 2 miR-1271 1 miR-136 1 
miR-1207-3p 1 miR-1272 1 miR-137 1 
miR-1207-5p 1 miR-1273 1 miR-138 1 
miR-1208 1 miR-1273c 1 miR-139-3p 1 
miR-122 1 miR-1274a 2 miR-139-5p 6 
miR-1224-5p 1 miR-1274b 1 miR-140-3p 1 
miR-1225-3p 1 miR-1275 1 miR-140-5p 2 
miR-1225-5p 1 miR-127-5p 1 miR-141 1 
miR-1227 1 miR-1276 1 miR-141-5p 3 
miR-1228 1 miR-1277 1 miR-142-3p 1 












miR-143 4 miR-193a-5p 1 miR-220a 1 
miR-144 5 miR-193b 1 miR-220b 1 
miR-145 1 miR-194 3 miR-220c 1 
miR-146a 1 miR-195 1 miR-221 2 
miR-146b-3p 1 miR-195* 2 miR-222 1 
miR-146b-5p 1 miR-196a 1 miR-222* 1 
miR-147 1 miR-196b 1 miR-223 1 
miR-147b 1 miR-197 1 miR-224 1 
miR-148a 1 miR-198 1 miR-2278 1 
miR-148b 1 miR-199a-3p 2 miR-23a 1 
miR-149 3 miR-199a-5p 1 miR-23b 1 
miR-150* 1 miR-199b-3p 2 miR-24 1 
miR-151-3p 1 miR-199b-5p 1 miR-25 1 
miR-152 1 miR-19a 5 miR-26a 1 
miR-153 1 miR-19a* 1 miR-26a-2* 1 
miR-154 5 miR-19b 5 miR-26b 1 
miR-155 1 miR-19b-1* 1 miR-27a 1 
miR-15a 1 miR-19b-2* 1 miR-27b 1 
miR-15a* 1 miR-200a 1 miR-28-3p 1 
miR-15b 1 miR-200b 1 miR-28-5p 2 
miR-15b* 1 miR-200c 1 miR-296-3p 1 
miR-16 1 miR-202 3 miR-297 1 
miR-16-1* 3 miR-203 4 miR-298 1 
miR-16-2* 2 miR-204 1 miR-299-3p 1 
miR-17 5 miR-205 1 miR-299-5p 1 
miR-17* 1 miR-2053 1 miR-29a 1 
miR-181a 5 miR-206 1 miR-29b 1 
miR-181b 5 miR-208a 1 miR-29b-2* 1 
miR-181c 5 miR-208b 1 miR-29c 1 
miR-181d 4 miR-20a 6 miR-300 7 
miR-182 1 miR-20b 5 miR-301a 1 
miR-1825 1 miR-2113 4 miR-301b 1 
miR-1826 1 miR-2114 1 miR-302a 4 
miR-1827 1 miR-2116 1 miR-302b 4 
miR-183 1 miR-2117 4 miR-302b* 1 
miR-184 1 miR-21 1 miR-302c 4 
miR-185 5 miR-21* 2 miR-302c* 2 
miR-186 6 miR-210 1 miR-302d 4 
miR-187 1 miR-211 1 miR-302d* 1 
miR-188-3p 1 miR-212 2 miR-302e 4 
miR-188-5p 4 miR-214 2 miR-302f 2 
miR-18a 5 miR-215 1 miR-3064-3p 2 
miR-18b 3 miR-216a 1 miR-30a 1 
miR-190 4 miR-216b 1 miR-30a* 2 
miR-190b 3 miR-217 2 miR-30b 1 
miR-191 1 miR-218 5 miR-30c 1 
miR-1911* 3 miR-219 1 miR-30d 1 
miR-192 1 miR-219-1* 1 miR-30d* 2 
miR-192* 5 miR-219-2* 1 miR-30e 1 












miR-31 2 miR-33a* 2 miR-376c 4 
miR-3118 1 miR-33b 1 miR-377 1 
miR-3119 5 miR-340 5 miR-378 1 
miR-3120 3 miR-342-3p 1 miR-379* 1 
miR-3121 2 miR-342-5p 1 miR-380 1 
miR-3122 1 miR-346 1 miR-380-5p 1 
miR-3123 4 miR-34a 2 miR-381 7 
miR-3125 1 miR-34a* 1 miR-382 1 
miR-3128 2 miR-34b 1 miR-383 1 
miR-3129-5p 1 miR-34c-3p 1 miR-384 1 
miR-3133 3 miR-34c-5p 2 miR-3909 1 
miR-3136-3p 3 miR-3545-3p 1 miR-3913-5p 1 
miR-3140-3p 1 miR-3591-3p 3 miR-3919 1 
miR-3143 1 miR-3607-5p 2 miR-3920 1 
miR-3145 1 miR-3609 1 miR-3922-5p 1 
miR-3153 2 miR-361-5p 1 miR-3925-5p 2 
miR-3158 3 miR-3611 1 miR-3938 1 
miR-3160-5p 1 miR-3613-3p 3 miR-3942-5p 1 
miR-3162-5p 1 miR-3616-3p 1 miR-3972 1 
miR-3163 4 miR-362-3p 1 miR-3973 1 
miR-3164 2 miR-362-5p 1 miR-3976 2 
miR-3173 2 miR-3646 1 miR-409-3p 1 
miR-3180-5p 3 miR-3647-5p 1 miR-409-5p 1 
miR-3182 2 miR-365 1 miR-410 2 
miR-3183 3 miR-3662 2 miR-411 1 
miR-3190 1 miR-3663-5p 1 miR-411* 1 
miR-3190* 1 miR-3664-5p 1 miR-412 1 
miR-32 3 miR-3667-3p 1 miR-421 5 
miR-3200-5p 1 miR-367 1 miR-422a 1 
miR-320a 1 miR-3672 2 miR-423-5p 1 
miR-320b 1 miR-3675-3p 2 miR-424 3 
miR-320c 1 miR-3682-5p 2 miR-425 1 
miR-320d 1 miR-3683 3 miR-4253 3 
miR-323-3p 5 miR-3688-5p 1 miR-4255 3 
miR-323-5p 1 miR-3689a 1 miR-4259 2 
miR-323b-3p 1 miR-3689b 1 miR-4262 2 
miR-323b-5p 1 miR-3689e 1 miR-4263 1 
miR-324-5p 1 miR-3689f 1 miR-4266 1 
miR-325 1 miR-369-3p 2 miR-4273 3 
miR-326 1 miR-370 3 miR-4275 1 
miR-328 3 miR-371-3p 2 miR-4276 2 
miR-329 1 miR-371-5p 6 miR-4279 3 
miR-330-3p 2 miR-372 5 miR-4280 1 
miR-330-5p 1 miR-373 4 miR-4282 3 
miR-331-5p 1 miR-374a 5 miR-4288 1 
miR-335 4 miR-374b 5 miR-4289 3 
miR-337-3p 1 miR-374c 1 miR-429 1 
miR-337-5p 1 miR-375 3 miR-4302 2 
miR-338-3p 1 miR-376a 3 miR-4306 2 












miR-431 1 miR-4660 1 miR-4796-3p 1 
miR-4311 1 miR-4661-5p 1 miR-4797-3p 1 
miR-432 1 miR-4662a 1 miR-4797-5p 1 
miR-4324 2 miR-4666-3p 2 miR-4799-5p 1 
miR-4325 1 miR-4668-5p 1 miR-4802-3p 1 
miR-433 2 miR-4670-3p 1 miR-4803 1 
miR-4419a 1 miR-4673 1 miR-4804-3p 1 
miR-4422 3 miR-4677-5p 1 miR-483-3p 3 
miR-4428 1 miR-4684-5p 1 miR-483-5p 1 
miR-4446-3p 1 miR-4686 3 miR-485-3p 4 
miR-4452 2 miR-4687-3p 1 miR-486-3p 1 
miR-4458 1 miR-4690-5p 1 miR-487a 1 
miR-4464 1 miR-4693-3p 3 miR-487b 1 
miR-4470 1 miR-4694-3p 1 miR-488 6 
miR-4475 1 miR-4698 1 miR-489 1 
miR-4477b 1 miR-4699-5p 2 miR-490-3p 1 
miR-448 4 miR-4703-5p 1 miR-490-5p 1 
miR-4480 2 miR-4709-3p 1 miR-491-3p 4 
miR-4481 1 miR-4709-5p 1 miR-491-5p 2 
miR-4495 1 miR-4712-3p 1 miR-492 1 
miR-449a 2 miR-4714-3p 1 miR-493 1 
miR-449b 2 miR-4714-5p 1 miR-494 5 
miR-449b* 1 miR-4715-5p 2 miR-495 7 
miR-4500 1 miR-4720-3p 1 miR-496 2 
miR-4501 1 miR-4721 1 miR-497 1 
miR-4502 2 miR-4723-3p 2 miR-497* 1 
miR-4520a 1 miR-4724-3p 1 miR-498 7 
miR-450a 1 miR-4729 1 miR-499-3p 1 
miR-450b-3p 1 miR-4735-5p 1 miR-499-5p 2 
miR-450b-5p 2 miR-4738-3p 3 miR-500 1 
miR-451 1 miR-4742-5p 2 miR-500* 1 
miR-4510 1 miR-4745-5p 1 miR-5002-5p 2 
miR-452 3 miR-4748 1 miR-5007-5p 1 
miR-4520a 2 miR-4752 1 miR-5008-3p 1 
miR-4520b 1 miR-4753-3p 2 miR-501-3p 2 
miR-4529-3p 1 miR-4760-3p 3 miR-501-5p 1 
miR-453 1 miR-4761-3p 1 miR-5011-5p 2 
miR-454 1 miR-4762-3p 1 miR-502-3p 2 
miR-455-3p 1 miR-4766-5p 1 miR-502-5p 1 
miR-455-5p 1 miR-4768-5p 1 miR-502-5p 1 
miR-4635 2 miR-4770 1 miR-5047 3 
miR-4642 1 miR-4775 1 miR-505 1 
miR-4643 1 miR-4776-3p 1 miR-506 1 
miR-4644 1 miR-4778-3p 2 miR-507 4 
miR-4645-3p 1 miR-4779 2 miR-508-3p 1 
miR-4645-5p 1 miR-4780 1 miR-508-5p 1 
miR-4656 1 miR-4786-3p 1 miR-509-3-5p 1 
miR-4659a 1 miR-4789-3p 3 miR-509-3p 1 
miR-4659b 1 miR-4789-5p 3 miR-509-5p 1 












miR-511 3 miR-526b 3 miR-556-5p 1 
miR-512-3p 1 miR-526b* 5 miR-557 2 
miR-512-5p 1 miR-527 1 miR-558 1 
miR-513a-3p 5 miR-532-5p 1 miR-5580-3p 1 
miR-513a-5p 1 miR-539 1 miR-5586-3p 1 
miR-513b 1 miR-539-3p 2 miR-559 2 
miR-513c 1 miR-541 1 miR-561 1 
miR-513c-3p 1 miR-542-3p 1 miR-562 2 
miR-514 3 miR-542-5p 1 miR-563 2 
miR-514b-3p 2 miR-543 1 miR-564 1 
miR-515-5p 5 miR-544 3 miR-567 1 
miR-516a-3p 1 miR-545 3 miR-568 4 
miR-516b 1 miR-545* 1 miR-5688 2 
miR-517a 1 miR-548a-3p 4 miR-5692b 2 
miR-517b 1 miR-548a-5p 3 miR-5692c 2 
miR-517c 1 miR-548aa 1 miR-569 1 
miR-518a-3p 2 miR-548ab 1 miR-5696 1 
miR-518a-5p 1 miR-548ah 1 miR-570 3 
miR-518b 1 miR-548ak 1 miR-571 5 
miR-518c 2 miR-548av-3p 1 miR-572 1 
miR-518d-3p 1 miR-548b-3p 4 miR-573 2 
miR-518d-5p 1 miR-548b-5p 2 miR-574-3p 1 
miR-518e 1 miR-548c-3p 4 miR-574-5p 1 
miR-518f 1 miR-548c-5p 2 miR-575 1 
miR-519a 2 miR-548d-3p 1 miR-576-3p 1 
miR-519b-3p 2 miR-548d-5p 2 miR-576-5p 3 
miR-519b-5p 1 miR-548e 3 miR-577 1 
miR-519c-3p 2 miR-548f 3 miR-578 6 
miR-519c-5p 1 miR-548g 1 miR-579 1 
miR-519d 4 miR-548h 2 miR-580 2 
miR-519e 1 miR-548i 2 miR-581 1 
miR-519e* 3 miR-548j 2  miR-582-3p 3 
miR-520a-3p 5 miR-548k 2 miR-582-5p 1 
miR-520a-5p 5 miR-548l 6 miR-583 1 
miR-520b 6 miR-548m 1 miR-584 1 
miR-520c-3p 6 miR-548n 1 miR-585 1 
miR-520c-5p 1 miR-548o 2  miR-586 1 
miR-520d-3p 5 miR-548p 3 miR-587 1 
miR-520d-5p 7 miR-548t 2 miR-588 1 
miR-520e 5 miR-548v 1 miR-589 1 
miR-520f 1 miR-548w 1 miR-590-3p 7 
miR-520g 1 miR-548y 1 miR-590-5p 1 
miR-520h 1 miR-549 1 miR-591 1 
miR-521 1 miR-550 1 miR-592 1 
miR-522 2 miR-551a 1 miR-593 1 
miR-524-3p 1 miR-551b* 2 miR-595 2 
miR-524-5p 7 miR-552 1 miR-597 1 
miR-525-3p 1 miR-553 1 miR-599 1 
miR-525-5p 4 miR-555 1 miR-600 1 












miR-602 1 miR-643 1 miR-769-5p 1 
miR-603 1 miR-644 1 miR-802 5 
miR-604 1 miR-645 1 miR-873 1 
miR-605 1 miR-646 2 miR-875-3p 1 
miR-606 1 miR-648 1 miR-875-5p 1 
miR-607 2 miR-649 2 miR-876-3p 1 
miR-608 1 miR-650 1 miR-876-5p 1 
miR-609 1 miR-651 2 miR-877 2 
miR-610 2 miR-653 1 miR-885-5p 1 
miR-612 1 miR-654-3p 1 miR-887 1 
miR-613 1 miR-655 3 miR-888 2 
miR-614 1 miR-656 1 miR-889 1 
miR-615-5p 1 miR-657 1 miR-890 1 
miR-616 2 miR-658 1 miR-891a 1 
miR-617 1 miR-659 2 miR-891b 2 
miR-618 1 miR-660 1 miR-892a 1 
miR-619 1 miR-661 1 miR-892b 1 
miR-620 1 miR-662 1 miR-9 4 
miR-621 1 miR-663b 1 miR-920 1 
miR-622 1 miR-664 1 miR-921 1 
miR-623 4 miR-665 1 miR-922 1 
miR-624 1 miR-668 1 miR-923 1 
miR-625 1 miR-671-3p 1 miR-924 1 
miR-626 1 miR-671-5p 1 miR-92a 1 
miR-627 1 miR-676-5p 1 miR-92b 1 
miR-628-3p 1 miR-7 1 miR-93 5 
miR-628-5p 3 miR-7-1* 3 miR-93* 1 
miR-629 1 miR-7-2* 3 miR-934 1 
miR-630 1 miR-708 3 miR-935 2 
miR-631 1 miR-720 1 miR-936 3 
miR-632 1 miR-758 1 miR-940 1 
miR-633 2 miR-759 2 miR-942 1 
miR-635 1 miR-765 2 miR-943 1 
miR-636 2 miR-767-3p 1 miR-944 1 
miR-639 1 miR-767-5p 5 miR-95 1 
miR-640 1 miR-768-3p 1 miR-96 1 
miR-641 4 miR-768-5p 1 miR-98 3 




















miR-1 1 miR-27b 2 miR-3564 1 
miR-101a 1 miR-290 3 miR-3570 1 
miR-105 1 miR-291a-3p 1 miR-3592 1 
miR-122 1 miR-292-5p 5 miR-362 1 
miR-124 3 miR-293 3 miR-369-3p 3 
miR-130a 1 miR-295 2 miR-369-5p 1 
miR-130b 1 miR-299 1 miR-374 1 
miR-137 2 miR-301a 1 miR-375 1 
miR-139-5p 1 miR-301b 1 miR-376a 1 
miR-181a 1 miR-30a 1 miR-376b-3p 1 
miR-181b 1 miR-30b-5p 1 miR-377 1 
miR-181c 1 miR-30c 1 miR-384-5p 2 
miR-181d 1 miR-30d 1 miR-409-5p 1 
miR-190 1 miR-30e 1 miR-431 1 
miR-1912-3p 1 miR-323 4 miR-434 4 
miR-19a 1 miR-325-5p 2 miR-488 2 
miR-19b 1 miR-327 1 miR-539 4 
miR-203 1 miR-33 3 miR-543* 1 
miR-222 1 miR-338* 3 miR-653 1 
miR-23a 4 miR-342-3p 1 miR-664 4 
miR-23b 4 miR-344-3p 1 miR-673 1 



























let-7c-3p 1 miR-1322 1 miR-2110 3 
let-7e 1 miR-1323 3 miR-216a 1 
miR-1 7 miR-134 1 miR-216b 1 
miR-101 2 miR-140-5p 1 miR-219-2-3p 2 
miR-106a 1 miR-141 2 miR-22 3 
miR-106a* 1 miR-142-3p 2 miR-220c 1 
miR-10a* 2 miR-142-5p 2 miR-223* 1 
miR-10b* 3 miR-143 1 miR-224 1 
miR-1179 1 miR-144 1 miR-23a 5 
miR-1182 1 miR-146a 1 miR-23b 5 
miR-1184 1 miR-146b-5p 1 miR-23c 1 
miR-1205 2 miR-148a 1 miR-26a 2 
miR-1206 1 miR-148b 1 miR-26b 2 
miR-122 5 miR-149-3p 1 miR-28-3p 1 
miR-1225-3p 1 miR-151-3p 1 miR-296-3p 1 
miR-1231 4 miR-152 1 miR-297 1 
miR-124 5 miR-153 1 miR-298 1 
miR-124* 1 miR-154 1 miR-29a 1 
miR-1246 1 miR-17 1 miR-29b 1 
miR-1252 1 miR-17* 1 miR-29c 1 
miR-1253 1 miR-181a 1 miR-301a 1 
miR-1255a 1 miR-181b 1 miR-301b 1 
miR-1255b 1 miR-181c 1 miR-302a 1 
miR-1257 1 miR-181d 1 miR-302a* 3 
miR-125a-5p 1 miR-182 1 miR-302b 1 
miR-125b 1 miR-183* 1 miR-302c 1 
miR-126 2 miR-1825 1 miR-302c* 3 
miR-1262 1 miR-1826 1 miR-302d 1 
miR-1263 1 miR-185 1 miR-302e 1 
miR-1264 1 miR-186 2 miR-302f 1 
miR-1266 1 miR-190 1 miR-30a 1 
miR-1267 1 miR-190b 1 miR-30b 1 
miR-1272 1 miR-1911 1 miR-30c 1 
miR-1276 1 miR-1915 3 miR-30d 1 
miR-1277 1 miR-193a-5p 1 miR-30e 1 
miR-1278 1 miR-196a 1 miR-3065-5p 2 
miR-1283 2 miR-196b 1 miR-31 1 
miR-1285 1 miR-19a 3 miR-3125 3 
miR-1290 1 miR-19b 4 miR-3132 2 
miR-1291 1 miR-200a 2 miR-3143 3 
miR-129-5p 1 miR-203 2 miR-3145 1 
miR-1297 2 miR-2053 1 miR-3149 2 
miR-1304 1 miR-2054 2 miR-3153 2 
miR-1306 1 miR-206 6 miR-3158-5p 1 
miR-1308 1 miR-208a 1 miR-3163 2 
miR-130a 1 miR-208b 1 miR-3170 1 
miR-130a* 3 miR-20a 1 miR-3174 2 












miR-320a 1 miR-424 1 miR-503 1 
miR-320b 1 miR-424* 1 miR-504 2 
miR-320c 1 miR-429 1 miR-505 3 
miR-320d 1 miR-4271 1 miR-506 4 
miR-323-3p 6 miR-4282 1 miR-509-3-5p 1 
miR-323b-5p 1 miR-4307 1 miR-509-5p 1 
miR-324-5p 2 miR-431 2 miR-512-3p 1 
miR-328 1 miR-4318 2 miR-513a-3p 2 
miR-330-3p 1 miR-432 1 miR-513a-5p 1 
miR-335 3 miR-4327 1 miR-513c 1 
miR-338-5p 1 miR-433 1 miR-514 1 
miR-33a 6 miR-4471 1 miR-515-3p 1 
miR-33a* 3 miR-450a 3 miR-515-5p 1 
miR-33b 6 miR-450b-5p 2 miR-516b 1 
miR-340 1 miR-4507 1 miR-518a-3p 1 
miR-34a-5p 1 miR-452 1 miR-518a-5p 5 
miR-34b 1 miR-4528 2 miR-518b 3 
miR-34c-3p 1 miR-454 1 miR-518c 1 
miR-361-3p 1 miR-455-3p 1 miR-518d-3p 1 
miR-361-5p 1 miR-4635 1 miR-518d-5p 2 
miR-362-5p 1 miR-4646-3p 1 miR-518e 2 
miR-3659 1 miR-4650-3p 1 miR-518f 2 
miR-3667-5p 1 miR-4658 1 miR-518f* 1 
miR-3673 1 miR-4664-5p 1 miR-519a 1 
miR-3679-3p 1 miR-4667-5p 2 miR-519b-3p 1 
miR-3691-3p 1 miR-4668-5p 1 miR-519b-5p 1 
miR-3692 2 miR-4685-5p 1 miR-519c-3p 1 
miR-369-3p 4 miR-4690-3p 1 miR-519c-5p 1 
miR-3714 1 miR-4700-5p 2 miR-520a-3p 1 
miR-371b-5p 2 miR-4701-5p 1 miR-520a-5p 1 
miR-373 2 miR-4703-5p 1 miR-520b 1 
miR-373* 3 miR-4704-5p 1 miR-520c-3p 1 
miR-374a 6 miR-4725-3p 1 miR-520c-5p 1 
miR-374b 6 miR-4726-3p 1 miR-520d-3p 1 
miR-374b* 1 miR-4742-3p 1 miR-520d-5p 4 
miR-377 2 miR-4752 1 miR-520e 1 
miR-378a-5p 1 miR-4760-3p 1 miR-520f 1 
miR-379 4 miR-486-3p 1 miR-520g 1 
miR-380 2 miR-488 1 miR-520h 1 
miR-382 1 miR-489 2 miR-522 1 
miR-383 1 miR-491-3p 1 miR-524-3p 1 
miR-3908 2 miR-491-5p 1 miR-524-5p 3 
miR-3910 2 miR-493* 2 miR-525-3p 1 
miR-3916 2 miR-494 4 miR-525-5p 1 
miR-3923 1 miR-495 6 miR-526a 1 
miR-3940-5p 1 miR-496 1 miR-526b 1 
miR-3942-5p 1 miR-499-3p 3 miR-527 4 
miR-409-3p 4 miR-499-5p 1 miR-532-5p 1 
miR-410 1 miR-5002-5p 1 miR-539 1 












miR-542-3p 1 miR-579 4 miR-653 1 
miR-543 4 miR-580 1 miR-655 1 
miR-544 1 miR-581 1 miR-656 1 
miR-545 2 miR-583 1 miR-657 1 
miR-548a-3p 1 miR-584 1 miR-659 1 
miR-548a-5p 2 miR-586 5 miR-662 1 
miR-548b-3p 1 miR-587 1 miR-664 5 
miR-548b-5p 1 miR-588 1 miR-665 1 
miR-548c-3p 3 miR-589 1 miR-671-3p 1 
miR-548c-5p 2 miR-590-3p 1 miR-675 1 
miR-548d-3p 1 miR-591 2 miR-6783-5p 1 
miR-548d-5p 1 miR-592 1 miR-6824-5p 1 
miR-548f 1 miR-593 4 miR-6844 1 
miR-548g 1 miR-598 1 miR-6859-5p 1 
miR-548h 1 miR-599 1 miR-7 1 
miR-548i 1 miR-600 1 miR-7-1* 2 
miR-548j 1 miR-601 1 miR-7-2* 2 
miR-548k 1 miR-603 1 miR-767-5p 1 
miR-548l 1 miR-605 1 miR-768-3p 1 
miR-548m 1 miR-607 1 miR-769-3p 1 
miR-548n 1 miR-608 1 miR-770-5p 1 
miR-548o 2 miR-609 3 miR-802 1 
miR-548p 1 miR-610 1 miR-8089 1 
miR-551b* 1 miR-611 1 miR-873 1 
miR-552 1 miR-612 1 miR-875-3p 1 
miR-553 1 miR-613 7 miR-876-3p 2 
miR-554 1 miR-615-3p 1 miR-877 1 
miR-555 1 miR-616* 3 miR-885-5p 1 
miR-556-3p 1 miR-617 1 miR-886-5p 1 
miR-557 1 miR-624* 3 miR-888 1 
miR-5572 1 miR-625 1 miR-891a 2 
miR-559 2 miR-626 1 miR-891b 2 
miR-5591-5p 1 miR-632 1 miR-892a 1 
miR-561 1 miR-633 5 miR-9 3 
miR-562 1 miR-635 2 miR-9* 1 
miR-568 1 miR-636 1 miR-924 1 
miR-569 3 miR-637 2 miR-93 1 
miR-570 2 miR-639 1 miR-935 2 
miR-574-5p 2 miR-641 1 miR-944 1 
miR-576-3p 1 miR-643 1 miR-95 1 
miR-577  5 miR-647 1 miR-96 1 
miR-578 1 miR-651 1   
 294 
 
gi|299522993:1352-3402      TGAGAAGGAGAGATGAGAGAAAGGTTTGCTTTTATCATTAAAAGGAAAGCAGATGGTGGA 60 
gi|299523000:1328-3264      ------------------------------------------------------------ 0 
gi|299523007:1223-3155      ------------------------------------------------------------ 0 
gi|299522998:1307-3357      TGAGAAGGAGAGATGAGAGAAAGGTTTGCTTTTATCATTAAAAGGAAAGCAGATGGTGGA 60 
gi|299523001:1262-3312      TGAGAAGGAGAGATGAGAGAAAGGTTTGCTTTTATCATTAAAAGGAAAGCAGATGGTGGA 60 
gi|299523003:1283-3219      ------------------------------------------------------------ 0 
gi|299522996:1373-3309      ------------------------------------------------------------ 0 
gi|299523006:1241-3177      ------------------------------------------------------------ 0 
                                                                                         
 
gi|299522993:1352-3402      GCTGAATATGCCACTTACCAGACTAAATCAACCACTCCAGCAGAGCAGAGAGGCTGAATA 120 
gi|299523000:1328-3264      ------------------------------------------------------TGAATA 6 
gi|299523007:1223-3155      ----------------------------------------------------------TA 2 
gi|299522998:1307-3357      GCTGAATATGCCACTTACCAGACTAAATCAACCACTCCAGCAGAGCAGAGAGGCTGAATA 120 
gi|299523001:1262-3312      GCTGAATATGCCACTTACCAGACTAAATCAACCACTCCAGCAGAGCAGAGAGGCTGAATA 120 
gi|299523003:1283-3219      ------------------------------------------------------TGAATA 6 
gi|299522996:1373-3309      ------------------------------------------------------TGAATA 6 
gi|299523006:1241-3177      ------------------------------------------------------TGAATA 6 
                                                                                      ** 
 
gi|299522993:1352-3402      GATTCCACAACCTGGTTTGCCAGTTCATCTTTTGACTCTATTAAAATCTTCAATAGTTGT 180 
gi|299523000:1328-3264      GATTCCACAACCTGGTTTGCCAGTTCATCTTTTGACTCTATTAAAATCTTCAATAGTTGT 66 
gi|299523007:1223-3155      GATTCCACAACCTGGTTTGCCAGTTCATCTTTTGACTCTATTAAAATCTTCAATAGTTGT 62 
gi|299522998:1307-3357      GATTCCACAACCTGGTTTGCCAGTTCATCTTTTGACTCTATTAAAATCTTCAATAGTTGT 180 
gi|299523001:1262-3312      GATTCCACAACCTGGTTTGCCAGTTCATCTTTTGACTCTATTAAAATCTTCAATAGTTGT 180 
gi|299523003:1283-3219      GATTCCACAACCTGGTTTGCCAGTTCATCTTTTGACTCTATTAAAATCTTCAATAGTTGT 66 
gi|299522996:1373-3309      GATTCCACAACCTGGTTTGCCAGTTCATCTTTTGACTCTATTAAAATCTTCAATAGTTGT 66 
gi|299523006:1241-3177      GATTCCACAACCTGGTTTGCCAGTTCATCTTTTGACTCTATTAAAATCTTCAATAGTTGT 66 









gi|299522993:1352-3402      TATTCTGTAGTTTCACTCTCATGAGTGCAACTGTGGCTTAGCTAATATTGCAATGTGGCT 240 
gi|299523000:1328-3264      TATTCTGTAGTTTCACTCTCATGAGTGCAACTGTGGCTTAGCTAATATTGCAATGTGGCT 126 
gi|299523007:1223-3155      TATTCTGTAGTTTCACTCTCATGAGTGCAACTGTGGCTTAGCTAATATTGCAATGTGGCT 122 
gi|299522998:1307-3357      TATTCTGTAGTTTCACTCTCATGAGTGCAACTGTGGCTTAGCTAATATTGCAATGTGGCT 240 
gi|299523001:1262-3312      TATTCTGTAGTTTCACTCTCATGAGTGCAACTGTGGCTTAGCTAATATTGCAATGTGGCT 240 
gi|299523003:1283-3219      TATTCTGTAGTTTCACTCTCATGAGTGCAACTGTGGCTTAGCTAATATTGCAATGTGGCT 126 
gi|299522996:1373-3309      TATTCTGTAGTTTCACTCTCATGAGTGCAACTGTGGCTTAGCTAATATTGCAATGTGGCT 126 
gi|299523006:1241-3177      TATTCTGTAGTTTCACTCTCATGAGTGCAACTGTGGCTTAGCTAATATTGCAATGTGGCT 126 
                            ************************************************************ 
 
gi|299522993:1352-3402      TGAATGTAGGTAGCATCCTTTGATGCTTCTTTGAAACTTGTATGAATTTGGGTATGAACA 300 
gi|299523000:1328-3264      TGAATGTAGGTAGCATCCTTTGATGCTTCTTTGAAACTTGTATGAATTTGGGTATGAACA 186 
gi|299523007:1223-3155      TGAATGTAGGTAGCATCCTTTGATGCTTCTTTGAAACTTGTATGAATTTGGGTATGAACA 182 
gi|299522998:1307-3357      TGAATGTAGGTAGCATCCTTTGATGCTTCTTTGAAACTTGTATGAATTTGGGTATGAACA 300 
gi|299523001:1262-3312      TGAATGTAGGTAGCATCCTTTGATGCTTCTTTGAAACTTGTATGAATTTGGGTATGAACA 300 
gi|299523003:1283-3219      TGAATGTAGGTAGCATCCTTTGATGCTTCTTTGAAACTTGTATGAATTTGGGTATGAACA 186 
gi|299522996:1373-3309      TGAATGTAGGTAGCATCCTTTGATGCTTCTTTGAAACTTGTATGAATTTGGGTATGAACA 186 
gi|299523006:1241-3177      TGAATGTAGGTAGCATCCTTTGATGCTTCTTTGAAACTTGTATGAATTTGGGTATGAACA 186 
                            ************************************************************ 
 
gi|299522993:1352-3402      GATTGCCTGCTTTCCCTTAAATAACACTTAGATTTATTGGACCAGTCAGCACAGCATGCC 360 
gi|299523000:1328-3264      GATTGCCTGCTTTCCCTTAAATAACACTTAGATTTATTGGACCAGTCAGCACAGCATGCC 246 
gi|299523007:1223-3155      GATTGCCTGCTTTCCCTTAAATAACACTTAGATTTATTGGACCAGTCAGCACAGCATGCC 242 
gi|299522998:1307-3357      GATTGCCTGCTTTCCCTTAAATAACACTTAGATTTATTGGACCAGTCAGCACAGCATGCC 360 
gi|299523001:1262-3312      GATTGCCTGCTTTCCCTTAAATAACACTTAGATTTATTGGACCAGTCAGCACAGCATGCC 360 
gi|299523003:1283-3219      GATTGCCTGCTTTCCCTTAAATAACACTTAGATTTATTGGACCAGTCAGCACAGCATGCC 246 
gi|299522996:1373-3309      GATTGCCTGCTTTCCCTTAAATAACACTTAGATTTATTGGACCAGTCAGCACAGCATGCC 246 
gi|299523006:1241-3177      GATTGCCTGCTTTCCCTTAAATAACACTTAGATTTATTGGACCAGTCAGCACAGCATGCC 246 









gi|299522993:1352-3402      TGGTTGTATTAAAGCAGGGATATGCTGTATTTTATAAAATTGGCAAAATTAGAGAAATAT 420 
gi|299523000:1328-3264      TGGTTGTATTAAAGCAGGGATATGCTGTATTTTATAAAATTGGCAAAATTAGAGAAATAT 306 
gi|299523007:1223-3155      TGGTTGTATTAAAGCAGGGATATGCTGTATTTTATAAAATTGGCAAAATTAGAGAAATAT 302 
gi|299522998:1307-3357      TGGTTGTATTAAAGCAGGGATATGCTGTATTTTATAAAATTGGCAAAATTAGAGAAATAT 420 
gi|299523001:1262-3312      TGGTTGTATTAAAGCAGGGATATGCTGTATTTTATAAAATTGGCAAAATTAGAGAAATAT 420 
gi|299523003:1283-3219      TGGTTGTATTAAAGCAGGGATATGCTGTATTTTATAAAATTGGCAAAATTAGAGAAATAT 306 
gi|299522996:1373-3309      TGGTTGTATTAAAGCAGGGATATGCTGTATTTTATAAAATTGGCAAAATTAGAGAAATAT 306 
gi|299523006:1241-3177      TGGTTGTATTAAAGCAGGGATATGCTGTATTTTATAAAATTGGCAAAATTAGAGAAATAT 306 
                            ************************************************************ 
 
gi|299522993:1352-3402      AGTTCACAATGAAATTATATTTTCTTTGTAAAGAAAGTGGCTTGAAATCTTTTTTGTTCA 480 
gi|299523000:1328-3264      AGTTCACAATGAAATTATATTTTCTTTGTAAAGAAAGTGGCTTGAAATCTTTTTTGTTCA 366 
gi|299523007:1223-3155      AGTTCACAATGAAATTATATTTTCTTTGTAAAGAAAGTGGCTTGAAATCTTTTTTGTTCA 362 
gi|299522998:1307-3357      AGTTCACAATGAAATTATATTTTCTTTGTAAAGAAAGTGGCTTGAAATCTTTTTTGTTCA 480 
gi|299523001:1262-3312      AGTTCACAATGAAATTATATTTTCTTTGTAAAGAAAGTGGCTTGAAATCTTTTTTGTTCA 480 
gi|299523003:1283-3219      AGTTCACAATGAAATTATATTTTCTTTGTAAAGAAAGTGGCTTGAAATCTTTTTTGTTCA 366 
gi|299522996:1373-3309      AGTTCACAATGAAATTATATTTTCTTTGTAAAGAAAGTGGCTTGAAATCTTTTTTGTTCA 366 
gi|299523006:1241-3177      AGTTCACAATGAAATTATATTTTCTTTGTAAAGAAAGTGGCTTGAAATCTTTTTTGTTCA 366 
                            ************************************************************ 
 
gi|299522993:1352-3402      AAGATTAATGCCAACTCTTAAGATTATTCTTTCACCAACTATAGAATGTATTTTATATAT 540 
gi|299523000:1328-3264      AAGATTAATGCCAACTCTTAAGATTATTCTTTCACCAACTATAGAATGTATTTTATATAT 426 
gi|299523007:1223-3155      AAGATTAATGCCAACTCTTAAGATTATTCTTTCACCAACTATAGAATGTATTTTATATAT 422 
gi|299522998:1307-3357      AAGATTAATGCCAACTCTTAAGATTATTCTTTCACCAACTATAGAATGTATTTTATATAT 540 
gi|299523001:1262-3312      AAGATTAATGCCAACTCTTAAGATTATTCTTTCACCAACTATAGAATGTATTTTATATAT 540 
gi|299523003:1283-3219      AAGATTAATGCCAACTCTTAAGATTATTCTTTCACCAACTATAGAATGTATTTTATATAT 426 
gi|299522996:1373-3309      AAGATTAATGCCAACTCTTAAGATTATTCTTTCACCAACTATAGAATGTATTTTATATAT 426 
gi|299523006:1241-3177      AAGATTAATGCCAACTCTTAAGATTATTCTTTCACCAACTATAGAATGTATTTTATATAT 426 









gi|299522993:1352-3402      CGTTCATTGTAAAAAGCCCTTAAAAATATGTGTATACTACTTTGGCTCTTGTGCATAAAA 600 
gi|299523000:1328-3264      CGTTCATTGTAAAAAGCCCTTAAAAATATGTGTATACTACTTTGGCTCTTGTGCATAAAA 486 
gi|299523007:1223-3155      CGTTCATTGTAAAAAGCCCTTAAAAATATGTGTATACTACTTTGGCTCTTGTGCATAAAA 482 
gi|299522998:1307-3357      CGTTCATTGTAAAAAGCCCTTAAAAATATGTGTATACTACTTTGGCTCTTGTGCATAAAA 600 
gi|299523001:1262-3312      CGTTCATTGTAAAAAGCCCTTAAAAATATGTGTATACTACTTTGGCTCTTGTGCATAAAA 600 
gi|299523003:1283-3219      CGTTCATTGTAAAAAGCCCTTAAAAATATGTGTATACTACTTTGGCTCTTGTGCATAAAA 486 
gi|299522996:1373-3309      CGTTCATTGTAAAAAGCCCTTAAAAATATGTGTATACTACTTTGGCTCTTGTGCATAAAA 486 
gi|299523006:1241-3177      CGTTCATTGTAAAAAGCCCTTAAAAATATGTGTATACTACTTTGGCTCTTGTGCATAAAA 486 
                            ************************************************************ 
 
gi|299522993:1352-3402      ACAAGAACACTGAAAATTGGGAATATGCACAAACTTGGCTTCTTTAACCAAGAATATTAT 660 
gi|299523000:1328-3264      ACAAGAACACTGAAAATTGGGAATATGCACAAACTTGGCTTCTTTAACCAAGAATATTAT 546 
gi|299523007:1223-3155      ACAAGAACACTGAAAATTGGGAATATGCACAAACTTGGCTTCTTTAACCAAGAATATTAT 542 
gi|299522998:1307-3357      ACAAGAACACTGAAAATTGGGAATATGCACAAACTTGGCTTCTTTAACCAAGAATATTAT 660 
gi|299523001:1262-3312      ACAAGAACACTGAAAATTGGGAATATGCACAAACTTGGCTTCTTTAACCAAGAATATTAT 660 
gi|299523003:1283-3219      ACAAGAACACTGAAAATTGGGAATATGCACAAACTTGGCTTCTTTAACCAAGAATATTAT 546 
gi|299522996:1373-3309      ACAAGAACACTGAAAATTGGGAATATGCACAAACTTGGCTTCTTTAACCAAGAATATTAT 546 
gi|299523006:1241-3177      ACAAGAACACTGAAAATTGGGAATATGCACAAACTTGGCTTCTTTAACCAAGAATATTAT 546 
                            ************************************************************ 
 
gi|299522993:1352-3402      TGGAAAATTCTCTAAAAGTTAATAGGGTAAATTCTCTATTTTTTGTAATGTGTTCGGTGA 720 
gi|299523000:1328-3264      TGGAAAATTCTCTAAAAGTTAATAGGGTAAATTCTCTATTTTTTGTAATGTGTTCGGTGA 606 
gi|299523007:1223-3155      TGGAAAATTCTCTAAAAGTTAATAGGGTAAATTCTCTATTTTTTGTAATGTGTTCGGTGA 602 
gi|299522998:1307-3357      TGGAAAATTCTCTAAAAGTTAATAGGGTAAATTCTCTATTTTTTGTAATGTGTTCGGTGA 720 
gi|299523001:1262-3312      TGGAAAATTCTCTAAAAGTTAATAGGGTAAATTCTCTATTTTTTGTAATGTGTTCGGTGA 720 
gi|299523003:1283-3219      TGGAAAATTCTCTAAAAGTTAATAGGGTAAATTCTCTATTTTTTGTAATGTGTTCGGTGA 606 
gi|299522996:1373-3309      TGGAAAATTCTCTAAAAGTTAATAGGGTAAATTCTCTATTTTTTGTAATGTGTTCGGTGA 606 
gi|299523006:1241-3177      TGGAAAATTCTCTAAAAGTTAATAGGGTAAATTCTCTATTTTTTGTAATGTGTTCGGTGA 606 









gi|299522993:1352-3402      TTTCAGAAAGCTAGAAAGTGTATGTGTGGCATTTGTTTTCACTTTTTAAAACATCCCTAA 780 
gi|299523000:1328-3264      TTTCAGAAAGCTAGAAAGTGTATGTGTGGCATTTGTTTTCACTTTTTAAAACATCCCTAA 666 
gi|299523007:1223-3155      TTTCAGAAAGCTAGAAAGTGTATGTGTGGCATTTGTTTTCACTTTTTAAAACATCCCTAA 662 
gi|299522998:1307-3357      TTTCAGAAAGCTAGAAAGTGTATGTGTGGCATTTGTTTTCACTTTTTAAAACATCCCTAA 780 
gi|299523001:1262-3312      TTTCAGAAAGCTAGAAAGTGTATGTGTGGCATTTGTTTTCACTTTTTAAAACATCCCTAA 780 
gi|299523003:1283-3219      TTTCAGAAAGCTAGAAAGTGTATGTGTGGCATTTGTTTTCACTTTTTAAAACATCCCTAA 666 
gi|299522996:1373-3309      TTTCAGAAAGCTAGAAAGTGTATGTGTGGCATTTGTTTTCACTTTTTAAAACATCCCTAA 666 
gi|299523006:1241-3177      TTTCAGAAAGCTAGAAAGTGTATGTGTGGCATTTGTTTTCACTTTTTAAAACATCCCTAA 666 
                            ************************************************************ 
 
gi|299522993:1352-3402      CTGATCGAATATATCAGTAATTTCAGAATCAGATGCATCCTTTCATAAGAAGTGAGAGGA 840 
gi|299523000:1328-3264      CTGATCGAATATATCAGTAATTTCAGAATCAGATGCATCCTTTCATAAGAAGTGAGAGGA 726 
gi|299523007:1223-3155      CTGATCGAATATATCAGTAATTTCAGAATCAGATGCATCCTTTCATAAGAAGTGAGAGGA 722 
gi|299522998:1307-3357      CTGATCGAATATATCAGTAATTTCAGAATCAGATGCATCCTTTCATAAGAAGTGAGAGGA 840 
gi|299523001:1262-3312      CTGATCGAATATATCAGTAATTTCAGAATCAGATGCATCCTTTCATAAGAAGTGAGAGGA 840 
gi|299523003:1283-3219      CTGATCGAATATATCAGTAATTTCAGAATCAGATGCATCCTTTCATAAGAAGTGAGAGGA 726 
gi|299522996:1373-3309      CTGATCGAATATATCAGTAATTTCAGAATCAGATGCATCCTTTCATAAGAAGTGAGAGGA 726 
gi|299523006:1241-3177      CTGATCGAATATATCAGTAATTTCAGAATCAGATGCATCCTTTCATAAGAAGTGAGAGGA 726 
                            ************************************************************ 
                                 
gi|299522993:1352-3402      CTCTGACAGCCATAACAGGAGTGCCACTTCATGGTGCGAAGTGAACACTGTAGTCTTGTT 900 
gi|299523000:1328-3264      CTCTGACAGCCATAACAGGAGTGCCACTTCATGGTGCGAAGTGAACACTGTAGTCTTGTT 786 
gi|299523007:1223-3155      CTCTGACAGCCATAACAGGAGTGCCACTTCATGGTGCGAAGTGAACACTGTAGTCTTGTT 782 
gi|299522998:1307-3357      CTCTGACAGCCATAACAGGAGTGCCACTTCATGGTGCGAAGTGAACACTGTAGTCTTGTT 900 
gi|299523001:1262-3312      CTCTGACAGCCATAACAGGAGTGCCACTTCATGGTGCGAAGTGAACACTGTAGTCTTGTT 900 
gi|299523003:1283-3219      CTCTGACAGCCATAACAGGAGTGCCACTTCATGGTGCGAAGTGAACACTGTAGTCTTGTT 786 
gi|299522996:1373-3309      CTCTGACAGCCATAACAGGAGTGCCACTTCATGGTGCGAAGTGAACACTGTAGTCTTGTT 786 
gi|299523006:1241-3177      CTCTGACAGCCATAACAGGAGTGCCACTTCATGGTGCGAAGTGAACACTGTAGTCTTGTT 786 









gi|299522993:1352-3402      GTTTTCCCAAAGAGAACTCCGTATGTTCTCTTAGGTTGAGTAACCCACTCTGAATTCTGG 960 
gi|299523000:1328-3264      GTTTTCCCAAAGAGAACTCCGTATGTTCTCTTAGGTTGAGTAACCCACTCTGAATTCTGG 846 
gi|299523007:1223-3155      GTTTTCCCAAAGAGAACTCCGTATGTTCTCTTAGGTTGAGTAACCCACTCTGAATTCTGG 842 
gi|299522998:1307-3357      GTTTTCCCAAAGAGAACTCCGTATGTTCTCTTAGGTTGAGTAACCCACTCTGAATTCTGG 960 
gi|299523001:1262-3312      GTTTTCCCAAAGAGAACTCCGTATGTTCTCTTAGGTTGAGTAACCCACTCTGAATTCTGG 960 
gi|299523003:1283-3219      GTTTTCCCAAAGAGAACTCCGTATGTTCTCTTAGGTTGAGTAACCCACTCTGAATTCTGG 846 
gi|299522996:1373-3309      GTTTTCCCAAAGAGAACTCCGTATGTTCTCTTAGGTTGAGTAACCCACTCTGAATTCTGG 846 
gi|299523006:1241-3177      GTTTTCCCAAAGAGAACTCCGTATGTTCTCTTAGGTTGAGTAACCCACTCTGAATTCTGG 846 
                            ************************************************************ 
                              miR-185 seed region 
gi|299522993:1352-3402      TTACATGTGTTTTTCTCTCCCTCCTTAAATAAAGAGAGGGGTTAAACATGCCCTCTAAAA 1020 
gi|299523000:1328-3264      TTACATGTGTTTTTCTCTCCCTCCTTAAATAAAGAGAGGGGTTAAACATGCCCTCTAAAA 906 
gi|299523007:1223-3155      TTACATGTGTTTTTCTCTCCCTCCTTAAATAAAGAGAGGGGTTAAACATGCCCTCTAAAA 902 
gi|299522998:1307-3357      TTACATGTGTTTTTCTCTCCCTCCTTAAATAAAGAGAGGGGTTAAACATGCCCTCTAAAA 1020 
gi|299523001:1262-3312      TTACATGTGTTTTTCTCTCCCTCCTTAAATAAAGAGAGGGGTTAAACATGCCCTCTAAAA 1020 
gi|299523003:1283-3219      TTACATGTGTTTTTCTCTCCCTCCTTAAATAAAGAGAGGGGTTAAACATGCCCTCTAAAA 906 
gi|299522996:1373-3309      TTACATGTGTTTTTCTCTCCCTCCTTAAATAAAGAGAGGGGTTAAACATGCCCTCTAAAA 906 
gi|299523006:1241-3177      TTACATGTGTTTTTCTCTCCCTCCTTAAATAAAGAGAGGGGTTAAACATGCCCTCTAAAA 906 
                            ************************************************************ 
 
gi|299522993:1352-3402      GTAGGTGGTTTTGAAGAGAATAAATTCATCAGATAACCTCAAGTCACATGAGAATCTTAG 1080 
gi|299523000:1328-3264      GTAGGTGGTTTTGAAGAGAATAAATTCATCAGATAACCTCAAGTCACATGAGAATCTTAG 966 
gi|299523007:1223-3155      GTAGGTGGTTTTGAAGAGAATAAATTCATCAGATAACCTCAAGTCACATGAGAATCTTAG 962 
gi|299522998:1307-3357      GTAGGTGGTTTTGAAGAGAATAAATTCATCAGATAACCTCAAGTCACATGAGAATCTTAG 1080 
gi|299523001:1262-3312      GTAGGTGGTTTTGAAGAGAATAAATTCATCAGATAACCTCAAGTCACATGAGAATCTTAG 1080 
gi|299523003:1283-3219      GTAGGTGGTTTTGAAGAGAATAAATTCATCAGATAACCTCAAGTCACATGAGAATCTTAG 966 
gi|299522996:1373-3309      GTAGGTGGTTTTGAAGAGAATAAATTCATCAGATAACCTCAAGTCACATGAGAATCTTAG 966 
gi|299523006:1241-3177      GTAGGTGGTTTTGAAGAGAATAAATTCATCAGATAACCTCAAGTCACATGAGAATCTTAG 966 









gi|299522993:1352-3402      TCCATTTACATTGCCTTGGCTAGTAAAAGCCATCTATGTATATGTCTTACCTCATCTCCT 1140 
gi|299523000:1328-3264      TCCATTTACATTGCCTTGGCTAGTAAAAGCCATCTATGTATATGTCTTACCTCATCTCCT 1026 
gi|299523007:1223-3155      TCCATTTACATTGCCTTGGCTAGTAAAAGCCATCTATGTATATGTCTTACCTCATCTCCT 1022 
gi|299522998:1307-3357      TCCATTTACATTGCCTTGGCTAGTAAAAGCCATCTATGTATATGTCTTACCTCATCTCCT 1140 
gi|299523001:1262-3312      TCCATTTACATTGCCTTGGCTAGTAAAAGCCATCTATGTATATGTCTTACCTCATCTCCT 1140 
gi|299523003:1283-3219      TCCATTTACATTGCCTTGGCTAGTAAAAGCCATCTATGTATATGTCTTACCTCATCTCCT 1026 
gi|299522996:1373-3309      TCCATTTACATTGCCTTGGCTAGTAAAAGCCATCTATGTATATGTCTTACCTCATCTCCT 1026 
gi|299523006:1241-3177      TCCATTTACATTGCCTTGGCTAGTAAAAGCCATCTATGTATATGTCTTACCTCATCTCCT 1026 
                            ************************************************************ 
 
gi|299522993:1352-3402      AAAAGGCAGAGTACAAAGTAAGCCATGTATCTCAGGAAGGTAACTTCATTTTGTCTATTT 1200 
gi|299523000:1328-3264      AAAAGGCAGAGTACAAAGTAAGCCATGTATCTCAGGAAGGTAACTTCATTTTGTCTATTT 1086 
gi|299523007:1223-3155      AAAAGGCAGAGTACAAAGTAAGCCATGTATCTCAGGAAGGTAACTTCATTTTGTCTATTT 1082 
gi|299522998:1307-3357      AAAAGGCAGAGTACAAAGTAAGCCATGTATCTCAGGAAGGTAACTTCATTTTGTCTATTT 1200 
gi|299523001:1262-3312      AAAAGGCAGAGTACAAAGTAAGCCATGTATCTCAGGAAGGTAACTTCATTTTGTCTATTT 1200 
gi|299523003:1283-3219      AAAAGGCAGAGTACAAAGTAAGCCATGTATCTCAGGAAGGTAACTTCATTTTGTCTATTT 1086 
gi|299522996:1373-3309      AAAAGGCAGAGTACAAAGTAAGCCATGTATCTCAGGAAGGTAACTTCATTTTGTCTATTT 1086 
gi|299523006:1241-3177      AAAAGGCAGAGTACAAAGTAAGCCATGTATCTCAGGAAGGTAACTTCATTTTGTCTATTT 1086 
                            ************************************************************ 
                                                                           miR-20a seed region 
gi|299522993:1352-3402      GCTGTTGATTGTACCAAGGGATGGAAGAAGTAAATATAGCTCAGGTAGCACTTTATACTC 1260 
gi|299523000:1328-3264      GCTGTTGATTGTACCAAGGGATGGAAGAAGTAAATATAGCTCAGGTAGCACTTTATACTC 1146 
gi|299523007:1223-3155      GCTGTTGATTGTACCAAGGGATGGAAGAAGTAAATATAGCTCAGGTAGCACTTTATACTC 1142 
gi|299522998:1307-3357      GCTGTTGATTGTACCAAGGGATGGAAGAAGTAAATATAGCTCAGGTAGCACTTTATACTC 1260 
gi|299523001:1262-3312      GCTGTTGATTGTACCAAGGGATGGAAGAAGTAAATATAGCTCAGGTAGCACTTTATACTC 1260 
gi|299523003:1283-3219      GCTGTTGATTGTACCAAGGGATGGAAGAAGTAAATATAGCTCAGGTAGCACTTTATACTC 1146 
gi|299522996:1373-3309      GCTGTTGATTGTACCAAGGGATGGAAGAAGTAAATATAGCTCAGGTAGCACTTTATACTC 1146 
gi|299523006:1241-3177      GCTGTTGATTGTACCAAGGGATGGAAGAAGTAAATATAGCTCAGGTAGCACTTTATACTC 1146 









gi|299522993:1352-3402      AGGCAGATCTCAGCCCTCTACTGAGTCCCTTAGCCAAGCAGTTTCTTTCAAAGAAGCCAG 1320 
gi|299523000:1328-3264      AGGCAGATCTCAGCCCTCTACTGAGTCCCTTAGCCAAGCAGTTTCTTTCAAAGAAGCCAG 1206 
gi|299523007:1223-3155      AGGCAGATCTCAGCCCTCTACTGAGTCCCTTAGCCAAGCAGTTTCTTTCAAAGAAGCCAG 1202 
gi|299522998:1307-3357      AGGCAGATCTCAGCCCTCTACTGAGTCCCTTAGCCAAGCAGTTTCTTTCAAAGAAGCCAG 1320 
gi|299523001:1262-3312      AGGCAGATCTCAGCCCTCTACTGAGTCCCTTAGCCAAGCAGTTTCTTTCAAAGAAGCCAG 1320 
gi|299523003:1283-3219      AGGCAGATCTCAGCCCTCTACTGAGTCCCTTAGCCAAGCAGTTTCTTTCAAAGAAGCCAG 1206 
gi|299522996:1373-3309      AGGCAGATCTCAGCCCTCTACTGAGTCCCTTAGCCAAGCAGTTTCTTTCAAAGAAGCCAG 1206 
gi|299523006:1241-3177      AGGCAGATCTCAGCCCTCTACTGAGTCCCTTAGCCAAGCAGTTTCTTTCAAAGAAGCCAG 1206 
                            ************************************************************ 
 
gi|299522993:1352-3402      CAGGCGAAAAGCAGGGACTGCCACTGCATTTCATATCACACTGTTAAAAGTTGTGTTTTG 1380 
gi|299523000:1328-3264      CAGGCGAAAAGCAGGGACTGCCACTGCATTTCATATCACACTGTTAAAAGTTGTGTTTTG 1266 
gi|299523007:1223-3155      CAGGCGAAAAGCAGGGACTGCCACTGCATTTCATATCACACTGTTAAAAGTTGTGTTTTG 1262 
gi|299522998:1307-3357      CAGGCGAAAAGCAGGGACTGCCACTGCATTTCATATCACACTGTTAAAAGTTGTGTTTTG 1380 
gi|299523001:1262-3312      CAGGCGAAAAGCAGGGACTGCCACTGCATTTCATATCACACTGTTAAAAGTTGTGTTTTG 1380 
gi|299523003:1283-3219      CAGGCGAAAAGCAGGGACTGCCACTGCATTTCATATCACACTGTTAAAAGTTGTGTTTTG 1266 
gi|299522996:1373-3309      CAGGCGAAAAGCAGGGACTGCCACTGCATTTCATATCACACTGTTAAAAGTTGTGTTTTG 1266 
gi|299523006:1241-3177      CAGGCGAAAAGCAGGGACTGCCACTGCATTTCATATCACACTGTTAAAAGTTGTGTTTTG 1266 
                            ************************************************************ 
                                           miR-19a seed region 
gi|299522993:1352-3402      AAATTTTATGTTTAGTTGCACAAATTGGGCCAAAGAAACATTGCCTTGAGGAAGATATGA 1440 
gi|299523000:1328-3264      AAATTTTATGTTTAGTTGCACAAATTGGGCCAAAGAAACATTGCCTTGAGGAAGATATGA 1326 
gi|299523007:1223-3155      AAATTTTATGTTTAGTTGCACAAATTGGGCCAAAGAAACATTGCCTTGAGGAAGATATGA 1322 
gi|299522998:1307-3357      AAATTTTATGTTTAGTTGCACAAATTGGGCCAAAGAAACATTGCCTTGAGGAAGATATGA 1440 
gi|299523001:1262-3312      AAATTTTATGTTTAGTTGCACAAATTGGGCCAAAGAAACATTGCCTTGAGGAAGATATGA 1440 
gi|299523003:1283-3219      AAATTTTATGTTTAGTTGCACAAATTGGGCCAAAGAAACATTGCCTTGAGGAAGATATGA 1326 
gi|299522996:1373-3309      AAATTTTATGTTTAGTTGCACAAATTGGGCCAAAGAAACATTGCCTTGAGGAAGATATGA 1326 
gi|299523006:1241-3177      AAATTTTATGTTTAGTTGCACAAATTGGGCCAAAGAAACATTGCCTTGAGGAAGATATGA 1326 









gi|299522993:1352-3402      TTGGAAAATCAAGAGTGTAGAAGAATAAATACTGTTTTACTGTCCAAAGACATGTTTATA 1500 
gi|299523000:1328-3264      TTGGAAAATCAAGAGTGTAGAAGAATAAATACTGTTTTACTGTCCAAAGACATGTTTATA 1386 
gi|299523007:1223-3155      TTGGAAAATCAAGAGTGTAGAAGAATAAATACTGTTTTACTGTCCAAAGACATGTTTATA 1382 
gi|299522998:1307-3357      TTGGAAAATCAAGAGTGTAGAAGAATAAATACTGTTTTACTGTCCAAAGACATGTTTATA 1500 
gi|299523001:1262-3312      TTGGAAAATCAAGAGTGTAGAAGAATAAATACTGTTTTACTGTCCAAAGACATGTTTATA 1500 
gi|299523003:1283-3219      TTGGAAAATCAAGAGTGTAGAAGAATAAATACTGTTTTACTGTCCAAAGACATGTTTATA 1386 
gi|299522996:1373-3309      TTGGAAAATCAAGAGTGTAGAAGAATAAATACTGTTTTACTGTCCAAAGACATGTTTATA 1386 
gi|299523006:1241-3177      TTGGAAAATCAAGAGTGTAGAAGAATAAATACTGTTTTACTGTCCAAAGACATGTTTATA 1386 
                            ************************************************************ 
 
gi|299522993:1352-3402      GTGCTCTGTAAATGTTCCTTTCCTTTGTAGTCTCTGGCAAGATGCTTTAGGAAGATAAAA 1560 
gi|299523000:1328-3264      GTGCTCTGTAAATGTTCCTTTCCTTTGTAGTCTCTGGCAAGATGCTTTAGGAAGATAAAA 1446 
gi|299523007:1223-3155      GTGCTCTGTAAATGTTCCTTTCCTTTGTAGTCTCTGGCAAGATGCTTTAGGAAGATAAAA 1442 
gi|299522998:1307-3357      GTGCTCTGTAAATGTTCCTTTCCTTTGTAGTCTCTGGCAAGATGCTTTAGGAAGATAAAA 1560 
gi|299523001:1262-3312      GTGCTCTGTAAATGTTCCTTTCCTTTGTAGTCTCTGGCAAGATGCTTTAGGAAGATAAAA 1560 
gi|299523003:1283-3219      GTGCTCTGTAAATGTTCCTTTCCTTTGTAGTCTCTGGCAAGATGCTTTAGGAAGATAAAA 1446 
gi|299522996:1373-3309      GTGCTCTGTAAATGTTCCTTTCCTTTGTAGTCTCTGGCAAGATGCTTTAGGAAGATAAAA 1446 
gi|299523006:1241-3177      GTGCTCTGTAAATGTTCCTTTCCTTTGTAGTCTCTGGCAAGATGCTTTAGGAAGATAAAA 1446 
                            ************************************************************ 
 
gi|299522993:1352-3402      GTTTGAGGAGAACAAACAGGAATTCTGAATTAAGCACAGAGTTGAAGTTTATACCCGTTT 1620 
gi|299523000:1328-3264      GTTTGAGGAGAACAAACAGGAATTCTGAATTAAGCACAGAGTTGAAGTTTATACCCGTTT 1506 
gi|299523007:1223-3155      GTTTGAGGAGAACAAACAGGAATTCTGAATTAAGCACAGAGTTGAAGTTTATACCCGTTT 1502 
gi|299522998:1307-3357      GTTTGAGGAGAACAAACAGGAATTCTGAATTAAGCACAGAGTTGAAGTTTATACCCGTTT 1620 
gi|299523001:1262-3312      GTTTGAGGAGAACAAACAGGAATTCTGAATTAAGCACAGAGTTGAAGTTTATACCCGTTT 1620 
gi|299523003:1283-3219      GTTTGAGGAGAACAAACAGGAATTCTGAATTAAGCACAGAGTTGAAGTTTATACCCGTTT 1506 
gi|299522996:1373-3309      GTTTGAGGAGAACAAACAGGAATTCTGAATTAAGCACAGAGTTGAAGTTTATACCCGTTT 1506 
gi|299523006:1241-3177      GTTTGAGGAGAACAAACAGGAATTCTGAATTAAGCACAGAGTTGAAGTTTATACCCGTTT 1506 









gi|299522993:1352-3402      CACATGCTTTTCAAGAATGTCGCAATTACTAAGAAGCAGATAATGGTGTTTTTTAGAAAC 1680 
gi|299523000:1328-3264      CACATGCTTTTCAAGAATGTCGCAATTACTAAGAAGCAGATAATGGTGTTTTTTAGAAAC 1566 
gi|299523007:1223-3155      CACATGCTTTTCAAGAATGTCGCAATTACTAAGAAGCAGATAATGGTGTTTTTTAGAAAC 1562 
gi|299522998:1307-3357      CACATGCTTTTCAAGAATGTCGCAATTACTAAGAAGCAGATAATGGTGTTTTTTAGAAAC 1680 
gi|299523001:1262-3312      CACATGCTTTTCAAGAATGTCGCAATTACTAAGAAGCAGATAATGGTGTTTTTTAGAAAC 1680 
gi|299523003:1283-3219      CACATGCTTTTCAAGAATGTCGCAATTACTAAGAAGCAGATAATGGTGTTTTTTAGAAAC 1566 
gi|299522996:1373-3309      CACATGCTTTTCAAGAATGTCGCAATTACTAAGAAGCAGATAATGGTGTTTTTTAGAAAC 1566 
gi|299523006:1241-3177      CACATGCTTTTCAAGAATGTCGCAATTACTAAGAAGCAGATAATGGTGTTTTTTAGAAAC 1566 
                            ************************************************************ 
                                                                         miR-374b seed region 
gi|299522993:1352-3402      CTAATTGAAGTATATTCAACCAAATACTTTAATGTATAAAATAAATATTATACAATATAC 1740 
gi|299523000:1328-3264      CTAATTGAAGTATATTCAACCAAATACTTTAATGTATAAAATAAATATTATACAATATAC 1626 
gi|299523007:1223-3155      CTAATTGAAGTATATTCAACCAAATACTTTAATGTATAAAATAAATATTATACAATATAC 1622 
gi|299522998:1307-3357      CTAATTGAAGTATATTCAACCAAATACTTTAATGTATAAAATAAATATTATACAATATAC 1740 
gi|299523001:1262-3312      CTAATTGAAGTATATTCAACCAAATACTTTAATGTATAAAATAAATATTATACAATATAC 1740 
gi|299523003:1283-3219      CTAATTGAAGTATATTCAACCAAATACTTTAATGTATAAAATAAATATTATACAATATAC 1626 
gi|299522996:1373-3309      CTAATTGAAGTATATTCAACCAAATACTTTAATGTATAAAATAAATATTATACAATATAC 1626 
gi|299523006:1241-3177      CTAATTGAAGTATATTCAACCAAATACTTTAATGTATAAAATAAATATTATACAATATAC 1626 
                            ************************************************************ 
                                       
gi|299522993:1352-3402      TTGTATAGCAGTTTCTGCTTCACATTTGATTTTTTCAAATTTAATATTTATATTAGAGAT 1800 
gi|299523000:1328-3264      TTGTATAGCAGTTTCTGCTTCACATTTGATTTTTTCAAATTTAATATTTATATTAGAGAT 1686 
gi|299523007:1223-3155      TTGTATAGCAGTTTCTGCTTCACATTTGATTTTTTCAAATTTAATATTTATATTAGAGAT 1682 
gi|299522998:1307-3357      TTGTATAGCAGTTTCTGCTTCACATTTGATTTTTTCAAATTTAATATTTATATTAGAGAT 1800 
gi|299523001:1262-3312      TTGTATAGCAGTTTCTGCTTCACATTTGATTTTTTCAAATTTAATATTTATATTAGAGAT 1800 
gi|299523003:1283-3219      TTGTATAGCAGTTTCTGCTTCACATTTGATTTTTTCAAATTTAATATTTATATTAGAGAT 1686 
gi|299522996:1373-3309      TTGTATAGCAGTTTCTGCTTCACATTTGATTTTTTCAAATTTAATATTTATATTAGAGAT 1686 
gi|299523006:1241-3177      TTGTATAGCAGTTTCTGCTTCACATTTGATTTTTTCAAATTTAATATTTATATTAGAGAT 1686 
                            ************************************************************ 








                                                                                 
gi|299522993:1352-3402      CTATATATGTATAAATATGTATTTTGTCAAATTTGTTACTTAAATATATAGAGACCAGTT 1860 
gi|299523000:1328-3264      CTATATATGTATAAATATGTATTTTGTCAAATTTGTTACTTAAATATATAGAGACCAGTT 1746 
gi|299523007:1223-3155      CTATATATGTATAAATATGTATTTTGTCAAATTTGTTACTTAAATATATAGAGACCAGTT 1742 
gi|299522998:1307-3357      CTATATATGTATAAATATGTATTTTGTCAAATTTGTTACTTAAATATATAGAGACCAGTT 1860 
gi|299523001:1262-3312      CTATATATGTATAAATATGTATTTTGTCAAATTTGTTACTTAAATATATAGAGACCAGTT 1860 
gi|299523003:1283-3219      CTATATATGTATAAATATGTATTTTGTCAAATTTGTTACTTAAATATATAGAGACCAGTT 1746 
gi|299522996:1373-3309      CTATATATGTATAAATATGTATTTTGTCAAATTTGTTACTTAAATATATAGAGACCAGTT 1746 
gi|299523006:1241-3177      CTATATATGTATAAATATGTATTTTGTCAAATTTGTTACTTAAATATATAGAGACCAGTT 1746 
                            ************************************************************ 
                             
gi|299522993:1352-3402      TTCTCTGGAAGTTTGTTTAAATGACAGAAGCGTATATGAATTCAAGAAAATTTAAGCTGC 1920 
gi|299523000:1328-3264      TTCTCTGGAAGTTTGTTTAAATGACAGAAGCGTATATGAATTCAAGAAAATTTAAGCTGC 1806 
gi|299523007:1223-3155      TTCTCTGGAAGTTTGTTTAAATGACAGAAGCGTATATGAATTCAAGAAAATTTAAGCTGC 1802 
gi|299522998:1307-3357      TTCTCTGGAAGTTTGTTTAAATGACAGAAGCGTATATGAATTCAAGAAAATTTAAGCTGC 1920 
gi|299523001:1262-3312      TTCTCTGGAAGTTTGTTTAAATGACAGAAGCGTATATGAATTCAAGAAAATTTAAGCTGC 1920 
gi|299523003:1283-3219      TTCTCTGGAAGTTTGTTTAAATGACAGAAGCGTATATGAATTCAAGAAAATTTAAGCTGC 1806 
gi|299522996:1373-3309      TTCTCTGGAAGTTTGTTTAAATGACAGAAGCGTATATGAATTCAAGAAAATTTAAGCTGC 1806 
gi|299523006:1241-3177      TTCTCTGGAAGTTTGTTTAAATGACAGAAGCGTATATGAATTCAAGAAAATTTAAGCTGC 1806 
                            ************************************************************ 
 
gi|299522993:1352-3402      AAAAATGTATTTGCTATAAAATGAGAAGTCTCACTGATAGAGGTTCTTTATTGCTCATTT 1980 
gi|299523000:1328-3264      AAAAATGTATTTGCTATAAAATGAGAAGTCTCACTGATAGAGGTTCTTTATTGCTCATTT 1866 
gi|299523007:1223-3155      AAAAATGTATTTGCTATAAAATGAGAAGTCTCACTGATAGAGGTTCTTTATTGCTCATTT 1862 
gi|299522998:1307-3357      AAAAATGTATTTGCTATAAAATGAGAAGTCTCACTGATAGAGGTTCTTTATTGCTCATTT 1980 
gi|299523001:1262-3312      AAAAATGTATTTGCTATAAAATGAGAAGTCTCACTGATAGAGGTTCTTTATTGCTCATTT 1980 
gi|299523003:1283-3219      AAAAATGTATTTGCTATAAAATGAGAAGTCTCACTGATAGAGGTTCTTTATTGCTCATTT 1866 
gi|299522996:1373-3309      AAAAATGTATTTGCTATAAAATGAGAAGTCTCACTGATAGAGGTTCTTTATTGCTCATTT 1866 
gi|299523006:1241-3177      AAAAATGTATTTGCTATAAAATGAGAAGTCTCACTGATAGAGGTTCTTTATTGCTCATTT 1866 









gi|299522993:1352-3402      TTTAAAAAATGGACTCTTGAAATCTGTTAAAATAAAATTGTACATTTGGAGATGTTTCAT 2040 
gi|299523000:1328-3264      TTTAAAAAATGGACTCTTGAAATCTGTTAAAATAAAATTGTACATTTGGAGATGTTTCAT 1926 
gi|299523007:1223-3155      TTTAAAAAATGGACTCTTGAAATCTGTTAAAATAAAATTGTACATTTGGAGATGTTTCAT 1922 
gi|299522998:1307-3357      TTTAAAAAATGGACTCTTGAAATCTGTTAAAATAAAATTGTACATTTGGAGATGTTTCAT 2040 
gi|299523001:1262-3312      TTTAAAAAATGGACTCTTGAAATCTGTTAAAATAAAATTGTACATTTGGAGATGTTTCAT 2040 
gi|299523003:1283-3219      TTTAAAAAATGGACTCTTGAAATCTGTTAAAATAAAATTGTACATTTGGAGATGTTTCAT 1926 
gi|299522996:1373-3309      TTTAAAAAATGGACTCTTGAAATCTGTTAAAATAAAATTGTACATTTGGAGATGTTTCAT 1926 
gi|299523006:1241-3177      TTTAAAAAATGGACTCTTGAAATCTGTTAAAATAAAATTGTACATTTGGAGATGTTTCAT 1926 
                            ************************************************************ 
 
gi|299522993:1352-3402      GAAAAAAAAAA 2051 
gi|299523000:1328-3264      GAAAAAAAAAA 1937 
gi|299523007:1223-3155      GAAAAAAAAAA 1933 
gi|299522998:1307-3357      GAAAAAAAAAA 2051 
gi|299523001:1262-3312      GAAAAAAAAAA 2051 
gi|299523003:1283-3219      GAAAAAAAAAA 1937 
gi|299522996:1373-3309      GAAAAAAAAAA 1937 
gi|299523006:1241-3177      GAAAAAAAAAA 1937 
                            *********** 
 
Supplementary Figure 1: 3‘UTR alignment of CD46 mRNA variants. Region bound by forward primer is highlighted in green while region 
bound by reverse primer is highlighted in blue. Seed regions of respective miRNAs are highlighted in yellow. gi|299522993: transcript variant a. 
gi|299523000: transcript variant d. gi|299523007: transcript variant n. gi|299522998: transcript variant c. gi|299523001: transcript variant e. 
gi|299523003: transcript variant f. gi|299522996: transcript variant b. gi|299523006: transcript variant l. 
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